fluticasone profile

Fluticasone: A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluticasone : A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5311101
CHEMBL ID	1201396
CHEBI ID	5134
SCHEMBL ID	4069
MeSH ID	M000602354

Synonym
AC-456
BIDD:GT0819
fluticasone
90566-53-3
C07815
fluticasone [inn:ban]
androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, s-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-
fluticasonum [latin]
fluticasona [spanish]
fluticaps
opn-375
optinose
CHEMBL1201396
chebi:5134 ,
D07981
fluticaps (tn)
fluticasone (inn)
s-(fluoromethyl) (6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
s-(fluoromethyl) (6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate
unii-cut2w21n7u
fluticasonum
hsdb 7740
fluticasone, inhaled
fluticasona
cut2w21n7u ,
fluticasone, topical
fluticasone [inn]
fluticasone [who-dd]
fluticasone [vandf]
fluticasone [hsdb]
fluticasone [mart.]
s-(fluoromethyl) (6.alpha.,11.beta.,16.alpha.,17.alpha.)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate
gtpl6699
SCHEMBL4069
DTXSID0044022 ,
DB13867
MGNNYOODZCAHBA-GQKYHHCASA-N
Q1002165
EX-A4418
EN300-19800841
(1r,2r,3as,3bs,5s,9as,9br,10s,11as)-5,9b-difluoro-1-{[(fluoromethyl)sulfanyl]carbonyl}-1,10-dihydroxy-2,9a,11a-trimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one
CS-0009547
HY-B0603
bdbm589230
us11554172, compound fluticasone-propionate
fluticasone (mart.)
s-fluoromethyl6alpha,9alpha-difluoro-11beta-hydroxy-16alpha-methyl-17alpha-propionyloxy-3-oxoandrosta-1,4-diene-17beta-carbothioate
fluticason
fluticasonum (latin)
(6alpha,11beta,16alpha,17alpha)-6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothiolic-s-(fluoromethyl)ester
dtxcid60820064
flonase.

Excerpt	Reference	Relevance
"Fluticasone is a synthetic ICS with potent anti-inflammatory effects, while formoterol is a selective β2-adrenergic receptor agonist with a rapid onset of bronchodilation within 5-10 minutes and a 12-hour duration of action."	( Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma. Corren, J; Tan, RA, 2014)	1.39
"Fluticasone propionate is a synthetic corticosteroid drug distinguished by its potent anti-inflammatory action with low systemic side effects in comparison to other corticosteroids making it a potential drug for local buccal delivery. "	( Design and In Vitro/In Vivo Evaluation of Ultra-Thin Mucoadhesive Buccal Film Containing Fluticasone Propionate. Ammar, HO; Ghorab, MM; Mahmoud, AA; Shahin, HI, 2017)	2.12
"Fluticasone propionate is a synthetic glucocorticoid with potent anti-inflammatory activity that has been used effectively in the treatment of chronic asthma. "	( Vibrational spectroscopic study of fluticasone propionate. Ali, HR; Edwards, HG; Kendrick, J; Scowen, IJ, 2009)	2.07
"Fluticasone is a corticosteroid drug which is used in inhaled and nasal formulations for the treatment of asthma and allergic rhinitis. "	( [Cushing's syndrome induced by combined treatment with inhaled fluticasone and oral ritonavir]. Chinet, T; Dupont, C; Giraud, V; Greffe, S; Leporrier, J; Rouveix, E, 2009)	2.04
"Fluticasone furoate is a new potent topical glucocorticoid for the treatment of allergic rhinitis."	( An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. Khippal, N; Kubavat, AH; Mittal, R; Ojha, T; Patel, T; Pawar, P; Shah, UB; Sinha, V, 2011)	1.31
"Fluticasone propionate is a potent corticosteroid with negligible absorption across the nasal mucosa and extensive first-pass hepatic metabolism."	( A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Fowler, PD; Gazis, AG; Jones, NS; Page, SR, 2002)	1.27
"Fluticasone furoate (FF) is a novel enhanced-affinity glucocorticoid that has been developed as topical therapy for allergic rhinitis. "	( Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Biggadike, K; Farrow, SN; Gray, DW; Haase, MV; Matthews, JL; Salter, M; Uings, IJ; West, MR, 2007)	2.02
"Fluticasone furoate is a novel-enhanced affinity glucocorticoid and its long-term safety must be assessed. "	( Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Bardin, PG; Caldwell, MF; Faris, MA; Fokkens, WJ; Muller, B; Rosenblut, A; Wu, WW, 2007)	2.11
"Fluticasone furoate is a new enhanced-affinity glucocorticoid with a unique combination of pharmacodynamic and physicochemical properties suitable for topical activity."	( Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Caldwell, MF; Ellsworth, A; Faris, MA; Fokkens, WJ; Jogi, R; Reinartz, S; Sidorenko, I; Sitkauskiene, B; van Oene, C, 2007)	2.17
"Fluticasone propionate is a new inhaled corticosteroid with a 2:1 efficacy ratio compared with beclomethasone dipropionate with regard to lung function and symptom scores, without increased systemic activity. "	( Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Bootsma, GP; Dekhuijzen, PN; Festen, J; Mulder, PG; van Herwaarden, CL, 1995)	2.09
"Fluticasone propionate is an androstane carbothioate glucocorticosteroid with almost twice the topical anti-inflammatory potency of beclomethasone dipropionate. "	( Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Faulds, D; Holliday, SM; Sorkin, EM, 1994)	2.17
"Fluticasone propionate is a highly lipophilic molecule with good uptake, binding and retention characteristics in human lung tissue."	( Fluticasone propionate--an update on preclinical and clinical experience. Bye, A; Fuller, R; Johnson, M, 1995)	2.46
"Fluticasone propionate is a new potent, topically active corticosteroid with negligable oral bioavailability. "	( A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Jacques, LA; Lund, VJ; Richards, DH; Scadding, GK, 1995)	2.02
"Fluticasone propionate is a new corticosteroid based on the androstane nucleus. "	( The anti-inflammatory profile of fluticasone propionate. Johnson, M, 1995)	2.02
"Fluticasone propionate is a new, topically active glucocorticoid which shows high specificity for the glucocorticoid receptor. "	( Fluticasone propionate in the treatment of inflammatory dermatoses. Chu, AC; Munn, S, )	3.02
"Fluticasone propionate is a new topically active synthetic steroid which can be measured in body fluids and which undergoes first pass metabolism."	( Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. Hill, SL; Llewellyn-Jones, CG; Stockley, RA, 1994)	1.41
"Fluticasone propionate is a topically active inhaled glucocorticosteroid which has few systemic effects at high doses."	( Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Burge, PS; Ciaccia, A; Croonenborgh, L; Fabbri, L; Parker, C; Warlies, F; Weeke, B, 1993)	1.37
"Fluticasone propionate is a synthetic steroid for use by the inhaled route. "	( A placebo controlled trial of fluticasone propionate in asthmatic children. Crescenzi, K; Havnen, J; MacKenzie, CA; Tabachnik, E; Taylor, M; Weinberg, EG, 1993)	2.02
"Fluticasone propionate is a corticosteroid with the potential for topical treatment of ulcerative colitis because of low systemic bioavailability. "	( Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Burke, DA; Giaffer, MH; Hawkey, CJ; Hawthorne, AB; Holdsworth, CD; Keech, ML; Record, CO, 1993)	2.03
"Fluticasone propionate is a potent inhaled corticosteroid that is effective in improving pulmonary function and symptoms in patients with asthma."	( Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids. DeBoisblanc, BP; Kellerman, DJ; Noonan, M; Okamoto, LJ, 1996)	3.18
"Fluticasone propionate is a potent fluorinated corticosteroid used for the topical therapy of dermatoses and as inhalation therapy for bronchial asthma and allergic rhinitis. "	( Fluticasone propionate: safety profile. Johnson, M, 1996)	3.18
"Fluticasone propionate is a fluorinated steroid reported to be highly effective when used topically in the nose for seasonal and perennial allergic and nonallergic rhinitis."	( Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Balder, B; Holmberg, K; Juliusson, S; Karlsson, G; Richards, DH; Smith, DL, 1997)	2.46
"Fluticasone propionate is a novel inhaled corticosteroid which has the interesting properties of a high activity combined with low gastrointestinal absorption and rapid liver metabolism. "	( Pharmacology of fluticasone propionate. Sastre, J, )	1.92
"Fluticasone propionate is a third generation inhaled corticosteroid with an optimal therapeutic index."	( Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Berger, WE; Hamedani, AG; Hendricks, VL; House, KW; Mahajan, P; Noonan, MJ; Peden, DB; Thomas, MR, 1998)	1.46
"Fluticasone propionate is a novel and potent corticosteroid. "	( Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. Glazenburg, EJ; Mulder, PG; Oranje, AP; Strobos, MA; Wolkerstorfer, A, 1998)	3.19
"Fluticasone propionate is a glucocorticoid with negligible oral bioavailability and very low intranasal bioavailability that is used as an intranasal spray for the treatment of rhinitis."	( Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. Dockhorn, RJ; Field, EA; Findlay, SR; Korenblat, PE; Kral, KM; Vargas, R, 1998)	2.15
"Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma."	( Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999)	2.01
"Fluticasone propionate is a corticosteroid with comparatively high receptor affinity and topical activity. "	( Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Faulds, D; Jarvis, B, 1999)	2.18
"Fluticasone propionate is an inhaled glucocorticoid with little systemic bioavailability via the oral route and infrequent association with systemic adverse effects at the recommended dosage."	( Adrenal suppression secondary to inhaled fluticasone propionate. Laoprasert, N; Sachs, MI; Taylor, AV; Zimmerman, D, 1999)	1.29
"Fluticasone propionate is a very effective topical treatment for asthma. "	( Effect of fluticasone propionate on interleukin-12 and interferon-gamma production in patients affected by allergic bronchial asthma. Arena, A; Gangemi, S; Guarneri, F; Merendino, RA; Purello-D'Ambrosio, F; Ricciardi, L, )	1.98
"Fluticasone propionate is an established corticosteroid administered intranasally for the treatment of rhinitis or by oral inhalation for the treatment of asthma. "	( A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Crim, C; Daley-Yates, PT; Pierre, LN, 2001)	1.99
"Fluticasone propionate is a potent topical anti-inflammatory corticosteroid with low systemic activity. "	( Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Bryson, HM; Faulds, D, 1992)	2.12
"Fluticasone propionate is a new corticosteroid with low systemic bioavailability. "	( Oral fluticasone propionate in active distal ulcerative colitis. Angus, P; Jewell, DP; Reid, M; Snook, JA, 1992)	2.24
"Fluticasone propionate is a promising therapeutic agent for Crohn's disease that offers the possibility of controlling inflammation without inducing systemic corticosteroid side effects and which merits evaluation in a double blind trial versus conventional corticosteroids."	( Fluticasone propionate in Crohn's disease. de Kaski, MC; Hodgson, HJ; Lavender, JP; Peters, AM, 1991)	2.45
"Fluticasone propionate is a new glucocorticosteroid with potent topical activity. "	( A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. Bronsky, EA; Furukawa, CT; Grossman, J; LaForce, CF; Lemanske, RF; Meltzer, EO; Orgel, HA; Paull, BD; Pearlman, DS; Ratner, PH, 1990)	2.03
"Fluticasone propionate is a potent, locally active glucocorticoid which has no demonstrable systemic side-effects when given by the oral or intranasal routes. "	( The human pharmacology of fluticasone propionate. Harding, SM, 1990)	2.02

Excerpt	Reference	Relevance
"Fluticasone propionate has been shown to restore the nasal epithelial barrier in allergic rhinitis to the level of healthy controls."	( Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro. Hellings, PW; Martens, K; Vanhulle, E; Vermeire, K; Viskens, AS, 2023)	3.07
"Fluticasone/formoterol has shown superior efficacy when compared to fluticasone or formoterol alone in multiple well-designed studies."	( Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma. Corren, J; Tan, RA, 2014)	1.39
"Fluticasone/formoterol has similar efficacy and tolerability profiles to budesonide/formoterol and fluticasone/salmeterol, but with the additional benefit of more rapid bronchodilation than fluticasone/salmeterol."	( Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma. Dissanayake, S; Grothe, B; Kaiser, K, 2012)	2.54
"Fluticasone propionate has some features of dissociated steroids which means predominance of transrepression over transactivation--beneficial from safety point of view."	( [Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part I. Mechanisms of actions and clinical effectiveness of treatment in children with asthma]. Bartkowiak-Emeryk, M; Breborowicz, A; Emeryk, A; Kulus, M; Kurzawa, R; Lis, G; Mazurek, H; Niedziela, M, 2004)	1.34
"Fluticasone propionate has selective inhibitory effects on Th2 cytokine synthesis following nasal challenge, while also decreasing release of chemokines, but not affecting levels of Th1 cytokines."	( Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Barnes, PJ; Durham, SR; Erin, EM; Hansel, TT; Higgins, LA; Murdoch, RD; Nicholson, GC; Tan, AJ; Williams, TJ; Zacharasiewicz, AS, 2005)	1.77
"Fluticasone has long-term effects on the nasal response to histamine in perennial allergic rhinitis and part of this effect is likely to be vascular."	( The effect of topical fluticasone propionate on intranasal histamine challenge in subjects with perennial allergic rhinitis. Birchall, MA; Fuller, RW; Henderson, JC; Phillips, I; Pride, NB; Studham, JM, 1995)	1.33
"Fluticasone propionate has high glucocorticoid receptor selectivity and affinity, demonstrating rapid receptor association and slow receptor dissociation."	( Fluticasone propionate--an update on preclinical and clinical experience. Bye, A; Fuller, R; Johnson, M, 1995)	2.46
"Fluticasone has greater systemic potency than budesonide or beclomethasone when given at microgram equivalent dosage."	( Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Kane, J; Makker, H; McDowell, P; O'Driscoll, BR; Wales, D, 1999)	1.02
"Fluticasone propionate has been formulated in a new nasal drop preparation."	( Pharmaceutical properties of fluticasone propionate nasal drops: a new formulation. Denyer, S, 1999)	1.32

Excerpt	Reference	Relevance
"Fluticasone ICS were a cause of steroid inhaler laryngitis, and the best treatment was their avoidance or cessation."	( Inhaled corticosteroids: hazardous effects on voice-an update. Gallivan, GJ; Gallivan, HK; Gallivan, KH, 2007)	1.06
"Fluticasone caused an increase in the number of positive nuclear staining cells in the airway epithelium from 34."	( Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Adcock, I; Barnes, PJ; Chung, KF; Hart, L; Lim, S, 2000)	1.03

Excerpt	Reference	Relevance
"Fluticasone propionate treatment decreases eosinophilic inflammation and improves the esophageal mucosal barrier integrity in adult EoE patients. "	( Histological Response to Fluticasone Propionate in Patients With Eosinophilic Esophagitis Is Associated With Improved Functional Esophageal Mucosal Integrity. Bredenoord, AJ; de Jonge, WJ; Smout, AJ; van den Bergh Weerman, MA; van den Wijngaard, RM; van Rhijn, BD; Verheij, J; Verseijden, C, 2015)	2.16
"Fluticasone-treated mice were slower in retrieving a piece of hidden food, but both groups were similarly fast when the food was visible."	( The olfactory system is affected by steroid aerosol treatment in mice. Barbato, A; Bondí, M; Calabrese, F; Mucignat-Caretta, C; Rubini, A, 2009)	1.07
"Fluticasone treatment significantly reduced responsiveness to bradykinin (P < 0.001 by Friedman anova) and methacholine (P = 0.02), but changes in responsiveness to bradykinin were significantly greater than those in methacholine responsiveness (P = 0.002)."	( Airways hyper-responsiveness to bradykinin and methacholine: effects of inhaled fluticasone. Proud, D; Reynolds, CJ; Togias, A, 2002)	1.26
"Fluticasone treatment resulted in a higher prebronchodilator FEV1 (1.17 +/- 0.08 L [mean +/- SEM] versus 1.07 +/- 0.08 L, p = 0.001), a higher PaO2 (66.6 +/- 1.4 mmHg versus 63.6 +/- 1.6 mmHg, p = 0.002), and a better dyspnea score on the chronic respiratory questionnaire (3.70 +/- 0.18 versus 3.47 +/- 0.19, p = 0.03)."	( Controlled trial of inhaled fluticasone propionate in moderate to severe COPD. Carvalho, P; Charan, NB; Souza, JP; Thompson, WH, 2002)	1.33
"Fluticasone-treated infants required significantly less volume of crystalloids and colloids for blood pressure support compared with control infants. "	( Effects of inhaled corticosteroids on systemic blood pressure in preterm infants. Fok, TF; Lee, CH; Liu, F; Ma, KC; Ng, PC; Wong, E, 2004)	1.77
"Fluticasone treatment resulted in a greater reduction in sputum eosinophils (geometric mean (SD) 11.9 (2.3)% to 1.7 (5.1)%) than montelukast (10.7 (2.3)% to 6.9 (3.8)%; p = 0.04) or placebo (15.4 (2.4)% to 7.8 (4.2)%; p = 0.002), and improvement in FEV(1) (mean (SD) 2.6 (0.9) l to 3.0 (0.9) l) than montelukast (2.8 (0.7) l to 2.8 (0.9) l; p = 0.02) or placebo (2.4 (0.8) l to 2.4 (0.9) l; p = 0.01)."	( Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Cartier, A; Hargreave, FE; Jayaram, L; Lemière, C; Man, SF; Pizzichini, E; Pizzichini, MM, 2005)	1.29
"More fluticasone-treated patients did not complete the 8.5-hour exercise challenges (36% on day 1 and 33% at week 4) compared with the fluticasone/salmeterol group (18% each) (P < or = .01)."	( Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Dorinsky, PM; Emmett, A; Kalberg, CJ; Nathan, RA; Rupp, NT; Weiler, JM, 2005)	1.19
"Fluticasone/salmeterol-treated asthma patients had 1.1 more symptom-free days per week (P=0.044); no such effect was observed for COPD (P=0.769)."	( Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD. Albers, JM; Costongs, RJ; Schermer, TR; Verblackt, HW; Westers, P, 2007)	1.33
"Fluticasone pretreatment did not increase FEV(1) responses to any albuterol formulation, except 0.6 mg racemic albuterol."	( Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma. Campos, M; Horvath, G; Mendes, ES; Wanner, A, 2008)	1.07
"More fluticasone propionate-treated patients compared with placebo-treated patients had reduced nasal mucosal eosinophil counts after 4 weeks of therapy (p <0.05)."	( Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. Blumenthal, M; Boltansky, H; Bronsky, EA; Dockhorn, RJ; Field, E; LaForce, C; Meltzer, EO; Ransom, J; Rogenes, P; Shapiro, G; Weakley, S; Weiler, JM; Wisniewski, M, 1996)	2.19
"Fluticasone propionate treatment down-regulated the hsp70 and HLA-DR expression in BAL (hsp70 P < 0.001, HLA-DR P < 0.05) and bronchial epithelium (hsp70 P < 0.05, HLA-DR P < 0.05)."	( Heat shock protein 70 upregulation is related to HLA-DR expression in bronchial asthma. Effects of inhaled glucocorticoids. Bertorelli, G; Bocchino, V; Chetta, A; Del Donno, M; Foresi, A; Olivieri, D; Testi, R; Zhuo, X, 1998)	1.02
"Fluticasone propionate treatment tended to prevent paranasal sinusitis, especially in rhinovirus-positive subjects."	( Sinusitis in the common cold. Alanen, A; Arstila, P; Kallio, T; Korsoff, L; Leinonen, M; Mäkelä, MJ; Mertsola, J; Puhakka, T; Pulkkinen, M; Ruuskanen, O; Suonpää, J, 1998)	1.02
"Fluticasone treatment was clinically effective (P <.005). "	( Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. Cameron, L; Durham, SR; Hamid, QA; Jacobson, MR; Juliusson, S; Kamil, A; Kay, AB; Lowhagen, O; Masuyama, K; Till, SJ, 1998)	1.74
"Fluticasone treatment significantly reduced NP eosinophilia (P =.02) and CD4(+) T lymphocytes (P =.02). "	( Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. Hamid, QA; Hamilos, DL; Kamil, A; Kramper, MA; Thawley, SE, 1999)	2.07
"Fluticasone propionate treatment resulted in significantly (P	( A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. Baker, J; Edwards, L; Lanier, RQ; Lincourt, WR; Raphael, GD; Rickard, K, 1999)	2.03
"Fluticasone propionate treatment did not affect peptidase activities in the asthmatic patients."	( Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics--comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids. Hoogsteden, HC; Naber, BA; Overbeek, SE; Van Der Velden, VH; Van Hal, PT; Versnel, MA, 1999)	1.02
"Fluticasone propionate treatment over a 54-week period was well tolerated, with few drug-related adverse events, which were primarily topical effects of inhaled corticosteroids."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	1.31
"Fluticasone propionate treatment was not associated with significant systemic effects."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	1.31
"Fluticasone propionate treatment was associated with significantly (p<0.001) lower risk-adjusted asthma-related charges compared with montelukast and zafirlukast treatment: $528, $967, and $1359, respectively In this cohort, fluticasone propionate also was associated with fewer hospitalizations, less need for additional controller agents, and longer maintenance on the index drug compared with montelukast and zafirlukast."	( Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Davis, EA; Pathak, DS; Stanford, RH, 2002)	1.31
"Fluticasone-treated patients had significantly greater increases in the mean percentages of symptom-free days (22% vs."	( Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. Brabson, JH; Clifford, D; Edwards, LD; Kerwin, E; Pepsin, PJ; Raphael, G; Rickard, K; Srebro, S, 2002)	1.32
"Fluticasone propionate treatment also led to significant increases in the absorptive surface epithelium as shown by an increase in the villus:crypt ratio (P less than 0.01), the epithelial cell height (P less than 0.01) and two- to three-fold increases in the area and length of the surface epithelium (P less than 0.001)."	( Morphometric studies in duodenal biopsies from patients with coeliac disease: the effect of the steroid fluticasone propionate. Record, CO; Zaitoun, A, 1991)	1.22
"Pre-treatment with fluticasone propionate also decreased ACE2 expression in SARS-CoV-2 infected Calu-3 cells."	( Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro. Hellings, PW; Martens, K; Vanhulle, E; Vermeire, K; Viskens, AS, 2023)	2.67
"Mice treated with fluticasone plus AC before infection with viable pneumococci developed significantly more lung CFUs at 48 h."	( Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function. Brown, JP; Crudgington, SW; Curtis, JL; Freeman, CM; Mancuso, P; McCubbrey, AL; Saxton, BL; Stolberg, VR; Taitano, SH, 2015)	0.74
"Treatment with fluticasone, mometasone, isotonic and hypertonic nasal saline completely prevented biofilm production in 66, 50, 84 and 38% of bacterial strains, respectively."	( Antibiofilm effects of topical corticosteroids and intranasal saline in patients with chronic rhinosinusitis with nasal polyps depend on bacterial species and their biofilm-forming capacity. Bakic, L; Bozic, DD; Cirkovic, I; Jotic, A; Milovanovic, J; Pavlovic, B, 2017)	0.79
"Treatment with fluticasone was associated with a smaller gain in height and weight."	( Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. Alos, N; Collet, JP; Davis, GM; Ducharme, FM; Khomenko, L; Leblond, H; Lemire, C; Noya, FJ; Platt, RW; Rivard, G; Savdie, C, 2009)	0.99
"Treatment with fluticasone propionate significantly decreased clinical response to allergen challenge (P < .01) compared with the controls and led to a decrease in values for substance P, neurokinin A, vasoactive intestinal peptide, histamine release, human serum albumin, and total protein after allergen challenge (P < .01)."	( Effect of fluticasone on neuropeptides in nasal lavage in persistent allergic rhinitis. Ewert, R; Felix, SB; Gläser, S; Gustavus, B; Koch, B; Kunkel, G; Noga, O; Schäper, C, 2010)	1.1
"Treatment with fluticasone propionate provided significantly greater relief of symptoms of sinus pain and pressure compared with placebo over the entire 14-day treatment period."	( Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Cook, CK; Goode-Sellers, ST; Howland, WC; Jacobs, RL; Philpot, EE; Prillaman, BA; Ratner, PH; Reed, KD, )	0.74
"Treatment with fluticasone at 440 microg twice daily resulted in no significant effects on BMD and a statistically significant but not clinically important temporary reduction in cortisol production."	( Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. Crim, CC; Duke, SP; Faulkner, K; Harding, SM; Herje, NE; Kemp, JP; Osur, S; Shrewsbury, SB, 2004)	0.98
"Treatment with fluticasone decreased nasal resistance and intra-epithelial eosinophils."	( Intranasal steroids decrease eosinophils but not mucin expression in nasal polyps. Burgel, PR; Cardell, LO; Nadel, JA; Ueki, IF, 2004)	0.66
"Treatment with fluticasone twice daily for 6 months improves pulmonary function and clinical outcomes in children with asthma younger than 2 years."	( Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Kofman, CD; Maffey, AF; Szulman, GA; Teper, AM; Vidaurreta, SM, 2005)	2.11
"Treatment with fluticasone suppressed sputum eosinophilia within a week while montelukast only attenuated it."	( Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Cartier, A; Hargreave, FE; Jayaram, L; Lemière, C; Man, SF; Pizzichini, E; Pizzichini, MM, 2005)	0.91
"Pretreatment with fluticasone propionate significantly inhibits the increase in mast cell numbers in the nasal mucosa of rats chronically exposed to toluene di-isocyanate (TDI), and suppresses TDI-induced mast cell degranulation."	( The anti-inflammatory profile of fluticasone propionate. Johnson, M, 1995)	0.9
"Treatment with fluticasone propionate aqueous nasal spray did not affect initial basal production of nitric oxide nor production following provocation with house dust mite extract."	( Nitric oxide metabolites in nasal lavage fluid of patients with house dust mite allergy. de Graaf-in't Veld, C; Garrelds, IM; Gerth van Wijk, R; van Amsterdam, JG; Zijlstra, FJ, 1995)	0.63
"Treatment with fluticasone propionate did not influence mast cell density, the tissue histamine concentration, the lavage histamine levels or the TAME-esterase activity, while a reduction in nasal symptoms and tryptase in nasal lavage fluid was revealed."	( Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid. Enerbäck, L; Holmberg, K; Juliusson, S; Karlsson, G; Pipkorn, U, 1993)	0.63
"Treatment with fluticasone propionate (as an aqueous nasal spray) significantly decreased the evoked interleukin-5 and ECP levels in the late phase reaction."	( Interleukin-5 and eosinophil cationic protein in nasal lavages of rhinitis patients. De Graaf-in 't Veld, T; Garrelds, IM; Gerth van Wijk, R; Nahori, MA; Vargaftig, BB; Zijlstra, FJ, 1995)	0.63
"Treatment with fluticasone propionate for 7 days caused a decrease in the concentrations of nasal IgE protein, IgE-producing cells, total epsilon mRNA, and all the cytokine mRNAs tested."	( Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge. Diaz-Sanchez, D; Fleming, J; Saxon, A; Tsien, A, 1999)	0.98
"Treatment with fluticasone propionate was more cost-effective than budesonide with respect to improvement in morning peak expiratory flow rate, successfully treated weeks, symptom-free days, symptom-free 24 h and episode-free days."	( The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Barnes, NC; Price, MJ; Thwaites, RM, 1999)	0.92
"Treatment with fluticasone propionate resulted in significantly greater improvements in pulmonary function compared with zafirlukast (P <.05) or placebo (P <.05)."	( Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. Bowers, BW; Busse, W; Edwards, L; Johnson, M; Rickard, K; Rogenes, PR; Srebro, S; Storms, W; Wolfe, J, 2001)	2.09
"Treatment with fluticasone propionate 88 kg twice daily was the most cost effective treatment compared with zafirlukast 20 mg twice daily in this 12-week clinical trial. "	( Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Edwards, L; Kalberg, C; Menendez, R; Rickard, K; Stanford, RH, 2001)	0.96
"Treatment with fluticasone significantly improved asthma-related quality-of-life measures compared with montelukast (P< or =.01)."	( Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Edwards, L; Friedman, BF; Goode-Sellers, S; Kalberg, C; Lockey, RF; Meltzer, EO; Rickard, K; Srebro, S, 2002)	0.94
"Treatment with fluticasone propionate significantly reduced the increase of absolute number of mature bone marrow eosinophils (P=0.014) and showed a tendency towards decrease in the immature bone marrow eosinophil number (P=0.057) compared to controls."	( Intranasal fluticasone propionate inhibits allergen induced bone marrow eosinophilia in mice. Johnson, M; Lötvall, J; Pullerits, T; Sergejeva, S; Tomaki, M; Zhao, LL, 2002)	1.04

Excerpt	Reference	Relevance
" In all, 132 patients (51%) reported 273 adverse events, the pattern of which was as expected in an atopic population with asthma; only 26 (10%) of these reports were considered either certainly, probably or possibly related to study treatment."	( An open study to assess the long-term safety of fluticasone propionate in asthmatic children. International Study Group. Berdel, D; Götz, MH; MacKenzie, CA; Parker, C; Radford, M; Tabachnik, E; Tsanakas, J, )	0.39
" Safety was assessed by recording all adverse events and by performing routine biochemistry and haematology screens including plasma cortisol concentration before and after treatment."	( Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Gillies, E; Gold, M; Gustafsson, P; Primhak, R; Radford, M; Tsanakas, J, 1993)	0.54
" Morning plasma cortisol concentrations and frequency of drug-related adverse events were similar in the fluticasone propionate and placebo groups."	( Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Banov, C; Bronsky, EA; Findlay, SR; Grossman, J; Kral, KM; Mendelson, L; Nathan, RA; Pearlman, D; Ratner, PH; Winder, JA, 1993)	1.94
" Safety assessments included routine clinical laboratory evaluations, morning plasma cortisol levels, and reporting of adverse events."	( A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema. Delescluse, J; van der Endt, JD, 1996)	0.54
" Drug-related adverse events were few and mild."	( Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Callen, J, 1996)	0.57
" Adverse events were few and mild."	( Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. Olsen, EA, 1996)	0.6
" In study 1, no drug-related adverse events were reported in the fluticasone group."	( Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Lebwohl, M, 1996)	0.84
" No serious drug-related adverse events occurred."	( Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997)	0.55
" Adverse events were primarily pharmacologic effects of inhaled corticosteroids, and those related to the study drug occurred with low frequency."	( Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. Berger, WE; Hamedani, AG; Hendricks, VL; House, KW; Mahajan, P; Noonan, MJ; Peden, DB; Thomas, MR, 1998)	0.73
" The incidence and severity of adverse events were similar across groups."	( Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Brown, A; Finn, A; Galant, SP; Gross, G; Hamedani, AG; Harding, SM; Pleskow, W; van Bavel, J, 1999)	0.56
"To compare the efficacy and adverse effects of inhaled fluticasone propionate (FP), 400 microgram/d, with those of budesonide (BUD), 800 microgram/d, in children with moderate to severe asthma."	( Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. Ferguson, AC; Manjra, A; Mark, S; Spier, S; Versteegh, FG; Zhang, P, 1999)	0.77
"To appraise the data on systemic adverse effects of inhaled corticosteroids."	( Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth, BJ, 1999)	0.3
"All inhaled corticosteroids exhibit dose-related systemic adverse effects, although these are less than with a comparable dose of oral corticosteroids."	( Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Lipworth, BJ, 1999)	0.3
" There were no clinically relevant differences in adverse events or serum cortisol levels between the two groups."	( Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Bons, J; Bugnas, B; Evano-Celli, I; Legendre, M; Prud'Homme, A; Stuart, AM; Tonnel, AB, 2000)	0.59
" In conclusion, the new HFA 134a fluticasone propionate pMDI is as effective and safe as the established CFC fluticasone propionate pMDI when used at a dosage of 1 mg day(-1)."	( Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Lundback, B; Perruchoud, AP; Sykes, AP; Yigla, M, 2000)	0.87
" The incidence and type of most adverse events were similar in the two treatment groups."	( Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Ayres, JG; Millar, AB; Sykes, AP, 2000)	0.59
" Safety assessments included monitoring of adverse events and morning serum cortisol concentrations."	( Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Anttila, H; Davies, PI; Hederos, CA; Ossip, MS; Ribeiro, BL; Van den Berg, NJ, 2000)	0.7
" Fluticasone propionate treatment over a 54-week period was well tolerated, with few drug-related adverse events, which were primarily topical effects of inhaled corticosteroids."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	1.5
" Fluticasone propionate was well tolerated for up to 64 weeks with few reports of drug-related adverse events or morning plasma cortisol abnormalities."	( Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Brown, A; Clements, DS; Duke, S; Harding, SM; House, KW; LaForce, CF; Pearlman, DS; Ruff, ME; Silvers, WS; Weinstein, SW, 2000)	1.5
"It is concluded that, at the doses studied and with the delivery devices used clinically, FP is at least as effective as BDP/BUD in the management of severe asthma and may offer clinical advantages with respect to steroid-related adverse effects."	( Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. Berend, N; Kellett, B; Kent, N; Sly, PD, 2001)	0.53
" Lung function, quality of life and adverse events were evaluated as primary outcome variables."	( [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002)	0.56
" Frequent adverse events included symptoms of asthma (5."	( [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma]. Beeh, KM; Beier, J; Buhl, R; Kornmann, O; Wiewrodt, R, 2002)	0.56
" Serum cortisol response, fluticasone levels, skin changes, and adverse events were analyzed."	( Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. Allen, DB; Friedlander, SF; Hebert, AA, 2002)	1.02
" No significant adverse cutaneous effects were noted."	( Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. Allen, DB; Friedlander, SF; Hebert, AA, 2002)	0.72
"05% appears to be safe for the treatment of severe eczema for up to 4 weeks in children 3 months of age and older."	( Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. Allen, DB; Friedlander, SF; Hebert, AA, 2002)	0.72
" Adverse events were collected for the total study period."	( Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics. Addlestone, R; Anderson, PB; Cantini, L; Jones, J; Langley, SJ; Mooney, P; Rossetti, A, 2002)	0.31
" The incidence of adverse effects (except for an increase in oral candidiasis with FSC and FP) were similar among the treatment groups."	( The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Darken, P; Davis, S; Hanania, NA; Horstman, D; Lee, B; Reisner, C; Shah, T, 2003)	0.62
" The most common drug-related adverse events were cough (2% FP vs 1% SCG) and hoarseness (1% FP vs 0% SCG)."	( Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Allen, DB; Bisgaard, H; Davies, P; Kalev, I; Milanowski, J; Willits, L, 2004)	0.58
" Rhinitis symptoms score (parent-rated), clinical evaluation of symptoms (investigator-rated) and adverse event profiles during the treatment period."	( Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis. Fokkens, WJ; Scadding, GK, 2004)	0.53
" Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective."	( Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Korting, HC; Roeder, A; Schäfer-Korting, M; Schaller, M, )	0.69
" Both treatments were well tolerated, and the adverse reactions showed no significant difference between the two groups."	( [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005)	0.57
" FP was well-tolerated, with similar reported adverse events in both groups."	( The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. Carlsen, KC; Cirule, I; Hughes, S; Kamin, W; Stick, S; Wixon, C, 2005)	0.63
" Safety was assessed according to adverse events recorded."	( Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Du, X; Humphries, M; Jiang, J; Wang, L; You-Ning, L, 2005)	0.61
" The overall incidence of adverse events was 59% for fluticasone propionate-salmeterol and 57% for fluticasone propionate."	( The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Dorinsky, P; Ellsworth, A; House, K; LaForce, C; Malone, R; Nimmagadda, S; Schoaf, L, 2005)	0.84
" Adverse events (69% vs 71%) and mean end point to baseline 12-hour urinary cortisol excretion ratios were similar."	( Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. Carranza Rosenzweig, JR; Crim, C; Decotiis, BA; Edwards, LD; Hanson, KM; Lincourt, WR; Ostrom, NK, 2005)	0.59
"0% ointment is an effective and safe therapeutic regimen in atopic dermatitis."	( Efficacy and safety of combination ointment "fluticasone propionate 0.005% plus mupirocin 2.0%" for the treatment of atopic dermatitis with clinical suspicion of secondary bacterial infection: an open label uncontrolled study. Khobragade, KJ, )	0.39
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Safety assessments included adverse events, 12-hour urinary cortisol excretion, and growth."	( Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Baker, JW; Blake, KV; Crim, C; Faris, MA; Kim, KT; Scott, CA; Wasserman, RL; Wu, W, 2006)	0.62
" The percentage of patients who experienced at least 1 adverse event was similar in the 2 groups."	( Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. Ceruti, E; Crim, C; Kleha, JF; Maspero, JF; Mehta, R; Qaqundah, PY; Scott, CA; Sugerman, RW; Wu, W, 2006)	0.64
" Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected."	( Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. Rizzo, MC; Solé, D, 2006)	0.33
" The most documented adverse effect is transitory decrease of growth rate."	( Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. Rizzo, MC; Solé, D, 2006)	0.33
" When administered in low doses, they seem to be safe and effective."	( Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. Rizzo, MC; Solé, D, 2006)	0.33
" We found sufficient evidence to support the suspicion that hypertrichosis might be a true adverse effect of ICS."	( Hypertrichosis as a side effect of inhaled steroids in children. de Jong-Van den Berg, LT; de Langen-Wouterse, JJ; de Vries, TW; Duiverman, EJ, 2007)	0.34
" Safety was assessed by monitoring adverse events (AEs), 24-h urinary cortisol excretion, nasal and ophthalmic examinations, electrocardiograms and clinical laboratory tests."	( Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Bardin, PG; Caldwell, MF; Faris, MA; Fokkens, WJ; Muller, B; Rosenblut, A; Wu, WW, 2007)	0.66
" This is a non-inferiority study where safety and efficacy outcomes were serially assessed, including adverse events, Baseline (BDI)/Transition Dyspnea Index (TDI), St."	( A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pul Balkissoon, R; Make, B, 2008)	0.35
" The incidence of adverse events was low and similar between the two groups and events were of the type expected in this population."	( Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. Chan, R; Jung, KS; Lee, YC; Park, SK; Shim, JJ; Uh, ST; Williams, AE, 2008)	0.59
" The incidences of adverse events were comparable across treatments."	( Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Barkai, L; Emeryk, A; Engelstätter, R; Hirsch, S; Pedersen, S; Vermeulen, J; Weber, H; Weber, HJ, 2009)	0.61
" However, the adverse event (AE) profiles of oral glucocorticoids, which result largely from the systemic absorption of those agents, have engendered concerns about the safety of INSs."	( Safety of intranasal corticosteroids in acute rhinosinusitis. Demoly, P, )	0.13
"Increased BDNF concentrations may underly the adverse effects of salmeterol monotherapy on airway responsiveness in asthma."	( Adverse effects of salmeterol in asthma: a neuronal perspective. Bratke, K; Edner, A; Kuepper, M; Lindner, Y; Lommatzsch, M; Virchow, JC, 2009)	0.35
"An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
"We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised patients with chronic asthma to regular formoterol versus regular salmeterol, when each are used with an inhaled corticosteroid as part of the randomised treatment."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Unpublished data on mortality and serious adverse events were sought from the sponsors and authors."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Asthma-related serious adverse events were rare, and there were no reported asthma-related deaths."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; Lasserson, TJ, 2010)	0.36
" Patients rated the side effect questions of the 15 domain ICQ on a 7-point Likert scale (0 = not at all, 6 = a very great deal) during scheduled visits."	( Difference between patient-reported side effects of ciclesonide versus fluticasone propionate. Caeser, M; Foster, JM; Müller, T; Postma, DS; van der Molen, T, 2010)	0.59
"The majority of side effect scores remained similar with ciclesonide but worsened statistically significantly with fluticasone propionate from baseline to the end of the study in within-treatment analyses."	( Difference between patient-reported side effects of ciclesonide versus fluticasone propionate. Caeser, M; Foster, JM; Müller, T; Postma, DS; van der Molen, T, 2010)	0.8
" Due to the adverse effects of these treatments, new drugs like leukotriene receptor antagonists are being investigated for the treatment of allergic rhinitis."	( Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Badyal, DK; Modgill, V; Verghese, A, 2010)	0.36
" Recent studies, which evaluated topical and systemic adverse events associated with ciclesonide (CIC), fluticasone furoate (FF), mometasone furoate (MF), triamcinolone acetonide, fluticasone propionate, budesonide, and beclomethasone dipropionate were summarized."	( Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Blaiss, MS, )	0.35
" Safety was assessed based on adverse events, clinical laboratory tests and vital sign evaluations."	( Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. Blazhko, V; D'Urzo, A; Kaiser, K; Nathan, RA, 2012)	0.69
" Adverse events (AEs) were reported by 174 patients (36."	( Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. Kaiser, K; Mansur, AH, 2013)	0.67
" Safety was assessed based on adverse events, vital signs, and clinical laboratory evaluations."	( Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Blahzko, V; Corren, J; Kaiser, K; Mansfield, LE; Pertseva, T, 2013)	0.7
" Secondary outcome measures included quality of life as measured by the Paediatric Asthma Quality of Life Questionnaire with Standardised Activities [PAQLQ(S)] and the Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ); time from randomisation to first exacerbation requiring treatment with a short course of oral corticosteroids; school attendance; hospital admissions; amount of rescue beta-2 agonist therapy prescribed; time from randomisation to treatment withdrawal (because of lack of efficacy or side effects); lung function at 48 weeks (as assessed by spirometry); cost-effectiveness; adverse events."	( Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. James, M; Lenney, W; McKay, AJ; Price, D; Tudur Smith, C; Williamson, PR, 2013)	0.39
" Adverse events were similar between the groups except for nervous system disorders, which were more frequently reported on fluticasone plus montelukast."	( Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. James, M; Lenney, W; McKay, AJ; Price, D; Tudur Smith, C; Williamson, PR, 2013)	0.6
" This systematic review could not derive any significant adverse effect on HPA function, growth and bone mineral density in asthmatic children when used for long duration and followed for up to three months."	( Safety of inhaled fluticasone propionate therapy for pediatric asthma - a systematic review. Muley, A; Muley, P; Shah, M, 2013)	0.72
"Our findings suggest that BT is safe for 5 years after BT in patients with severe refractory asthma."	( Safety of bronchial thermoplasty in patients with severe refractory asthma. Armstrong, B; Chung, KF; Corris, PA; Cox, G; Laviolette, M; Niven, RM; Pavord, ID; Shargill, NS; Thomson, NC, 2013)	0.39
" During the whole study the safety of patients was monitored by recording adverse events; in addition, a systemic exposure to fluticasone was evaluated by testing the changes of cortisol in serum and in a 24-hour collection of urine in a subgroup consisting of 45 patients."	( Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice dail Bocheńska-Marciniak, M; Kuna, P; Kupryś-Lipińska, I; Tworek, D; Vanderbist, F, 2013)	0.83
" No significant quantitative or qualitative differences were shown between the groups in the recorded adverse events, qualified as related to treatment with fluticasone."	( Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice dail Bocheńska-Marciniak, M; Kuna, P; Kupryś-Lipińska, I; Tworek, D; Vanderbist, F, 2013)	0.82
" The secondary analyses were PEF, level of asthma control, serum cortisol levels, frequency of adverse events, adherence to treatment, and appropriate inhaler use."	( Efficacy and safety of the single-capsule combination of fluticasone/formoterol in patients with persistent asthma: a non-inferiority trial. Antilla, M; Castro, F; Cruz, Á; Rosário, N; Rubin, A; Stelmach, R, )	0.38
" The incidence of treatment-emergent adverse events was similar between the tralokinumab and placebo groups."	( Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Brightling, CE; Chanez, P; Korn, S; Leigh, R; May, RD; O'Byrne, PM; Piper, E; Ranade, K; She, D; Streicher, K, 2015)	0.42
" A rapid-onset, long-lasting medication with few adverse effects may contribute to improve adherence to therapy, along with an effective patient education and a good physician-patient communication."	( A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler. Canonica, W; Foschino, MP; Latorre, M; Paggiaro, P; Papi, A, 2015)	0.64
" Local adverse reactions are reported which resolve spontaneously within a few days without need for discontinuation of treatment."	( Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports. Bahceciler, N; Galip, N, 2015)	0.42
"Topical steroids are known for their anti-inflammatory properties and are commonly prescribed to treat many adverse skin conditions such as eczema and psoriasis."	( Longitudinal in vivo tracking of adverse effects following topical steroid treatment. Arp, Z; Boppart, SA; Bower, AJ; Chaney, EJ; Hughes-Earle, A; Li, J; Marjanovic, M; Zhao, Y, 2016)	0.43
" Adverse events (AEs) were monitored."	( Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial. Adachi, M; Goldfrad, C; Jacques, L; Nishimura, Y, 2016)	0.72
" Safety was assessed by child- or caregiver-reported adverse events, nasal examinations, vital signs, and laboratory assessments."	( Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Berger, W; Fineman, S; Gawchik, S; Sher, E, 2018)	0.71
"The incidence of treatment-related adverse events (TRAEs) was low in both the AZE/FP (16%) and FP-only (12%) groups after 90 days' continuous use."	( Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Berger, W; Fineman, S; Gawchik, S; Sher, E, 2018)	0.71
"The intranasal formulation of AZE and FP was safe and well tolerated after 3 months' continuous use in children with allergic rhinitis."	( Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. Berger, W; Fineman, S; Gawchik, S; Sher, E, 2018)	0.71
"There were no deaths, serious treatment-emergent adverse events (TEAEs), severe TEAEs or discontinuations from the study related to a TEAE."	( Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Comer, GM; Eagle, G; Falk, GW; Hirano, I; Roumet, MC; Safroneeva, E; Schoepfer, A, 2020)	0.8
"APT-1011 was safe and well tolerated in adolescents and adults with EoE."	( Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Comer, GM; Eagle, G; Falk, GW; Hirano, I; Roumet, MC; Safroneeva, E; Schoepfer, A, 2020)	0.8
" Adverse drug reactions, morning peak flow (mPEF) and asthma symptoms were evaluated 24 weeks after administration."	( [A PHASE III STUDY TO EVALUATE SAFETY AND EFFICACY OF FLUTICASONE/FORMOTEROL COMBINATION (FLUTIFORM Ishikawa, Y; Kamata, M; Katsunuma, T, 2020)	0.81
" Clinical practice has shown that montelukast sodium combined with fluticasone in the treatment of adult BA can improve clinical efficacy and reduce adverse reactions."	( Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis. Han, H; Liu, Q; Liu, X; Luo, H, 2020)	1.04
"This study assessed the efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult BA through total effective rate, pulmonary function (FEV1, FVC, PEF, FEV1/FVC), and adverse reactions."	( Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis. Han, H; Liu, Q; Liu, X; Luo, H, 2020)	1.03
" However, an increase in serious adverse events with the use of both regular formoterol and regular salmeterol (long-acting beta₂-agonists) compared with placebo for chronic asthma has been demonstrated in previous Cochrane Reviews."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; O'Shea, O; Stovold, E, 2021)	0.62
"To assess risks of mortality and non-fatal serious adverse events in trials that have randomised patients with chronic asthma to regular formoterol and an inhaled corticosteroid versus regular salmeterol and an inhaled corticosteroid."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; O'Shea, O; Stovold, E, 2021)	0.62
" We sought unpublished data on mortality and serious adverse events from study sponsors and authors."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; O'Shea, O; Stovold, E, 2021)	0.62
" In all, 201 adults reported non-fatal serious adverse events."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; O'Shea, O; Stovold, E, 2021)	0.62
" Evidence on all-cause non-fatal serious adverse events indicates that there is probably little to no difference between formoterol/budesonide and salmeterol/fluticasone inhalers."	( Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cates, CJ; O'Shea, O; Stovold, E, 2021)	0.82
"MP-AzeFlu is as safe and mild as placebo and azelastine, which also is associated with symptom relief and the improvement of quality of life in AR patients."	( Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis. Guan, B; Shi, X; Wang, M; Xun, Y; Zhong, Z, 2022)	0.72
" Secondary outcomes included risk of hospitalization, pulmonary function, asthma control level, quality of life, and adverse events (AEs)."	( Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021)	0.9
" Based on clinical comparisons in asthma and COPD, we conclude that the BUD/formoterol (BUD/FORM) combination is as effective and safe as the FP and FF combinations, and is in some cases even better as it can be used as "maintenance plus reliever therapy" (MART) in asthma and as maintenance in COPD."	( May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide? Brattsand, R; Selroos, O, 2022)	0.72
"Mon + Flu is effective and safe for the treatment of CVA in children."	( An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis. Li, S; Wei, Z, 2023)	1.16

Excerpt	Reference	Relevance
" Available pharmacodynamic data are only preliminary; however, large placebo- and drug-controlled clinical studies involving almost 4000 patients with seasonal allergic rhinitis and 1500 with perennial allergic and nonallergic rhinitis have confirmed the efficacy of intranasal fluticasone propionate in the control of nasal symptoms."	( Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Bryson, HM; Faulds, D, 1992)	0.85
"To evaluate the pharmacokinetic and systemic pharmacodynamic properties of inhaled fluticasone propionate (FP)."	( Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Barth, J; Derendorf, H; Falcoz, C; Hochhaus, G; Krieg, M; Meibohm, B; Möllmann, H; Stöckmann, R; Wagner, M; Weisser, H, 1998)	0.78
" Systemic pharmacodynamic effects were evaluated by measuring endogenous serum cortisol and circulating white blood cells, and analyzed with previously developed integrated pharmacokinetic/pharmacodynamic (PK/PD) models."	( Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Barth, J; Derendorf, H; Falcoz, C; Hochhaus, G; Krieg, M; Meibohm, B; Möllmann, H; Stöckmann, R; Wagner, M; Weisser, H, 1998)	0.55
"After inhalation, FP follows linear pharmacokinetics and exhibits dose-dependent systemic pharmacodynamic effects that can be described by PK/PD modeling."	( Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Barth, J; Derendorf, H; Falcoz, C; Hochhaus, G; Krieg, M; Meibohm, B; Möllmann, H; Stöckmann, R; Wagner, M; Weisser, H, 1998)	0.55
"The aim of this paper is to carry out a detailed Bayesian population pharmacokinetic analysis of a three-period cross-over study of the drug fluticasone propionate carried out in 12 healthy male volunteers."	( The Bayesian analysis of a pivotal pharmacokinetic study. Falcoz, C; Rahman, NJ; Stephens, DA; Wakefield, JC, 1999)	0.5
" The pharmacodynamic parameters kout and IC50 were estimated from the model equation with kin(t) derived by the new approach."	( Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chakraborty, A; Jusko, WJ; Krzyzanski, W, 2000)	0.31
" Population pharmacokinetic data consist of such data on a number of individuals, possibly along with individual-specific characteristics."	( The combination of population pharmacokinetic studies. Rahman, N; Wakefield, J, 2000)	0.31
"This pharmacokinetic substudy was part of a previously published open-label, randomised, placebo-controlled, 7-period crossover study to evaluate the short-term effects on plasma cortisol levels of inhaled BUD (400, 800, 1600 microg twice daily) and FP (375, 750, 1000 microg twice daily) via pMDI in a group of healthy male volunteers."	( Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. Brown, K; Donnelly, R; Li, B; Minto, C; Seale, JP; Tattam, B, 2000)	0.57
"Both drugs had a rapid absorption half-life (BUD 10 min vs FP 11."	( Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. Brown, K; Donnelly, R; Li, B; Minto, C; Seale, JP; Tattam, B, 2000)	0.57
" Three observations may be of clinical relevance: (1) there is considerable intersubject variability in the rate of absorption of both drugs from the lung; (2) in some individuals there was a long t(1/2),z for BUD, resulting in higher and more sustained plasma drug levels in the 4-12 h postdose period than would be predicted from single-dose pharmacokinetic data; and (3) there is evidence of diurnal variation in FP pharmacokinetics, with higher-than-expected plasma drug concentrations in the morning compared with the evening."	( Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. Brown, K; Donnelly, R; Li, B; Minto, C; Seale, JP; Tattam, B, 2000)	0.57
" The 2 DPIs therefore have very similar pharmacokinetic profiles."	( Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma. Daley-Yates, PT; Falcoz, C; Harding, SM; Horton, J; Mackie, AE, 2000)	0.63
"To investigate the potential for systemic pharmacodynamic and pharmacokinetic interactions between inhaled salmeterol and fluticasone propionate when repeat doses of the two drugs are given in combination to healthy subjects."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.69
" The systemic pharmacodynamic effects of inhaled salmeterol were not affected by the co-administration of fluticasone propionate."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.7
"These results in healthy subjects indicate that there is no systemic pharmacodynamic or pharmacokinetic interaction between inhaled salmeterol and fluticasone propionate when given in combination."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.68
"The volume of distribution was found to be larger and the elimination half-life and mean absorption time longer for fluticasone than for budesonide."	( Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Edsbäcker, S; Källén, A; Löfdahl, CG; Thorsson, L, 2001)	0.78
"Budesonide and fluticasone differ in their pharmacokinetic properties in that although clearance is the same, the rate of uptake and elimination is slower for fluticasone."	( Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Edsbäcker, S; Källén, A; Löfdahl, CG; Thorsson, L, 2001)	0.93
"Direct comparisons of the pharmacokinetic (PK) and systemic pharmacodynamic (PD) properties of inhaled corticosteroids after single and multiple dosing in the same subjects are scarce."	( Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. Barth, J; Daley-Yates, PT; Derendorf, H; Dimova, H; Falcoz, C; Hochhaus, G; Krieg, M; Krishnaswami, S; Lawlor, C; Möllmann, AC; Möllmann, H; Stöckmann, R; Tang, Y; Wagner, M, 2001)	0.51
" Drug trough levels were determined on days 1, 5, 12, 13, and 14, and a full pharmacokinetic profile was established on day 14, and 24-hour serum cortisol profiles were assessed prior to treatment (i."	( Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. Derendorf, H; Hermann, R; Hochhaus, G; LaVallee, N; Locher, M; Siebert-Weigel, M, 2004)	0.32
"Reports characterizing the pharmacokinetics of inhaled fluticasone propionate (FP) using compartmental approaches have suggested that the absorption of FP into the systemic circulation is rapid with a half-life of approximately 10 min."	( Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Barth, J; Derendorf, H; Hochhaus, G; Krishnaswami, S; Möllmann, H, 2005)	0.83
" The profiles were fitted using one- and two-compartment pharmacokinetic models with first order absorption."	( Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Barth, J; Derendorf, H; Hochhaus, G; Krishnaswami, S; Möllmann, H, 2005)	0.58
"This manuscript describes the preparation, characterization, and pharmacokinetic studies for fluticasone and budesonide nanosuspensions in pulmonary delivery."	( Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. Chiang, PC; Pretzer, DK; Thurston, A; Yang, JZ; Young, AL, 2008)	2.01
" Pharmacokinetic results showed a greater initial absorption of salmeterol with DPI-C but greater continued absorption and a 40% greater AUC with DPI-A, which we attribute to slower but more extensive oral absorption because of the greater mass of swallowed large particles of salmeterol generated by DPI-A."	( Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011)	0.62
"Prediction of pharmacokinetic (PK) profile for inhaled drugs in humans provides valuable information to aid toxicology safety assessment, evaluate the potential for systemic accumulation on multiple dosing and enable an estimate for the clinical plasma assay requirements."	( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Harrison, A; Jones, RM, 2012)	0.38
" Until further evidence is provided it may be warranted to emphasize pharmacokinetic or pharmacodynamic assessments of drug delivery to the lung."	( Aerosol particle size does not predict pharmacokinetic determined lung dose in children. Bisgaard, H; Bønnelykke, K; Chawes, BL; Moore, AC; Vindfeld, S, 2013)	0.39
" Pharmacokinetics (area under concentration-versus-time curve [AUC], maximum plasma concentration [Cmax], time to Cmax [tmax], and elimination half-life [t½]), safety, and tolerability were assessed for each treatment."	( Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. Gillespie, M; Song, S; Steinfeld, J, )	0.45
" Geometric mean AUC0-t and Cmax for Fp MDPI 800 μg were 19% and 18% higher, respectively, compared with Fp DPI 1000 μg, and 47% and 82% higher, respectively, compared with Fp MDI 880 μg."	( Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. Gillespie, M; Song, S; Steinfeld, J, )	0.45
"There was no pharmacokinetic interaction when GSK961081 and FP were administered concurrently."	( Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers. Ambery, C; Norris, V; Riley, T, 2014)	0.62
" Highest concentrations in plasma following 12 mg administration occurred 1 day postdose and declined with a half-life of approximately 45 days."	( Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees. Dhollander, A; Getgood, A; Helliwell, J; Malone, A; Price, J, 2019)	0.78
"Approach 1 suggested PK profiles which agreed well with the published pharmacokinetic profiles."	( Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. Absar, M; Bhagwat, S; Chen, MJ; Delvadia, R; Hochhaus, G; Saluja, B; Schilling, U; Wei, X, 2017)	0.46
"The fate of orally inhaled drugs is determined by pulmonary pharmacokinetic processes such as particle deposition, pulmonary drug dissolution, and mucociliary clearance."	( A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs. Borghardt, JM; Hartung, N, 2020)	0.56
"Human pharmacokinetic studies of lung-targeted drugs are typically limited to measurements of systemic plasma concentrations, which provide no direct information on lung target-site concentrations."	( Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. Badorrek, P; Ellinghusen, BD; Eriksson, UG; Faulenbach, C; Fridén, M; Hohlfeld, JM; Holz, O; Lundqvist, AJ; Müller, M; Sadiq, MW; Stomilovic, S, 2021)	0.62
" Pharmacokinetic profiles were generated by combining data from multiple individuals, covering all sample timings."	( Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. Badorrek, P; Ellinghusen, BD; Eriksson, UG; Faulenbach, C; Fridén, M; Hohlfeld, JM; Holz, O; Lundqvist, AJ; Müller, M; Sadiq, MW; Stomilovic, S, 2021)	0.62
"Combining pharmacokinetic data derived from several individuals and techniques sampling different lung compartments enabled generation of pharmacokinetic profiles for evaluation of lung targeting after inhaled and oral drug delivery."	( Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation. Badorrek, P; Ellinghusen, BD; Eriksson, UG; Faulenbach, C; Fridén, M; Hohlfeld, JM; Holz, O; Lundqvist, AJ; Müller, M; Sadiq, MW; Stomilovic, S, 2021)	0.62
" Systemic disposition parameter estimates were obtained from published pharmacokinetic data after intravenous dosing to improve robustness."	( Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics. Amini, E; Bulitta, JB; Chen, MJ; Drescher, SK; Hochhaus, G; Jiao, Y; Kurumaddali, A; Shao, J, 2023)	1.17

Excerpt	Reference	Relevance
"Beneficial effects of treatment of viral croup with inhaled corticosteroids and administered with a jet-nebulizer have been reported in recent years."	( Effects of inhaled fluticasone propionate administered with metered dose inhaler and spacer in mild to moderate croup: a negative preliminary report. Roorda, RJ; Walhof, CM, 1998)	0.63
"To observe the efficacy of Fluticasone inhalation combined with Jinacon (JNC) orally taken in treating patients of chronic asthma (CA) of moderate degree."	( [Clinical observation on treatment of asthma in moderate degree with fluticasone inhalation combined with jinacon]. Li, MH; Liu, YH; Yang, BY, 2001)	0.84
"Seventy-two CA patients were divided into three groups randomly and treated with Fluticasone inhalation combined with JNC, Fluticasone inhalation alone and JNC alone respectively for 4 weeks."	( [Clinical observation on treatment of asthma in moderate degree with fluticasone inhalation combined with jinacon]. Li, MH; Liu, YH; Yang, BY, 2001)	0.77
"Fluticasone inhalation combined with JNC orally taken is an effective therapy in treating patients of chronic asthma of moderate degree."	( [Clinical observation on treatment of asthma in moderate degree with fluticasone inhalation combined with jinacon]. Li, MH; Liu, YH; Yang, BY, 2001)	1.99
"To observe the effect of Fluticasone inhalation combined with Xiaoqinglong decoction (XQLD) on pulmonary function and serum interleukin-16 (IL-16) level in asthma patients."	( [Effect of fluticasone inhalation combined with xiaoqinglong decoction on pulmonary function and serum interleukin-16 level in asthma patients]. Shi, Q; Wang, L; Zhang, X, 2003)	1.01
" The treated group was treated with Fluticasone inhalation combined with XQLD, Fluticasone group treated with Fluticasone inhalation, and XQLD group treated with XQLD respectively."	( [Effect of fluticasone inhalation combined with xiaoqinglong decoction on pulmonary function and serum interleukin-16 level in asthma patients]. Shi, Q; Wang, L; Zhang, X, 2003)	0.98
"The effects of Fluticasone inhalation combined with XQLD on pulmonary function and serum IL-16 levels were superior to those of Fluticasone inhalation and XQLD alone in asthma patients."	( [Effect of fluticasone inhalation combined with xiaoqinglong decoction on pulmonary function and serum interleukin-16 level in asthma patients]. Shi, Q; Wang, L; Zhang, X, 2003)	1.06
" Whether inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown."	( Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. Cowie, RL; FitzGerald, M; Ford, G; Mainra, RR; Man, SF; Marciniuk, DD; Melenka, LS; Ramesh, W; Rousseau, R; Sin, DD; Wilde, E; Williams, D; Wong, E; York, E, 2006)	0.71
"If inhaled corticosteroids by themselves or in combination with a long-acting beta2-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease."	( Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. Cowie, RL; FitzGerald, M; Ford, G; Mainra, RR; Man, SF; Marciniuk, DD; Melenka, LS; Ramesh, W; Rousseau, R; Sin, DD; Wilde, E; Williams, D; Wong, E; York, E, 2006)	0.71
" The GLISTEN trial compared the efficacy of two long-acting anti-muscarinic antagonists (LAMA), when combined with an inhaled corticosteroid (ICS) and a long-acting β2 agonist (LABA)."	( Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ, 2015)	0.63
"This randomised, blinded, placebo-controlled trial in moderate/severe COPD patients compared once-daily glycopyrronium (GLY) 50 µg, once-daily tiotropium (TIO) 18 µg or placebo (PLA), when combined with salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily."	( Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ, 2015)	0.81
"To evaluate and contrast the therapeutic effect and safety of fluticasone aerosol combined with theophylline tablets in patients with moderate to severe asthma, compared with salmeterol/fluticasone propionate aerosol."	( Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)	0.67
"After a screening period, patients meeting the inclusion criteria were randomly assigned to the experiment group (fluticasone aerosol combined with theophylline tablets) or the control group (salmeterol/fluticasone aerosol combined with placebo tablets) for 12 weeks of treatment."	( Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)	0.64
"There was no significant difference in therapeutic effect and safety between the 2 groups in treating patients with moderate to severe persistent asthma, which suggests that fluticasone aerosol combined with theophylline tablets is worth considering for use in primary hospitals or for low-income populations."	( Intervention Studies of Inhaled Corticosteroids Combined with Long-acting Theophylline or Long-acting β Chen, P; Dai, A; Kong, L; Shang, S; Wang, Y, 2016)	0.63
" Clinical practice has shown that montelukast sodium combined with fluticasone in the treatment of adult BA can improve clinical efficacy and reduce adverse reactions."	( Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis. Han, H; Liu, Q; Liu, X; Luo, H, 2020)	1.04
"The Chinese databases (CNKI, VIP, Wanfang, Chinese Biomedical Database) and English databases (PubMed, the Cochrane Library, Embase, Web of Science) were searched by computer, for the randomized controlled clinical studies of montelukast sodium combined with fluticasone in the treatment of adult BA from establishment of database to October 2020."	( Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis. Han, H; Liu, Q; Liu, X; Luo, H, 2020)	0.98
"This study assessed the efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult BA through total effective rate, pulmonary function (FEV1, FVC, PEF, FEV1/FVC), and adverse reactions."	( Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis. Han, H; Liu, Q; Liu, X; Luo, H, 2020)	1.03
"This study will provide reliable evidence-based evidence for the clinical application of montelukast sodium combined with fluticasone in the treatment of adult BA."	( Efficacy and safety of montelukast sodium combined with fluticasone in the treatment of adult bronchial asthma: A protocol for systematic review and meta-analysis. Han, H; Liu, Q; Liu, X; Luo, H, 2020)	1.01
" The aim of this study is to evaluate the effectiveness of acupuncture therapy combined with fluticasone propionate nasal spray in comparison to fluticasone propionate nasal spray alone in the relief of symptoms for PAR."	( Effect of acupuncture therapy combined with fluticasone propionate in the treatment of persistent allergic rhinitis: study protocol for a randomized controlled trial. Fan, Q; Feng, Y; Fu, W; Hou, Y; Li, B; Nie, W; Shi, L; Sun, Z; Wu, F; Zhang, W; Zhao, H; Zhou, Z, 2022)	1.2
" The treatment group will receive the nasal fluticasone propionate combined with acupuncture, and the control group will receive fluticasone propionate nasal spray alone for 6 weeks."	( Effect of acupuncture therapy combined with fluticasone propionate in the treatment of persistent allergic rhinitis: study protocol for a randomized controlled trial. Fan, Q; Feng, Y; Fu, W; Hou, Y; Li, B; Nie, W; Shi, L; Sun, Z; Wu, F; Zhang, W; Zhao, H; Zhou, Z, 2022)	1.24
"This clinical trial will be able to provide high level evidence on the acupuncture therapy combined with fluticasone propionate nasal spray in the treatment of PAR."	( Effect of acupuncture therapy combined with fluticasone propionate in the treatment of persistent allergic rhinitis: study protocol for a randomized controlled trial. Fan, Q; Feng, Y; Fu, W; Hou, Y; Li, B; Nie, W; Shi, L; Sun, Z; Wu, F; Zhang, W; Zhao, H; Zhou, Z, 2022)	1.2
"To observe the clinical efficacy of self-made Lifei Dingchuan decoction combined with western medicine in the treatment of cough variant asthma (phlegm-heat accumulation in the lung syndrome)."	( Study on the Effect of Self-Made Lifei Dingchuan Decoction Combined with Western Medicine on Cough Variant Asthma. Huang, Z; Jian, X; Li, J; Li, K; Liang, B, 2022)	0.72
" The study was aimed to investigate the clinical efficacy of fluticasone propionate aerosol combined with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (ACEI/ARB) in the treatment of IgAN."	( The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. Sun, L; Wang, Z; Zhang, X; Zi, X, 2023)	1.46
" The patients of the supportive care plus fluticasone group were treated with fluticasone propionate aerosol (250 ?g Bid) combined with ACEI/ARB, while the supportive care group was merely treated with ACEI/ARB."	( The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. Sun, L; Wang, Z; Zhang, X; Zi, X, 2023)	1.48
"Fluticasone propionate aerosol combined with ACEI/ARB can reduce the level of proteinuria in thetreatment of IgAN, and has no significant effects on renal function."	( The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy. Sun, L; Wang, Z; Zhang, X; Zi, X, 2023)	2.66

Excerpt	Reference	Relevance
"Morphometric measurements have been performed on small intestinal biopsy specimens from patients with untreated coeliac disease before and after six weeks oral treatment with a steroid of low systemic bioavailability (fluticasone propionate)."	( Morphometric studies in duodenal biopsies from patients with coeliac disease: the effect of the steroid fluticasone propionate. Record, CO; Zaitoun, A, 1991)	0.68
" Oral corticosteroids have been used for patients who seem to be resistant to gluten withdrawal but preparations with low systemic bioavailability might be preferable."	( A pilot study of fluticasone propionate in untreated coeliac disease. al Mardini, H; Gillespie, S; Laker, M; Mitchison, HC; Record, CO; Zaitoun, A, 1991)	0.62
"Fluticasone propionate, a topically active corticosteroid of low systemic bioavailability after oral administration, has been used in a pilot study for the treatment of mild and moderately active Crohn's disease."	( Fluticasone propionate in Crohn's disease. de Kaski, MC; Hodgson, HJ; Lavender, JP; Peters, AM, 1991)	3.17
" On this basis, the expected extraction ratio would approach unity and oral systemic bioavailability would approach zero."	( The human pharmacology of fluticasone propionate. Harding, SM, 1990)	0.58
" Whether an improved tolerability profile compared with other corticosteroids is a major clinical benefit of the extremely low oral bioavailability of inhaled fluticasone propionate requires confirmation."	( Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Faulds, D; Holliday, SM; Sorkin, EM, 1994)	0.92
" A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects."	( A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Allam, C; Grove, A; Jackson, CM; Lipworth, BJ; McFarlane, LC; McPhate, G, 1994)	0.52
" It's high topical potency and low systemic bioavailability make it suitable for use in asthmatic children."	( A placebo controlled trial of fluticasone propionate in asthmatic children. Crescenzi, K; Havnen, J; MacKenzie, CA; Tabachnik, E; Taylor, M; Weinberg, EG, 1993)	0.57
"Fluticasone propionate, an inhaled corticosteroid with negligible systemic bioavailability via the oral route, is efficacious in the treatment of asthma when administered via metered-dose inhaler."	( Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Goldstein, MF; Hamedani, AG; Kellerman, DJ; Noonan, MJ; Pearlman, DS; Schaberg, A; Tashkin, DP, 1997)	2
"To investigate effects on adrenal function of fluticasone, a recently released inhaled steroid preparation with lower systemic bioavailability than beclomethasone dipropionate."	( Adrenal function and high dose inhaled corticosteroids for asthma. Conway, E; Honour, JW; Milner, AD; Yiallouros, PK, 1997)	0.56
" This, together with an estimated mean absorption time of nearly 5 h and a known oral bioavailability of less than 1%, indicates prolonged residence at and slow absorption from the lungs."	( Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Barth, J; Derendorf, H; Falcoz, C; Hochhaus, G; Krieg, M; Meibohm, B; Möllmann, H; Stöckmann, R; Wagner, M; Weisser, H, 1998)	0.55
"Fluticasone propionate is a glucocorticoid with negligible oral bioavailability and very low intranasal bioavailability that is used as an intranasal spray for the treatment of rhinitis."	( Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. Dockhorn, RJ; Field, EA; Findlay, SR; Korenblat, PE; Kral, KM; Vargas, R, 1998)	2.15
"To compare the systemic bioavailability (assessed by cortisol suppression) of high-dose budesonide when given by four inhaler devices and orally."	( Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Kane, J; Makker, H; McDowell, P; O'Driscoll, BR; Wales, D, 1999)	0.3
" Fluticasone propionate is an inhaled glucocorticoid with little systemic bioavailability via the oral route and infrequent association with systemic adverse effects at the recommended dosage."	( Adrenal suppression secondary to inhaled fluticasone propionate. Laoprasert, N; Sachs, MI; Taylor, AV; Zimmerman, D, 1999)	1.48
"Our findings suggest that the degree of airway obstruction affects the systemic bioavailability of FP."	( Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Berar-Yanay, N; Davidovich, A; Magadle, R; Weiner, P, 1999)	0.54
"The use of a large volume spacer with FP by pMDI results in a twofold increase in the systemic bioavailability as assessed by sensitive measures of adrenal suppression."	( Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler. Coutie, WJ; Dempsey, OJ; Lipworth, BJ; Wilson, AM, 1999)	0.53
"The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant."	( Differences in lung bioavailability between different propellants for fluticasone propionate. Lipworth, BJ; Orr, LC; Sims, EJ; Wilson, AM, 1999)	0.79
" However, newer INS such as fluticasone propionate (FP) and mometasone furoate, which have substantially reduced bioavailability via gastrointestinal absorption, are unlikely to do so."	( Do intranasal corticosteroids affect childhood growth? Allen, DB, 2000)	0.6
" Consistent with previous reports of FP's higher volume of distribution (V) and lower systemic bioavailability (F), the V/F ratio was lower for BUD than FP (498 l vs 8100 l)."	( Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. Brown, K; Donnelly, R; Li, B; Minto, C; Seale, JP; Tattam, B, 2000)	0.57
" Three observations may be of clinical relevance: (1) there is considerable intersubject variability in the rate of absorption of both drugs from the lung; (2) in some individuals there was a long t(1/2),z for BUD, resulting in higher and more sustained plasma drug levels in the 4-12 h postdose period than would be predicted from single-dose pharmacokinetic data; and (3) there is evidence of diurnal variation in FP pharmacokinetics, with higher-than-expected plasma drug concentrations in the morning compared with the evening."	( Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. Brown, K; Donnelly, R; Li, B; Minto, C; Seale, JP; Tattam, B, 2000)	0.57
"001), and systemic bioavailability (10."	( Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Brown, R; Brutsche, IC; Brutsche, MH; Custovic, A; Daley-Yates, PT; Langley, SJ; Masterson, CM; Munawar, M; Woodcock, A, 2000)	0.55
" Systemic bioavailability of INSs, by way of nasal and intestinal absorption, can be substantial; but current INSs vary significantly in their degree of first-pass hepatic inactivation and clearance from the body of the swallowed drug."	( Systemic effects of intranasal steroids: an endocrinologist's perspective. Allen, DB, 2000)	0.31
" The bioavailability of FP after inhalation represents absorption of the drug from the lungs, since the bioavailability of the swallowed portion of the inhaled dose is negligible."	( Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. Brindley, C; Bye, A; Falcoz, C; Mackie, AE, 2000)	0.57
"When corrected for the bioavailability (of FP) achieved by each inhalation device, the rate of absorption of FP over the first 2 hours was rapid from all devices."	( Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered-dose inhaler in healthy volunteers. Brindley, C; Bye, A; Falcoz, C; Mackie, AE, 2000)	0.57
"54 microg/L for CFC MDI and HFA MDI, respectively); bioavailability values of inhaled FP from the 2 MDIs were also similar (geometric mean values: 26."	( Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Bye, A; Daley-Yates, PT; Falcoz, C; Mackie, AE; McDowall, JE; Ventresca, P, 2000)	0.63
"The bioavailability values of FP after inhalation via a CFC MDI and an HFA MDI are similar."	( Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Bye, A; Daley-Yates, PT; Falcoz, C; Mackie, AE; McDowall, JE; Ventresca, P, 2000)	0.63
"The aim of these studies was to determine the absolute bioavailability in healthy volunteers of inhaled fluticasone propionate (FP) administered as a single dose via the Diskhaler and Diskus powder devices, and the pharmacokinetics of inhaled FP after repeated administration via the Diskhaler device."	( Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Bye, A; Daley-Yates, PT; Falcoz, C; Mackie, AE; McDowall, JE; Ventresca, P, 2000)	0.84
" Mean bioavailability values via the Diskhaler and Diskus were 11."	( Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Bye, A; Daley-Yates, PT; Falcoz, C; Mackie, AE; McDowall, JE; Ventresca, P, 2000)	0.63
"The pharmacokinetics of FP administered by the 2 powder devices are similar in healthy volunteers, although systemic bioavailability was greater with the Diskus."	( Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Bye, A; Daley-Yates, PT; Falcoz, C; Mackie, AE; McDowall, JE; Ventresca, P, 2000)	0.63
"The aim of this study was to determine the absolute oral bioavailability of fluticasone propionate (FP) in healthy volunteers."	( Bioavailability of orally administered micronised fluticasone propionate. Bye, A; Daley-Yates, PT; Falcoz, C; McDowall, JE; Oliver, R; Ventresca, P, 2000)	0.79
" At a dose of 10 mg twice daily the absolute oral bioavailability of the drug was <1% when a liquid chromatography-mass spectrometry assay was used to assess plasma concentrations."	( Bioavailability of orally administered micronised fluticasone propionate. Bye, A; Daley-Yates, PT; Falcoz, C; McDowall, JE; Oliver, R; Ventresca, P, 2000)	0.56
"To measure and compare the systemic bioavailability of fluticasone propionate aqueous nasal spray and a new nasal drop formulation, using a sensitive analytical method and high dose regimen."	( Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Baker, RC; Daley-Yates, PT, 2001)	0.85
" The bioavailability from the nasal drops was approximately eight times lower than from the nasal spray."	( Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Baker, RC; Daley-Yates, PT, 2001)	0.6
" We therefore decided to compare systemic bioavailability of HFA-beclomethasone dipropionate (BDP) vs HFA-fluticasone propionate (FP)."	( Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Fowler, SJ; Lipworth, BJ; Orr, LC; Sims, EJ; Wilson, AM, 2001)	0.75
" This suggests that the greater glucocorticoid potency of HFA-FP may be offset by the greater lung bioavailability of HFA-BDP."	( Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Fowler, SJ; Lipworth, BJ; Orr, LC; Sims, EJ; Wilson, AM, 2001)	0.54
" Previous studies indicated that fluticasone propionate (FP) had low bioavailability and high local potency."	( A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma. Chuang, SL; Hsieh, KS; Huang, CF; Huang, YF; Huang, YY; Liu, CC; Nong, BR, 2001)	0.88
"This article reviews available data on the comparative structure-activity relationships, chemistry, pharmacology, pharmacokinetics, and systemic bioavailability of fluticasone propionate and mometasone furoate to assess whether claims of differences in the absolute systemic bioavailability of the 2 compounds are supported by the published literature."	( A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Crim, C; Daley-Yates, PT; Pierre, LN, 2001)	0.75
" A systematic review was conducted of the identified literature pertaining to the molecular structure, topical potency, lipophilicity, pharmacokinetics, and bioavailability of the 2 agents."	( A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Crim, C; Daley-Yates, PT; Pierre, LN, 2001)	0.55
" When administered intranasally, mometasone furoate is reported to have comparable relative systemic bioavailability to that of fluticasone propionate (mean plasma area under the curve, 123 pmol x h/L vs 112 pmol x h/L, respectively)."	( A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Crim, C; Daley-Yates, PT; Pierre, LN, 2001)	0.76
"The goal of this study was to establish a reliable method to evaluate systemic bioavailability and to determine equisystemic effects (microgram dose producing equal systemic cortisol suppression) of inhaled corticosteroids (ICS)."	( Systemic effect comparisons of six inhaled corticosteroid preparations. Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, CA; Szefler, SJ, 2002)	0.31
"To determine if differences between holding chambers in previous in vitro aerosol studies would agree with the bioavailability of inhaled fluticasone propionate between the same holding chambers in children with asthma."	( Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. Asmus, MJ; Chesrown, S; Hendeles, L; Hochhaus, G; Liang, J, 2002)	0.83
"Differences in inhaled fluticasone bioavailability between these holding chambers in children with asthma corroborate differences reported in earlier in vitro aerosol studies."	( Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. Asmus, MJ; Chesrown, S; Hendeles, L; Hochhaus, G; Liang, J, 2002)	0.94
" UCCRs can be used to monitor the bioavailability of inhaled steroids in young infants."	( Estimation of the dose of fluticasone propionate inhaled by infants after bronchiolitis: Effect on urinary cortisol excretion. Davies, T; O'Callaghan, C; Wong, J, 2002)	0.61
" Hence, the lung bioavailability will determine the overall systemic absorption and the systemic bioactivity."	( A novel method for assessing dissolution of aerosol inhaler products. Davies, NM; Feddah, MR, 2003)	0.32
" This fear may be reduced with newer agents with lower oral bioavailability if their theoretical advantage of fewer systemic adverse effects than the standard treatment of inhaled beclometasone is realized in practice."	( Fluticasone and beclometasone: what are their effects on children's growth? Griffiths, P; Saini, K, 2003)	1.76
" Therefore, measuring airway blood flow may be a useful, site-specific parameter to assess the tissue bioavailability and vasoconstrictive efficacy of inhaled glucocorticosteroids."	( Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Danta, I; Duncan, RC; Mendes, ES; Pereira, A; Wanner, A, 2003)	0.32
" We have developed and validated a bioassay which can measure glucocorticoid bioavailability directly from small amounts of human serum to help elucidate underlying mechanisms."	( A novel specific bioassay for the determination of glucocorticoid bioavailability in human serum. Hendriks-Stegeman, BI; Jansen, M; van Buul-Offers, SC; van den Brink, CE; van der Burg, B; van der Saag, PT; Vermeer, H, 2003)	0.32
" Within ICS, fluticasone is endowed of a potent antiinflammatory activity, due to its high affinity for the the glucocorticoid receptor (allowing the use of 50% of the dose of other ICS) and of a negligible oral bioavailability (<1%), indicating a low potential for systemic exposure."	( [Fluticasone propionate in the treatment of airway inflammations (asthma and rhinitis)]. Donati, G; Magnoni, MS; Solidoro, P, 2003)	1.6
"To investigate the effect of the nasal corticosteroid fluticasone propionate on the bioavailability and pharmacokinetics of single-dose intranasal hydromorphone hydrochloride in patients with allergic rhinitis."	( Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Archer, SM; Davis, GA; McNamara, PJ; Rudy, AC; Wermeling, DP, 2004)	0.97
" Mean (% coefficient of variation) absolute bioavailability of intranasal hydromorphone was 51."	( Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Archer, SM; Davis, GA; McNamara, PJ; Rudy, AC; Wermeling, DP, 2004)	0.73
"FP and MF have similar and very low systemic bioavailability when administered intranasally using a high-dose regimen."	( Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Andrews, SM; Callejas, S; Daley-Yates, PT; Kunka, RL; Ng, C; Yin, Y, 2004)	0.65
" The systemic bioavailability of MF is claimed to be negligible, leading to a minimal potential for systemic adverse effects."	( Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Fardon, TC; Haggart, K; Lee, DK; Lipworth, BJ; McFarlane, LC, 2004)	0.57
" The bioavailability of the drug was determined in terms of the suppression of the endogenous cortisol concentrations in the horses during the period of treatment."	( Biological availability of inhaled fluticasone propionate in horses. Dijkstra, AV; Fink-Gremmels, J; Laan, TT; van Nieuwstadt, RA; Westermann, CM, 2004)	0.6
" Oral bioavailability can be neglected because of almost total inactivation in liver during first pass."	( [Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part I. Mechanisms of actions and clinical effectiveness of treatment in children with asthma]. Bartkowiak-Emeryk, M; Breborowicz, A; Emeryk, A; Kulus, M; Kurzawa, R; Lis, G; Mazurek, H; Niedziela, M, 2004)	0.61
" Bioavailability of steroid depends on oral absorption and absorption from respiratory system."	( [Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part II. Safety aspects of therapy with fluticasone propionate in asthmatic children]. Bartkowiak-Emeryk, M; Breborowicz, A; Emeryk, A; Kulus, M; Kurzawa, R; Lis, G; Mazurek, H; Niedziela, M, 2004)	0.61
" Subjects who had blood drawn for bioavailability showed no correlation between FP levels and end-treatment post-CST cortisols."	( Topical fluticasone propionate lotion does not cause HPA axis suppression. Allen, DB; Friedlander, SF; Hebert, AA, 2006)	0.77
" The bioavailability of these products is essential in order to determine the incidence of side effects."	( Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. Rizzo, MC; Solé, D, 2006)	0.33
"To determine whether an antistatic valved holding chamber/mask improves lung bioavailability of hydrofluoroalkane (HFA) fluticasone in young children."	( Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask. Chesrown, S; Hendeles, L; Hochhaus, G; Khan, Y; Shuster, JJ; Spencer, T; Tang, Y, 2006)	0.81
"In general, drugs are well absorbed from the lung, and the pulmonary absorption of therapeutic protein and peptide drugs, which are poorly absorbed from the gastrointestinal tract, was observed."	( [Control of pulmonary absorption of drugs by various pharmaceutical excipients]. Yamada, K, 2007)	0.34
" The systemic bioavailability of MF has been claimed to be minimal (1%)."	( Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Fardon, TC; Haggart, K; Hochhaus, G; Lee, DK; Lipworth, BJ; McFarlane, LC; Tayab, ZR, 2007)	0.56
" MF has comparable bioavailability to FP based on the steady-state concentrations observed for the different doses."	( Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Fardon, TC; Haggart, K; Hochhaus, G; Lee, DK; Lipworth, BJ; McFarlane, LC; Tayab, ZR, 2007)	0.56
"The objectives of this study were to estimate the absolute bioavailability of fluticasone furoate nasal spray and to describe the intranasal (IN) and IV pharmacokinetics of fluticasone furoate in healthy subjects."	( Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Allen, A; Down, G; Newland, A; Reynard, K; Rousell, V; Salmon, E; Scott, R, 2007)	0.84
" Sample-size sensitivity was assessed by estimating the 90% CI for the absolute bioavailability of IN fluticasone furoate, based on different estimated bioavailabilities and within-subject SDs."	( Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Allen, A; Down, G; Newland, A; Reynard, K; Rousell, V; Salmon, E; Scott, R, 2007)	0.82
"The geometric mean of the absolute bioavailability of fluticasone furoate 880 microg IN qSh for 10 doses in these healthy subjects was low--0."	( Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Allen, A; Down, G; Newland, A; Reynard, K; Rousell, V; Salmon, E; Scott, R, 2007)	0.86
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" The systemic bioavailability of inhaled fluticasone propionate is primarily dependent on delivery by the pulmonary route and hence the performance of antistatic spacers can be evaluated using adrenal suppression as a sensitive surrogate for relative bioavailability to the lung after an inhalation."	( In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. Hopkinson, P; Lipworth, BJ; McFarlane, L; Menzies, D; Nair, A, 2009)	0.86
"This study compares the relative bioavailability to the lung of inhaled fluticasone delivered via conventional pressurized metered dose inhalers (pMDI) and three antistatic spacers (plastic Zerostat-V, plastic Aerochamber Max, and metal Nebuchamber) in patients with asthma."	( In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. Hopkinson, P; Lipworth, BJ; McFarlane, L; Menzies, D; Nair, A, 2009)	0.82
"The systemic bioavailability of inhaled fluticasone propionate (FP) depends primarily on lung absorption and can be quantified by measuring suppression of overnight and early morning urinary cortisol/creatinine (OUCC and EMUCC, respectively)."	( In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. Hopkinson, P; Lipworth, BJ; McFarlane, L; Menzies, D; Nair, A, 2009)	0.86
"All three antistatic spacers significantly increased the relative systemic bioavailability of HFA-FP compared with the standard pMDI."	( In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. Hopkinson, P; Lipworth, BJ; McFarlane, L; Menzies, D; Nair, A, 2009)	0.59
" The relative bioavailability to the lung of inhaled fluticasone and salmeterol combination is primarily dependent on respirable dose delivery and can be reliably quantified using adrenal suppression and early fall in serum potassium (marker of systemic beta-2 adrenoreceptor response) as surrogate markers for delivered lung dose."	( A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Clearie, K; Lipworth, BJ; McFarlane, L; Meldrum, K; Menzies, D; Nair, A, 2009)	0.82
"To compare the in vivo relative bioavailability to the lung of Hydrofluoroalkane(HFA) Seretide delivered via Synchro-Breathe (SB); an optimally prepared 750 ml large volume plastic spacer, Volumatic (VM); and conventional Evohaler pMDI (EH)."	( A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Clearie, K; Lipworth, BJ; McFarlane, L; Meldrum, K; Menzies, D; Nair, A, 2009)	0.57
"The breath-actuated Synchro-Breathe device was comparable to an optimally prepared Volumatic spacer, and resulted in commensurate improvement in relative lung bioavailability for both fluticasone and salmeterol moieties compared to pMDI."	( A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. Clearie, K; Lipworth, BJ; McFarlane, L; Meldrum, K; Menzies, D; Nair, A, 2009)	0.76
" Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimise systemic exposure and reduce systemically driven adverse events."	( Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma. Ballard, SA; Chunn, S; Dybowski, JA; Fulton, CK; Glossop, PA; Guillabert, E; Hewson, CA; Jones, RM; Lamb, DJ; Millan, DS; Napier, CM; Payne-Cook, TA; Renery, ER; Selby, MD; Tutt, MF; Yeadon, M, 2011)	0.37
" Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events."	( Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Bunnage, ME; Burrows, JL; Butcher, KJ; Dodd, PG; Evans, TJ; Fairman, DA; Hughes, SJ; Kilty, IC; Lemaitre, A; Lewthwaite, RA; Mahnke, A; Mathias, JP; Millan, DS; Philip, J; Phillips, C; Smith, RT; Stefaniak, MH; Yeadon, M, 2011)	0.37
"We determined lung bioavailability of a fluticasone propionate (FP) pressurised metred-dose inhaler (Flovent HFA; GlaxoSmithKline, Research Triangle Park, NC, USA) administered via AeroChamber Plus (Monaghan Medical, Plattsburgh, NY, USA) with Facemask and Babyhaler (GlaxoSmithKline) valved holding chambers (VHCs) using a population pharmacokinetic approach."	( Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. Blake, K; Hendeles, L; Kunka, RL; Mehta, R; Spencer, T, 2012)	0.94
" Administering as a dry powder formulation slowed the rat lung absorption rate of the least soluble compound (fluticasone propionate), impacting the prediction of C(max) and MRT."	( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Harrison, A; Jones, RM, 2012)	0.59
" • For new combination medicinal products such as MP29-02, the determination of possible pharmacokinetic (PK) drug-drug interactions between both active components and formulation-based bioavailability alterations is essential."	( Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012)	0.63
"• This paper provides for the first time information on potential drug-drug interactions, AZE and FP bioavailability and disposition characteristics of each component administered by the novel nasal spray formulation MP29-02."	( Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012)	0.63
" Azelastine bioavailability was similar for MP29-02 and Astelin®."	( Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Bousquet, J; Derendorf, H; Hermann, R; Mascher, H; Maus, J; Munzel, U; Petzold, U, 2012)	0.63
" The bioavailability of both inhaled FF and FP represents absorption from the lung as the oral bioavailability from the swallowed portion of the inhaled dose is negligible (<1."	( Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Allen, A; Bareille, PJ; Rousell, VM, 2013)	1.83
" Pharmacokinetic studies have revealed no drug-drug interactions but a discrete increase in bioavailability of fluticasone propionate which was considered clinically unimportant."	( New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. Wolthers, OD, 2013)	0.6
" Fluticasone propionate may have higher potency and lower systemic bioavailability than budesonide, but there is little data on its effects as an intranasal irrigation on the hypothalamic-pituitary-adrenal axis or on ocular findings."	( The effect of intranasal fluticasone propionate irrigations on salivary cortisol, intraocular pressure, and posterior subcapsular cataracts in postsurgical chronic rhinosinusitis patients. Citardi, MJ; Fakhri, S; Farhood, Z; Feldman, RM; Luong, A; Man, LX; Orlander, PR, 2013)	1.6
"Both approaches derived the total lung doses and the central to peripheral lung deposition ratios from clinically relevant cascade impactor studies, but differed in the way the pulmonary absorption rate was derived."	( Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. Absar, M; Bhagwat, S; Chen, MJ; Delvadia, R; Hochhaus, G; Saluja, B; Schilling, U; Wei, X, 2017)	0.46
" Similarly, within approach 2, input parameters for the pulmonary absorption rate constant derived from dissolution rate experiments were able to reasonably predict the pharmacokinetic profiles published in literature."	( Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers. Absar, M; Bhagwat, S; Chen, MJ; Delvadia, R; Hochhaus, G; Saluja, B; Schilling, U; Wei, X, 2017)	0.46
" There was a delayed onset of symptoms in many cases, most likely due to the relatively lower systemic bioavailability of intranasal fluticasone."	( Prescribing intranasal steroids in HIV-positive patients: systematic review of the literature. McGilligan, JA; Mohammed, H; Richardson, D; Robinson, M; Seymour, N; Williams, D, 2021)	0.83
"Dissolution rate impacts the absorption rate of poorly soluble inhaled drugs."	( Characterization of Membrane-Type Dissolution Profiles of Clinically Available Orally Inhaled Products Using a Weibull Fit and a Mechanistic Model. Franek, F; Fransson, R; Frenning, G; Tehler, U; van der Zwaan, I, 2022)	0.72
"Study 1: For intravenous MF and FP, respectively: absolute bioavailability was 11."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.97
"Single inhaled and intravenous doses of MF and FP (400 μg) resulted in similar bioavailability and reductions in serum cortisol."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.97

Excerpt	Relevance	Reference
" Consistent with its minimal systemic availability, intranasal fluticasone propionate in a dosage of up to 4 mg/day does not cause adrenal suppression."	( Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Bryson, HM; Faulds, D, 1992)	0.91
" Overall, the administration of fluticasone propionate once daily in the morning was as effective as the twice daily dosage regimen, and either regimen was more effective than placebo."	( Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Bronsky, EA; Fireman, P; Grossman, J; LaForce, CF; Lemanske, RF; Nathan, RA; Pearlman, DS; Ratner, PH; Rogenes, PR, 1991)	0.95
" This was confirmed by the absence of unchanged drug in the plasma up to 6 h after dosing with 1 mg or 16 mg of drug."	( The human pharmacology of fluticasone propionate. Harding, SM, 1990)	0.58
" In clinical studies, inhaled fluticasone propionate was at least as effective as beclomethasone dipropionate or budesonide when administered at half the dosage of the comparators in patients with mild to moderate or severe asthma."	( Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Faulds, D; Holliday, SM; Sorkin, EM, 1994)	1.01
" Their dosage of oral prednisone was adjusted weekly according to predetermined criteria."	( Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Boltansky, H; Busse, WW; Chervinsky, P; de Boisblanc, BP; Kellerman, D; Noonan, M; Pearlman, D; Pinnas, J; Repsher, L; Weisberg, SC, 1995)	1.73
" Reduced lymphocyte and mast cell activity was found with high dose FP even in those receiving low dose maintenance BDP prior to the study, suggesting a dose-response effect of inhaled corticosteroids on airway inflammation."	( Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Booth, H; Gardiner, PV; Harkawat, R; Richmond, I; Walters, EH; Ward, C, 1995)	0.59
" Used in conventional dosage inhaled corticosteroids are very safe; in high dosage systemic effects are more evident."	( Fluticasone propionate for asthma prophylaxis. , 1994)	1.73
" A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects."	( A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Allam, C; Grove, A; Jackson, CM; Lipworth, BJ; McFarlane, LC; McPhate, G, 1994)	0.52
" No significant differences for individual symptoms were found between the two fluticasone propionate groups except that those taking the twice daily dosage used less antihistamine (P < ."	( Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Chodirker, WB; Dolovich, J; Drouin, MA; Hargreave, FE; Hebert, J; Knight, A; Small, P; Wong, AG; Yang, WH, 1994)	0.84
" We evaluated the efficacy, onset of action, and safety of two dosing regimens of the new corticosteroid fluticasone propionate compared with that of beclomethasone dipropionate in patients with moderate to severe seasonal allergic rhinitis."	( Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. Dockhorn, RJ; Field, EA; Findlay, SR; LaForce, CF; Meltzer, EO; Nathan, RA; Rogenes, PR; Stricker, W; Weakley, S, 1994)	1.95
" For the dosage tested, we found no depression of adrenal function, neither in circadian cortisol secretion nor in hCRH-stimulation-test."	( [Adrenal cortex function in children with bronchial asthma in fluticasone therapy]. Büttner, P; Hoffmann-Streb, A; L'Allemand, D; Niggemann, B; Wahn, U, 1993)	0.53
" Both fluticasone propionate dosages were well tolerated and neither dosage appears to interfere with the hypothalamic-pituitary-adrenal axis in children."	( Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Banov, C; Bronsky, EA; Findlay, SR; Grossman, J; Kral, KM; Mendelson, L; Nathan, RA; Pearlman, D; Ratner, PH; Winder, JA, 1993)	2.21
" The complete absence of suppression of the corticoadrenal axis by fluticasone propionate was encouraging, however, and a higher dosage schedule should be assessed."	( Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Burke, DA; Giaffer, MH; Hawkey, CJ; Hawthorne, AB; Holdsworth, CD; Keech, ML; Record, CO, 1993)	0.82
"In order to examine fluticasone propionate's mechanism of inhibiting nasal allergic symptoms, topical dosing of FP to patients with Japanese cedar pollinosis was started before the pollen scattering season, and the kinetics of basophilic cells and eosinophils which infiltrated into the surface of nasal mucous membrane were observed."	( [The effect of fluticasone propionate topically dosed prior to the pollen scattering season on cellular infiltration into the surface of nasal mucous membrane in patients with Japanese cedar pollinosis]. Ikeda, M; Okubo, K; Okuda, M; Onishi, M; Suihou, X; Yokoshima, K, 1993)	0.96
"Fluticasone propionate aqueous nasal spray given once daily in the morning is safe and effective therapy for perennial allergic rhinitis and is as effective as twice daily dosing with fluticasone propionate or beclomethasone dipropionate."	( Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. Bronsky, EA; Dockhorn, RJ; Grossman, J; Lumry, W; Meltzer, EO; Rogenes, PR; Seltzer, JM; van As, A, 1993)	2.12
" Differences among the three fluticasone propionate dosing groups for these efficacy measures were not statistically significant."	( Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. Chervinsky, P; LaForce, C; Pearlman, D; Schaberg, A; Sheffer, AL, 1996)	2.03
" The pharmacokinetics of FP can be regarded as being linear over this dosing range."	( Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Bye, A; Fuller, RW; Mackie, AE; Ventresca, GP, 1996)	0.58
"Methacholine is frequently used to determine bronchial hyperresponsiveness (BHR) and to generate dose-response curves."	( Effects of fluticasone propionate on methacholine dose-response curves in nonsmoking atopic asthmatics. Bogaard, JM; Hoogsteden, HC; Mulder, PG; Overbeek, SE; Rijnbeek, PR; Vons, C, 1996)	0.68
" Fluticasone propionate at a dosage of 400 microg x day(-1) from the Diskhaler provided a more rapid and greater improvement in lung function in children with mild-to-moderate asthma than BUD 400 microg day(-1) from the Turbuhaler."	( Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). Efthimiou, J; Hedlin, G; Hoekx, JC; Hollingworth, K; Pedersen, W; Sorva, R, 1996)	2.65
"In a previous single dosing comparison between fluticasone propionate and budesonide differences in cortisol levels measured at 08."	( Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Clark, DJ; Lipworth, BJ, 1997)	0.82
"With repeated dosing across a dose range of 250-1000 micrograms twice daily, fluticasone propionate produced significantly greater adrenal suppression than budesonide for both plasma and urinary cortisol."	( Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Clark, DJ; Lipworth, BJ, 1997)	0.79
" Intranasal fluticasone propionate has shown clinical efficacy similar to that of other intranasal corticosteroids, including beclomethasone (administered at up to a 2-fold higher dosage than fluticasone), budesonide, flunisolide and triamcinolone acetonide, and provides greater relief from nasal symptoms (including nasal blockage) than antihistamine agents and intranasal sodium cromoglycate."	( Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Benfield, P; Wiseman, LR, 1997)	1.07
"The present study was undertaken to see whether the difference in plasma cortisol suppression between single and repeated dosing of fluticasone propionate (FP) can be explained by systemic accumulation."	( Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Dahlström, K; Edsbäcker, S; Källén, A; Paulson, J; Thorsson, L; Wirén, JE, 1997)	0.76
"The systemic potency was examined in a dose-response study in 81 healthy male volunteers."	( A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Brundin, RM; Eckernäs, SA; Grahnén, A; Jansson, B; Johansson, M; Ling-Andersson, A; Lönnebo, A, 1997)	0.53
"Multiple dosing for 7 days with FP-DH and BUD-TBH resulted in dose-dependent cortisol suppression by both drugs, most pronounced at the two highest dose levels."	( A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Brundin, RM; Eckernäs, SA; Grahnén, A; Jansson, B; Johansson, M; Ling-Andersson, A; Lönnebo, A, 1997)	0.53
"In a previous single dosing study in asthmatic school children fluticasone propionate produced significantly greater suppression of overnight urinary cortisol excretion than budesonide at high doses of 800 micrograms/day or greater."	( Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Clark, DJ; Lipworth, BJ; McFarlane, LC, 1997)	0.78
" Further dose-ranging studies are required at steady-state in asthmatic subjects in order to see whether differences occur at lower doses on the steep part of the dose-response curve for both plasma and urinary cortisol suppression."	( Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. Clark, DJ; Lipworth, BJ; McFarlane, L; Wilson, AM, 1997)	0.55
"Comparison of the risk-benefit profiles of different inhaled glucocorticoids has been limited by inadequate information about the dose-response relationships for efficacy relative to side effects."	( Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Badcock, CA; Baker, AB; Day, RO; Donnelly, R; Seale, JP; Williams, KM, 1997)	0.6
" To address possible differences in steady-state time-course, the aim of this study was to determine if repeated dosing with inhaled fluticasone would have facilitatory effects on lymphocyte beta2-AR."	( Effects of oral and inhaled corticosteroid on lymphocyte beta2-adrenoceptor function in asthmatic patients. Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)	0.5
"Repeated dosing with high-dose inhaled fluticasone did not up-regulate lymphocyte beta2-AR as compared with a single dose of oral prednisolone, despite having significantly suppressed early morning plasma cortisol."	( Effects of oral and inhaled corticosteroid on lymphocyte beta2-adrenoceptor function in asthmatic patients. Lipworth, BJ; McFarlane, LC; Tan, KS, 1997)	0.57
" The addition of methacholine challenge testing allowed definition of a dose-response relationship that was not apparent with traditional efficacy variables."	( Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. Chervinsky, P; Crescenzi, KL; Kellerman, DJ; Liddle, R; Noonan, MJ; Wolfe, J, 1998)	0.58
" Adult asthmatics (364, aged 18-79) requiring inhaled corticosteroids in a daily dosage of 400 microg up to and including 1000 microg and demonstrating a mean morning peak expiratory flow rate (PEFR) calculated from the last 7 days of the run-in of less than 85% of the response after salbutamol, a baseline forced expiratory volume in 1 sec (FEV1) between 50 and 90% of their predicted normal value, and an ability to correctly use both devices, were randomized to a 12-week treatment period."	( A study on the clinical equivalence and patient preference of fluticasone propionate 250 microg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler inhaler in adult asthmatic patients. Bosman, HG; Greefhorst, AP; Janssen, PG; Pieters, WR; Prins, J; Schreurs, AJ; Stallaert, RA; van Helmond, JL; van Uffelen, R, 1998)	0.54
"0169), and a significant dose-response relationship was demonstrated at 24 hours between stromal cell apoptosis and dexamethasone concentration (P = ."	( Do corticosteroids induce apoptosis in nasal polyp inflammatory cells? In vivo and in vitro studies. Birchall, MA; George, SJ; Lai, T; Saunders, MW; Wheatley, AH, 1999)	0.3
" In comparative trials in which fluticasone propionate was given at half the dosage of beclomethasone dipropionate, budesonide or flunisolide, fluticasone propionate < or =250 microg twice daily produced equivalent or greater improvement in spirometric parameters and equivalent reductions in the use of as-needed beta2-agonists than beclomethasone dipropionate, budesonide or flunisolide."	( Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Faulds, D; Jarvis, B, 1999)	1.02
" The drug is well tolerated and there is no evidence of a clinically significant effect of this dosage on HPA axis function."	( Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Faulds, D; Jarvis, B, 1999)	0.74
"Current evidence suggests that addition of the long-acting beta2-agonist salmeterol to an inhaled corticosteroid in patients with persistent asthma symptoms provides greater clinical benefit than doubling the dosage of the inhaled corticosteroid."	( Salmeterol/fluticasone propionate combination. Jarvis, B; Spencer, CM, 1999)	0.69
" The effect of the treatment on bronchial hyperreactivity and indices of the methacholine dose-response curve were analysed, as well as indices of inflammation of the airway mucosa with special emphasis on the antigen presenting dendritic cell."	( Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. Hoogsteden, HC; Lambrecht, BN; Prins, JB; Verhoeven, GT, 1999)	0.5
"To evaluate the dose-response relationship for adrenocortical activity with fluticasone propionate (FP) and to assess basal and dynamic markers after stopping treatment for 3 days."	( Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Lipworth, BJ; Sims, EJ; Wilson, AM, 1999)	0.86
" FP was given at steady-state with twice daily divided dosing at 0800 h and 2200 h at doses of 375 micrograms, 875 micrograms, and 1750 micrograms per day."	( Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Lipworth, BJ; Sims, EJ; Wilson, AM, 1999)	0.63
"Adrenal suppression can occur from inhaled fluticasone propionate at a dosage less than has been previously reported."	( Adrenal suppression secondary to inhaled fluticasone propionate. Laoprasert, N; Sachs, MI; Taylor, AV; Zimmerman, D, 1999)	0.83
" Therefore, human lung epithelial cells (A549) and human alveolar macrophages were stimulated with swine dust or lipopolysaccharide (LPS), and the inhibitory effect of budesonide and fluticasone propionate on cytokine release was studied in a dose-response (10(-13)-10(-8) M) manner."	( Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Ek, A; Larsson, K; Palmberg, L; Siljerud, S, 1999)	1.94
" Both dosing regimens were well tolerated, with an overall incidence of adverse events which was similar to placebo."	( Clinical performance of fluticasone propionate nasal drops. Holmström, M, 1999)	0.61
"To determine the systemic dose-response relationships with oral prednisolone and inhaled fluticasone propionate administered in a putative 11:1 mg equivalent basis, in terms of effects on adrenal, bone and haematological markers."	( Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Lipworth, BJ; Wilson, AM, 1999)	0.74
"Systemic tissues exhibit different dose-response relationships for the effects of inhaled and oral corticosteroids with suppression of cortisol being greater than osteocalcin or eosinophils."	( Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Lipworth, BJ; Wilson, AM, 1999)	0.52
" Depending on the intensity of allergen exposure, complaints now occur in February/March only, requiring updating of the therapy in respect of dosage and number of drugs used."	( [Two out-of-the-ordinary (?) case reports an asthmatic disease]. Hausen, T, 2000)	0.31
"Pharmacokinetic data consist of drug concentrations with associated known sampling times and are collected following the administration of known dosage regimens."	( The combination of population pharmacokinetic studies. Rahman, N; Wakefield, J, 2000)	0.31
" Multiple day dosing also improved activity."	( Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. Egging, EA; Gullikson, GW; Hammerbeck, DM; Hupperts, AM; Johnson, DD; McGurran, SM; Radziszewski, PL, 2000)	0.31
"Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients)."	( Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. Duke, S; Grady, J; Harding, S; Munk, ZM; Prillaman, B; Rooklin, A; Stevens, A; Wolfe, J, 2000)	0.82
"Two 12-week, randomized, double-blind, parallel-group studies were performed to compare the efficacy and safety of once- and twice-daily dosing of fluticasone propionate (FP) in the treatment of mild to moderate asthma, considered to require the equivalent of either 200 or 500 microg of FP daily."	( Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Boulet, LP; Brett, W; Cowie, RL; Gold, M; Marques, A; Negro, RD; Robson, R; Stepner, NM; Thorburn, WS, )	0.59
" Although twice-daily dosing demonstrated small but statistically significant improvements over once-daily dosing, patients of both groups generally maintained a good level of asthma control on both regimens according to current treatment guidelines."	( Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Boulet, LP; Brett, W; Cowie, RL; Gold, M; Marques, A; Negro, RD; Robson, R; Stepner, NM; Thorburn, WS, )	0.39
"Twice-daily dosing of FP is more effective than once-daily dosing, although the latter can maintain asthma control in most patients."	( Comparison of once- with twice-daily dosing of fluticasone propionate in mild and moderate asthma. Boulet, LP; Brett, W; Cowie, RL; Gold, M; Marques, A; Negro, RD; Robson, R; Stepner, NM; Thorburn, WS, )	0.39
" Each of the products provided an emitted dose which was within +/- 25% of the mean value indicating accurate and consistent dosing (93, 112 and 221 microg per metered dose for the salbutamol 100 microg and fluticasone propionate 125 and 250 microg HFA 134a pMDIs, respectively)."	( Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Cripps, A; Riebe, M; Schulze, M; Woodhouse, R, 2000)	0.49
" In conclusion, the new HFA 134a fluticasone propionate pMDI is as effective and safe as the established CFC fluticasone propionate pMDI when used at a dosage of 1 mg day(-1)."	( Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Lundback, B; Perruchoud, AP; Sykes, AP; Yigla, M, 2000)	0.87
"Pharmacokinetic variability is likely to be a significant factor contributing to the interindividual differences in dose requirements, anti-inflammatory response and side-effects with inhaled corticosteroids (ICS), but there is limited information about the disposition of ICS during regular dosing with a pressurized metered dose inhaler (pMDI)."	( Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. Brown, K; Donnelly, R; Li, B; Minto, C; Seale, JP; Tattam, B, 2000)	0.57
" No dose-response effect or clinically relevant differences were observed in morning plasma cortisol concentrations or after cosyntropin stimulation."	( A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Finn, A; Harding, SM; Jones, R; Li, JT; Nathan, RA; Payne, JE; Wolford, JP, 2000)	0.61
" When comparing the two active dosing regimens, significant differences in favor of twice-daily dosing were noted in FEV(1), albuterol use, and withdrawal due to lack of efficacy."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	0.59
"Fluticasone propionate powder improved lung function when administered either qd or bid over a 1-year period to patients with moderate asthma, with twice-daily dosing demonstrating significantly greater improvement in some efficacy parameters than once-daily dosing over the first 12 weeks of treatment."	( Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Adelglass, J; Clifford, DP; Duke, SP; Faris, M; Harding, SM; Wire, PD; ZuWallack, R, 2000)	2.03
" A review of available information indicates that (1) sensitive tests can measure the effects of INSs on biologic feedback systems, but they do not accurately predict clinically relevant adverse effects; (2) the primary factors that influence the relationship between therapeutic and adverse systemic effects of INSs are dosing frequency and efficiency of hepatic inactivation of swallowed drug; (3) INS treatment in recommended doses does not cause clinically significant hypothalamic-pituitary-adrenal axis suppression; (4) growth suppression can occur with twice-daily administration of certain INSs but does not appear to occur with once-daily dosing or with agents with more complete first-pass hepatic inactivation; (5) harmful effects of INSs on bone metabolism have not yet been adequately studied but would not be expected with the use of an INS dose and dosing frequency that do not suppress basal hypothalamic-pituitary-adrenal axis function or growth; and (6) these conclusions apply to INS treatment alone and in recommended doses-the risk of adverse effects in individual patients who are treated with INSs is increased by excessive dosing or concomitant inhaled corticosteroid or other topical corticosteroid therapy."	( Systemic effects of intranasal steroids: an endocrinologist's perspective. Allen, DB, 2000)	0.31
" A test lasting a few weeks at sufficient dosage is needed for subjective and objective (respiratory function tests) assessment."	( [Corticosteroid therapy of non-asthmatic chronic obstructive bronchopneumopathies]. Jébrak, G; Marceau, A; Pichot-Vérité, MH; Rullon, I, 2000)	0.31
"Once daily dosing of dry powder FP 200 microg is an effective and convenient alternative for children whose asthma is controlled with a more frequent dosing regimen of inhaled corticosteroids."	( Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Brown, A; Clements, DS; Duke, S; Harding, SM; House, KW; LaForce, CF; Pearlman, DS; Ruff, ME; Silvers, WS; Weinstein, SW, 2000)	0.59
" To this end two groups of subjects were enrolled: 20 healthy nonatopic control subjects (group A) and 20 atopic patients with severe bronchial asthma receiving fluticasone propionate at the total dosage of 1 mg/day for 8 weeks (group B)."	( Effect of fluticasone propionate on soluble CD30 release in patients with severe allergic asthma. Gangemi, S; Marotta, G; Merendino, RA; Purello-D'Ambrosio, F; Ruello, G, )	0.73
" Plasma concentrations were near the lower limit of quantitation (50 pg/mL) at the MF DPI 400-microg qd dosage and approximately 250 pg/mL at the 1,200-microg qd dosage."	( Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Affrime, MB; Flannery, BE; Herron, JM; Kosoglou, T; Thonoor, CM, 2000)	0.31
"The MF 800-microg bid dosage (1,600 microg/d), which is twice the highest projected clinical dosage, represents the lower limit for consistently detectable systemic effects of MF."	( Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Affrime, MB; Flannery, BE; Herron, JM; Kosoglou, T; Thonoor, CM, 2000)	0.31
" At each visit, a dose-response curve to inhaled salbutamol was constructed using a total cumulative dose of 800 microg."	( Additive effects of salmeterol and fluticasone or theophylline in COPD. Calderaro, F; Cazzola, M; Centanni, S; Di Lorenzo, G; Di Perna, F; Testi, R, 2000)	0.58
" Dosing regimens are needed for long-term management of corticosteroid-sensitive sites."	( Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. Lebwohl, MG; Meador, SL; Singer, G; Tan, MH, 2001)	0.62
"This analysis included all 7 studies in the meta-analysis that compared budesonide with FP dosed at approximately half the dose of budesonide and that included measurement of daily morning peak expiratory flow (PEF)."	( Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Price, MJ; Stanford, RH; Stempel, DA; Thwaites, R, 2000)	0.58
" Dosing continued on the evening of day 10 and on day 11, and on day 12 the effect of repeat-dose treatment with salmeterol and salmeterol/fluticasone propionate on the systemic effects of cumulative doses of inhaled salbutamol (up to a total dosage of 3,200 microg) was evaluated."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	0.69
" For fluticasone propionate, there were no statistically significant differences between salmeterol/fluticasone propionate and fluticasone propionate with respect to Cmax, plasma concentration at the end of the dosing interval (Ct), terminal elimination half-life (t1/2) or time to Cmax (tmax)."	( Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Daniel, MJ; Falcoz, C; Kirby, S; Milleri, S; Squassante, L; Ventresca, GP; Ziviani, L, )	1
" All dosage groups showed improvement at endpoint."	( Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Bonnaud, G; Haahtela, T; Luna, JM; Lutsky, BN; O'Connor, B; Querfurt, H; Wegener, T, 2001)	0.52
" The patient profiles are subsequently used to determine the dosing performance of fluticasone propionate Diskus and budesonide Turbuhaler inhalers."	( Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Burnell, PK; Doig, S; Gibson, GJ; Jenkins, R; Johal, B; Small, T, 2001)	0.54
"00 h serum cortisol were measured after each placebo and dosing period."	( Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. Fowler, SJ; Lipworth, BJ; Orr, LC; Sims, EJ; Wilson, AM, 2001)	0.54
"To examine the dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma."	( Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Beasley, R; Cheng, S; Holt, S; Shirtcliffe, P; Suder, A; Weatherall, M, 2001)	0.84
" The dose-response curve for the raw data began to reach a plateau at around 100-200 microg/day and peaked by 500 microg/day."	( Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Beasley, R; Cheng, S; Holt, S; Shirtcliffe, P; Suder, A; Weatherall, M, 2001)	0.59
" However, these findings were limited by the lack of data on individual patients and by the paucity of dose-response studies that included doses of >500 microg/day."	( Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Beasley, R; Cheng, S; Holt, S; Shirtcliffe, P; Suder, A; Weatherall, M, 2001)	0.59
"We assessed corticosteroid penetration in eyelid skin in vitro to obtain information leading to the establishment of safer dosing regimens."	( The penetration of 0.005% fluticasone propionate ointment in eyelid skin. Esser, AC; Lebwohl, M; Tan, MH; Wei, H, 2001)	0.61
" To explore the presence of a dose-response effect."	( Inhaled fluticasone propionate for chronic asthma. Adams, N; Bestall, J; Jones, PW, 2001)	0.74
" Although there appears to be a dose-response effect, in most patients with mild-moderate asthma improvements with low dose FP are only a little less than those with high doses."	( Inhaled fluticasone propionate for chronic asthma. Adams, N; Bestall, J; Jones, PW, 2001)	0.74
"Fluticasone propionate or beclomethasone dipropionate, both at a dosage of 200 microg administered twice daily via a dry powder inhaler (Diskhaler) for 12 months."	( Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Boner, AL; de Benedictis, FM; Green, RJ; Medley, H; Teper, A; Williams, L, 2001)	1.75
" We compared two different dosage schedules of inhaled fluticasone propionate (FP) in chronic persistent childhood asthma with respect to efficacy (airways hyperresponsiveness [PD(20)], lung function, exhaled nitric oxide [eNO]) and safety (height)."	( One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height. Arends, LR; Brand, PL; de Vries, TW; Duiverman, EJ; Postma, DS; Visser, MJ, 2001)	0.81
" The algorithm was designed to calculate CCS based on 5 input parameters: name of drug, dose, dosing interval, time(s) of dosing, and type of inhaler device."	( An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy. Derendorf, H; Hochhaus, G; Krishnaswami, S, 2000)	0.31
"Direct comparisons of the pharmacokinetic (PK) and systemic pharmacodynamic (PD) properties of inhaled corticosteroids after single and multiple dosing in the same subjects are scarce."	( Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. Barth, J; Daley-Yates, PT; Derendorf, H; Dimova, H; Falcoz, C; Hochhaus, G; Krieg, M; Krishnaswami, S; Lawlor, C; Möllmann, AC; Möllmann, H; Stöckmann, R; Tang, Y; Wagner, M, 2001)	0.51
"5 microg/dL) were then switched either to lower fluticasone dosage or to other inhaled steroid formulation."	( Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Clark, P; Eid, N; Looney, S; Morton, R; Olds, B; Sheikh, S, 2002)	0.79
"The purpose of this investigation was to compare the relative beneficial and systemic effects in a dose-response relationship for 2 ICSs."	( Significant variability in response to inhaled corticosteroids for persistent asthma. Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kiley, J; King, TS; Kraft, M; Lazarus, SC; Lemanske, RF; Martin, RJ; Mauger, E; Peters, SP; Sorkness, CA; Szefler, SJ, 2002)	0.31
" For the six ICS and matching placebos (beclomethasone-chlorofluorocarbon [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose-response effect."	( Systemic effect comparisons of six inhaled corticosteroid preparations. Boushey, HA; Cherniack, RM; Chinchilli, VM; Craig, TJ; Dolovich, M; Drazen, JM; Fagan, JK; Fahy, JV; Fish, JE; Ford, JG; Israel, E; Kraft, M; Kunselman, SJ; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, CA; Szefler, SJ, 2002)	0.52
" The three children, aged 7-9 yrs, had been prescribed inhaled fluticasone, dosage 500-2,000 microg x day(-1) and duration 5 months-5 yrs."	( Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Acerini, CL; Buck, JJ; McCance, DR; Murphy, NP; Ross-Russell, R; Todd, GR; Warner, JT, 2002)	0.8
"Budesonide is associated with a dose-response effect in adults and children with moderate to severe asthma."	( Efficacy of budesonide in moderate to severe asthma. O'Connell, EJ, 2002)	0.31
" The dosage was 50 microg two dose unit sprays and BSP 500 microg, each 4 times daily."	( Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. Hegarty, AM; Hodgson, TA; Lewsey, JD; Porter, SR, 2002)	1.76
" Those who did not relapse continued for an additional 24 weeks on intermittent dosing for safety monitoring."	( Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Gupta, AK; Hanifin, J; Rajagopalan, R, 2002)	0.63
"In paediatric and adult subjects, once stabilized with regular FP treatment, the risk of relapse of AD can be significantly reduced by extended intermittent dosing with FP cream in addition to regular emollient therapy."	( Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Gupta, AK; Hanifin, J; Rajagopalan, R, 2002)	0.63
" An algorithm for the dosage of prednisone including rules for reducing dose was developed and applied at all centers."	( Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Balkissoon, RC; Baughman, RP; Iannuzzi, MC; Judson, MA; Lower, EE; Moller, DR; Winget, DB, 2002)	0.77
" The algorithm for decreasing corticosteroid dosage was exactly applied in over 80% of patient visits and oral corticosteroids were used throughout most of the year of treatment."	( Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Balkissoon, RC; Baughman, RP; Iannuzzi, MC; Judson, MA; Lower, EE; Moller, DR; Winget, DB, 2002)	0.77
" The long-term management of these corticosteroid-sensitive sites requires the use of dosing regimens that are effective, but also safe."	( An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas. Lebwohl, MG; Meador, SL; Singer, G; Tan, MH, 2002)	0.55
"Inhaled corticosteroids (ICS) are typically associated with a flat dose-response curve when traditional efficacy values are examined (eg, FEV(1))."	( Effects of varying doses of fluticasone propionate on the physiology and bronchial wall immunopathology in mild-to-moderate asthma. Burke, CM; Cormican, L; Murphy, M; O'Sullivan, S; Poulter, LW, 2002)	0.61
"The apparent lack of a dose-response for ICS treatment in patients with asthma further validates the preferential use of add-on therapy over increasing the dose of ICS."	( Effects of varying doses of fluticasone propionate on the physiology and bronchial wall immunopathology in mild-to-moderate asthma. Burke, CM; Cormican, L; Murphy, M; O'Sullivan, S; Poulter, LW, 2002)	0.61
"These data suggest that, at the dosage and for the treatment period used, inhaled steroids do not seem to suppress the HPA axis in the majority of patients."	( Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test. Boner, AL; Gottardi, E; Peroni, DG; Pescollderungg, L; Pietrobelli, A; Radetti, G, 2003)	0.32
" The highest topical steroid dosage was 500 micro g Fluticasone or 800 micro g Budesonide per day."	( [Early results of ultrasound based calculation of broadband ultrasound attenuation and speed of sound in children and adolescents suffering from asthma]. Beyermann, H; John, S; Kaiser, WA; Mainz, J; Malich, A; Mentzel, HJ; Meutzel, HJ; Vogt, S; Wünsche, K; Zintl, F, 2003)	0.57
" Significant benefit was gained from adding salmeterol in a group of patients who appeared to have been at the top of their steroid dose-response curve receiving FP250."	( Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Browning, D; Colman, NC; Dal Negro, R; Fletcher, CP; Ind, PW; James, MH, 2003)	0.62
"Few dose ranging studies have investigated optimal dosing with inhaled corticosteroids in children with asthma."	( Fluticasone propionate in asthma: a long term dose comparison study. Cserhati, E; Geppe, N; Hofman, J; Hughes, S; Medley, H; Petrov, D; Verona, E, 2003)	1.76
" Attention to dosage is required as the amount of Candida increased with dose of fluticasone."	( Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Fukushima, C; Kohno, S; Matsuse, H; Miyazaki, Y; Obase, Y; Shimoda, T; Tomari, S, 2003)	0.78
"Both patients were treated with interferon-alpha in dosages of 3 million units of IFN-alpha 2b or an equivalent dosage of interferon-acon thrice weekly subcutaneously."	( [Interferon-alpha treatment of the Churg-Strauss syndrome]. Förster, M; Kroegel, C; Mock, B; Reissig, A; Schilder, C, 2003)	0.32
" Areas under the dose-response curve were calculated to determine relative potencies."	( Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Bousquet, J; Henriquet, C; Mathieu, M; Roumestan, C, 2003)	1.76
"The aim of the present dose-response study was to estimate the minimal effective doses (MEDs) of budesonide and of fluticasone propionate via dry-powder inhaler in adults with mild to moderate asthma."	( A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Greefhorst, LA; Joubert, JR; Kuna, P; Magnussen, H, 2003)	0.73
" Once-daily dosage regimens did not receive approval."	( Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Meyer, RJ; Purucker, ME; Rosebraugh, CJ; Zhou, F, 2003)	0.75
"Twice-daily dosing was numerically superior to once-daily dosing at the same nominal dose in all comparative studies for the primary end point, change in predose FEV(1)."	( Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Meyer, RJ; Purucker, ME; Rosebraugh, CJ; Zhou, F, 2003)	0.75
"In the FDA review of once-daily dosing of the FD regimen, 100 or 200 microg once-daily dosing was not shown to be significantly better than placebo."	( Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day. Meyer, RJ; Purucker, ME; Rosebraugh, CJ; Zhou, F, 2003)	0.75
" The study population comprised 174 929 consulting patients, of whom 9878 patients were prescribed budesonide, fluticasone, or beclomethasone with full dosing instructions."	( Differential prescribing of inhaled corticosteroids in New Zealand general practice. Hall, J; Penrose, A; Reid, J; Tomlin, A, 2003)	0.53
" These data indicate that FP is more effective than a twofold higher dosage of BDP and that better compliance with the use of FP, probably because of improved various factors associated with FP compliance, contributes to FP efficacy."	( Efficacy of fluticasone propionate compared with beclomethasone dipropionate in bronchial asthma: improvement in compliance and symptoms by fluticasone. Akazawa, K; Gejyo, F; Hasegawa, T; Kawada, T; Koya, T; Sasahara, K; Satoh, H; Suzuki, E; Suzuki, T, )	0.51
"A study was undertaken to examine the dose-response relation of inhaled fluticasone in adolescents and adults with asthma."	( Clinical dose-response relationship of fluticasone propionate in adults with asthma. Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2004)	0.83
" No significant correlations were found between FP dosage and height SDS, OC, AKP, IGFBP-3, and SC."	( Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Bergadá, I; Colom, AJ; Kofman, CD; Maffey, AF; Teper, AM; Vidaurreta, SM, 2004)	0.65
"if patients with asthma remain symptomatic in spite of chronic treatment with inhaled corticosteroids (ICS), increasing the ICS dosage or adding another drug to the treatment regimen are possible therapeutic alternatives."	( Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Bergmann, KC; Braun, R; Lindemann, L; Steinkamp, G, 2004)	0.71
" Although compliance to this type of medication is often suboptimal and once-daily dosing can help to improve adherence to the treatment, the clinical implications of such a mode of administration should be determined."	( Once-daily inhaled corticosteroids for the treatment of asthma. Boulet, LP, 2004)	0.32
" An increased frequency of dosing seems preferable if asthma becomes uncontrolled or is severe, although this requires further study."	( Once-daily inhaled corticosteroids for the treatment of asthma. Boulet, LP, 2004)	0.32
"5 microg) according to asthma severity compared with traditional fixed dosing (FD) regimens."	( Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)	0.54
"5, mean inhaled corticosteroids 735 microg/day, mean forced expiratory volume in 1 second [FEV(1)] 84% predicted) were randomised after 2 weeks' run-in to either: budesonide/formoterol adjustable maintenance dosing (AMD), budesonide/formoterol FD or salmeterol/fluticasone (Seretide Diskus dagger 50/250 microg) FD."	( Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)	0.72
"Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control by reducing exacerbations and reliever medication usage compared with fixed-dose salmeterol/fluticasone."	( Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Aalbers, R; Backer, V; Jorup, C; Kava, TT; Omenaas, ER; Sandström, T; Welte, T, 2004)	0.73
" Long-term comparisons with CFC-BDP have confirmed the durability of the 2:1 daily dosing ratio of CFC-BDP:QVAR in adults."	( The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Donnell, D; Van Schayck, CP, 2004)	0.32
"To examine the dose-response relation of inhaled fluticasone for both efficacy and adrenal function in children with asthma."	( Systematic review of the dose-response relation of inhaled fluticasone propionate. Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2004)	0.82
"Systematic review of double blind randomised dose-response studies of fluticasone in children of at least 4 weeks duration."	( Systematic review of the dose-response relation of inhaled fluticasone propionate. Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2004)	0.8
" The dose-response curve for each efficacy outcome measure suggested that the response began to plateau between 100 and 200 microg per day with additional efficacy at the 400 microg per day dose shown in one study of severe asthmatics."	( Systematic review of the dose-response relation of inhaled fluticasone propionate. Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2004)	0.57
"There is insufficient data to determine the dose-response of fluticasone in children at doses >400 microg per day."	( Systematic review of the dose-response relation of inhaled fluticasone propionate. Beasley, R; Holt, S; Masoli, M; Weatherall, M, 2004)	0.81
" This pharmacological effect, even at low doses (	( Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. Cooper, DA; Gowers, A; McMurchie, M; Pett, S; Samaras, K, 2005)	0.33
" In most SFC patients the fluticasone dosage can be reduced by 50 % without losing asthma control."	( [Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment]. Liefring, E; Molitor, S; Trautmann, M, 2005)	0.9
" Twice-daily dosing was associated with significantly greater efficacy compared with once-daily dosing, for all outcome measures except night wakenings."	( Fluticasone given once versus twice a day: meta-analysis. Beasley, R; Masoli, M; Weatherall, M, 2005)	1.77
"Greater clinical benefit in controlling the symptoms of asthma is frequently observed through combining moderate doses of inhaled glucocorticoids together with long-acting beta(2)-agonists, as compared with increasing glucocorticoid dosage alone."	( Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. Corrigan, CJ; Faith, A; Hawrylowicz, CM; Lavender, P; Lee, TH; Peek, EJ; Richards, DF, 2005)	0.33
" To explore the presence of a dose-response effect."	( Inhaled fluticasone versus placebo for chronic asthma in adults and children. Adams, NP; Bestall, JC; Jones, PW; Lasserson, TJ, 2005)	0.76
" Drug use in the 6 months before and after step-up in treatment from inhaled corticosteroids [ICs; total daily dosage of < or =1000 microg beclomethasone dipropionate (BDP) or equivalent] to either salmeterol/fluticasone propionate combination (SFC) or concurrent BDP and long-acting beta(2)-agonists (LABAs) given in separate inhalers was compared."	( Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Angus, R; Cheesbrough, A; Reagon, R, 2005)	0.71
" The addition of a low-dose long-acting beta(2) agonist is superior to the simple increase of the dosage of inhaled corticosteroids."	( [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma]. Cai, BQ; Chen, BY; Chen, XD; Feng, YL; Guo, XJ; Kang, J; Li, Q; Lin, YP; Qiu, C; Shen, HH; Sun, TY; Tao, JJ; Wang, DQ; Xiao, BR; Xie, CM; Xu, YP; Yin, KS; Zhang, DP; Zheng, JP; Zhong, NS; Zhou, JY; Zhou, X, 2005)	0.57
"A patient-driven, adjustable maintenance dosing (AMD) approach to asthma therapy, in which the dose is adjusted by patients according to the severity of their symptoms, has recently been compared with fixed-dose therapy in open-label studies."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.53
"This study used a double-blind, double-dummy design to compare the efficacy of 2 treatment approaches: stable dosing of salmeterol/fluticasone propionate (SAL/FP) and AMD of formoterol/budesonide (FOR/BUD)."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.74
" After 4 weeks of stable dosing in both groups, eligible patients continued the study for an additional 48 weeks, receiving either a stable dose of SAL/FP or AMD of FOR/BUD."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.53
" Over weeks 1 through 52, patients receiving stable dosing of SAL/FP had a significantly greater percentage of symptom-free days compared with those receiving AMD of FOR/BUD (median, 58."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.53
"In this adult population with persistent asthma, stable dosing of SAL/FP 50/250 microg BID resulted in significantly greater increases in symptom-free days, days free of rescue medication, and morning PEE, as well as almost halving the exacerbation rate, compared with AMD of FOR/BUD 6/200 microg."	( The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent ast Boulet, LP; FitzGerald, JM; Follows, RM, 2005)	0.53
" PC20 more than doubled with each active treatment, but no statistically significant dose-response effect could be established."	( Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Derom, E; Engelstätter, R; Marissens, S; Pauwels, R; Van De Velde, V; Vincken, W, 2005)	0.61
" To test for the presence of a dose-response effect."	( Inhaled fluticasone at different doses for chronic asthma in adults and children. Adams, NP; Bestall, JC; Cates, C; Griffiths, B; Jones, PW; Lasserson, TJ, 2005)	0.76
" In asthmatics with mild to moderate disease who were not on oral steroids a dose-response effect was present with FP for change in morning peak expiratory flow (PEF)."	( Inhaled fluticasone at different doses for chronic asthma in adults and children. Adams, NP; Bestall, JC; Cates, C; Griffiths, B; Jones, PW; Lasserson, TJ, 2005)	0.76
" To explore the presence of a dose-response effect."	( Fluticasone versus placebo for chronic asthma in adults and children. Adams, NP; Bestall, JC; Cates, C; Jones, PW; Lasserson, TJ, 2005)	1.77
" All patients received inhaled corticosteroids; only 44 had high dosed corticosteroids."	( [Treatment compliance in asthma: a Tunisian transversal study]. Ali, BK; Ikram, D; Radhouane, F; Sonia, M, 2005)	0.33
"Patients should be clearly warned that the prescribed dosing for fluticasone nasal spray should be carefully followed because overuse may cause serious side effects."	( Systemic effects of fluticasone nasal spray: report of 2 cases. Licata, AA, )	0.69
" Higher dosage and frequency of use exacerbated problems."	( Inhaled corticosteroids: hazardous effects on voice-an update. Gallivan, GJ; Gallivan, HK; Gallivan, KH, 2007)	0.34
" Effective maintenance therapywith the correct dosage ofinhalational corticosteroids administered correctly can probably stop the potentially fatal asthma type II from developing."	( [Fatal asthma in childhod preventable by recognizing risk factors and presenting features]. Corel, LJ; de Hoog, M; Joosten, KF; Tiddens, HA; Verbruggen, SC, 2006)	0.33
" Visual analogue scores on asthma severity, symptoms, and dosing regimen preference were obtained."	( Once-daily fluticasone propionate in stable asthma: study on airway inflammation. Chan, DF; Chan, K; Fok, TF; Li, AM; Sung, RY; Tsang, TW, 2006)	0.72
"We evaluated whether sputum eosinophil counts could demonstrate a dose-response to inhaled corticosteroids, and compared the response with other inflammatory markers."	( Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. Goldsmith, CH; Hargreave, FE; Jayaram, L; Kelly, MM; Leigh, R; Parameswaran, K, 2006)	0.33
"5% entered a 6-week sequential, placebo-controlled, patient-blinded, cumulative dose-response study."	( Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. Goldsmith, CH; Hargreave, FE; Jayaram, L; Kelly, MM; Leigh, R; Parameswaran, K, 2006)	0.33
"The dose-response relationship of inhaled fluticasone propionate (FP) for adrenal suppression in adults with asthma is not clear."	( Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Beasley, R; Holt, S; Masoli, M; Shirtcliffe, P; Weatherall, M, 2006)	1.03
" The key findings are that all inhaled corticosteroids demonstrate a dose-response relationship for efficacy measures, but most of the benefit in mild-to-moderate severity disease is gained in the low-to-moderate dose range of each drug."	( The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Adams, NP; Jones, PW, 2006)	0.33
" Further considerations for measuring long-term outcomes and dose-response relationships might be required to provide further evidence on the cost effectiveness of combination therapy with ICS plus LABA."	( Single-inhaler combination therapy for asthma: a review of cost effectiveness. Akazawa, M; Stempel, DA, 2006)	0.33
"Response to salmeterol does not vary between ADRB2 genotypes after chronic dosing with an inhaled corticosteroid."	( Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. Anderson, WH; Baitinger, LA; Bleecker, ER; Dorinsky, PM; Edwards, LD; Klotsman, M; Yancey, SW, 2006)	0.33
"There are discrepancies in the results of dose-response studies of inhaled steroids."	( Dose-response studies of fluticasone propionate and budesonide: classification based on asthma severity. Mikhak, Z, )	0.43
" If the dosing performance of FP-DH is dependent on inspiratory effort, establishment of a method of inhalation that makes it independent of inspiratory flow rate is important in clinical practice."	( [Analysis of the factors associated with drugs remaining in the Diskhaler following inhalation of fluticasone propionate]. Iga, T; Ozeki, T; Takayanagi, R; Yamada, Y; Yamamura, Y; Yokoyama, H, 2006)	0.55
"We conducted a double blind, randomised, placebo-controlled, crossover study evaluating the effects of halving inhaled steroid dosage plus salmeterol, or salmeterol and tiotropium."	( A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Fardon, T; Haggart, K; Lee, DK; Lipworth, BJ, 2007)	0.58
" A twice daily dosing is more efficient, particularly for initiation of maintenance therapy, than a once daily dosing."	( [Fluticasone propionate in children and infants with asthma]. Devillier, P; Foussier, V; Le Bourgeois, M; Marchac, V; Polak, M, 2007)	1.25
"To examine the effect of dosing frequency and mode of delivery of therapy on adherence and clinical outcomes."	( Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. Bilderback, A; Edelman, JM; Hustad, CM; Rand, C; Schiller, K; Zeiger, RS, 2007)	0.63
" In the DB, a dose-response relationship was observed with fluticasone and asthma rescue-free days (P = ."	( Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. Bilderback, A; Edelman, JM; Hustad, CM; Rand, C; Schiller, K; Zeiger, RS, 2007)	0.87
"Timing and duration of linear growth suppression in children on long-term inhaled corticosteroids (ICS) are not entirely clear; we undertook a "pragmatic" study to determine growth of asthmatic children on long-term ICS managed by a flexible dosing step-down approach."	( Growth deceleration of children on inhaled corticosteroids is compensated for after the first 12 months of treatment. Anthracopoulos, MB; Fretzayas, A; Giannakopoulou, E; Nicolaidou, P; Panagiotakos, DB; Papadimitriou, A; Priftis, KN; Syridou, G, 2007)	0.34
" The aims of this study were to evaluate the long-term efficacy (including symptom-free days and exacerbations) and impact on HRQoL of a stable-dose regimen of salmeterol/fluticasone propionate (SAL/FP) and an adjustable maintenance dosing (AMD) regimen of formoterol/budesonide (FOR/BUD) where treatment is adjusted based on symptoms [SAM40056]."	( Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Price, DB; Williams, AE; Yoxall, S, 2007)	0.92
" The following pharmacokinetic parameters were derived: IN administration: AUC from time 0 to the end of the dosing interval (AUC(0-tau)), AUC(0-t), C(max), and T(max); IV administration: AUC(0-infinity), AUC(0-t), t(1/2), C(max), T(max), total systemic clearance, and volume of distribution at steady state."	( Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Allen, A; Down, G; Newland, A; Reynard, K; Rousell, V; Salmon, E; Scott, R, 2007)	0.61
" For patients in group A, a fixed dosage was maintained for 18 months, while those in group B received tailored dosage or withdrawal of therapy according to the clinical control level (well or total control)."	( [A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients]. Liu, CT; Pang, YM; Tan, CW; Wang, G; Wang, YM, 2007)	0.34
" The two FSC treatments were similar except that QD dosing did not maintain improvements in lung function for 24h compared with twice daily dosing."	( Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Dorinsky, PM; Kerwin, EM; Meltzer, EO; Nathan, RA; Ortega, HG; Schoaf, L; Yancey, SW, 2008)	0.66
" Traditional press-and-breathe Metered Dose Inhalers (pMDIs) have recently improved their ecological appeal, can be used in every clinical and environmental situation, their dosing is convenient and highly reproducible, but their efficient delivery remains highly technique dependent."	( Inhalatory therapy training: a priority challenge for the physician. Melani, AS, 2007)	0.34
" At the end of the crossover dosing and after completion of the attributes questionnaires, preference for individual attributes of FF or FP nasal spray and overall patient preference were evaluated in a third questionnaire that asked "Based on these attributes, which product did you prefer overall?" Additionally, a follow-up phone call was conducted 24 hours after the study to assess any adverse events following study treatment."	( Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Dalal, AA; Leflein, J; Lim, J; Meltzer, EO; Meltzer, S; Philpot, EE; Prillaman, BA; Stahlman, JE, 2008)	0.57
" This study was interested in identifying the optimal time of dosing using 2 surrogate markers of glucocorticoid action."	( Evaluation of the administration time effect on the cumulative cortisol suppression and cumulative lymphocytes suppression for once-daily inhaled corticosteroids: a population modeling/simulation approach. Goyal, N; Hochhaus, G; Stark, JG; Wu, K, 2008)	0.35
" To test for the presence of a dose-response effect."	( Fluticasone at different doses for chronic asthma in adults and children. Adams, NP; Bestall, JC; Cates, CJ; Griffiths, B; Jones, P; Lasserson, TJ, 2008)	1.79
" In asthmatics with mild to moderate disease who were not on oral steroids, FP did not exhibit a dose-response effect in the lower dose comparisons in FEV1 (50mcg, 100mcg, 200mcg and 4-500mcg daily)."	( Fluticasone at different doses for chronic asthma in adults and children. Adams, NP; Bestall, JC; Cates, CJ; Griffiths, B; Jones, P; Lasserson, TJ, 2008)	1.79
" A significant dose-response occurred between low and higher doses of ciclesonide for exacerbations and asthma control definitions."	( Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Barkai, L; Emeryk, A; Engelstätter, R; Hirsch, S; Pedersen, S; Vermeulen, J; Weber, H; Weber, HJ, 2009)	0.61
"In subjects with persistent asthma, the ADRB2 Arg16Gly polymorphism does not alter lung function responses to SAL or FSC over the 12 hour dosing interval following acute and chronic dosing."	( Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms. Anderson, WH; Edwards, LD; Klotsman, M; Ortega, HG; Yancey, SW, 2009)	0.58
"Chronic dosing with fluticasone propionate/salmeterol in a single device provides superior protection compared with an inhaled corticosteroid alone in protecting against exercise-induced asthma in children with persistent asthma."	( Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. Matz, J; Ortega, HG; Pearlman, D; Qaqundah, P; Stempel, DA; Yancey, SW, 2009)	2.12
" A few days later, typical secondary adrenal failure developed and was confirmed by dosage of cortisol and ACTH, both low."	( [Iatrogenic Cushing's syndrome, diabetes mellitus and secondary adrenal failure in a human immunodeficiency virus patient treated with ritonavir boosted atazanavir and fluticasone]. Beressi, J-; Collet-Gaudillat, C; Desforges-Bullet, V; Doll, J; Petit-Aubert, G; Roussin-Bretagne, S, 2009)	0.55
" An appropriate dosage regimen for inhaled GC in cats has not been investigated."	( Effects of fluticasone propionate dosage in an experimental model of feline asthma. Cohen, RL; Cohn, LA; DeClue, AE; Reinero, CR, 2010)	0.75
" Urine FP17betaCA was absent in subjects prior to FP therapy, detectable (180-1991 ng FP17betaCA/g creatinine) throughout the dosing period and reached below the LOQ at 6 days after therapy cessation."	( Liquid chromatography-tandem mass spectrometry analysis of urinary fluticasone propionate-17beta-carboxylic acid for monitoring compliance with inhaled-fluticasone propionate therapy. Hagan, JB; Korpi-Steiner, NL; Netzel, BC; Seegmiller, JC; Singh, RJ, 2010)	0.6
" The CIC showed the least serum cortisol suppression of the tested dosing regimens."	( Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. Derendorf, H; Derom, E; Lahu, G; Nave, R; Xu, J, 2010)	0.59
"Outcomes evaluated were peak nasal inspiratory flow, nasal resistance, blood flow, and oxymetazoline dose-response curve (DRC)."	( Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Clearie, K; Khan, F; Lipworth, B; Vaidyanathan, S; Williamson, P, 2010)	1.8
" dosing schedule, formulation, etc."	( Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Blanchette, CM; Charles, MS; Dalal, AA; Lavallee, D; Mapel, D; Silver, H, 2010)	0.36
" Mometasone furoate delivered through a dry powder inhaler (MF-DPI) is an inhaled corticosteroid (ICS) approved for once-daily dosing in most patients."	( Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. Friedman, HS; McLaughlin, J; Navaratnam, P, 2010)	0.6
" Eye functions including cataract formation, corneal ectasia, ocular hypertension or glaucoma, and dry eye were not observed in any of the patients in the study group and were not correlated with total steroid dosage (t=0."	( Evaluation impact of long-term usage of inhaled fluticasone propionate on ocular functions in children with asthma. Emin, O; Fatih, M; Mustafa, O; Nedim, S; Osman, C, 2011)	0.62
"Differences between mometasone furoate (MF), administered once daily, and fluticasone propionate (FP), administered twice daily, dosing regimens may affect adherence and short-acting β(2) agonist (SABA) use."	( Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. Friedman, HS; Navaratnam, P; Urdaneta, E, )	0.57
" Due to a flattening growth curve Cushing's syndrome was suspected and the dosage of fluticasone was gradually decreased after which the boy became less active and his appetite decreased."	( [Adrenal cortex insufficiency in children due to inhaled corticosteroids]. Eijkemans, M; Otten, BJ; Yntema, JB, 2011)	0.59
" Dose-response analysis was conducted using variance-weighted least squares regression in the observational studies."	( Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Cavallazzi, R; Loke, YK; Singh, S, 2011)	0.37
" Determination of the significance of the observed differences in pharmacokinetics from this single-dose study requires further exploration in studies using clinically relevant dosing regimens."	( Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. Harrison, LI; Needham, MJ; Novak, CC; Ratner, P, 2011)	0.62
" The limitations of the analysis are that the results from a single study, TORCH, have a large bearing on the overall findings of the analysis, and that there is heterogeneity in the length and the dosing of the included studies, although it does not appear that heterogeneity affected the reported results."	( Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Edwards, SJ; Gray, J; Halpin, DM; Morais, J; Singh, D, 2011)	0.64
" Patients were randomised to one of three sparse sampling schedules for blood collection throughout the 12-h dosing interval on the 8th day of each treatment for pharmacokinetic analysis."	( Bioavailability of inhaled fluticasone propionate via chambers/masks in young children. Blake, K; Hendeles, L; Kunka, RL; Mehta, R; Spencer, T, 2012)	0.68
"Prediction of pharmacokinetic (PK) profile for inhaled drugs in humans provides valuable information to aid toxicology safety assessment, evaluate the potential for systemic accumulation on multiple dosing and enable an estimate for the clinical plasma assay requirements."	( A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Harrison, A; Jones, RM, 2012)	0.38
"For the primary outcome there was significant protection after single and long-term dosing with fluticasone alone and fluticasone-salmeterol combination, whereas salmeterol alone only afforded protection after the first dose."	( Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. Burns, P; Lipworth, BJ; Nair, A; Short, P, 2012)	0.87
"Chronic dosing with fluticasone but not salmeterol confers anti-inflammatory activity against nasal AMP challenge, but there was no potentiation of fluticasone when given in combination with salmeterol."	( Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. Burns, P; Lipworth, BJ; Nair, A; Short, P, 2012)	0.98
"A dose-response effect was observed for once-daily FF 25-200 μg including (p < 0."	( Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Bateman, ED; Bleecker, ER; Busse, WW; Davis, AM; Forth, R; Haumann, B; Jacques, L; Lötvall, J; Medley, H; Woodcock, A, 2012)	0.68
"6 years, and the mean (±SEM) steroid dosage used was 183."	( Bone mineral density and associated parameters in pre-pubertal children with asthma treated with long-term fluticasone propionate. Çakır, E; Dundaröz, MR; Erenberk, U; Ozkaya, E; Uzuner, S, )	0.34
"Seventy-three children with asthma received inhaled fluticasone treatment at a starting dosage of 250 μg/d for 3 months, when the dosage was reduced by a third."	( [Effects of inhaled corticosteroids on bone age and growth in children with asthma]. Chen, M; Guo, C; Huang, H; Li, Y; Wang, T; Ye, YY; Yi, HL, 2012)	0.63
" Eventually, her mother discovered the cause was inhaled fluticasone, prescribed at normal dosage for asthma."	( Peripheral oedema as a side-effect of fluticasone. Godden, C; Myers, A, 2010)	0.88
" These results have implications during dosage form design, testing, and for usage patient use."	( In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs. Church, T; Finlay, WH; Hoe, S; Lewis, D; Shemirani, FM; Vehring, R, 2013)	0.39
", approved dosing regimen in the United States), in SAR via a post hoc analysis of data from a previously published direct-comparison study."	( Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Bachert, C; Canonica, GW; Carr, WW; Lieberman, P; Meltzer, E; Mullol, J; Munzel, U; Murray, R; Price, D; Ratner, P; Virchow, JC, )	0.38
" This would suggest that FF is exhibiting absorption rate-limited pharmacokinetics following inhaled FF dosing and that the apparent t(½β) is an estimate of absorption rate."	( Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Allen, A; Bareille, PJ; Rousell, VM, 2013)	1.83
" SB-705498 was well tolerated and pharmacokinetics exposure results supported the dosing regimen."	( The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Bareille, P; Bentley, J; Denyer, J; Horak, F; Lemell, P; Murdoch, RD; Smart, K; Yarnall, K; Zieglmayer, P; Zieglmayer, R, 2013)	0.39
" Information on study design, study population, drugs and dosage used, follow up period, measures used to evaluate safety and outcomes was abstracted independently by three reviewers."	( Safety of inhaled fluticasone propionate therapy for pediatric asthma - a systematic review. Muley, A; Muley, P; Shah, M, 2013)	0.72
" Studies which had monitored HPA function varied in dosage of drug, mode of administration and duration."	( Safety of inhaled fluticasone propionate therapy for pediatric asthma - a systematic review. Muley, A; Muley, P; Shah, M, 2013)	0.72
" The comparison of efficacy of fluticasone at a dose of 125 μg BID with the generic product at a dose of 250 μg BID showed a weak dose-response relationship concerning the change in morning PEF, which arises from the almost flat dose-response curve in the range of medium and high doses for this drug."	( Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice dail Bocheńska-Marciniak, M; Kuna, P; Kupryś-Lipińska, I; Tworek, D; Vanderbist, F, 2013)	0.91
" Controlling for FP dosage and baseline characteristics, FSC patients had lower risks of asthma-related exacerbations, fewer SABAs and systemic corticosteroids, higher costs of asthma medications and total asthma-related health care, and lower total asthma-related health-care costs excluding study medication cost."	( Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations. Delea, TE; Hagiwara, M; Stanford, RH, )	0.4
" The dose-response effect of inhaled corticosteroids (ICS) on PC20 has been inconsistent and within-patient variability of PC20 is not well established."	( Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma. Castro, M; Holbrook, JT; Irvin, CG; Kaminsky, DA; Shade, D; Sugar, EA; Sumino, K; Wei, CY; Wise, RA, 2014)	0.4
" A subsample of 259 families had controller medication use monitored objectively for approximately 1 month by MDILog (fluticasone propionate), TrackCap (montelukast), or dosage counter (fluticasone/salmeterol combination)."	( Complementary and alternative medicine use and adherence to asthma medications among Latino and non-Latino white families. Adams, SK; Canino, G; Fedele, DA; Fritz, GK; Jandasek, B; Koinis-Mitchell, D; Kopel, SJ; McQuaid, EL; Mitchell, J; Seifer, R, )	0.34
" Two of these studies were active comparator dosage trials administered with either fluticasone propionate cream or ointment once or twice daily, the third study was a placebo control."	( A statistical model to predict the reduction of lichenification in atopic dermatitis. Glazenburg, EJ; Mulder, PG; Oranje, AP, 2015)	0.64
" The NLC containing FP can be considered good systems for dosage forms useful for increasing the effectiveness of fluticasone decreasing its side effects."	( Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers. Bondì, ML; Botto, C; Cavallaro, G; Di Vincenzo, S; Ferraro, M; Gerbino, S; Giammona, G; Gjomarkaj, M; Pace, E, 2014)	0.61
" All children with asthma were taking inhaled fluticasone propionate at a dosage of 250 µg or more per day for at least 1 year."	( Effect of inhaled fluticasone propionate on retinal nerve fiber layer thickness in asthmatic children. Akcam, M; Dereci, S; Dundar, B; Pirgon, O; Turkyilmaz, K, )	0.72
" In contrast, dosage forms containing non-respirable carriers (e."	( Quantitative Macro-Raman Spectroscopy on Microparticle-Based Pharmaceutical Dosage Forms. Hoe, S; Lechuga-Ballesteros, D; Vehring, R; Wang, H; Williams, L, 2015)	0.42
" Its pharmacological characteristics allow rapid speed of onset and dosage flexibility required for step-up and step-down strategies, improving adherence to treatment of asthmatic patients."	( Revising old principles of inhaled treatment in new fixed combinations for asthma. Melani, A; Rossi, A; Scichilone, N, 2015)	0.42
"To study the reservoir effect of topical steroids in a steroid-responsive condition which may enable a decrease in the dosing frequency of topical steroids."	( The reservoir effect of topical steroids in vitiliginous skin: A cross-sectional study. Nasir, F; Singh, SK, )	0.13
" We aimed to assess the efficacy and safety of two dosing regimens of tralokinumab in patients with severe uncontrolled asthma."	( Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Brightling, CE; Chanez, P; Korn, S; Leigh, R; May, RD; O'Byrne, PM; Piper, E; Ranade, K; She, D; Streicher, K, 2015)	0.42
" Patients aged 18-75 years with severe asthma and two to six exacerbations in the previous year were randomly assigned (1:1), via an interactive voice-response or web-response system, to one of two dosing regimen groups (every 2 weeks, or every 2 weeks for 12 weeks then every 4 weeks) and further randomised (2:1), via computer-generated permuted-block randomisation (block size of six), to receive tralokinumab 300 mg or placebo for 1 year."	( Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Brightling, CE; Chanez, P; Korn, S; Leigh, R; May, RD; O'Byrne, PM; Piper, E; Ranade, K; She, D; Streicher, K, 2015)	0.42
"Despite extensive use of inhaled corticosteroid/long-acting β2-agonist combinations in asthma, limited data evaluating dose-response for this combination class are available."	( An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Dissanayake, S; Grothe, B; Jain, M; McIver, T; Papi, A, 2015)	0.65
"No dose-response was evident for spirometric outcomes (FEV1, FEV1 AUC0-12, PEFR) either overall or in either subgroup."	( An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Dissanayake, S; Grothe, B; Jain, M; McIver, T; Papi, A, 2015)	0.65
"The dose-response relationship between two dose levels of fluticasone/formoterol (flutiform(®), 100/10 μg and 500/20 μg) was evaluated in asthmatic patients."	( Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial. Diamant, Z; Kanniess, F; Lomax, M, 2016)	0.96
"A significant dose-response was found between low- and high-dose fluticasone/formoterol in the post hoc subgroup (patients who received both doses), but not in the overall population, with the higher dose demonstrating a greater reduction in airway responsiveness to AMP."	( Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial. Diamant, Z; Kanniess, F; Lomax, M, 2016)	0.95
"Fluticasone propionate (FLU) and Azelastine hydrochloride (AZE) are co-formulated with phenylethyl alcohol (PEA) and Benzalkonium chloride (BENZ) (as preservatives) in pharmaceutical dosage form for treatment of seasonal allergies."	( Simultaneous determination of Fluticasone propionate and Azelastine hydrochloride in the presence of pharmaceutical dosage form additives. El-Mosallamy, SS; El-Zeany, BA; Hassan, NY; Merey, HA, 2016)	2.17
" This study was undertaken to determine the prevalence of steroid-induced cataract and glaucoma in patients with chronic obstructive pulmonary disease (COPD) and to assess a dose-response relationship between them."	( Prevalence of Steroid-Induced Cataract and Glaucoma in Chronic Obstructive Pulmonary Disease Patients Attending a Tertiary Care Center in India. Agrawal, R; Kumar, H; Kumar, S; Nath, T; Roy, SS; Satsangi, SK, )	0.13
" We also observed a dose-response relationship with the highest prevalence of cataract (39."	( Prevalence of Steroid-Induced Cataract and Glaucoma in Chronic Obstructive Pulmonary Disease Patients Attending a Tertiary Care Center in India. Agrawal, R; Kumar, H; Kumar, S; Nath, T; Roy, SS; Satsangi, SK, )	0.13
"EP-104IAR is capable of providing a safe and prolonged local exposure to a corticosteroid in the synovial joint while minimizing systemic exposure, with peak exposures occurring within a matter of days after dosing before declining in all tissues in a predictable manner."	( Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees. Dhollander, A; Getgood, A; Helliwell, J; Malone, A; Price, J, 2019)	0.78
" The model was applied to the evaluation of three different inhaled corticosteroids (ICSs) used for asthma management in children (a total of 16 drugs with different dosage forms and strengths or different manufacturers)."	( Method Development for Clinical Comprehensive Evaluation of Pediatric Drugs Based on Multi-Criteria Decision Analysis: Application to Inhaled Corticosteroids for Children with Asthma. Han, S; Hu, L; Jia, L; Liu, Y; Meng, Y; Nie, X; Peng, X; Wang, X; Yu, Y; Zhang, M; Zhang, X, 2018)	0.48
" The advantage of them are related with higher adherence and better acceptability by the patients as compared to both components dosed with individual inhalers."	( Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction. Antohe, I; Antoniu, SA; Gavrilovici, C, 2018)	0.48
" Two months of treatment by a double dosage of proton pump inhibitors led to no regression of disorders, and the repeated biopsies from the stenotic segments resulted in over 30 eosinophil counts in the high-power microscopic field, which histologically corresponds to eosinophilic esophagitis."	( An enigma of eosinophilic esophagitis. Damjanov, D; Jocić, T; Krnetić, Ž; Savić, Ž; Vračarić, V; Živojinov, M, 2017)	0.46
" Asthma guidelines and clinician prescribing practice need to be modified in accordance with the currently available evidence of the dose-response relationship of ICS in adult asthma."	( Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. Beasley, R; Bird, G; Harper, J; Maijers, I; Pavord, ID; Weatherall, M, 2019)	0.51
"This study intended to investigate the in vivo pulmonary fate of intratracheally dosed nanosuspensions of fluticasone propionate (FP)."	( Fluticasone propionate nanosuspensions for sustained nebulization delivery: An in vitro and in vivo evaluation. Chen, WY; Cong, ZQ; Fu, TT; Liao, YH; Liu, CY; Yang, FF; Zhao, Y; Zheng, Y, 2019)	2.17
"Two inhales of FP/FM (50/5μg) at one time, twice daily were administered for 24 weeks to Japanese asthma patients aged 5 to ＜16 years who had asthma symptoms during the observation period while using the same dosage of ICS during a certain period of time."	( [A PHASE III STUDY TO EVALUATE SAFETY AND EFFICACY OF FLUTICASONE/FORMOTEROL COMBINATION (FLUTIFORM Ishikawa, Y; Kamata, M; Katsunuma, T, 2020)	0.81
" Les chats ont initialement été évalués au moment du recrutement et puis à huit semaines avec des radiographies thoraciques, lavage bronchoalvéolaire, tests de fonction pulmonaire et dosage de la fructosamine."	( Treatment of naturally occurring asthma with inhaled fluticasone or oral prednisolone: A randomized pilot trial. Bain, P; Egan, A; Knoll, J; Oura, TJ; Rozanski, EA; Sharp, CR; Verschoor-Kirss, M, 2021)	0.87
" MON, or combination of MFC, with no limitation of dosage or duration."	( Efficacy and safety of salmeterol/fluticasone compared with montelukast alone (or add-on therapy to fluticasone) in the treatment of bronchial asthma in children and adolescents: a systematic review and meta-analysis. Hong, JG; Lu, J; Qin, Z; Zhou, XJ, 2021)	0.9
"This study compared the bronchoprotective and benefit/risk profiles of various inhaled corticosteroid (ICS) dosing regimens in mild asthma."	( Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma. Aggarwal, B; Cruz, AA; Daley-Yates, P; Fulmali, S; Lulic, Z; Singh, D, 2022)	0.72
"The model-predicted time course of ICS-induced bronchoprotection with regular daily maintenance dosing and 100% adherence showed that all ICS at the highest recommended doses for mild asthma exceeded the threshold for clinically significant bronchoprotective effect for all or most of the 28-day dosing period, mean (90% CI); 100% (96."	( Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma. Aggarwal, B; Cruz, AA; Daley-Yates, P; Fulmali, S; Lulic, Z; Singh, D, 2022)	0.72
"At doses recommended for mild asthma, all ICS regimens provide sustained bronchoprotective efficacy when dosed regularly with high adherence."	( Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma. Aggarwal, B; Cruz, AA; Daley-Yates, P; Fulmali, S; Lulic, Z; Singh, D, 2022)	0.72
"APT-1011 dosing regimens were superior for histologic and endoscopic responses, and for reduction in dysphagia frequency vs placebo."	( Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. Comer, GM; Dellon, ES; Eagle, G; Falk, GW; Hirano, I; Knoop, K; Lucendo, AJ; Nezamis, J; Schlag, C; Schoepfer, AM, 2022)	2.16
" We aimed to perform a systematic review and dose-response meta-analysis on available observational data."	( Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis. de Torres, JP; Ho, T; Kiflen, M; Pitre, T; Seijo, LM; Zeraatkar, D, 2022)	0.72
" A preference of this mode is broader versatility, due to that its straighter dose-response should allow a better adaptation to disease fluctuations, and that its rapid activity enables use as "anti-inflammatory reliever"."	( May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide? Brattsand, R; Selroos, O, 2022)	0.72
" Low plasma concentrations of 6β-hydroxy mometasone were detected after intravenous dosing (Study 1) and after multiple inhaled dosing (Study 2); mometasone was not detected in any samples."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.97
" Repeat dosing of inhaled MF and FP in the therapeutic range (800 μg/day) resulted in greater systemic exposure for MF, and a 35% reduction in serum cortisol that was 2-fold greater than for FP."	( Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate. Daley-Yates, PT; Deans, A; Mehta, R; Sousa, AR, 2022)	0.97
" Systemic disposition parameter estimates were obtained from published pharmacokinetic data after intravenous dosing to improve robustness."	( Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics. Amini, E; Bulitta, JB; Chen, MJ; Drescher, SK; Hochhaus, G; Jiao, Y; Kurumaddali, A; Shao, J, 2023)	1.17
" This article reviews efficacy versus systemic activity profiles for various adherence patterns and dosing regimens of fluticasone furoate (FF)-containing and budesonide (BUD)-containing asthma therapies in clinical trials and real-world studies."	( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023)	1.34
"We performed a structured literature review (1 January 2000-3 March 2022) and mathematical modelling analysis of FF-containing and BUD-containing regular daily dosing in patients with mild-to-severe asthma, as-needed BUD/formoterol (FOR) in mild asthma, and BUD/FOR maintenance and reliever therapy (MART) dosing in moderate-to-severe asthma, to assess efficacy (bronchoprotection) and systemic activity (cortisol suppression) profiles of dosing patterns of ICS use in multiple adherence scenarios."	( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023)	1.13
" Focusing on FF-containing or BUD-containing treatments at comparable adherence rates, regular daily FF or FF/vilanterol (VI) dosing provided more prolonged bronchoprotection and fewer systemic effects than daily BUD, daily BUD/FOR, or BUD/FOR MART dosing, especially in low adherence scenarios."	( Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management. Berend, N; Daley-Yates, P; Igea, JM; Macchia, L; Plank, M; Singh, D; Verma, M, 2023)	1.13

Role	Description
anti-allergic agent	A drug used to treat allergic reactions.
anti-asthmatic drug	A drug used to treat asthma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
11beta-hydroxy steroid	Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
3-oxo-Delta(4) steroid	A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
corticosteroid	A natural or synthetic analogue of the hormones secreted by the adrenal gland.
fluorinated steroid	A steroid which is substituted with one or more fluorine atoms in any position.
17alpha-hydroxy steroid	The alpha-stereoisomer of 17-hydroxy steroid.
thioester	A compound of general formula RC(=O)SR'. Compare with thionoester, RC(=S)OR'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID639693	Solubility in simulated lung fluid	2011	Journal of medicinal chemistry, Nov-24, Volume: 54, Issue:22	Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1363681	Anti-inflammatory activity in Brown Norway rat model of ovalbumin-induced inflammation assessed inhibition of eosinophil infiltration in bronchoalveolar lavage at 0.3 mg/kg, it administered 1 hr before ovalbumin aerosol challenge and measured 24 hrs post	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.
AID1363682	Anti-inflammatory activity in Brown Norway rat model of ovalbumin-induced inflammation assessed inhibition of neutrophil infiltration in bronchoalveolar lavage at 0.3 mg/kg, it administered 1 hr before ovalbumin aerosol challenge and measured 24 hrs post	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID639736	Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced neutrophilia in lungs at 100 ug administered 2 hr prior to LPS-challenge	2011	Journal of medicinal chemistry, Nov-24, Volume: 54, Issue:22	Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	427 (15.00)	18.2507
2000's	1367 (48.02)	29.6817
2010's	845 (29.68)	24.3611
2020's	208 (7.31)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,220 (40.13%)	5.53%
Reviews	330 (10.86%)	6.00%
Case Studies	218 (7.17%)	4.05%
Observational	14 (0.46%)	0.25%
Other	1,258 (41.38%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (588)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomised, Placebo-controlled, Four-way Crossover Repeat Dose Study to Evaluate the Effect of the Inhaled Fluticasone Furoate (FF)/GW642444M Combination on Electrocardiographic Parameters, With Moxifloxacin as a Positive Control, in Healthy Subjects [NCT01209026]	Phase 1	85 participants (Actual)	Interventional	2010-06-23	Completed
A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily [NCT00353873]	Phase 4	506 participants (Actual)	Interventional	2005-11-18	Completed
Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients [NCT01131806]	Phase 4	124 participants (Anticipated)	Interventional	2009-12-31	Recruiting
The Effect of Once-daily Fluticasone Furoate on Methacholine-induced Bronchoconstriction in Mild Asthmatics [NCT03898466]	Phase 4	14 participants (Actual)	Interventional	2018-10-30	Completed
Post-Marketing Observational Study to Evaluate Safety Profile of Flixotide 50 μg pMDI Treatment in Chinese Subjects With Asthma Aged 1-<4 Years [NCT03273946]		158 participants (Actual)	Observational	2018-01-09	Completed
A Phase III, Randomized, Open-label, Non-inferiority Study Comparative of Formoterol/Fluticasone Eurofarma 12/250 µg, Foraseq® 12/400 µg and Fluticasone 500 µg in Asthma Patients [NCT01202084]	Phase 3	222 participants (Actual)	Interventional	2012-01-31	Completed
"Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -" [NCT00269087]	Phase 3	122 participants (Actual)	Interventional	2005-01-28	Completed
A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis [NCT00275561]	Phase 2	42 participants (Actual)	Interventional	2005-11-30	Completed
A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroi [NCT00379288]	Phase 3	404 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized, Open-labelled Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids (ICS) on Adult Healthy Volunteers [NCT02476825]	Phase 4	30 participants (Actual)	Interventional	2016-01-20	Active, not recruiting
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US W [NCT03949842]	Phase 4	0 participants (Actual)	Interventional	2019-06-27	Withdrawn(stopped due to The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.)
Sub-Sensitivity to Long-Acting Bronchodilators (LABA) [NCT01117116]		21 participants (Actual)	Interventional	2010-03-31	Completed
Drug Use Investigation for ALLERMIST [NCT01376206]		2,000 participants (Actual)	Observational	2009-12-31	Completed
Phase 3, Multicenter, Randomized, Parallel-Group, Open-Label, Comparative Non-Inferiority Fixed-Dose Combination Formoterol 6 mcg/Fluticasone 125 mcg Versus Alenia® (Formoterol 6 mcg/Budesonide 200 mcg) in the Treatment of Moderate Asthma [NCT05735431]	Phase 3	132 participants (Anticipated)	Interventional	2024-07-30	Not yet recruiting
Retrospective, Real-life Evaluation of the Effectiveness, Cost-effectiveness and Direct Healthcare Costs of Qvar Pressurised Metered-dose Inhaler (pMDI) Compared With Beclometasone Dipropionate pMDI and Fluticasone pMDI in the Management of Chronic Obstru [NCT01141452]		815,377 participants (Actual)	Observational	2001-01-31	Completed
An Open-label, Non-randomised, Three-way Crossover, Single Dose Study to Determine the Absolute Bioavailability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder, in Healthy Subjects [NCT01299558]	Phase 1	16 participants (Actual)	Interventional	2010-05-17	Completed
Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis [NCT03781596]	Phase 4	100 participants (Anticipated)	Interventional	2018-10-02	Recruiting
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT03751202]	Phase 1	34 participants (Actual)	Interventional	2018-11-20	Completed
Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation [NCT03673384]		50 participants (Actual)	Interventional	2015-03-02	Completed
Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric) [NCT01332422]		300 participants (Actual)	Observational	2009-11-30	Completed
Nebulized Corticosteroid for Post Extubation Stridor in Children: A Randomized Double Blind Controlled Trial [NCT02523820]	Phase 3	144 participants (Actual)	Interventional	2015-01-31	Completed
Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy [NCT01260753]	Phase 2	24 participants (Anticipated)	Interventional	2010-12-31	Completed
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in Adult Subjects With Asthma [NCT03879837]	Phase 3	1,902 participants (Actual)	Interventional	2019-03-25	Completed
Retrospective, Real-life Observational Evaluation of the Effectiveness and Cost-effectiveness of Extra-fine Hydrofluoroalkane (HFA) Beclometasone (BDP) Compared With Fluticasone Propionate (FP) in the Management of Asthma in a Representative Population in [NCT01287351]		82,903 participants (Actual)	Observational	2004-01-31	Completed
Effect of High Dose Inhaled Budesonide and Fluticasone on Adrenal Function in Patients With Moderate to Severe COPD [NCT01186653]	Phase 4	22 participants (Actual)	Interventional	2007-10-31	Completed
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures [NCT01199757]		540 participants (Actual)	Observational	2009-07-10	Completed
A PHASE III, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY COMPARATIVE STUDY BETWEEN SERETIDE® 50/250 µG AND SALMETEROL/FLUTICASONE SINGLE INHALATION CAPSULE 50/250 µG EUROFARMA IN PATIENTS WITH ASTHMA [NCT01202097]	Phase 3	334 participants (Anticipated)	Interventional	2011-08-31	Completed
Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combinati [NCT03004131]	Phase 4	82 participants (Actual)	Interventional	2017-01-07	Completed
Personalized Treatment Algorithms for Difficult-to-treat Asthma: Bench to Community [NCT04179461]	Phase 2	21 participants (Actual)	Interventional	2018-03-16	Completed
Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays Single-centre, Randomised, Open-label, Three-period, Six-sequence Cross-over Trial (W [NCT01194622]	Phase 1	30 participants (Actual)	Interventional	2010-08-31	Completed
Arnuity Ellipta Drug Use Investigation [NCT03184480]		336 participants (Actual)	Observational	2017-08-19	Completed
Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease: a Multi-center, Randomized, Controlled Trial [NCT03169504]	Phase 3	150 participants (Anticipated)	Interventional	2017-05-31	Not yet recruiting
Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthm [NCT01312961]	Phase 2	104 participants (Actual)	Interventional	2011-03-31	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-Severe Asth [NCT03387852]	Phase 2	296 participants (Actual)	Interventional	2018-03-12	Completed
An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma [NCT02573233]	Phase 2	42 participants (Actual)	Interventional	2016-01-27	Completed
Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover Phase 1/2a Study Testing Safety/Efficacy of Advair HFA (Salmeterol, Fluticasone) in Resting & Exercising Healthy & High Altitude Pulmonary Edema (HAPE) Predisposed Subjects [NCT06040268]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2023-12-12	Recruiting
A Double-dummy, Double-blind, Randomized, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in [NCT05776927]	Phase 3	304 participants (Anticipated)	Interventional	2024-12-23	Not yet recruiting
A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoat [NCT00519636]	Phase 4	360 participants (Actual)	Interventional	2007-08-31	Completed
Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects [NCT02889809]	Phase 4	477 participants (Actual)	Interventional	2016-10-20	Completed
A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powde [NCT02924688]	Phase 3	2,436 participants (Actual)	Interventional	2016-10-13	Completed
A Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center, Parallel Group Study to Show the Superiority in Lung Function of 12 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Res [NCT03240575]	Phase 4	302 participants (Actual)	Interventional	2017-08-14	Completed
Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone) [NCT01332409]		2,000 participants (Actual)	Observational	2009-08-31	Completed
Phase I Single Blind, Randomised, Cross-over Pharmacodynamic Dose Response Study in Healthy Volunteers of Two Pressurized Metered Dose Inhalers (pMDIs) That Deliver Salmeterol and Fluticasone Propionate [NCT02232087]	Phase 1	52 participants (Actual)	Interventional	2014-07-31	Completed
A Single-dose, Randomised, Crossover, Placebo-controlled, Double-dummy, Pharmacodynamic Clinical Trial Assessing Two Fixed Dose Combinations of Long-acting Beta-agonist (LABA) and Inhaled Corticosteroid (ICS) [NCT02094274]	Phase 1	30 participants (Actual)	Interventional	2013-11-30	Completed
A Multicenter, Partially-Blinded, Randomized, 24-Week, Parallel-Group, Non-Inferiority, Open-Label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With [NCT03158311]	Phase 3	1,426 participants (Actual)	Interventional	2018-02-05	Completed
Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting [NCT01337323]		3 participants (Actual)	Observational	2010-09-30	Terminated(stopped due to Insufficient number of patient records met inclusion criteria)
Effects of Treated and Untreated Allergic Rhinitis on Mood, Cognitive Functions and Actual Driving Performance [NCT01318681]		22 participants (Actual)	Interventional	2011-01-31	Completed
Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Density in Adults With Asthma [NCT00394355]	Phase 4	566 participants (Actual)	Interventional	2006-09-30	Completed
A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmo [NCT01336608]	Phase 3	446 participants (Actual)	Interventional	2011-03-04	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT05697003]	Phase 1	34 participants (Anticipated)	Interventional	2023-02-17	Active, not recruiting
A Randomized, Double-Blind (3rd Party Open), Placebo-Controlled, 2-Way Crossover Study To Determine The Effects Of A Single Inhaled Dose Of 500 MCG Fluticasone Propionate On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge I [NCT01364519]	Phase 1	17 participants (Actual)	Interventional	2011-07-31	Completed
A Proof Of Concept Study to Investigate the Clinical, Histological And Molecular Predictors of Response to Oral and Intranasal Corticosteroid in Nasal Polyposis [NCT00788749]	Phase 4	60 participants (Actual)	Interventional	2004-05-31	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. SERETIDE D [NCT03894280]	Phase 1	36 participants (Actual)	Interventional	2019-03-12	Completed
Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis [NCT04242368]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2020-07-01	Withdrawn(stopped due to COVID-19 pandemic, unable to recruit and conduct study procedures per state, local, and university policies.)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis Wit [NCT00562159]	Phase 3	439 participants (Actual)	Interventional	2007-11-30	Completed
A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With [NCT00118716]	Phase 4	248 participants (Actual)	Interventional	2003-12-23	Completed
A Multicenter, Double-Blind, Randomized, Crossover Design Study to Evaluate the Effect of Montelukast Vs. Salmeterol on the Inhibition of Exercise-Induced Bronchoconstriction in Asthmatic Patients Aged 6-14 Years [NCT00127166]	Phase 3	154 participants (Actual)	Interventional	2005-12-31	Completed
Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate: Defining a Urine Threshold and Decision Limit for Vilanterol in Doping Control Analysis [NCT03739294]	Phase 2	26 participants (Actual)	Interventional	2019-02-08	Completed
Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental [NCT04652245]	Phase 4	216 participants (Actual)	Interventional	2020-12-14	Completed
Effectiveness of Cycling of Topical Steroid Therapy in Maintaining Clinical and Histologic Remission in Eosinophilic Esophagitis [NCT05444543]	Phase 4	30 participants (Anticipated)	Interventional	2021-11-17	Recruiting
A Single-blind, Randomized, Active-controlled, Multi-center and Phase IV Study to Evaluate the Small Airway Parameters of Fluticasone/Formoterol (Flutiform®) Compared to Fluticasone/Salmeterol in Asthma Patients [NCT02491970]	Phase 4	15 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Difficulty of patients enrollments)
Randomised, Double-blind, Triple Dummy, Partial Cross-over (Each Active Treatment With Placebo) Study Using an Environmental Challenge Chamber (ECC) to Assess the Safety and Efficacy of 2 Weeks of Oral BI 671800 ED 50, 200 or 400 mg Bid, Compared to Monte [NCT01007721]	Phase 2	146 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOV [NCT05397834]	Phase 1	36 participants (Actual)	Interventional	2022-05-11	Active, not recruiting
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma [NCT02554786]	Phase 3	2,216 participants (Actual)	Interventional	2015-12-29	Completed
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing [NCT03199976]	Phase 4	80 participants (Actual)	Interventional	2016-04-20	Completed
Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays Single-centre, Randomised, Open-label, Three-period, Six-sequence Cross-over Trial (William's Design) [NCT01190852]	Phase 1	30 participants (Actual)	Interventional	2010-08-31	Completed
Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma? [NCT02318043]		84 participants (Actual)	Interventional	2007-01-31	Completed
A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma [NCT03012061]	Phase 2	425 participants (Actual)	Interventional	2017-01-25	Completed
An Escalating Dose, Randomized, Placebo-controlled, Incomplete-block, 2-period Cross-over Study to Assess the Dose Response for Topical Efficacy Via Airway Responsiveness to Adenosine-5'-Monophosphate (AMP) Challenge and the Dose Response for Systemic Act [NCT02991859]	Phase 2	56 participants (Actual)	Interventional	2017-02-09	Completed
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With [NCT02980133]	Phase 3	841 participants (Actual)	Interventional	2016-12-28	Completed
A Multicenter, Randomized, Parallel-group, Placebo-controlled, 4-week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 µg Inhalation Powder With Advair® Diskus 100/50 µg in Asthma Patients [NCT03394989]	Phase 3	1,366 participants (Actual)	Interventional	2018-10-17	Completed
A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation [NCT03676413]	Phase 3	451 participants (Actual)	Interventional	2018-10-02	Completed
An Open Label, Randomised, Six-way Crossover, Single Dose Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination [NCT02064504]	Phase 1	48 participants (Actual)	Interventional	2014-02-19	Completed
As Needed Versus Regular Use of Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis: A Randomized Controlled Trial [NCT05299086]		68 participants (Anticipated)	Interventional	2022-04-04	Recruiting
Comparison of Exacerbation Risk and Health Outcomes in Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Patients Using Stiolto Versus Trelegy, a Real-World Study [NCT05169424]		9,117 participants (Actual)	Observational	2021-12-17	Completed
A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination With Formoterol Fumarate in Subjects With COPD [NCT01168310]	Phase 2	468 participants (Actual)	Interventional	2010-08-31	Completed
A Randomized, Placebo-controlled, Double-blind, Six-way Crossover, Single-dose Exposure Study to Compare the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™100/10μg and 250/10μg) in a Single Inhaler (SkyePharma HFA MDI) With the [NCT00830102]	Phase 2	64 participants (Actual)	Interventional	2004-10-31	Completed
A Phase IV, Open Label, Multicentre, Randomised, 2-way Cross-over Exploratory Clinical Trial Comparing TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on Lung Stiffness Reduction Assessed Through Area Under the Reactance Curve (AX) in COPD. [NCT04671355]	Phase 4	0 participants (Actual)	Interventional	2021-10-04	Withdrawn(stopped due to Continuing delays due to COVID-19 pandemic)
Inhaled Corticosteroids do Not Modify the Systemic Inflammation Induced by Exercise in Patients With Chronic Obstructive Pulmonary Disease [NCT02209974]	Phase 4	23 participants (Actual)	Interventional	2004-02-29	Completed
A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects With Partly Controlled and Uncontrolled Asthma [NCT01516086]	Phase 2	498 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005, Incorporating Amendment 1 and 2 [NCT00747318]	Phase 3	280 participants (Actual)	Interventional	2008-09-30	Completed
A Single (Assessor)-Blind, Randomised, Three-period, Cross-over Study to Compare the Safety of Flutiform pMDI, Fluticasone pMDI, and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years With Mild Persistent Asthma by Means of Knemom [NCT02063139]	Phase 2	48 participants (Actual)	Interventional	2014-02-28	Completed
A Randomized, Placebo-controlled, Double-blind, Crossover, Single-dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 µg HFA pMDI and FlutiForm 250/10 µg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderat [NCT00734292]	Phase 2	39 participants (Anticipated)	Interventional	2008-09-30	Completed
"A 12 Week Multicenter, Open-Label, Randomized, Observational Study Comparing Singulair® 10 Mg As Controller Monotherapy In Adults With Mild Asthma To Low Dose Inhaled Corticosteroid Treatment" [NCT00545324]	Phase 4	399 participants (Actual)	Interventional	2002-09-30	Completed
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial [NCT02778867]	Phase 2/Phase 3	129 participants (Actual)	Interventional	2016-05-20	Completed
A Pilot Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo Nasal Spray in Reducing Nasal Allergic Symptoms Following Ragweed Exposure in the Allergen BioCube (ABC) [NCT01076439]	Phase 4	0 participants (Actual)	Interventional		Withdrawn
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma [NCT03535870]		1,556 participants (Actual)	Interventional	2018-04-26	Completed
A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled [NCT00079937]	Phase 3	628 participants (Actual)	Interventional	2004-04-30	Completed
A Randomized, Double-blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen [NCT00929968]	Phase 2	35 participants (Actual)	Interventional	2009-06-30	Completed
Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data. [NCT01332344]		5,180 participants (Actual)	Observational	2009-06-30	Completed
An 8 Day, Randomised, Double Blind, 3-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Fluticasone Propionate in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR) [NCT00612820]	Phase 2	55 participants (Actual)	Interventional	2008-01-31	Completed
A Randomised, Phase II, Double-Blind, Double-Dummy, Four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 mcg Bid, MDI), Ciclesonide (400 mcg qd, MDI), Ciclesonide (800 mcg qd, MDI) or Placebo in Free [NCT00535366]	Phase 2	103 participants (Actual)	Interventional	2007-10-31	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg or 250/10 µg Twice Daily) in a Single Inhaler (Sky [NCT00393952]	Phase 3	557 participants (Actual)	Interventional	2006-06-30	Completed
Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD [NCT01209715]	Phase 2	0 participants (Actual)	Interventional	2010-10-31	Withdrawn(stopped due to Due to the ubiquitous use of ICS in the treatment of COPD in 2012, it was hard to find the study population.)
Long-term Effects of Inhaled Corticosteroids (ICS) Treatment on Sputum Bacterial and Viral Loads in Chronic Obstructive Pulmonary Disease (COPD) Patients [NCT01213693]		60 participants (Actual)	Interventional	2009-05-31	Completed
An Open-label, Randomised, 3-way Crossover Single Dose Study to Demonstrate Dose Proportionality of Fluticasone Furoate (FF) and Equivalence of Vilanterol (VI) When Administered as FF/VI Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subje [NCT01213849]	Phase 1	24 participants (Actual)	Interventional	2010-10-04	Completed
A Pivotal, Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respir [NCT04466176]	Phase 1	34 participants (Actual)	Interventional	2020-07-01	Completed
A Pilot Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent [NCT04462822]	Phase 1	14 participants (Actual)	Interventional	2020-08-24	Completed
A Retrospective Evaluation of the Effectiveness of Fixed-dose Combination Inhaled Corticosteroid /. Long-acting Beta Agonist (ICS/LABA) Therapy in the Management of Asthma in a Representative UK Primary Care Population [NCT01141465]		815,377 participants (Actual)	Observational	2001-01-31	Completed
Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis [NCT00651118]	Phase 3	832 participants (Actual)	Interventional	2008-03-31	Completed
Effects on Small Airways Obstruction of Two Long-term Treatments With Extrafine Beclomethasone/Formoterol vs Fluticasone/Salmeterol in Asthma [NCT01255579]	Phase 4	10 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS® 100/50 (Flutica [NCT03756883]	Phase 3	999 participants (Actual)	Interventional	2018-12-03	Completed
A Multi-centre, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Anti-IgE Monoclonal Antibody to Treat Allergic Asthma Patients Not Adequately Controlled Despite Med/High ICS/LABA. [NCT03468790]	Phase 3	393 participants (Actual)	Interventional	2018-05-09	Completed
A Retrospective Evaluation of the Effectiveness and Cost-effectiveness of HFA-BDP MDI (Qvar®) Compared With CFC-BDP MDI and FP MDI Used in the Management of Asthma in a Representative UK UK Primary Care Population [NCT01141439]		815,377 participants (Actual)	Observational	2001-01-31	Completed
Comparison of Bronchodilator Efficacy of Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Combination Treatment Administered Via Discair® With Original Products Seretide Diskus 500 mcg Inhalation Powder Plus Spiriva 18 mcg Inhalation Powder Treatment in Pat [NCT03395002]	Phase 4	58 participants (Actual)	Interventional	2018-03-22	Completed
A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma [NCT03063086]	Phase 2	116 participants (Actual)	Interventional	2017-01-21	Completed
A Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Effectiveness of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD [NCT03745261]	Phase 3	240 participants (Anticipated)	Interventional	2018-06-20	Recruiting
A Randomized, Double-blind, Parallel Group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK3772847 Compared With Placebo in Participants With Moderately Severe Asthma [NCT03207243]	Phase 2	165 participants (Actual)	Interventional	2017-09-14	Completed
An Exploratory, Randomised, Double-blind, Double-dummy, Active-controlled, Two Period Cross-over Study to Investigate the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) Delivered by the Respimat® Inhaler [NCT03055988]	Phase 4	76 participants (Actual)	Interventional	2017-03-29	Completed
"CONNected Electronic Inhalers Asthma Control Trial 2 (CONNECT 2), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes i [NCT04677959]	Phase 4	427 participants (Actual)	Interventional	2021-02-16	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center Study to Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease [NCT01013701]	Phase 4	7 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to Terminated based on mutual agreement between PI and sponsor (Glaxo Smith Kline))
A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiov [NCT01313676]	Phase 3	16,568 participants (Actual)	Interventional	2011-01-25	Completed
A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma [NCT01018186]	Phase 3	503 participants (Actual)	Interventional	2009-10-19	Completed
A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT01192191]	Phase 3	187 participants (Actual)	Interventional	2010-08-31	Completed
Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator [NCT02678949]		105 participants (Anticipated)	Interventional	2016-03-31	Not yet recruiting
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma [NCT00736801]		35 participants (Actual)	Interventional	2005-09-30	Completed
A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents With Irri [NCT00730756]	Phase 2	102 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized Double Blind Study of the Dose Response Effects of Fluticasone Propionate on Hypertonic-saline Induced Bronchoconstriction in Asthmatic Subjects [NCT00606242]	Phase 4	44 participants (Actual)	Interventional	2000-01-31	Completed
A 2-year Observational Study to Evaluate Safety of Seretide 50/500μg Twice Daily Administered by DISKUS, in Patients With COPD [NCT00662805]		762 participants (Actual)	Observational	2004-06-30	Completed
Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair [NCT00927758]	Phase 2	105 participants (Actual)	Interventional	2009-06-30	Completed
Comparative, Multicentre, Randomized, Double-blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With So-called 'Red Face' L [NCT00690105]	Phase 4	577 participants (Actual)	Interventional	2004-02-29	Completed
A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over [NCT00783458]	Phase 4	100 participants (Actual)	Interventional	2004-12-01	Completed
A Double Blind (3rd Party Open), 3-Way Crossover Study To Explore The Reproducibility Of Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis (Out Of Season) And The Effect Of A Single Dose Of Ibuprofen Or Flutic [NCT01064726]	Phase 1	18 participants (Actual)	Interventional	2009-10-31	Completed
Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) in a Multi-center, Double-Blinded, Placebo-controlled Trial [NCT05275686]	Phase 2	80 participants (Anticipated)	Interventional	2022-04-20	Recruiting
An Open-Label, 2-Part, Randomized, Crossover Study to Compare the Bioavailability of Intranasal Administration of 200 and 400 µg of OPTINOSE™ FLUTICASONE With 400 µg of Flonase® (Fluticasone Propionate) Nasal Spray (Part 1), and Intranasal Administration [NCT02266927]	Phase 1	28 participants (Actual)	Interventional	2014-09-30	Completed
A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With [NCT00393991]	Phase 3	475 participants (Actual)	Interventional	2006-07-31	Completed
The Causal Relation of Nasal Nitric Oxide Levels to the Severity of Chronic Rhinosinusitis and Its Inflammatory Phenotype [NCT04171167]		88 participants (Actual)	Interventional	2017-04-04	Active, not recruiting
201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects With Asthma and Exercise-Induced Bronchoconst [NCT02730351]	Phase 4	75 participants (Actual)	Interventional	2016-05-25	Completed
AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) [NCT02238353]	Phase 4	45 participants (Anticipated)	Interventional	2014-10-31	Recruiting
An Open-Label, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of High Strength Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to Hi [NCT02437604]	Phase 1	43 participants (Actual)	Interventional	2015-05-31	Completed
Evaluation of Clinical Efficacy of HFA-Propelled Beclomethasone Dipropionate Metered-Dose Inhaler Versus Fluticasone Propionate Multidose Dry Powder Inhaler on Small Airways in Poorly Controlled Asthmatic Adolescent and Adult Patients [NCT00071552]	Phase 4	49 participants (Actual)	Interventional	2004-01-31	Terminated(stopped due to Very poor enrollment)
Effectiveness of Single Inhaler Maintenance and Reliever Therapy With Spiromax® Budesonide/Formoterol (SMART) Versus Fixed Dose Treatment With Diskus® Fluticasone/Salmeterol in Patients With a Chronic Obstructive Pulmonary Disease (COPD) [NCT02477397]	Phase 3	201 participants (Actual)	Interventional	2015-05-01	Active, not recruiting
Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a With the Respiratory Epithelium in Children Affected by Allergic Rhinoconjunctivitis [NCT03449836]	Phase 3	60 participants (Anticipated)	Interventional	2018-03-01	Not yet recruiting
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µg/Inhalation: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects [NCT03060044]	Phase 1	64 participants (Actual)	Interventional	2016-07-31	Completed
Phase IV Study; Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation [NCT02136875]	Phase 4	37 participants (Actual)	Interventional	2008-07-31	Completed
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µG/Inhalation; A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects [NCT02162485]	Phase 1	129 participants (Actual)	Interventional	2014-06-30	Completed
Effects of Hypertonic Saline and Fluticasone Nasal Sprays on Radiologic Scoring of Patients With Chronic Sinusitis and Nasal Polyps [NCT03174483]		60 participants (Anticipated)	Interventional	2017-06-30	Recruiting
Randomized Controlled Trial Evaluating Combination Rupatadine and Fluticasone Propionate Compared to Azelastine Hydrochloride and Fluticasone Propionate in Treating Allergic Rhinitis [NCT04601324]	Phase 4	0 participants (Actual)	Interventional	2020-12-15	Withdrawn(stopped due to PI did not pursue this study)
201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD [NCT02573870]	Phase 2	63 participants (Actual)	Interventional	2015-12-01	Completed
Evaluation of the Effects of Varying Doses of Inhaled Corticosteroids on Suppression of Total Exhaled, Bronchial, and Alveolar Nitric Oxide as Markers of Endogenous Inflammation in Patients With Moderate-to-severe COPD [NCT00568347]		39 participants (Actual)	Observational	2006-01-31	Completed
Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma [NCT02577497]	Phase 4	31 participants (Actual)	Interventional	2016-06-30	Completed
Seretide 100 DK vs Flixotide 100 DK in IMT in Moderate Asthma in Adults on Static Lung Volumes (Mechanistic Study) [NCT00461500]	Phase 4	81 participants (Actual)	Interventional	2007-03-31	Completed
A Six-Week, Randomised, Double-Blind, Triple-Dummy, Parallel Group, Multiple Dose, Pilot Study Comparing Tiotropium Inhalation Capsules to Salmeterol Inhalation Aerosol Combined With Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulm [NCT00239499]	Phase 4	107 participants	Interventional	2003-09-30	Completed
The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD) [NCT00741767]		0 participants (Actual)	Interventional	2008-08-31	Withdrawn(stopped due to Study subject enrollment difficulties)
A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population [NCT00546000]	Phase 4	56 participants (Actual)	Interventional	2007-07-31	Completed
A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 [NCT00542880]	Phase 4	442 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhi [NCT00682643]	Phase 4	550 participants (Actual)	Interventional	2008-06-30	Completed
A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoat [NCT00539006]	Phase 4	377 participants (Actual)	Interventional	2007-08-31	Completed
A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salb [NCT00669617]	Phase 3	89 participants (Actual)	Interventional	2008-04-30	Completed
Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams [NCT00803465]		115 participants (Actual)	Observational	2003-04-30	Completed
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamys® Administered in Korean Patients According to the Prescribing Information [NCT01001130]		3,244 participants (Actual)	Observational	2010-05-31	Completed
A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50mcg HFA (2 Inhalations of 50/25mcg) Twice Daily Compared With Fluticasone Propionate 100mcg HFA (2 Inhalations of 50mcg) Twice Daily in Subje [NCT00441441]	Phase 3	351 participants (Actual)	Interventional	2007-02-28	Completed
A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis [NCT00435461]	Phase 4	1,000 participants (Actual)	Interventional	2006-12-20	Completed
Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study. [NCT02290717]		0 participants (Actual)	Interventional	2015-05-31	Withdrawn(stopped due to Difficulty including patients)
A Two-arm, Randomised, Assessor-blind, Parallel Group Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) and Relvar® Ellipta® DPI on Ventilation Heterogeneity in Subjects With Partially Controlled or Uncontrolled Asthma [NCT02753712]	Phase 3	105 participants (Actual)	Interventional	2016-06-15	Completed
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers [NCT05381207]	Early Phase 1	60 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Efficacy and Safety of Fluticasone Furoate/Vilanterol vs. Umeclidinium/Vilanterol in Patients With COPD-asthma Phenotype vs. Emphysema Phenotype. A Controled Clinical Trial. [NCT05342558]	Phase 4	133 participants (Actual)	Interventional	2017-09-19	Completed
Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects [NCT00616538]	Phase 4	121 participants (Actual)	Interventional	2006-12-31	Completed
Ciclesonide vs Fluticasone Propionate Nasal Sprays in Patients With Nasal Poplyposis; a Randomized Clinical Trial [NCT02665806]	Phase 3	32 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA. [NCT00646620]	Phase 3	48 participants (Actual)	Interventional	2003-04-30	Completed
Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma [NCT00980707]	Phase 4	10 participants (Actual)	Interventional	2009-08-31	Completed
STUDY NUMBER: PMC-101-APT Usability and Adherence of Spiromax® Inhaler Device, Turbohaler® and Diskus® Inhaler Devices for Fixed Combination of Corticosteroid/Long-acting beta2- Agonist, in Adults With Asthma or COPD [NCT02757209]		84 participants (Actual)	Interventional	2016-04-30	Completed
A 12 Month Open-label Randomized Parallel Group Study to Investigate the Influence of Salmeterol Xinafoate/Fluticasone Propionate Either in Fixed Combination or Separately Via Diskus Inhalers on the Course of the Disease and Frequency of Exacerbations in [NCT00527826]	Phase 4	214 participants (Actual)	Interventional	2007-11-30	Completed
Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS. [NCT00867737]	Phase 4	30 participants (Anticipated)	Interventional	2008-09-30	Recruiting
A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Twice Daily Via DISKUS® Inhaler Versus Salmeterol 50mcg Twice Daily Via DISKUS® Inhaler on Bone Mineral [NCT00355342]	Phase 4	186 participants (Actual)	Interventional	2004-04-28	Completed
A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis [NCT00903227]	Phase 4	25 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT03975166]	Phase 1	34 participants (Actual)	Interventional	2019-05-21	Completed
Effect of Charcoal on Gastrointestinal Absorption of Salmeterol and Fluticasone Propionate. [NCT01564199]	Phase 1	20 participants (Actual)	Interventional	2012-04-30	Completed
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis [NCT00119015]	Phase 4	102 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to Difficulty in recruitment)
A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis [NCT00655109]	Phase 4	60 participants (Actual)	Interventional	2008-02-29	Completed
A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation P [NCT00784550]	Phase 4	342 participants (Actual)	Interventional	2008-12-31	Completed
Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis [NCT00783224]	Phase 3	351 participants (Actual)	Interventional	2005-09-30	Completed
Bioequivalence of Two Fluticasone Propionate 0.005% Topical Ointments [NCT00803218]		56 participants (Actual)	Observational	2002-11-30	Completed
Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis. [NCT00740792]	Phase 3	776 participants (Actual)	Interventional	2008-08-31	Completed
A Study to Compare GW815SF HFA MDI With Concomitant Treatment With Salmeterol Xinafoate DPI Plus Fluticasone Propionate DPI and to Assess Long-term Safety of GW815SF HFA MDI [NCT00448435]	Phase 3	51 participants (Actual)	Interventional	2007-04-30	Completed
Randomized, Double-blind, Two Way Cross-over, Proof of Concept Study to Compare Efficacy, Safety, Pharmacokinetics & Pharmacodynamics of QAV680 Versus Placebo, With an Extended Open-label Corticosteroid Period, in Steroid-free, Mild to Moderate Persistent [NCT00814216]	Phase 2	37 participants (Actual)	Interventional	2008-12-31	Completed
SERETIDE vs FLIXOTIDE in Mild Persistent Asthma (GINAII) [NCT00455923]	Phase 4	100 participants (Actual)	Interventional	2005-05-03	Completed
A Randomized, Double-blind, Two-way Cross-over Study Evaluating Systemic Bioavailability and Airway Clearance of SymbicortTurbuhaler 320/9mcg vs SeretideDiskus 50/500mcg After Single Inhalations in Patients With COPD and Healthy Volunteers [NCT00379028]	Phase 4	54 participants (Actual)	Interventional	2006-09-30	Completed
Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution Alone and In Combination on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen. [NCT01007253]	Phase 4	21 participants (Actual)	Interventional	2009-11-30	Completed
Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure: A Randomized, Double-blind, Placebo Controlled Trial [NCT04208581]	Phase 3	372 participants (Anticipated)	Interventional	2019-10-08	Enrolling by invitation
A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adu [NCT01147848]	Phase 3	810 participants (Actual)	Interventional	2010-06-30	Completed
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and A [NCT01134042]	Phase 3	587 participants (Actual)	Interventional	2010-06-30	Completed
A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA. [NCT00646009]	Phase 3	48 participants (Anticipated)	Interventional	2003-03-31	Completed
A Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm® pMDI 250/10µg (2 Puffs Bid) vs Fluticasone pMDI 250µg (2 Puffs Bid) Plus Formoterol pMDI 12µg (2 Puffs Bid) Administered C [NCT00734318]	Phase 3	1,667 participants (Actual)	Interventional	2008-09-30	Completed
Investigator Initiated, Placebo Controlled, Randomized Pilot Trial on the Influence of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers With COPD Stage GOLD 0 or 1. [NCT00908362]	Phase 1	45 participants (Anticipated)	Interventional	2009-05-31	Completed
A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season. [NCT01192178]	Phase 4	339 participants (Actual)	Interventional	2010-08-31	Completed
A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma [NCT01086384]	Phase 3	2,020 participants (Actual)	Interventional	2010-02-22	Completed
A Phase III, 4-week, Randomized, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI), 'Open' Triple Therapy (FF/VI + UMEC) and Dual Therapy (FF/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT02731846]	Phase 3	0 participants (Actual)	Interventional	2016-06-30	Withdrawn(stopped due to It has been determined on June 10th that the 205165 study will not progress. This decision has been made prior to study start, no patients were screened.)
A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma [NCT00829257]	Phase 4	15 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized, Double-Blind, Cross-Over Study to Demonstrate Superiority of Fluticasone/Salmeterol Over Double the Dose of Fluticasone on Methacholine Hyper-Reactivity in Patients With Persistent, Mild to Moderate Asthma [NCT00830505]	Phase 4	38 participants (Actual)	Interventional	2009-04-30	Completed
The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide [NCT02546349]	Phase 4	143 participants (Anticipated)	Interventional	2014-07-31	Active, not recruiting
A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age [NCT00646594]	Phase 3	1,200 participants (Anticipated)	Interventional	2003-11-30	Completed
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma [NCT02649478]		1,430 participants (Actual)	Interventional	2014-08-31	Completed
Arg/Arg Genotype and Long Acting Beta Agonists in Asthma. Improved Quality of Care for Patients With Asthma. [NCT00521222]		90 participants (Actual)	Interventional	2007-06-30	Completed
Multi-centre, DB, R and Stratified Parallel Group Study to Compare the Efficacy and Safety of FP 500mcg Bid vs. SRT 50/250mcg Via Diskus in COPD Pts With Partial Reversible Obstruction [NCT00549146]	Phase 3	290 participants (Actual)	Interventional	2003-11-30	Completed
HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in [NCT01165138]	Phase 3	612 participants (Actual)	Interventional	2010-08-20	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects. [NCT00877539]	Phase 1	29 participants (Actual)	Interventional	2009-06-30	Completed
A Proof of Concept Study to Evaluate Effects of Intranasal Salmeterol and Fluticasone Given Alone and in Combination in Allergic Rhinitis [NCT01388595]	Phase 4	23 participants (Actual)	Interventional	2006-11-30	Completed
Multicenter, Phase III, Randomized, Open Label Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD). [NCT01393145]	Phase 3	0 participants (Actual)	Interventional	2011-08-31	Withdrawn
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) [NCT01395849]		2,116 participants (Actual)	Observational	2007-10-31	Completed
Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment [NCT01395875]		2,849 participants (Actual)	Observational	2011-03-31	Completed
A Randomized, Open Label, Multicenter, Phase 4 Study for the Comparison of Efficacy of Tiotropium Plus Salmeterol/ Fluticasone Propionate Compared With Tiotropium Alone in COPD Patients [NCT00864812]	Phase 4	509 participants (Actual)	Interventional	2009-03-31	Completed
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone [NCT05457855]		75,678 participants (Actual)	Observational	2022-02-01	Active, not recruiting
A Methodological Pilot Study to Assess the Suitability of a Low Dose LPS Inhalation as a Challenge Model in Early Translational Drug Development [NCT01400568]		12 participants (Anticipated)	Interventional	2011-08-31	Completed
A Phase 1, Open-Label Study to Investigate the Effect of Albuterol (Salbutamol) and Fluticasone on the Pharmacokinetics of Inhaled Technosphere® Insulin Inhalation Powder in Healthy Subjects [NCT00674050]	Phase 1	13 participants (Actual)	Interventional	2008-05-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects With Perennial Allergic Rhinitis [NCT00570492]	Phase 4	474 participants (Actual)	Interventional	2007-11-26	Completed
The Effect of Intranasal Corticosteroid on the Immune Response Following Nasal Allergen Challenge in Patients Suffering From Seasonal Allergic Rhinitis [NCT00755066]		48 participants (Actual)	Interventional		Completed
A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over [NCT00817050]	Phase 4	100 participants (Actual)	Interventional	2004-12-01	Completed
A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma [NCT00995800]	Phase 2	46 participants (Actual)	Interventional	2009-10-31	Completed
A Randomised, Single Blind, Cross-over Study to Compare a Fixed Dose Combination of Fluticasone Propionate / Formoterol Fumarate (Breath Actuated Inhaler (BAI)) With a Fixed Dose Combination of Indacaterol Maleate / Glycopyrronium Bromide (Ultibro® Breezh [NCT02693769]	Phase 2/Phase 3	2 participants (Actual)	Interventional	2016-07-31	Terminated(stopped due to Recruitment issues)
Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients ( [NCT00530842]	Phase 4	344 participants (Actual)	Interventional	2007-09-30	Completed
A Randomised, Placebo-controlled, 4-period, Incomplete Block, Crossover Study of 7 Days Dosing of Intranasal GW784568X (100mcg, 200mcg and 400mcg od), Fluticasone Propionate (200mcg od) and Placebo (Blinded for GW784568X vs Placebo) to Evaluate the Effica [NCT00404586]	Phase 1	45 participants (Actual)	Interventional	2006-09-11	Completed
Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial [NCT01868113]	Phase 3	1,010 participants (Actual)	Interventional	2012-12-31	Completed
A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asth [NCT00296491]	Phase 4	725 participants (Actual)	Interventional	2005-09-30	Completed
Prospective, Comparative, Double-blind, Parallel, Multicentric, Randomized Study Between Two Brands of Fluticasone Propionate Nasal Topic in The Control of Perene Allergic Rhinithis Symptoms [NCT04332978]	Phase 3	566 participants (Actual)	Interventional	2014-07-04	Completed
A Proof of Concept Study to Evaluate Comparative Efficacy of an Azelastine/Fluticasone Combination Nasal Spray vs. Twice the Dose of Fluticasone in Persistent Allergic Rhinitis [NCT00845598]	Phase 4	0 participants (Actual)	Interventional	2010-08-31	Withdrawn(stopped due to Could not get IMP)
Investigating the Mechanism of Inhaled Corticosteroids Associated Pneumonia by Longitudinal Characterisation of the Airway Microbiome in Patients With Severe COPD [NCT02972476]	Phase 4	158 participants (Actual)	Interventional	2016-12-31	Completed
Bronchiectasis in COPD Patients : Role of Prophylaxis With Inhaled Steroids and Antibiotic on the Natural History of the Disease [NCT00524095]	Phase 2	210 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to we decided not to go on treatment phase)
A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa [NCT00584987]	Phase 4	64 participants (Actual)	Interventional	2007-06-30	Completed
Comparison of Stepwise Treatment of Asthmatic Children With Salmeterol/Fluticasone Propionate Combination Product (Seretide®) and/or Fluticasone Propionate (Flixotide®) Based on PD20 Methacholine and Symptoms or Based on Symptoms Only (Children Asthma The [NCT00158834]	Phase 3	200 participants	Interventional	1999-11-30	Completed
Dose Response of FENO to Inhaled Steroids in Mild-to-moderate Asthma [NCT00995657]	Phase 4	21 participants (Actual)	Interventional	2009-10-31	Completed
Efficacy and Safety of Mometasone Furoate Aqueous Nasal Spray vs Placebo and Flonase® (Fluticasone Propionate) in Seasonal Allergic Rhinitis Patients (I94-001) [NCT03882047]	Phase 3	313 participants (Actual)	Interventional	1994-08-11	Completed
A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Pe [NCT00424008]	Phase 3	722 participants (Actual)	Interventional	2007-04-30	Completed
A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma [NCT00452348]	Phase 4	628 participants (Actual)	Interventional	2007-05-31	Completed
Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) [NCT00395304]	Phase 3	182 participants (Actual)	Interventional	2007-03-31	Completed
Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks [NCT00363480]	Phase 4	221 participants (Actual)	Interventional	2006-05-17	Completed
An Exploratory Study to Evaluate the Response of Salmeterol Plus Fluticasone vs Fluticasone Alone to Experimental Nasal Inoculation With Rhinovirus [NCT00503009]	Phase 4	16 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to lack of data)
A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis [NCT00502775]	Phase 4	680 participants (Actual)	Interventional	2007-08-31	Completed
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial [NCT00156819]	Phase 4	500 participants (Actual)	Interventional	2003-06-30	Completed
Fluticasone Propionate Nasal Spray (Flixonase) Safety in Patients With Allergic Rhinitis Registered in the UK General Practice Research Database [NCT01077609]		1 participants (Actual)	Observational	2008-01-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes [NCT00284856]	Phase 3	1,640 participants (Actual)	Interventional	2006-05-31	Completed
Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma [NCT00294398]		152 participants (Actual)	Interventional	2006-03-31	Completed
A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma [NCT00452699]	Phase 4	621 participants (Actual)	Interventional	2007-05-31	Completed
Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients - a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population [NCT01877954]		2,654 participants (Actual)	Observational	2011-02-28	Completed
Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6- [NCT00242775]	Phase 3	2,100 participants	Interventional	2005-05-31	Completed
Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study) [NCT00220259]		240 participants	Interventional	2001-05-31	Completed
Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy & Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent & Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma [NCT00563056]	Phase 3	227 participants (Actual)	Interventional	2007-09-30	Completed
Evaluation of the Sensitivity of Pharmacokinetics to Differences in the Aerodynamic Particle Size Distribution of Three Different Formulations of Fluticasone Propionate Dry Powder Inhalers [NCT01966692]	Phase 1	41 participants (Actual)	Interventional	2016-11-30	Completed
A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma [NCT00235053]	Phase 4	13 participants	Interventional	2005-08-31	Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis [NCT01231464]	Phase 3	365 participants (Actual)	Interventional	2009-09-30	Completed
Respiratory Function in Infants With Persistent Wheezing [NCT00301171]		54 participants (Anticipated)	Interventional	2003-09-30	Completed
A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents. [NCT01159912]	Phase 3	350 participants (Actual)	Interventional	2010-06-30	Completed
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease ( [NCT01331694]		76,130 participants (Actual)	Observational	2009-07-31	Completed
A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twi [NCT01147744]	Phase 2	700 participants (Actual)	Interventional	2010-06-28	Completed
A Multicentre, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Product (Seretide®) 50/100 mcg With Fluticasone Propionate (Flixotide® ) 200 mcg, Both Delivered Twice Daily [NCT00197106]	Phase 4	176 participants (Actual)	Interventional	2005-06-30	Completed
Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate [NCT02883439]		0 participants (Actual)	Interventional	2016-08-31	Withdrawn(stopped due to no available patients)
Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 Versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics [NCT01086410]	Phase 3	185 participants (Actual)	Interventional	2010-03-31	Completed
A Randomised, Double-blind, Placebo-controlled, Four-way Crossover, Repeat Dose Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination, GW642444M and Fluticasone Furoate on the Allergen-induced Asthmatic Response in Subjects With [NCT01128595]	Phase 2	27 participants (Actual)	Interventional	2010-05-31	Completed
A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chron [NCT01124422]	Phase 4	255 participants (Actual)	Interventional	2010-07-19	Completed
A Pilot, Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respiren [NCT04546256]	Phase 1	14 participants (Actual)	Interventional	2020-09-01	Completed
An Adolescent Sub-study Within FLUTE-2: A Randomized, Double-blind, Placebo-Controlled Study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), With an Open-label Extension, in Adolescent Subjects With Eosinophilic Esophagitis [NCT05083312]	Phase 3	6 participants (Actual)	Interventional	2021-09-30	Completed
WEUSRTP4850: Phase II: Asthma Treatment in Pregnancy and the Frequency of Adverse Pregnancy Outcomes [NCT01681979]		1 participants (Actual)	Observational	2012-07-31	Completed
A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Effectiveness of on Severe / Very Severe COPD Patients [NCT02270424]	Phase 3	564 participants (Anticipated)	Interventional	2014-10-31	Not yet recruiting
A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Ch [NCT01342913]	Phase 3	528 participants (Actual)	Interventional	2011-02-01	Completed
A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With [NCT01323621]	Phase 3	512 participants (Actual)	Interventional	2011-03-18	Completed
Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics [NCT03002389]	Phase 2	95 participants (Anticipated)	Interventional	2017-11-05	Recruiting
The Effects of Montelukast on Sputum Cells and Inflammatory Markers in Smokers With Asthma [NCT00712335]	Phase 4	105 participants (Actual)	Interventional	2007-02-28	Completed
A Randomized Clinical Trial to Assess the Effects of Inhaled Fluticasone on Sputum Neutrophils After Low-dose Inhaled Endotoxin Challenge in Healthy Subjects [NCT00869596]	Phase 1	22 participants (Actual)	Interventional	2009-03-31	Completed
Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis. [NCT00689832]	Phase 4	487 participants (Actual)	Interventional	2004-02-29	Completed
An Open-label, Randomised, Two-way Crossover Study, to Evaluate and Compare the Pharmacokinetics of Fluticasone Furoate, Administered From a Novel Dry Powder Device (Repeat Dose) and Intravenously (Single Dose), in Healthy Caucasian, Japanese, Korean and [NCT01000597]	Phase 1	80 participants (Actual)	Interventional	2009-09-17	Completed
Repeated High-dose Inhaled Corticosteroids for Asthma [NCT00695604]	Phase 2	0 participants (Actual)	Interventional	2008-05-31	Withdrawn(stopped due to Study was not able to be completed, no results analyzed.)
Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea? DREAM-A Pilot Study [NCT01184118]		36 participants (Actual)	Interventional	2009-03-31	Completed
A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy [NCT00975195]	Phase 4	2,488 participants (Actual)	Interventional	2009-02-28	Completed
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications [NCT05736874]	Phase 3	1,407 participants (Actual)	Interventional	2021-08-06	Completed
APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients With Eosinophilic Esophagitis [NCT05095116]		0 participants	Expanded Access		Available
A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota [NCT02833480]	Phase 2	69 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Randomised, Double-blind, Placebo-controlled, Three-way Crossover, Repeat Dose Pilot Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination and Fluticasone Furoate on the Allergen-induced Early Asthmatic Response in Subjects Wit [NCT01128569]	Phase 2	52 participants (Actual)	Interventional	2010-01-31	Completed
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb Study to Assess the Efficacy, Safety & Product Attributes of Rhinocort Aqua(Budesonide) Versus Placebo and FluticasonePropionate as an Active Comparator in Patients 1 [NCT00641680]	Phase 3	750 participants (Anticipated)	Interventional	2003-04-30	Completed
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma [NCT00843193]	Phase 2	198 participants (Actual)	Interventional	2008-12-09	Completed
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purp [NCT00848965]	Phase 4	59 participants (Actual)	Interventional	2007-10-31	Completed
Management of Asthma in School-age Children on Therapy [NCT01526161]	Phase 4	229 participants (Actual)	Interventional	2009-04-30	Completed
Prospective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic Esophagitis [NCT00880906]		50 participants (Actual)	Interventional	2008-08-31	Completed
Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals [NCT06077019]		60 participants (Anticipated)	Interventional	2023-10-05	Recruiting
A Randomised, Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Pharmacodynamics and Pharmacokinetics of GW685698X and GW642444M When Administered Separately and in Combination as a Single Dose From a Novel Dry Powder Device in Hea [NCT00625196]	Phase 1	16 participants (Actual)	Interventional	2008-02-27	Completed
A Three-way Incomplete Block Crossover Study to Investigate the 24-hour Pulmonary Function of Three Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT01072149]	Phase 3	54 participants (Actual)	Interventional	2010-01-01	Completed
Dose-ranging Study of the Safety and Efficacy of Fluticasone Propionate and Salmeterol Xinafoate in Healthy Patients With Abdominal Contour Defects [NCT01712451]	Phase 2	200 participants (Actual)	Interventional	2011-08-31	Completed
A Randomised Controlled Open-Label Phase IV Mono Centre Study to Compare the Response Profiles of Montelukast Versus Fluticasone in Children With Pre-School Asthma [NCT00543686]	Phase 2	100 participants (Anticipated)	Interventional	2007-08-31	Completed
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) [NCT01395862]		1,001 participants (Actual)	Observational	2007-11-30	Completed
Randomised, Double-blind, Double-dummy, Parallel-group, Comparative Study of Salmeterol/FP 50/100mcg bd Inhalation Powder Via Diskus With Oral Montelukast (5mg QD) Chewable Tablets in Children 6-14 Years [NCT00328718]	Phase 3	526 participants	Interventional	2005-10-31	Completed
Special Drug Use Investigation for ALLERMIST (Long Term) [NCT01420822]		500 participants (Actual)	Observational	2010-12-31	Completed
Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients [NCT01431924]		7,779 participants (Actual)	Observational	2010-10-31	Completed
A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescent and Adult Subjects With Exercise-Induced Bronchoconstriction [NCT01435902]	Phase 3	0 participants (Actual)	Interventional	2012-01-31	Withdrawn(stopped due to Study was cancelled prior to enrolling any subjects)
The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study [NCT00407264]	Phase 2	90 participants	Interventional	2002-02-28	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Ol [NCT00609674]	Phase 4	315 participants (Actual)	Interventional	2008-01-31	Completed
Effects of Fluticasone On Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease [NCT00175565]	Phase 4	50 participants	Interventional	2002-01-31	Completed
Single Dose Bioequivalence Study of Azelastine Hydrochloride/Fluticasone Propionate 137microgram/50 Microgram Nasal Spray and DYMISTA Nasal Spray in Healthy Adult Human Subjects [NCT06180083]	Phase 1	56 participants (Actual)	Interventional	2023-03-24	Completed
A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive P [NCT00411372]	Phase 3	0 participants (Actual)	Interventional	2006-11-30	Withdrawn(stopped due to No subjects enrolled. Study was canceled before active)
Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist. [NCT00158847]	Phase 4	200 participants	Interventional	2000-04-30	Terminated
Assessment of the Effects of Multiple Nasal Antigen Challenges With Dust Mite Allergen on Local and Systemic Allergic Inflammation and Bronchoreactivity in Subjects With Allergic Rhinitis Sensitive to House Dust Mite - a Feasibility and Site Evaluation St [NCT00513487]		18 participants (Anticipated)	Interventional	2007-07-31	Completed
Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma [NCT00187499]		0 participants	Interventional	2002-10-31	Completed
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation [NCT01860066]	Phase 3	0 participants (Actual)	Interventional	2013-12-31	Withdrawn
Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis [NCT00123656]	Phase 2	30 participants (Actual)	Interventional	2004-08-31	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT06025214]	Phase 1	34 participants (Anticipated)	Interventional	2023-08-22	Recruiting
A Randomized, Open-labeled, Multicenter Clinical Trial to Compare the Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Moderate-to-severe Persistent Allergic Rhinitis [NCT05080322]	Phase 4	150 participants (Anticipated)	Interventional	2023-02-10	Recruiting
A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250 [NCT00633217]	Phase 4	247 participants (Actual)	Interventional	2008-03-31	Completed
Randomized Study of Early Treatment With Inhaled Corticosteroids Versus Observation for Patients Who Have Decreased Lung Function Status Post Allogeneic Stem Cell Transplantation [NCT00656916]	Phase 2	1 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Terminated due to slow accrual.)
Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction? [NCT00716963]	Phase 4	7 participants (Actual)	Interventional	2008-07-31	Completed
INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol [NCT03152149]	Phase 4	80 participants (Actual)	Interventional	2017-06-01	Completed
[NCT00476073]	Phase 3	228 participants (Actual)	Interventional	2007-04-30	Completed
Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial [NCT00440687]	Phase 4	256 participants	Interventional	2001-01-31	Completed
Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/ [NCT00479739]	Phase 4	700 participants (Actual)	Interventional	2002-11-30	Completed
Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management [NCT01242098]		137 participants (Actual)	Observational	2008-01-31	Completed
A Proof of Concept Study to Evaluate Differential Tachyphylaxis of Alpha 1 and Alpha 2 Adrenoreceptor Mediated Decongestant Response to Oxymetazoline and Its Acute Reversal by Corticosteroid in Healthy Volunteers [NCT00487032]	Phase 4	19 participants (Actual)	Interventional	2008-05-31	Completed
A Randomized, Open-label, Parallel-group, 6 Week Treatment, Multi-center, Phase III Study to Investigate the Efficacy and Safety of 100ug and 200ug Twice Daily of Budesonide Turbuhaler® and 50ug and 100umg Twice Daily of Fluticasone Diskus® in Japanese Ch [NCT00504062]	Phase 3	240 participants (Actual)	Interventional	2006-10-31	Completed
Proof of Concept Study to Assess Downstream Effects of Using Combined Intranasal Fluticasone Propionate Plus Azelastine Nasal Spray on Asthmatic Inflammation in Patients With Persistent Asthma and Allergic Rhinitis [NCT02953106]	Phase 4	7 participants (Actual)	Interventional	2017-01-20	Terminated(stopped due to The company providing study IMP was unable to supply further batches of IMP.)
A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalati [NCT04665895]	Phase 3	451 participants (Actual)	Interventional	2020-12-09	Completed
Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen [NCT00791973]	Phase 4	15 participants (Actual)	Interventional	2008-11-30	Completed
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 45.5, 90.9 and 181.8 mcg b.i.d. Administered Via Respimat® Inhaler and Fluticason [NCT01397201]	Phase 2	30 participants (Actual)	Interventional	2011-07-01	Terminated
A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year [NCT05054322]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2021-09-22	Recruiting
The Effect of Salmeterol on Eosinophil (EOS) Function [NCT00214019]		36 participants (Actual)	Interventional	2003-11-30	Completed
An Open-label, Randomised, Replicate, Six-way Crossover, Single Dose Study to Determine the Bioequivalence of Fluticasone Furoate (FF) Inhalation Powder (Single Strip Configuration) Compared With FF Inhalation Powder (Two Strip Configuration) and Compared [NCT01485445]	Phase 1	30 participants (Actual)	Interventional	2011-12-21	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Site Study to Evaluate the Therapeutic Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray, to Dymista™ Nasal Spray [NCT02249663]	Phase 3	1,535 participants (Anticipated)	Interventional	2014-08-31	Recruiting
Multicenter Randomised Controlled Trial of Episodic Fluticasone Versus Placebo in Viral-induced Asthma in Children [NCT00238927]	Phase 4	150 participants	Interventional	1999-11-30	Completed
Randomized, Double-Blind Comparison of Advair 100/50 BID vs Salmeterol BID vs Albuterol QID in Subjects With ARG/ARG Genotype 12 Years of Age and Older With Presistent Asthma on Short-Acting Beta2-Agonists Alone [NCT00102882]	Phase 4	547 participants (Actual)	Interventional	2004-10-31	Completed
A Randomised, Double Blind, Placebo Controlled, 2-way Crossover, 3 Phase Study, to Investigate the Trial Models, Vienna Challenge Chamber, in and Out of Season, and Park Study in Season and the Clinical Efficacy of Rpt Doses of Fluticasone Propionate in S [NCT00400998]	Phase 2	41 participants (Actual)	Interventional	2006-03-31	Completed
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Switching From Salmeterol/Fluticasone to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic COPD Patients [NCT02516592]	Phase 4	500 participants (Actual)	Interventional	2015-10-13	Completed
Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial [NCT00266578]	Phase 3	30 participants (Actual)	Interventional	2002-10-31	Completed
A 13-week, Double-blind, Parallel Group, Multi-centre Study to Compare the Bronchial Anti-inflammatory Activity of the Combination of Salmeterol/Fluticasone Propionate 50/500mcg Twice Daily Compared With Placebo Twice Daily in Patients With Chronic Obstru [NCT00268177]	Phase 3	130 participants	Interventional	2002-10-31	Completed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered [NCT00268216]	Phase 3	6,228 participants (Actual)	Interventional	2000-09-30	Completed
A Multicentre, Stratified, Randomised, Double Blind, Parallel Group Trial to Evaluate Whether a Treatment Strategy Based on Aiming for Total Control Results in Better AHR Than a Treatment Strategy Based on Maintaining Well Control [NCT00291382]	Phase 4	150 participants (Actual)	Interventional	2005-11-30	Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 10 [NCT00102765]	Phase 4	479 participants (Actual)	Interventional	2004-11-30	Completed
Advair - CRP Study [NCT00120978]	Phase 4	250 participants	Interventional	2004-12-31	Recruiting
The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Exhaled Nitric Oxide, Inflammatory Markers in Exhaled Breath Condensate and Conventional Parameters [NCT00402207]		33 participants	Interventional	2005-08-31	Completed
A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asth [NCT00296530]	Phase 4	600 participants (Actual)	Interventional	2005-09-30	Completed
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications [NCT04885530]	Phase 3	15,000 participants (Anticipated)	Interventional	2021-06-08	Active, not recruiting
Open Randomized Low Interventional Clinical Trial to Compare Efficiency in Control Symptoms Between Fluticasone Propionate/Formoterol K-haler (Medium Strength) vs High Strength ICS/LABA in the Treatment of Patients With Persistent Asthma [NCT04271839]	Phase 4	0 participants (Actual)	Interventional	2020-06-11	Withdrawn(stopped due to The trial has been terminated early due to the SARS-CoV-2 pandemic.)
Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone. [NCT00306163]	Phase 3	37 participants (Actual)	Interventional	2006-05-31	Completed
FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis [NCT03191864]	Phase 2	106 participants (Actual)	Interventional	2017-06-22	Completed
A Study to Investigate the Effect of Inhaled Fluticasone Propionate on the Bronchial Responsiveness to Leukotriene D4 in Asthmatics Patients [NCT00453778]	Phase 4	14 participants	Interventional	2002-11-30	Completed
Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids [NCT00456313]	Phase 4	0 participants (Actual)	Interventional	2007-12-31	Withdrawn(stopped due to lack of data)
A Study to Validate Key Therapeutic Targets and Biomarkers During Allergen Exposure in Subjects With Allergic Rhinitis [NCT00348361]	Phase 1	48 participants	Interventional	2005-04-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 Days in Adult and Adolescent Subjects With Seaso [NCT00115622]	Phase 3	304 participants (Actual)	Interventional	2004-12-31	Completed
A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [NCT00116402]	Phase 1	15 participants (Actual)	Interventional	2005-01-31	Completed
[NCT00475813]	Phase 3	211 participants (Actual)	Interventional	2007-03-31	Completed
SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea [NCT00480649]	Phase 4	424 participants (Actual)	Interventional	2004-01-31	Completed
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 22.7, 45.5 and 90.9 Doses b.i.d. Administered Via Respimat® Inhaler and Fluticaso [NCT01397162]	Phase 2	29 participants (Actual)	Interventional	2011-07-21	Terminated
Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial [NCT01246921]	Phase 4	50 participants (Anticipated)	Interventional	2009-09-30	Recruiting
An Open Label, Multicentre Study to Evaluate Patient Satisfaction With Fluticasone/Salmeterol HFA MDI With Counter in Adult Subjects (18 Years of Age and Older) With Asthma or COPD. [NCT00404261]	Phase 4	132 participants (Actual)	Interventional	2007-01-31	Completed
A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease [NCT00387036]	Phase 2	12 participants (Actual)	Interventional	2006-12-31	Terminated(stopped due to Termininated for business reasons)
Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study- [NCT00449046]	Phase 3	40 participants (Actual)	Interventional	2007-03-31	Completed
A Randomized, Assessor-blind, Placebo Controlled, Multicenter, Clinical Endpoint Bioequivalence Study to Compare the Efficacy and Safety of Generic Fluticasone Propionate Inhalation Aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd) to Flovent HFA (Flutica [NCT05363202]	Phase 3	790 participants (Anticipated)	Interventional	2022-04-15	Recruiting
Genotype Stratified Treatment With Anticholinergic vs. Beta-agonist (Long Acting) and Exacerbations (GABLE) [NCT00706446]		255 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Funding was terminated)
A Double Blind, Placebo Controlled Randomized Trial Evaluating the Effects of Fluticasone Nasal Spray in Subjects With Seasonal Allergic Rhinitis and a History of Sleep Disturbance on Cognitive Performance and Daytime Sleepiness [NCT00997620]	Phase 4	40 participants (Actual)	Interventional	2010-03-31	Completed
The Addition of Vitamin D to Fluticasone Propionate in the Management of Seasonal Allergic Rhinitis [NCT01103934]	Phase 4	35 participants (Actual)	Interventional	2010-06-30	Completed
Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway [NCT01231230]		14 participants (Actual)	Interventional	2007-05-31	Completed
Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population [NCT01328964]		9,906 participants (Actual)	Observational	2009-06-30	Completed
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy [NCT01347060]		17,448 participants (Actual)	Observational	2009-07-31	Completed
A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma [NCT01520688]	Phase 4	32 participants (Actual)	Interventional	2012-02-29	Completed
A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® Inhaler Combination Product 250/50mcg Twice Daily With Salmeterol DISKUS® Inhaler 50mcg Twice Daily on the Annual Rate of Moderate [NCT00144911]	Phase 4	740 participants (Actual)	Interventional	2004-10-31	Completed
A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice [NCT00184977]	Phase 4	270 participants	Interventional	1998-12-31	Completed
A Six-Week, Randomized, Double-Blind, Quadruple-Dummy Parallel Group Multiple Dose Study Comparing the Efficacy and Safety of Tiotropium Inhalation Capsules Plus Formoterol Inhalation Capsules to Salmeterol Inhalation Aerosol Plus Fluticasone Inhalation A [NCT00239421]	Phase 4	605 participants	Interventional	2003-11-30	Completed
A 6-week Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Fluticasone 250μg/Salmeterol 50μg Combination (FSC 250/50) on Exertional Dyspnea in Patients With Symptomatic Mild COPD [NCT00559312]		18 participants (Actual)	Interventional	2007-12-31	Completed
Early Anti-inflammatory Treatment of Asymptomatic or Mildly Symptomatic Airway Hyperresponsiveness [NCT00567463]		83 participants (Actual)	Interventional	1998-12-31	Terminated(stopped due to Completed)
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Safety and Efficacy of Fluticasone Propionate Combined With Formoterol Fumarate in Patients With Chronic Obstructive Pulmonary Disease [NCT00403286]	Phase 2	457 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only [NCT00351143]	Phase 4	274 participants (Actual)	Interventional	2005-07-26	Completed
Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response [NCT00473915]	Phase 4	20 participants (Anticipated)	Interventional	2007-04-30	Completed
Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD. [NCT01243788]	Phase 4	450 participants (Anticipated)	Interventional	2009-07-31	Recruiting
A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With [NCT01323634]	Phase 3	519 participants (Actual)	Interventional	2011-03-18	Completed
A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary D [NCT01315249]	Phase 3	523 participants (Actual)	Interventional	2011-03-31	Completed
Prospective, Randomised, Open-label, Multicentre, Active Drug Controlled, Parallel Group Design Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate 400 mcg + Formoterol 24 mcg pMDI Via HFA-134a (Foster™) vs. Fluticasone Propionate 500 [NCT00497237]	Phase 3	382 participants (Anticipated)	Interventional	2007-04-30	Completed
A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects With Asthma [NCT01244984]	Phase 3	243 participants (Actual)	Interventional	2010-07-31	Completed
Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges* [NCT01240889]		60 participants (Actual)	Interventional	2010-11-30	Completed
A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease [NCT00995475]	Phase 4	18 participants (Actual)	Interventional	2006-10-31	Completed
An Open-label, Randomized, Parallel-Group, Multi-Site Study to Evaluate the Efficacy and Safety of Azelastine HCl-Fluticasone Propionate Nasal Spray 137-50 mcg/Spray in Perennial Allergic Rhinitis Patients [NCT06051786]	Phase 2	136 participants (Actual)	Interventional	2020-08-20	Completed
A Randomised, Double-blind, Placebo-controlled, Incomplete Block, 4-period Crossover, Study to Investigate the Effects of 5-day Repeat Inhaled Doses of Fluticasone Propionate (BID, 50-2000 mcg) on Airway Responsiveness to Adenosine 5-monophosphate (AMP) C [NCT00400855]	Phase 2	49 participants (Actual)	Interventional	2005-01-31	Completed
A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg BID With Salmeterol Diskus 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects [NCT00115492]	Phase 4	797 participants (Actual)	Interventional	2004-12-31	Completed
A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With [NCT00118690]	Phase 4	227 participants (Actual)	Interventional	2003-12-31	Completed
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerb [NCT03926026]	Phase 2	36 participants (Actual)	Interventional	2019-03-18	Completed
DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) [NCT00394368]	Phase 3	180 participants	Interventional	2004-11-30	Completed
A Proof of Concept Study to Evaluate if Concomitant Topical Intranasal Steroid Prevents Tolerance and Rebound Congestion Due to Regular Oxymetazoline in Persistent Allergic Rhinitis. [NCT00846326]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to The suppliers were unable to provide the investigational medicinal product (IMP))
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers [NCT00576069]		60 participants (Anticipated)	Observational	2007-10-25	Recruiting
A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High [NCT01576718]	Phase 2	889 participants (Actual)	Interventional	2012-04-30	Completed
Randomised, Double-blind Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS ® Inhlaer 50/100mcg Twice Daily vs. FLIXOTIDE® Inhaler 200mcg Twice Daily. [NCT00169546]	Phase 4	64 participants (Actual)	Interventional	2003-01-31	Completed
Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma [NCT00409630]		0 participants (Actual)	Interventional		Withdrawn(stopped due to Sponsor decided against going forward with the study.)
A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids. [NCT01431950]	Phase 3	238 participants (Actual)	Interventional	2011-09-30	Completed
A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis [NCT00426283]	Phase 2	42 participants (Actual)	Interventional	2007-01-31	Completed
Fluticasone Furate/Vilaterol in Exercising Asthmatic Adolescents: a Randomized and Open Label Trial [NCT04750603]	Phase 4	92 participants (Actual)	Interventional	2018-12-01	Completed
Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids? [NCT00509197]		12 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Inability to complete the recruitment.)
Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis [NCT00660517]	Phase 3	607 participants (Actual)	Interventional	2007-12-31	Completed
Enhancement of In-vitro GC Function in Patients With COPD. A Randomised, Double Blind, Placebo Controlled, Parallel-group Study to Investigate the Effect of Theophylline and Fluticasone on Induced Sputum Cells Obtained Form COPD Patients [NCT00241631]	Phase 2	49 participants (Actual)	Interventional	2006-04-30	Completed
A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation [NCT01834885]	Phase 3	0 participants (Actual)	Interventional	2013-12-31	Withdrawn
The Role of Perioperative Systemic Steroids in Patients With Chronic Rhinosinusitis Without Polyps (CRSsNP) [NCT02748070]		81 participants (Actual)	Interventional	2015-08-31	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT05982990]	Phase 1	34 participants (Actual)	Interventional	2023-08-01	Active, not recruiting
Dose-response of Salmeterol Delivered by Advair Diskus in Children: Bioassay by Methacholine Challenge Using Oscillometry as the Endpoint [NCT01907334]	Phase 4	10 participants (Actual)	Interventional	2013-08-31	Completed
A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment o [NCT01686633]	Phase 3	1,040 participants (Actual)	Interventional	2012-09-20	Completed
A Pivotal, Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respir [NCT04564456]	Phase 1	34 participants (Actual)	Interventional	2020-09-22	Completed
Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD [NCT00233051]		20 participants (Actual)	Interventional	2003-04-30	Terminated
A Randomized, Double-blind, Placebo-controlled,Parallel-group Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc. )in the Treatmen [NCT02279563]	Phase 2	595 participants (Actual)	Interventional	2013-12-31	Enrolling by invitation
A Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the Low Ai [NCT02218762]	Phase 1	0 participants (Actual)	Interventional	2014-10-31	Withdrawn(stopped due to It was decided that data from this study are no longer required and therefore it is not necessary to expose patients to the study medication)
A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Mul [NCT00252863]	Phase 3	1,600 participants	Interventional	2004-12-31	Completed
A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Fluticasone Furoate Nasal Spray (Lek Pharmaceuticals) With Veramyst® Nasal Spray (GlaxoSmithKline) in the Relief of the Signs and Sympt [NCT01279057]	Phase 3	727 participants (Actual)	Interventional	2010-12-27	Completed
A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 14-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled Fluticasone Furoate 100ug (Micrograms) in Children Aged 5-11 Years With Pe [NCT01332292]	Phase 2	27 participants (Actual)	Interventional	2010-05-31	Completed
See Detailed Description [NCT00269126]	Phase 3	150 participants (Actual)	Interventional	2005-02-28	Completed
An Open-label, Multi-centre, Randomized, Parallel Group Clinical Effectiveness Study to Determine the Level of Asthma Control in Adolescent and Adult Patients With ADVAIR Versus Usual Care for 24 Weeks. [NCT00273026]	Phase 4	680 participants	Interventional	2004-11-08	Terminated
Steroid-sparing Management of the Salmeterol/Fluticasone 50/100µg b.i.d. Combination Compared to Fluticasone 200µg b.i.d. in Children and Adolescents With Moderate Asthma [NCT00315744]	Phase 4	285 participants (Actual)	Interventional	2004-11-04	Completed
[NCT00280358]	Phase 1	30 participants	Interventional		Completed
Relative Potency of Inhaled Corticosteroids: Validation of a Clinical Model [NCT00292838]	Phase 4	40 participants	Interventional	2001-01-31	Completed
A Randomised, Double-blind, Double Dummy, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Eve [NCT01499446]	Phase 2	669 participants (Actual)	Interventional	2003-09-30	Completed
A Double-blind, Double Dummy, Randomised, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Flutiform pMDI With Fluticasone pMDI and With Seretide pMDI in Paediatric Subjects Aged 5 to Less Than 12 Years With Moderate to Severe Persi [NCT01511367]	Phase 3	498 participants (Anticipated)	Interventional	2012-03-31	Completed
[NCT01624129]		20 participants (Anticipated)	Observational	2011-01-31	Recruiting
[NCT01657487]	Phase 4	120 participants (Anticipated)	Interventional	2010-04-30	Recruiting
A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric S [NCT01915914]	Phase 4	107 participants (Actual)	Interventional	2013-12-23	Completed
Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone [NCT01702701]	Phase 3	0 participants (Actual)	Interventional	2012-01-31	Withdrawn
A Randomized, Double-blind, Placebo-controlled, Four-way Crossover Study to Evaluate and Compare the Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate /Vilanterol in Different Dose Combination (50/25mcg, 100/25mcg and 200/25mcg) After Single an [NCT01711463]	Phase 1	16 participants (Actual)	Interventional	2012-12-05	Completed
A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers Without Charcoal Block [NCT02466347]	Phase 1	45 participants (Actual)	Interventional	2014-06-30	Completed
A Phase II, Monocentric, Open, Randomized, 6-way Cross-over Clinical Pharmacology Study to Evaluate the Lung Bioavailability of BDP/B17MP and Formoterol and the Total Systemic Exposure Across Two Different Strengths of CHF 1535 NEXThaler Dry Powder Inhale [NCT01738087]	Phase 2	30 participants (Actual)	Interventional	2012-11-30	Completed
Effects Of Extra-fine Particle HFA-becLomethasone (HFA-QVAR) Versus Course Particle Treatment In Smokers and Ex-smokers With Asthma [NCT01741285]	Phase 4	40 participants (Actual)	Interventional	2013-04-30	Completed
A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects With Partly Controlled and Uncontrolled Asthma [NCT01516073]	Phase 2	629 participants (Actual)	Interventional	2012-03-31	Completed
WEUSKOP6416: Evaluating Serious Pneumonia in Subjects With Chronic Obstructive Pulmonary Disease (COPD) to Inform Risk Minimization: A Retrospective Observational Study [NCT01763463]		1 participants (Actual)	Observational	2012-07-31	Completed
Randomised Controlled, Double Blind Trial of Topical Twice Weekly Fluticasone Propionate Maintenance Treatment to Reduce Risk of Relapse in Mild or Moderate Atopic Dermatitis in Children [NCT01772056]	Phase 3	54 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to Patient recruitment is very slow, economic grant has ended and the number of patients is enough according to sample size (22 children/ arm).)
A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma [NCT00540839]	Phase 3	0 participants (Actual)	Interventional	2007-11-30	Withdrawn(stopped due to Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing study was sufficient for regulatory purposes.)
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI [NCT00394199]	Phase 3	357 participants (Actual)	Interventional	2006-06-30	Completed
Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma [NCT00394121]	Phase 3	400 participants (Anticipated)	Interventional	2006-03-31	Completed
A Randomised, Double-blind, Two-way Crossover Study to Investigate the Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma [NCT02502734]	Phase 3	60 participants (Actual)	Interventional	2015-09-07	Completed
COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) [NCT01846962]	Phase 4	64 participants (Actual)	Interventional	2012-11-30	Completed
A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject With Allergic Rhinitis [NCT00398476]	Phase 3	127 participants (Actual)	Interventional	2006-12-01	Completed
Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population [NCT01337336]		1 participants (Actual)	Observational	2010-10-31	Completed
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant [NCT01307462]	Phase 2	36 participants (Actual)	Interventional	2011-06-30	Completed
Open Label, Three-Way Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride and Multiple Doses of Fluticasone Propionate on the Absorption and Tolerab [NCT01365650]	Phase 1	24 participants (Actual)	Interventional	2007-12-31	Completed
Environmental Control as Add-on Therapy in Childhood Asthma [NCT02251379]	Phase 2	155 participants (Actual)	Interventional	2014-10-01	Completed
Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease [NCT01387178]		22,223 participants (Actual)	Observational	2008-07-31	Completed
A Randomized, Double Blind, Placebo-controlled Three-way Crossover Study in Mild Asthmatics to Evaluate the Effect of Smoking Status on the Attenuation by Inhaled Corticosteroids of the Allergen-induced Asthmatic Response. [NCT01400906]	Phase 2	36 participants (Actual)	Interventional	2011-07-20	Completed
An Exploratory, Multi-centre, Double-blind, Placebocontrolled Crossover Study, to Investigate the Bronchodilatory Efficacy of a Single Dose of Indacaterol in Fixed Combination With Mometasone Furoate Delivered Via a MDDPI (Twisthaler®) in Adult Patients W [NCT00556673]	Phase 2	31 participants (Actual)	Interventional	2007-10-31	Completed
Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA) [NCT00318708]	Phase 3	92 participants (Actual)	Interventional	2006-06-30	Completed
A Randomised, Open Label, Five-way Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol From SERETIDE/ADVAIR 250HFA MDI Alone and With AeroChamber-Max Spacer and VOLUMATIC Both in Their Washed and Unwashed States in Adu [NCT00369993]	Phase 2	20 participants (Actual)	Interventional	2005-03-31	Completed
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease [NCT01554488]	Phase 4	25 participants (Actual)	Interventional	2013-03-12	Terminated(stopped due to Low subject accrual)
[NCT01578278]	Phase 2	606 participants (Actual)	Interventional	2011-12-31	Completed
Effects of Broccoli Sprout Extract on Allergic Rhinitis [NCT02885025]	Phase 2	47 participants (Actual)	Interventional	2016-10-01	Completed
Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages >4 Years to <12 Years With Seasonal Allergic Rhinitis [NCT01915823]	Phase 3	348 participants (Actual)	Interventional	2013-07-31	Completed
A Randomised, Open-label, 2-group PK (3-period) and PD (5-period) Crossover Study to Compare Systemic Exposure and Pharmacodynamic Effects of Fluticasone/Formoterol BAI and pMDI in Healthy Volunteers [NCT02403713]	Phase 1	125 participants (Anticipated)	Interventional	2014-08-31	Completed
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator [NCT01794780]	Phase 4	2,229 participants (Actual)	Interventional	2013-02-05	Completed
The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma. [NCT02338362]	Phase 4	22 participants (Actual)	Interventional	2014-09-30	Completed
A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediat [NCT01687296]	Phase 3	261 participants (Actual)	Interventional	2012-11-12	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With a History of Grass Pollen Induced Rhinoconjunctivi [NCT00550550]	Phase 3	345 participants (Actual)	Interventional	2007-11-30	Completed
A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 µg b.i.d. Administered Via Respimat® Inhaler and Fluticasone [NCT01396278]	Phase 2	9 participants (Actual)	Interventional	2011-07-01	Terminated
A 12 Week Study to Evaluate the Effect of Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) on Arterial Stiffness Compared With Tiotropium Bromide 18 mcg De [NCT01395888]	Phase 3	260 participants (Actual)	Interventional	2011-06-30	Completed
A Randomised, Double-blind, Double-dummy, Single Dose, Four Way Cross-over Study to Compare the Pharmacokinetics and Pharmacodynamics of GSK961081 and Fluticasone Propionate When Administered Alone, Concurrently and as a Combination Blend in Healthy Subje [NCT01449799]	Phase 1	24 participants (Actual)	Interventional	2011-07-13	Completed
Replication of the INSPIRE Trial in Healthcare Claims Data [NCT05179512]		98,278 participants (Actual)	Observational	2020-09-22	Completed
Once-Daily Single-Inhaler Triple Versus Dual Therapy in Patients With COPD (IMPACT Trial) [NCT05062304]		17,281 participants (Actual)	Observational	2020-12-13	Completed
Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/500mcg Delivered Twice Daily Via the DISKUS/ACCUHALER* Inhaler With Tiot [NCT00361959]	Phase 4	1,270 participants (Actual)	Interventional	2003-06-30	Completed
Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation [NCT03072849]		40 participants (Anticipated)	Observational	2015-04-30	Recruiting
A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma [NCT01253603]	Phase 2	170 participants (Actual)	Interventional	2010-11-30	Completed
TITLE: Double-blinded, Double-dummy, Study Comparing Fluticasone-salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence. [NCT00731770]	Phase 4	10 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persisten [NCT01092143]	Phase 2	389 participants (Actual)	Interventional	2010-03-18	Completed
Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers [NCT01216735]		32 participants (Actual)	Interventional	2008-09-30	Completed
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in A [NCT01498679]	Phase 3	311 participants (Actual)	Interventional	2012-01-31	Completed
Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD) [NCT01381471]		11,060 participants (Actual)	Observational	2009-08-31	Completed
A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model [NCT01439815]	Phase 4	22 participants (Actual)	Interventional	2011-09-30	Completed
A Pilot Randomised Controlled Superiority Trial of Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults [NCT04265105]	Phase 2/Phase 3	18 participants (Actual)	Interventional	2021-12-22	Completed
Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit [NCT01332357]		6,139 participants (Actual)	Observational	2009-06-30	Completed
Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease [NCT00984659]	Phase 4	366 participants (Actual)	Interventional	2009-10-29	Completed
Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids [NCT02610816]	Phase 2/Phase 3	67 participants (Actual)	Interventional	2016-03-21	Completed
An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the Low [NCT01890863]	Phase 1	36 participants (Actual)	Interventional	2013-08-05	Completed
Pooled Analysis of Individual Subjects' Data After Combining the Data From the Bioequivalence Studies Conducted for Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals (Test, T) vs ADVAIR DISKUS® 250/ [NCT04790838]		82 participants (Actual)	Observational	2019-06-02	Completed
Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis [NCT01794741]	Phase 3	405 participants (Actual)	Interventional	2013-02-28	Completed
A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma [NCT02571777]	Phase 3	3,092 participants (Actual)	Interventional	2015-12-08	Completed
A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffne [NCT01691885]	Phase 3	45 participants (Actual)	Interventional	2012-11-30	Completed
A Dose-ranging Study of Fluticasone Furoate (FF) Inhalation Powder in Children Aged 5-11 Years With Asthma [NCT01563029]	Phase 2	597 participants (Actual)	Interventional	2012-03-28	Completed
Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age [NCT04957927]	Phase 4	60 participants (Anticipated)	Interventional	2020-12-12	Recruiting
A Multicenter, Randomized, Single Blind, Active Controlled, Parallel Group Study to Determine Efficacy and Safety of Nebulized Fluticasone Propionate 1mg BID Compared With Nebulized Budesonide 2mg BID Administered for 12 Weeks in Chinese Adult and Adolesc [NCT01687283]	Phase 3	316 participants (Actual)	Interventional	2012-09-27	Completed
A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone [NCT02301975]	Phase 3	1,526 participants (Actual)	Interventional	2015-03-01	Completed
Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis [NCT00895817]		42 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. SERETIDE D [NCT04124094]	Phase 1	36 participants (Actual)	Interventional	2019-10-01	Completed
A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis [NCT02874144]	Phase 2	43 participants (Actual)	Interventional	2016-06-20	Completed
A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared With Salmeterol DISKUS 50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary D [NCT00346749]	Phase 4	180 participants	Interventional	2006-12-31	Terminated(stopped due to The study was terminated due to difficulties with finding sites and subjects willing to participate.)
A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis [NCT05314621]	Phase 4	61 participants (Actual)	Interventional	2021-12-31	Completed
A Phase III, Randomized, Multicenter, Parallel-group Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation [NCT05664061]	Phase 3	451 participants (Anticipated)	Interventional	2023-01-30	Recruiting
A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma [NCT02175771]	Phase 3	758 participants (Actual)	Interventional	2014-07-31	Completed
A 16-Week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (Bid) Using a Novel Bi-directional Devi [NCT01624662]	Phase 3	323 participants (Actual)	Interventional	2013-10-30	Completed
A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax (Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compared With Single Doses of Fluticasone Propionate S [NCT01772368]	Phase 2	72 participants (Actual)	Interventional	2013-01-31	Completed
A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide (125mcg) Once [NCT01772134]	Phase 3	617 participants (Actual)	Interventional	2013-01-01	Completed
Individualized Therapy For Asthma in Toddlers [NCT01606306]	Phase 3	300 participants (Actual)	Interventional	2013-02-28	Completed
A Randomised, Placebo-controlled, Double-blind, Two Period Crossover Study to Characterise the Exhaled Nitric Oxide Time Profile as a Biomarker of Airway Inflammation in Adult Asthma Patients Following Repeat Administration of Inhaled Fluticasone Furoate [NCT02712047]	Phase 2	28 participants (Actual)	Interventional	2016-04-29	Completed
PD of Hydrofluoroalkane Propellant of Inhaled Fluticasone Propionate Following Administration in Pediatric Subjects 6-12 Months of Age With Asthma [NCT00370097]	Phase 1	16 participants (Actual)	Interventional	2006-08-30	Completed
Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis [NCT02019758]	Phase 4	129 participants (Actual)	Interventional	2015-01-01	Completed
Uncontrolled Lower Respiratory Symptoms in the World Trade Center Survivor Program [NCT02024204]		60 participants (Actual)	Interventional	2014-04-09	Completed
A Randomized, Double-blind Placebo-controlled Study of Treatments With Salmeterol, Fluticasone Propionate and Their Combination to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease [NCT00358358]	Phase 4	163 participants (Actual)	Interventional	2006-03-31	Completed
An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation [NCT05922761]	Phase 2	45 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Repeat Dose, Randomised, Double Blind, 2-way Crossover Study to Assess the Safety and Systemic Exposure of an Investigational Formulation Compared to Concurrent Administration of Individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS Inhalers in [NCT00364442]	Phase 1	12 participants (Actual)	Interventional	2005-01-28	Completed
Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily [NCT00370591]	Phase 4	48 participants (Actual)	Interventional	2002-12-31	Completed
Biomarkers of Irritant-Induced and Allergic Asthma [NCT02740543]	Phase 2	18 participants (Actual)	Interventional	2013-12-31	Completed
A Comparison of Budesonide Nasal Irrigation in Different Head Positions and Fluticasone Nasal Spray in Post-operative Functional Endoscopic Sinus Surgery Patients With Chronic Rhinosinusitis With Nasal Polyposis [NCT02194062]		32 participants (Actual)	Interventional	2015-01-31	Completed
Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma [NCT04503460]	Phase 4	24 participants (Anticipated)	Interventional	2021-07-23	Recruiting
A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video [NCT03591068]	Phase 3	11 participants (Actual)	Interventional	2018-06-07	Completed
Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment [NCT01537133]		84 participants (Actual)	Interventional	2012-10-31	Completed
SEAL (Stopping Eczema and ALlergy) Study: Prevent the Allergic March by Enhancing the Skin Barrier [NCT03742414]	Phase 2	875 participants (Anticipated)	Interventional	2021-06-30	Recruiting
Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers [NCT01225913]	Phase 4	50 participants (Anticipated)	Interventional	2007-10-31	Recruiting
A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort® Nasal Spray (Triamcinolone, 55µg) in Comparison With Flixonase® Nasal Spray (Fluticasone, 50 µg) in Ad [NCT03317015]	Phase 3	260 participants (Actual)	Interventional	2016-11-30	Completed
MethaCholine Bronchoprovocation - Influence of High Potency Inhaled corticoSteroids in Asthma (MeCIS) Study [NCT00705341]	Phase 4	219 participants (Actual)	Interventional	2009-01-31	Completed
A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers With Charcoal Block [NCT02466503]	Phase 1	45 participants (Actual)	Interventional	2014-08-31	Completed
A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma [NCT04953741]	Phase 4	90 participants (Anticipated)	Interventional	2021-08-01	Not yet recruiting
A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared With Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects With Chronic Obstructive Pulmonary Disease [NCT02105974]	Phase 3	1,621 participants (Actual)	Interventional	2014-04-07	Completed
A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptom [NCT02141854]	Phase 3	882 participants (Actual)	Interventional	2014-06-30	Completed
12-Month OL Evaluating the Safety of Intranasal Administration Fluticasone BID Using OptiNose Device in Subjects With CS With or Without Nasal Polyps [NCT01623310]	Phase 3	223 participants (Actual)	Interventional	2013-09-30	Completed
Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients [NCT02415179]		52 participants (Actual)	Interventional	2015-05-31	Completed
The Role of Doxycycline in Management of Moderate to Severe Chronic Rhinosinusitis With Nasal Polyps [NCT02569437]	Phase 2	49 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to A high percentage of patients were dropping out of the study and were not able to complete the protocol.)
Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial [NCT02061280]	Phase 4	108 participants (Actual)	Interventional	2013-10-31	Completed
Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis [NCT02402465]	Phase 4	20 participants (Anticipated)	Interventional	2015-02-28	Recruiting
24-week Study to Evaluate Efficacy and Safety of the Combination Budesonide / Indacaterol vs Fluticasone / Salmeterol in Patients With COPD [NCT02055352]	Phase 4	222 participants (Actual)	Interventional	2014-05-30	Completed
A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma [NCT03112577]	Phase 1	32 participants (Actual)	Interventional	2017-06-15	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study With Pharmacokinetic Endpoints Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xina [NCT05085587]	Phase 1	18 participants (Anticipated)	Interventional	2021-10-01	Active, not recruiting
A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down [NCT02388373]	Phase 4	225 participants (Actual)	Interventional	2014-07-31	Completed
Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis [NCT04281108]	Phase 3	143 participants (Actual)	Interventional	2020-01-30	Completed
Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects [NCT01957150]	Phase 4	283 participants (Actual)	Interventional	2014-01-28	Completed
Elocon vs Fluticasone in Localized Psoriasis [NCT00763529]	Phase 4	245 participants (Actual)	Interventional	2003-01-01	Completed
The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children: A Pilot Study [NCT03040596]	Phase 1	12 participants (Anticipated)	Interventional	2017-03-01	Recruiting
Long-acting Beta Agonist Step Down Study [NCT01437995]	Phase 4	459 participants (Actual)	Interventional	2012-03-31	Completed
A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled [NCT01436071]	Phase 3	248 participants (Actual)	Interventional	2011-09-30	Completed
A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial [NCT00691665]	Phase 4	130 participants (Actual)	Interventional	2008-05-31	Completed
Multicentre, Randomized, Double-blind, Parallel Group Phase III Study to Assess Efficacy and Safety of Dymista® Compared to Azep® and Flixonase® Nasal Sprays in the Treatment of Chinese Patients With Allergic Rhinitis/Rhinoconjunctivitis [NCT03599791]	Phase 3	900 participants (Actual)	Interventional	2018-06-29	Completed
Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies [NCT01332461]		5,677 participants (Actual)	Observational	2009-11-30	Completed
A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps [NCT01623323]	Phase 3	705 participants (Actual)	Interventional	2013-09-30	Completed
An Open Label, Multi-centre, Post Marketing Surveillance to Observe the Safety and Effectiveness of ARNUITY Administered in Patients With Asthma in Usual Practice [NCT03595930]		668 participants (Actual)	Observational [Patient Registry]	2018-09-21	Completed
Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma [NCT03141424]	Phase 4	110 participants (Anticipated)	Interventional	2022-06-01	Recruiting
A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy [NCT01573767]	Phase 2	463 participants (Actual)	Interventional	2012-04-30	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT03820180]	Phase 1	34 participants (Actual)	Interventional	2019-01-23	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharm [NCT04746040]	Phase 1	50 participants (Actual)	Interventional	2021-01-18	Active, not recruiting
A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fluticasone Propionate DPI Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Persistent Asthma Uncontrolled on Non-steroidal Therapy [NCT01479621]	Phase 2	909 participants (Actual)	Interventional	2012-01-31	Completed
SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma [NCT01475721]	Phase 4	11,751 participants (Actual)	Interventional	2011-11-18	Completed
An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD) [NCT00119158]	Phase 4	90 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized, Double-blind, Repeat Dose, Two Period Crossover Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Inhaled Fluticasone Furoate/Vilanterol 100/25 Micrograms in Children Aged 5 to 11 Years With Persistent [NCT01453023]	Phase 2	26 participants (Actual)	Interventional	2011-10-31	Completed
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20) [NCT01430403]	Phase 4	478 participants (Actual)	Interventional	2011-09-30	Completed
Management of Recurrent Croup: Comparison Between Inhaled Fluticasone and Oral Prednisolone [NCT01748162]	Phase 3	10 participants (Actual)	Interventional	2012-09-30	Terminated
A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma. [NCT01845025]	Phase 4	827 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was a commercial reason and not due to any change in benefit-risk.)
A Double-Blind, Randomized, Double-Dummy, Multicenter Study to Evaluate and Compare Oral Montelukast and Inhaled Fluticasone in the Control of Asthma for 6- to 14-Year-Olds With Mild Persistent Asthma [NCT00489346]	Phase 3	994 participants (Actual)	Interventional	2001-10-31	Completed
A Randomised, Double-blind, Double Dummy, 3 Way Cross-over Study Evaluating the Effects of ADOAIR 50/250mcg Twice Daily Plus Tiotropium Bromide 18mcg Once Daily Compared With the Individual Treatments (Tiotropium Bromide 18mcg Alone and ADOAIR 50/250mcg A [NCT01751113]	Phase 4	53 participants (Actual)	Interventional	2013-02-28	Completed
A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-d [NCT02164513]	Phase 3	10,355 participants (Actual)	Interventional	2014-06-30	Completed
Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat [NCT01969721]	Phase 3	229 participants (Actual)	Interventional	2013-10-31	Completed
Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy [NCT00891436]	Phase 4	20 participants (Actual)	Interventional	2009-04-30	Completed
Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis [NCT00883168]	Phase 3	1,791 participants (Actual)	Interventional	2009-04-30	Completed
A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With [NCT01706198]	Phase 3	4,233 participants (Actual)	Interventional	2012-11-01	Completed
Comparison of Conventional Medicine, TCM Treatment and Combination of Both Conventional Medicine and TCM Treatment for Patients With Chronic Obstructive Pulmonary Disease: A Randomized Comparative Effectiveness Research Trial [NCT01836016]	Phase 3	360 participants (Anticipated)	Interventional	2013-05-31	Not yet recruiting
SAPS:Smoking Asthmatics Pilot Study: [NCT01696214]	Phase 4	20 participants (Actual)	Interventional	2012-10-31	Completed
The Effect of Vilanterol Against Methacholine-induced Bronchoconstriction in Mild Asthmatics [NCT03315000]	Phase 4	17 participants (Actual)	Interventional	2017-10-13	Completed
DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD [NCT01822899]	Phase 3	717 participants (Actual)	Interventional	2013-04-04	Completed
A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma [NCT00557440]	Phase 2	37 participants (Actual)	Interventional	2007-11-30	Completed
A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose [NCT01836471]	Phase 2	345 participants (Actual)	Interventional	2013-05-31	Completed
A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multi [NCT02680561]	Phase 1	20 participants (Actual)	Interventional	2016-04-30	Completed
A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe CO [NCT02603393]	Phase 4	1,053 participants (Actual)	Interventional	2015-11-20	Completed
A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOV [NCT05021887]	Phase 1	50 participants (Anticipated)	Interventional	2021-08-13	Recruiting
Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg [NCT01762800]	Phase 4	407 participants (Actual)	Interventional	2013-02-28	Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Nasal Spray, 50 mcg With Flonase® Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rh [NCT02246920]	Phase 3	1,474 participants (Actual)	Interventional	2014-03-01	Terminated(stopped due to Development Halted)
Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps. [NCT05143502]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2022-01-01	Active, not recruiting
A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Seretide® Evohaler (Supplied by Allen & Hanburys, UK) and a Generic Salmeterol/Fluticasone HFA pMDI (Manufactured by Cipla Ltd, India) on Functional Respiratory I [NCT01795664]	Phase 3	16 participants (Actual)	Interventional	2013-03-31	Completed
A Randomized, Placebo-Controlled, Crossover Study to Assess the Effects of Inhaled Fluticasone on Markers of Inflammation After Allergen Challenge in Patients With Allergic Asthma [NCT00623714]	Phase 1	13 participants (Actual)	Interventional	2008-01-31	Completed
The Pharmacokinetics of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols [NCT00692978]	Phase 4	30 participants (Actual)	Interventional	2008-08-31	Completed
Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome [NCT00603044]	Phase 4	24 participants (Actual)	Interventional	2008-01-31	Completed
Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Multiple Doses of Fluticasone Propionate in Healthy Subjects [NCT01365611]	Phase 1	36 participants (Actual)	Interventional	2007-02-28	Completed
Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis [NCT01622231]	Phase 3	61 participants (Actual)	Interventional	2012-06-30	Completed
A Randomised, Double-blind, Double-dummy, Placebo Controlled Multi-centre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder and Fluticasone Propionate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents [NCT01436110]	Phase 3	351 participants (Actual)	Interventional	2011-09-30	Completed
A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in [NCT01908140]	Phase 3	933 participants (Actual)	Interventional	2013-09-30	Completed
[NCT02230696]	Phase 3	951 participants (Actual)	Interventional	2014-08-31	Completed
A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients [NCT02245672]	Phase 3	1,128 participants (Actual)	Interventional	2014-10-31	Completed
A Randomised, Repeat-dose, Placebo-controlled, Three-way Crossover, Double Dummy Study to Evaluate and Compare the Efficacy of Fluticasone Furoate Inhalation Powder Delivered Via the Single Strip Dry Powder Inhaler When Administered Either in the Morning [NCT01808339]	Phase 2	28 participants (Actual)	Interventional	2013-03-31	Completed
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Brom [NCT01772147]	Phase 3	608 participants (Actual)	Interventional	2013-01-31	Completed
Optimizing Discharge After Emergency Department Visits for Children With Uncontrolled Asthma [NCT01881412]		118 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to Funding complete)
Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma: A Randomized, Double-blind, Double-dummy, Positive-controlled, Parallel-group Trail [NCT03461627]	Phase 3	300 participants (Anticipated)	Interventional	2017-04-01	Recruiting
Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated Chronic Obstructive Pulmonary Disease Patients [NCT01933984]		51 participants (Actual)	Interventional	2013-08-31	Completed
A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily Via a Dry Powder Inhaler Compared With Placebo in Subjects of Asian Ancestry With Chronic Obstructive Pulmonary Disease [NCT01376245]	Phase 3	646 participants (Actual)	Interventional	2011-04-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy of Once-Daily Fluticasone Propionate Aqueous Nasal Spray 200mcg for 14 Days on Ocular Symptoms Associated With Seasonal Allergic Rhinitis [NCT01817790]	Phase 3	626 participants (Actual)	Interventional	2012-12-31	Completed
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With [NCT01706328]	Phase 3	828 participants (Actual)	Interventional	2012-10-15	Completed
A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma [NCT01462344]	Phase 4	6,250 participants (Actual)	Interventional	2011-11-17	Completed
A Randomized, Multiple-Dose,Double-Blind,Crossover Trial to Assess the Systemic Exposure of Fluticasone Propionate (FP)/Formoterol Fumarate (FF) Fixed-Dose Combination in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [NCT00774761]	Phase 2	97 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10ug Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) [NCT00649025]	Phase 3	438 participants (Actual)	Interventional	2008-03-31	Completed
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma [NCT02260492]	Phase 1	879 participants (Actual)	Interventional	2014-09-30	Completed
A 6-month, Open Label, Randomised, Efficacy Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via the Dry Powder Inhaler ELLIPTA™ Compared With Usual ICS/LABA Maintenance Therapy Delivere [NCT02446418]	Phase 3	423 participants (Actual)	Interventional	2015-07-09	Completed
A Pilot Study to Investigate Pharmacokinetic Characteristics After Co-administration of HCP0910 and HGP1011 [NCT02441114]	Phase 1	10 participants (Actual)	Interventional	2015-07-31	Completed
A Double-Blind Placebo-Controlled Crossover Study to Evaluate Objective Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure in an Environmental Exposure Unit [NCT03443843]	Phase 4	82 participants (Actual)	Interventional	2018-02-21	Completed
A Double Blind, Double Dummy, Randomised, Multicentre, Two Arm Parallel Group Study to Assess the Efficacy and Safety of FLUTIFORM® pMDI (2 Puffs Bid) vs Seretide® pMDI (2 Puffs Bid) in Subjects Aged ≥12 Years With Moderate to Severe Persistent, Reversibl [NCT03387241]	Phase 3	330 participants (Anticipated)	Interventional	2017-06-02	Recruiting
The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series [NCT03594565]	Early Phase 1	13 participants (Actual)	Interventional	2016-03-31	Completed
A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptom [NCT02139644]	Phase 3	787 participants (Actual)	Interventional	2014-06-30	Completed
201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmat [NCT02094937]	Phase 3	430 participants (Actual)	Interventional	2014-03-27	Completed
A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Devi [NCT01622569]	Phase 3	323 participants (Actual)	Interventional	2013-11-19	Completed
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering [NCT05535738]	Phase 2/Phase 3	45 participants (Anticipated)	Interventional	2022-11-15	Recruiting
Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment [NCT02141633]		31 participants (Actual)	Interventional	2013-04-30	Completed
Best African American Response to Asthma Drugs [NCT01967173]	Phase 3	574 participants (Actual)	Interventional	2014-02-28	Completed
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations [NCT02066129]	Phase 3	254 participants (Actual)	Interventional	2014-07-31	Completed
Randomized, Parallel, Placebo-controlled, Multiple Dose, Multicenter Study to Compare the Efficacy of Fluticasone/Salmeterol (Test) to Advair® Diskus (GSK) in Adult Asthma Patients [NCT02496715]	Phase 3	0 participants (Actual)	Interventional	2015-09-30	Withdrawn(stopped due to Development terminated.)
A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol 100/25mcg Versus Fluticasone Furoate 100mcg on Asthma Control in Patients With Uncontrolled Asthma [NCT03363191]	Phase 4	0 participants (Actual)	Interventional	2018-03-07	Withdrawn(stopped due to The study was withdrawn due to an internal decision.)
Comparison of Efficacy and Safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Treatment Administered Via Capsair and Original Product Seretide Diskus 500 mcg Inhalation Powder Treatment in Patients With Moderate-severe Chronic Obstructive Pulmo [NCT03363503]	Phase 4	64 participants (Actual)	Interventional	2018-04-13	Terminated(stopped due to Adequate number of patients could not be reached in the relevant centers.)
Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Vilanterol [NCT06066606]		30 participants (Anticipated)	Interventional	2023-10-05	Recruiting
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler 50/250 µg/Dose Products and Seretide Diskus 50/250 µg/Dose in Healthy Subjects [NCT03238482]	Phase 1	64 participants (Actual)	Interventional	2017-08-16	Completed
A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD [NCT01709903]	Phase 3	744 participants (Actual)	Interventional	2012-11-30	Completed
DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD [NCT01817764]	Phase 3	707 participants (Actual)	Interventional	2013-03-01	Completed
Medical vs Surgical Treatment Decision in Pediatric Obstructive Sleep Apnea Using Sleep Questionnaire [NCT05651750]	Phase 4	90 participants (Anticipated)	Interventional	2022-11-15	Recruiting
Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis [NCT01630135]	Phase 3	261 participants (Actual)	Interventional	2012-06-30	Completed
A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Dai [NCT01627327]	Phase 3	623 participants (Actual)	Interventional	2012-04-01	Completed
Utility of Nasal Steroids for Treatment of Childhood Obstructive Sleep Apnea [NCT02180672]	Phase 3	211 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00079937 (6) [back to overview]	Change in Mean Nocturnal Asthma Symptom Score From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period
NCT00079937 (6) [back to overview]	Change in Mean Daily Number of Puffs of Asthma Rescue Medication From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period
NCT00079937 (6) [back to overview]	Percentage of Participants With at Least 1 Adverse Event
NCT00079937 (6) [back to overview]	Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period
NCT00079937 (6) [back to overview]	Rate of Clinically Significant Asthma Exacerbations Per Patient in the 52-week Treatment Period
NCT00079937 (6) [back to overview]	Change in Pediatric Asthma Quality of Life Questionnaire (Standardized) [PAQLQ(S)] Scores From Baseline to the End of the 24-week Fixed-dose Steroid Treatment Period (Week 24)
NCT00118716 (7) [back to overview]	Percent of Symptom-free Days
NCT00118716 (7) [back to overview]	Four-hour Serial Post-dose FEV1 Area Under the Curve (AUC) on Treatment Day 1
NCT00118716 (7) [back to overview]	Percent of Rescue-free Days
NCT00118716 (7) [back to overview]	Maximal Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Following Exercise Challenge at Week 4
NCT00118716 (7) [back to overview]	Change From Baseline in Morning Peak Expiratory Flow (AM PEF)
NCT00118716 (7) [back to overview]	Change From Baseline in Evening (PM) PEF
NCT00118716 (7) [back to overview]	Change From Baseline in Pediatric Asthma Quality of Life Questionnaire (PAQLQ)
NCT00119015 (5) [back to overview]	Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period
NCT00119015 (5) [back to overview]	Change From Baseline in Sneezing Symptom Score Over 2 Week Randomized Treatment Period
NCT00119015 (5) [back to overview]	Change From Baseline in Runny Nose Symptom Score Over 2 Week Randomized Treatment Period
NCT00119015 (5) [back to overview]	Change From Baseline in Other Symptom Score Over 2 Week Randomized Treatment Period
NCT00119015 (5) [back to overview]	Change From Baseline in Stuffy Nose Symptom Score Over 2 Week Randomized Treatment Period
NCT00119158 (2) [back to overview]	The Time to Clearance of the Disease
NCT00119158 (2) [back to overview]	Change From Baseline in the m-EASI (Eczema Area Severity Index) Score.
NCT00127166 (5) [back to overview]	Maximum Post-exercise Percent (%) Fall in FEV1
NCT00127166 (5) [back to overview]	Time to Recovery to Within 5% of Baseline FEV1
NCT00127166 (5) [back to overview]	Maximum FEV1 % Predicted Following First Beta-agonist Use
NCT00127166 (5) [back to overview]	Average (Avg) %-Change in FEV1 After First Beta (β)-Agonist Use and Prior to Second β-agonist Use
NCT00127166 (5) [back to overview]	Area Under the Curve for %-Change From Pre-exercise Baseline FEV1 in Liters (L), From 0 to 20 Minutes (AUC(0-20))
NCT00156819 (1) [back to overview]	Treatment Failure
NCT00197106 (9) [back to overview]	Mean Change From Baseline in Percentage Predicted Forced Expiratory Volume in One Second (FEV1) at Week 26
NCT00197106 (9) [back to overview]	Percentage of Symptom-free Days During the Entire Treatment Period
NCT00197106 (9) [back to overview]	Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period
NCT00197106 (9) [back to overview]	Percent Change From Baseline in RINT Measurements at Week 26
NCT00197106 (9) [back to overview]	Mean Change From Baseline in Provocation Dose (PD20) Causing a 20% Fall in FEV1 at Week 26
NCT00197106 (9) [back to overview]	Geometric Means of Nitric Oxide (NO) at Week 26
NCT00197106 (9) [back to overview]	Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 26
NCT00197106 (9) [back to overview]	Number of Asthma Exacerbations Per Treatment Group at Week 26
NCT00197106 (9) [back to overview]	Mean Change From Baseline in Midexpiratory Flow (MEF 50) at Week 26
NCT00214019 (1) [back to overview]	Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge
NCT00241631 (3) [back to overview]	Interleukin 8 (IL8)
NCT00241631 (3) [back to overview]	Sputum Inflammatory Cell Counts
NCT00241631 (3) [back to overview]	Total Sputum Eosinophils
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Pulse Rate
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Peak Expiratory Flow (PEF)
NCT00269087 (25) [back to overview]	Mean Area Under the Plasma Concentration-time Curve From Zero up to the Last Quantifiable Plasma Concentration [AUC (0-t)] of Salmeterol
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT00269087 (25) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)
NCT00269087 (25) [back to overview]	Number of Participants With Abnormal Oropharyngeal Examination Findings
NCT00269087 (25) [back to overview]	Number of Participants With Abnormal (Outliers From the Normal Range) Clinical Chemistry Parameters
NCT00269087 (25) [back to overview]	Number of Participants With Abnormal (Shift From Baseline) Urinalysis Parameters
NCT00269087 (25) [back to overview]	Number of Participants With Abnormal (Outliers From the Normal Range) Hematology Parameters
NCT00269087 (25) [back to overview]	Number of Participants With Abnormal (Clinically Significant) Ophthalmological Examinations Findings
NCT00269087 (25) [back to overview]	Number of Participants With Abnormal (Clinically Significant) Electrocardiogram (ECG) Findings
NCT00269087 (25) [back to overview]	Mean Level of Plasma Cortisol 2
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Weight
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Maximal Expiratory Flow Rate at 25% (V25) and 50% (V50) of Vital Capacity
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Level of Plasma Cortisol 1
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Forced Vital Capacity (FVC)
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Bone Mineral Density (BMD)
NCT00269087 (25) [back to overview]	Change From Baseline in Symptom Score With Respect to Breathlessness, Cough, Sputum and Nighttime Awakenings
NCT00269087 (25) [back to overview]	Median Tmax of Salmeterol
NCT00269087 (25) [back to overview]	Median Time of Observed Maximum Plasma Concentration (Tmax) of FP
NCT00269087 (25) [back to overview]	Mean Observed Maximum Plasma Concentration (Cmax) of Fluticasone Propionate (FP)
NCT00269087 (25) [back to overview]	Mean Frequency of Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
NCT00269087 (25) [back to overview]	Mean Cmax of Salmeterol
NCT00269087 (25) [back to overview]	Mean Change From Baseline in Percent of Days Without Use of Rescue Medication
NCT00269087 (25) [back to overview]	Mean Area Under the Plasma Concentration-time Curve Over a Dosing Interval [AUC(0-tau)] of FP
NCT00275561 (3) [back to overview]	Number of Participants With Partial or Complete Response to Dysphagia
NCT00275561 (3) [back to overview]	Number of Participants With Complete Response to Dysphagia
NCT00275561 (3) [back to overview]	Number of Participants With Complete Histologic Response
NCT00284856 (3) [back to overview]	Change From Baseline in Mean Daytime Symptom Score Over a 6-month Treatment Period
NCT00284856 (3) [back to overview]	Change From Baseline in Average Morning (AM) PEFR (Peak Expiratory Flow Rate) Over a 6-month Treatment Period
NCT00284856 (3) [back to overview]	Percentage of Asthma-control Days Over the 6-month Treatment Period
NCT00294398 (2) [back to overview]	Number of Inhaled Corticosteroid (ICS) Prescriptions Refilled (Confirmed by Primary Care Physician)
NCT00294398 (2) [back to overview]	Asthma-related Quality of Life
NCT00296491 (10) [back to overview]	Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Intent-to-Treat Population
NCT00296491 (10) [back to overview]	Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Per Protocol Population
NCT00296491 (10) [back to overview]	Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol/Salbutamol-Free Days for Per Protocol Population
NCT00296491 (10) [back to overview]	Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol-Salbutamol Free Days for Intent-to-Treat Population
NCT00296491 (10) [back to overview]	Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Intent-to-Treat Population
NCT00296491 (10) [back to overview]	Rhinitis: Mean Change From Baseline at 1-2 Weeks in Nightime Total Nasal Symptom Scores (N-TNSS)
NCT00296491 (10) [back to overview]	Rhinitis: Mean Change From Baseline at 1-2 Weeks in Daytime Total Nasal Symptom Scores (D-TNNS).
NCT00296491 (10) [back to overview]	Mean Change From Baseline at Endpoint in Morning Peak Expiratory Flow (PEF) for Per Protocol Population
NCT00296491 (10) [back to overview]	Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population
NCT00296491 (10) [back to overview]	Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Per Protocol Population
NCT00306163 (1) [back to overview]	PC20 AMP (Post-treatment Compared to Baseline)
NCT00318708 (7) [back to overview]	AM Peak Expiratory Flow (PEF)
NCT00318708 (7) [back to overview]	Methacholine Provocative Concentration (PC20)
NCT00318708 (7) [back to overview]	Juniper Asthma Control Questionnaire (ACQ) Results
NCT00318708 (7) [back to overview]	Forced Expiratory Volume in One Second (FEV1)
NCT00318708 (7) [back to overview]	Exhaled Nitric Oxide (eNO)
NCT00318708 (7) [back to overview]	Asthma Rescue Medication Use
NCT00318708 (7) [back to overview]	Asthma Quality of Life Questionnaire (AQLQ)
NCT00353873 (4) [back to overview]	Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population
NCT00353873 (4) [back to overview]	Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma
NCT00353873 (4) [back to overview]	Number of Participants Who Achieved WC Asthma
NCT00353873 (4) [back to overview]	Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population
NCT00355342 (2) [back to overview]	Percent Change From Baseline in BMD at the Total Hip
NCT00355342 (2) [back to overview]	Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine L1-L4
NCT00363480 (17) [back to overview]	Assessment of Tolerability by Number of Participants With at Least One Treatment Emergent Serious and, Non-serious AE
NCT00363480 (17) [back to overview]	Change From Baseline in Number of Additional Usage of Salbutamol at Week 12
NCT00363480 (17) [back to overview]	Change From Baseline in Percentage of Participants With ACT Score of 20-25 at Week 12
NCT00363480 (17) [back to overview]	Number of Participants With Emergency Visits Due to Asthma
NCT00363480 (17) [back to overview]	Number of Participants With Well Controlled and Totally Controlled Asthma at Week 12
NCT00363480 (17) [back to overview]	Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control Test (ACT) Score of 20-25 for Week 9 to Week 12
NCT00363480 (17) [back to overview]	Correlation of Change in AQLQ Score and Change in ACT Score
NCT00363480 (17) [back to overview]	Number of Participants With Occurrence of (Near-) Incidents Associated With Peak Flow Measurements
NCT00363480 (17) [back to overview]	Percent Change From Baseline in Number of Nights With no Nocturnal Awakening at Week 12
NCT00363480 (17) [back to overview]	Assessment of Tolerability by Change From Baseline of Pulse Rate
NCT00363480 (17) [back to overview]	Change From Baseline in Quality of Life Using the Asthma Quality of Life Questionnaire (AQLQ)
NCT00363480 (17) [back to overview]	Change From Baseline in Mean Morning Percent Predicted Peak Expiratory Flow (PEF) at Week 12
NCT00363480 (17) [back to overview]	Change From Baseline in Mean ACT Score at Visit 6
NCT00363480 (17) [back to overview]	Change From Baseline in Mean 24-hour Symptom Score at Week 12
NCT00363480 (17) [back to overview]	Assessment of Tolerability by Change From Baseline of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT00363480 (17) [back to overview]	Change From Baseline in Forced Expiratory Volume (FEV1) to Week 12
NCT00363480 (17) [back to overview]	Number of Participants With Adverse Events (AE) Leading to a Change in Asthma Treatment
NCT00379288 (1) [back to overview]	The Number of All Randomized Subjects Reporting Adverse Events (AEs).
NCT00387036 (2) [back to overview]	Standardized Dyspnea Score at Isotime During Exercise
NCT00387036 (2) [back to overview]	Exercise Endurance Time
NCT00394355 (4) [back to overview]	Mean Percent Change in the Femoral Neck BMD From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point
NCT00394355 (4) [back to overview]	Mean Percent Change in the Left Total Femur From the Averaged Baseline Value to the Averaged Value at the Endpoint of Treatment Time Point
NCT00394355 (4) [back to overview]	Summary of Change From Baseline to Endpoint in FEV1 (Forced Expiratory Volume in One Second).
NCT00394355 (4) [back to overview]	Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From the Averaged Baseline Value to the Endpoint of Treatment Time Point
NCT00395304 (14) [back to overview]	Change From Baseline in the Logarithm Base 2 of the Methacholine PC20
NCT00395304 (14) [back to overview]	Change From Baseline in the Asthma Control Test (ACT)
NCT00395304 (14) [back to overview]	Change From Baseline in the Impulse Oscillometry Resistance at 5 Hertz
NCT00395304 (14) [back to overview]	Change From Baseline in the Evening Peak Expiratory Flow Rate (PEFR) % Predicted
NCT00395304 (14) [back to overview]	Number of Participants With Asthma Exacerbations
NCT00395304 (14) [back to overview]	Change From Baseline in the Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) % Predicted
NCT00395304 (14) [back to overview]	Change From Baseline in the Pre-bronchodilator FEV1/FVC Ratio
NCT00395304 (14) [back to overview]	Change From Baseline in Asthma Quality of Life
NCT00395304 (14) [back to overview]	Change From Baseline in the Pre-bronchodilator Forced Vital Capacity (FVC) % Predicted
NCT00395304 (14) [back to overview]	The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1.
NCT00395304 (14) [back to overview]	Change From Baseline in the Post-bronchodilator FEV1 Percent Predicted
NCT00395304 (14) [back to overview]	Change From Baseline in the Peak Expiratory Flow Rate (PEFR) Variability
NCT00395304 (14) [back to overview]	Change From Baseline in the Natural Logarithm of Exhaled Nitric Oxide (eNO)
NCT00395304 (14) [back to overview]	Change From Baseline in the Morning Peak Expiratory Flow Rate (PEFR) % Predicted
NCT00398476 (18) [back to overview]	Number of Participants With Preference for Satisfaction With Scent/Odor in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Satisfied With Product in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Who Satisfied Not to Have Scent/Odor in IAQ
NCT00398476 (18) [back to overview]	Number of Participants Satisfied With an After Taste in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Product Make Want to Sneeze in IAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Product Have an Immediate Taste in IAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Product Have an After Taste in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Satisfied With an Immediate Taste in IAQ
NCT00398476 (18) [back to overview]	Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing
NCT00398476 (18) [back to overview]	Number of Participants With Preference for Scent/Odor in IAQ and DAQ
NCT00398476 (18) [back to overview]	Number of Participants With Preference for Satisfaction With Scent/Odor in IAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Nasal Irritation in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Nasal Irritation Bothersome in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Medicine Run Out of Nose in IAQ and DAQ
NCT00398476 (18) [back to overview]	Number of Participants Who Satisfied Not to Have Scent/Odor in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Medicine Run Down Throat in IAQ and DAQ
NCT00398476 (18) [back to overview]	Number of Participants Comply With Product if Prescribed in DAQ
NCT00398476 (18) [back to overview]	Number of Participants Reported Product Feel Soothing in IAQ and DAQ
NCT00424008 (4) [back to overview]	Onset-of-action Based on Change From Baseline FEV1 at the 5 Min Pulmonary Function Test (PFT) Assessment on Day 1
NCT00424008 (4) [back to overview]	Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score at Week 12 Endpoint
NCT00424008 (4) [back to overview]	The Area Under the Curve From 0 to 12 Hours [AUC](0-12 hr) of the Change From Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1)
NCT00424008 (4) [back to overview]	The Proportion of Symptom-free Days and Nights (Combined) Over the 12-week Treatment Period.
NCT00426283 (6) [back to overview]	Percentage of Participants Who Attained Remission.
NCT00426283 (6) [back to overview]	Percent of Participants With Decreased Cortisol Levels After 3 Months
NCT00426283 (6) [back to overview]	Association of Subject Age, Body Mass Index Z-score, and Allergic Status to Response to Flovent
NCT00426283 (6) [back to overview]	Association of Compliance With Therapy and Response to Flovent
NCT00426283 (6) [back to overview]	EoE Score After 3 Months
NCT00426283 (6) [back to overview]	Percent of Participants With Abdominal Pain After Therapy
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Symptoms Score (NSS)
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in Pre-dose Instantaneous Total Nasal Symptom Score (Pre-dose iTNSS) and Pre-dose Instantaneous Total Ocular Symptom Scores (Pre-dose iTOSS)
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in Peak NasalIinspiratory Flow (PNIF)
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Reflective Total Ocular Symptom Scores (N-rTOSS)
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) and Component Nasal Symptoms Score
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in Daytime Reflective Total Ocular Symptom Scores (D-rTOSS)
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in D-rTNSS
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in 24-hour Reflective Total Ocular Symptom Scores (24-hour rTOSS)
NCT00435461 (10) [back to overview]	Mean Change From Baseline Over the Two-week Treatment Period in 24-hour Reflective Total Nasal Symptom Scores (24-hour rTNSS) and Component Nasal Score
NCT00435461 (10) [back to overview]	Mean Change From Baseline for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
NCT00441441 (24) [back to overview]	Albuterol Use
NCT00441441 (24) [back to overview]	AM Peak Expiratory Flow
NCT00441441 (24) [back to overview]	Asthma Exacerbations: Worsening of Asthma Requiring Emergency Intervention, Hospitalization, or Treatment With Asthma Medications Prohibited by the Protocols
NCT00441441 (24) [back to overview]	Asthma Symptom Scores
NCT00441441 (24) [back to overview]	Cardiovascular Adverse Events Reported During the Post-Treatment Period
NCT00441441 (24) [back to overview]	Cardiovascular Adverse Events Reported During Treatment Period
NCT00441441 (24) [back to overview]	Clinic Morning (AM) Forced Expiratory Volume in Participants 6-11 Years
NCT00441441 (24) [back to overview]	Clinically Significant Unfavorable ECGs at Week 12
NCT00441441 (24) [back to overview]	Possible Drug-Related Adverse Events
NCT00441441 (24) [back to overview]	ECG Measures - Heart Rate
NCT00441441 (24) [back to overview]	Percentage of Symptom Free Days
NCT00441441 (24) [back to overview]	Percent of Albuterol-free Days
NCT00441441 (24) [back to overview]	Number of Participants With the Indicated Levels of 24-hour Urinary Cortisol Excretion
NCT00441441 (24) [back to overview]	Number of Participants With the Indicated Levels of 24 Hour Urinary Cortisol Excretion by Spacer Use
NCT00441441 (24) [back to overview]	Investigator Evaluations of Electrocardiogram (ECG) Results
NCT00441441 (24) [back to overview]	Geometric Mean Values of 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population at Baseline and Week 12
NCT00441441 (24) [back to overview]	Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12
NCT00441441 (24) [back to overview]	Geometric Mean Values of 24-hour Urinary Cortisol Excretion at Baseline and Week 12
NCT00441441 (24) [back to overview]	Geometric Mean Values of 24 Hour Urinary Cortisol Excretion by Spacer Use at Baseline and Week 12
NCT00441441 (24) [back to overview]	ECG Measures - QT Interval
NCT00441441 (24) [back to overview]	Geometric Mean Ratio for Baseline: Week 12 24-hour Urinary Cortisol Excretion by Spacer Use Excluding Participants With Abnormal Urinary Cortisol Excretion Values at Baseline From the Cortisol Population
NCT00441441 (24) [back to overview]	Geometric Mean Ratio for Baseline:Week12 24-hour Urinary Cortisol Excretion
NCT00441441 (24) [back to overview]	Geometric Mean Ratio for Week12: Baseline for 24 Hour Urinary Cortisol Excretion by Spacer Use
NCT00441441 (24) [back to overview]	Geometric Mean Ratio for Week12:Baseline for 24-hour Urinary Cortisol Excretion
NCT00448435 (14) [back to overview]	Percentage of Subjects With Symptom-Free Nights & Days After 20 Weeks of Treatment
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 20-week Extension Treatment Period
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Morning PEF During the 20-week Extension Treatment Period
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Evening PEF During the 4-week Treatment Periods
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Evening PEF During the 20-week Extension Treatment Period
NCT00448435 (14) [back to overview]	Percentage of Subjects With Rescue Medication-Free Nights & Days After 20 Weeks of Treatment
NCT00448435 (14) [back to overview]	Percentage of Subjects With Symptom-Free Nights & Days
NCT00448435 (14) [back to overview]	Percentage of Subjects With Rescue Medication-Free Nights and Days
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline of Circadian Variation in PEF(%) During the 20-Week Extension Treatment Period
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline of Circadian Variation in Morning PEF(%) During the 4-week Treatment Periods
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 4-week Treatment Periods
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Percent Predicted Morning PEF(%) During the 20-Week Extension Treatment Period
NCT00448435 (14) [back to overview]	Adjusted Mean Change From Baseline in Percent Personal Best Morning PEF(%) During the 4-week Treatment Periods
NCT00449046 (8) [back to overview]	Change From Baseline in Evening Peak Expiratory Flow (PEF) During Weeks 1-24
NCT00449046 (8) [back to overview]	Change From Baseline in Circadian Variation in Peak Expiratory Flow (PEF) During Weeks 1-24
NCT00449046 (8) [back to overview]	Change From Baseline in Morning Peak Expiratory Flow (PEF) During Weeks 1-24
NCT00449046 (8) [back to overview]	Change From Baseline in Percent Predicted Morning Peak Expiratory Flow (PEF) During Weeks 1-24
NCT00449046 (8) [back to overview]	Serious Adverse Events (SAEs) - On Therapy
NCT00449046 (8) [back to overview]	Most Frequent Adverse Events - On Therapy
NCT00449046 (8) [back to overview]	Number of Participants With Rescue Medication-Free Nights and Days
NCT00449046 (8) [back to overview]	Number of Participants With Symptom-Free Nights and Days
NCT00452348 (4) [back to overview]	Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52
NCT00452348 (4) [back to overview]	Rate of Asthma Attacks Per Participant Per Year
NCT00452348 (4) [back to overview]	Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52
NCT00452348 (4) [back to overview]	Mean Change From Baseline in AM PEF Over Weeks 1-52
NCT00452699 (4) [back to overview]	Rate of Asthma Attacks Per Participant Per Year
NCT00452699 (4) [back to overview]	Mean Change From Baseline in AM PEF Over Weeks 1-52
NCT00452699 (4) [back to overview]	Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52
NCT00452699 (4) [back to overview]	Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52
NCT00455923 (2) [back to overview]	Number of Exacerbations: in Total and by Degree of Severity
NCT00455923 (2) [back to overview]	Number of Participants in Each Arm With a Need for an Increase in Study Medication
NCT00461500 (13) [back to overview]	Change From Baseline in Pre-dose (Percent Predicted) FEV1 Through Week 12 (Using Last Observation Carried Forward [LOCF] Approach)
NCT00461500 (13) [back to overview]	Change From Baseline in Asthma Control Test (ACT) Score at Week 12
NCT00461500 (13) [back to overview]	Change From Baseline in FEV1 Reversibility Through Week 12 (Using Last Observation Carried Forward [LOCF] Approach)
NCT00461500 (13) [back to overview]	Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Over Weeks 5-12
NCT00461500 (13) [back to overview]	Change From Baseline in Overall Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12
NCT00461500 (13) [back to overview]	Number of Participants Who Achieved Well-Controlled Asthma During Weeks 5-12
NCT00461500 (13) [back to overview]	Change From Baseline in Pre-dose FEV1 (Forced Expiratory Volume in One Second) Through Week 12 (Using Last Observation Carried Forward [LOCF] Approach)
NCT00461500 (13) [back to overview]	Median Number of Weeks to First Achieve Well-Controlled Asthma During Weeks 5-12
NCT00461500 (13) [back to overview]	ACT Score in Classes at Week 12
NCT00461500 (13) [back to overview]	Number of Participants Who Achieved Total-controlled Asthma During Weeks 5-12
NCT00461500 (13) [back to overview]	Change From Baseline (BL) in Pre-dose FEF 25-75% (Forced Expiratory Flow) Through Week 12 (Using Last Observation Carried Forward [LOCF] Approach)
NCT00461500 (13) [back to overview]	Number of Participants With at Least One Exacerbation During 12-Week Treatment Period
NCT00461500 (13) [back to overview]	Change From Baseline in Pre-dose Forced Expiratory Vital Capacity (FVC) Through Week 12 (Using Last Observation Carried Forward [LOCF] Approach)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Daytime Reflective Total Ocular Symptom Score (D-rTOSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Evening Peak Nasal Inspiratory Flow (PNIF)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Morning Peak Nasal Inspiratory Flow (PNIF)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Nighttime Reflective Total Nasal Symptom Score (N-rTNSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Nighttime Reflective Total Ocular Symptom Score (N-rTOSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Pre-Dose Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Pre-Dose Instantaneous Total Ocular Symptom Score (iTOSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in the Nighttime Symptom Score (NSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in 24 Hour Reflective Total Nasal Symptom Score (24 Hour rTNSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline at Day 15 for Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in 24 Hour Reflective Total Ocular Symptoms Score (rTOSS)
NCT00502775 (12) [back to overview]	Mean Change From Baseline in Daytime Reflective Total Nasal Symptom Score (D-rTNSS)
NCT00509197 (4) [back to overview]	Change in Forced Expiratory Volume in One Second (FEV1)
NCT00509197 (4) [back to overview]	Asthma Control Questionnaire (ACQ) Score After 4 Weeks of Treatment With Inhaled Corticosteroids (ICS) or Placebo
NCT00509197 (4) [back to overview]	Change in Provocative Concentration of Methacholine Inducing a 20% Fall in FEV1 (PC20)
NCT00509197 (4) [back to overview]	Asthma Quality of Life Questionnaire (AQLQ) Score After 4 Weeks of Treatment
NCT00519636 (7) [back to overview]	Comparation of Mean Change From Baseline Over Each Treatment Period in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos
NCT00519636 (7) [back to overview]	Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Each Treatment Period of Active Drug Nasal Sprays Versus Placebos
NCT00519636 (7) [back to overview]	Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor
NCT00519636 (7) [back to overview]	Comparision of Mean Change From Baseline Over Each Treatment Period in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos
NCT00519636 (7) [back to overview]	Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) on Preference for: Gentleness of Mist
NCT00519636 (7) [back to overview]	Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) on Preference for: Ease of Use
NCT00519636 (7) [back to overview]	Subject Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) on Preference for: Leaking Out of Nose/Down Throat
NCT00521222 (5) [back to overview]	Absolute Change in Morning Peak Flow
NCT00521222 (5) [back to overview]	Change in Asthma Symptom Score
NCT00521222 (5) [back to overview]	Change in Forced Expiratory Volume in 1 Second (FEV1) Post-Bronchodilator
NCT00521222 (5) [back to overview]	Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-Bronchodilator
NCT00521222 (5) [back to overview]	Change in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted Pre-Bronchodilator
NCT00527826 (15) [back to overview]	Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52
NCT00527826 (15) [back to overview]	Mean Change From Baseline in Inspiratory Vital Capacity (IVC) at Week 52
NCT00527826 (15) [back to overview]	Mean Change From Baseline in the Activity Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
NCT00527826 (15) [back to overview]	Mean Change From Baseline in the Impact Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
NCT00527826 (15) [back to overview]	Mean Change From Baseline in the Symptom Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
NCT00527826 (15) [back to overview]	Mean Change From Baseline in the Tiffeaneau Index at Week 52
NCT00527826 (15) [back to overview]	Number of Participants With the Indicated Number of Days at the Intensive Care Unit (ICU)
NCT00527826 (15) [back to overview]	Mean Change From Baseline in the Total Score of the St. George's Respiratory Questionnaire (SGRQ) at Week 52
NCT00527826 (15) [back to overview]	Mean Number of Exacerbations Per Year: Poisson Model
NCT00527826 (15) [back to overview]	Mean Number of Days Rescue Medication Was Used
NCT00527826 (15) [back to overview]	Mean Total Costs (Related to COPD) Per Participant
NCT00527826 (15) [back to overview]	Mean Number of Exacerbations Per Year: Negative Binomial Model
NCT00527826 (15) [back to overview]	Mean Number of COPD-related Visits at/by Physician
NCT00527826 (15) [back to overview]	Compliance and Adherence to Study Medication
NCT00527826 (15) [back to overview]	Number of Participants With the Indicated Number of Hospital Stays
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Symptom Intensity During Exercise
NCT00530842 (59) [back to overview]	Symptom Intensity During Exercise
NCT00530842 (59) [back to overview]	Symptom Intensity During Exercise
NCT00530842 (59) [back to overview]	Symptom Intensity During Exercise
NCT00530842 (59) [back to overview]	Locus of Symptom Limitation at Peak Exercise During Exercise
NCT00530842 (59) [back to overview]	Locus of Symptom Limitation at Peak Exercise During Exercise
NCT00530842 (59) [back to overview]	Locus of Symptom Limitation at Peak Exercise During Exercise
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Forced Vital Capacity (FVC)
NCT00530842 (59) [back to overview]	Static Lung Volumes
NCT00530842 (59) [back to overview]	Slow Vital Capacity (SVC)
NCT00530842 (59) [back to overview]	Slow Vital Capacity (SVC)
NCT00530842 (59) [back to overview]	Slow Vital Capacity (SVC)
NCT00530842 (59) [back to overview]	Slow Vital Capacity (SVC)
NCT00530842 (59) [back to overview]	Post-dose TGV(FRC) (After 8 Weeks)
NCT00530842 (59) [back to overview]	Post-dose TGV(FRC) (After 4 Weeks)
NCT00530842 (59) [back to overview]	Forced Vital Capacity (FVC)
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Forced Vital Capacity (FVC)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Vital Capacity (FVC)
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1)
NCT00530842 (59) [back to overview]	FEV1 Over FVC (Percent)
NCT00530842 (59) [back to overview]	FEV1 Over FVC (Percent)
NCT00530842 (59) [back to overview]	FEV1 Over FVC (Percent)
NCT00530842 (59) [back to overview]	FEV1 Over FVC (Percent)
NCT00530842 (59) [back to overview]	Endurance Time (After 8 Weeks)
NCT00530842 (59) [back to overview]	Endurance Time (After 4 Weeks)
NCT00530842 (59) [back to overview]	Dyspnea and Leg Discomfort
NCT00530842 (59) [back to overview]	Dyspnea and Leg Discomfort
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00530842 (59) [back to overview]	Static Lung Volumes (Percent)
NCT00539006 (7) [back to overview]	Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor
NCT00539006 (7) [back to overview]	Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat
NCT00539006 (7) [back to overview]	Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist
NCT00539006 (7) [back to overview]	Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use
NCT00539006 (7) [back to overview]	Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos
NCT00539006 (7) [back to overview]	Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos
NCT00539006 (7) [back to overview]	Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos
NCT00542880 (16) [back to overview]	FEV1 Before Evening Dose
NCT00542880 (16) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Before Morning Dose
NCT00542880 (16) [back to overview]	Peak Expiratory Flow (PEF) 5 Minutes After Morning Dose
NCT00542880 (16) [back to overview]	PEF 15 Minutes After Morning Dose
NCT00542880 (16) [back to overview]	PEF Before Evening Dose
NCT00542880 (16) [back to overview]	PEF Before Morning Dose
NCT00542880 (16) [back to overview]	The Clinical Chronic Obstructive Pulmonary Disease (COPD) Questionnaire (Change From Pre to End of Treatment)
NCT00542880 (16) [back to overview]	Change in Forced Vital Capacity (FVC) From Before Dose to5 Minutes After Dose at the Clinic
NCT00542880 (16) [back to overview]	Change in PEF From Before Dose to 15 Minutes After Dose in the Morning
NCT00542880 (16) [back to overview]	Change in FEV1from Before Dose to 5 Minutes After Dose in the Morning
NCT00542880 (16) [back to overview]	Change in FEV1 From Before Dose to 5 Minutes After Dose at the Clinic
NCT00542880 (16) [back to overview]	Capacity of Daily Living in the Morning (CDLM) (Change From Pre to End of Treatment)
NCT00542880 (16) [back to overview]	Change in FEV1 From Before Dose to 15 Minutes After Dose in the Morning
NCT00542880 (16) [back to overview]	Change in PEF From Before Dose to 5 Minutes After Dose in the Morning
NCT00542880 (16) [back to overview]	Difficulty in Getting Out From Bed (MASQ) (Change From Pre to End of Treatment)
NCT00542880 (16) [back to overview]	FEV1 15 Minutes After Morning Dose
NCT00546000 (2) [back to overview]	Record Skin Atrophy, Pigmentation Change, Hematological and Chemistry Assessments, and Changes in Atopic Dermatitis Severity
NCT00546000 (2) [back to overview]	Post Treatment Serum Cortisol Values Will be Compared.
NCT00550550 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Symptom Scores (DSS) Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) Total Score Over the Entire GPS
NCT00550550 (4) [back to overview]	Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)
NCT00550550 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS
NCT00556673 (15) [back to overview]	Maximum (Peak) Plasma Concentration (Cmax) of Mometasone Furoate
NCT00556673 (15) [back to overview]	Maximum (Peak) Plasma Concentration (Cmax) of Indacaterol
NCT00556673 (15) [back to overview]	Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)
NCT00556673 (15) [back to overview]	Change From Period Baseline in Trough Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)
NCT00556673 (15) [back to overview]	Change From Period Baseline in Trough Forced Vital Capacity (FVC)
NCT00556673 (15) [back to overview]	Change From Period Baseline in Trough FEV1/FVC Ratio
NCT00556673 (15) [back to overview]	Change From Period Baseline in Peak Percent Predicted Forced Expiratory Volume in 1 Second (FEV1)
NCT00556673 (15) [back to overview]	Change From Period Baseline in Peak Forced Vital Capacity (FVC)
NCT00556673 (15) [back to overview]	Change From Period Baseline in Peak FEV1/FVC Ratio
NCT00556673 (15) [back to overview]	Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
NCT00556673 (15) [back to overview]	Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose for Mometasone Furoate
NCT00556673 (15) [back to overview]	Area Under the Concentration-time Curve From Time 0 to 24 Hours Post-dose for Indacaterol
NCT00556673 (15) [back to overview]	Area Under the Concentration-time Curve From Time 0 to 12 Hours Post-dose for Mometasone Furoate
NCT00556673 (15) [back to overview]	Time to Reach Peak or Maximum Concentration Following Drug Administration for Mometasone Furoate
NCT00556673 (15) [back to overview]	Time to Reach Peak or Maximum Concentration Following Drug Administration for Indacaterol
NCT00557440 (5) [back to overview]	Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)
NCT00557440 (5) [back to overview]	Time to Peak Forced Expiratory Volume in 1 Second (FEV1)
NCT00557440 (5) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) at Single Time Points
NCT00557440 (5) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) Standardized Area Under the Curve (AUC) Between Baseline (Pre-dose) and 24 Hours Post-dose
NCT00557440 (5) [back to overview]	Forced Vital Capacity (FVC) at Single Time Points
NCT00562159 (4) [back to overview]	Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)
NCT00562159 (4) [back to overview]	Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire With Standardized Activities (RQLQ(S)) Total Score Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Symptom Score (DSS) Over the Entire GPS
NCT00562159 (4) [back to overview]	Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS
NCT00570492 (17) [back to overview]	Change From Baseline in the Growth Velocity of Pre-pubescent Pediatric Participants to the End of the 52-week Double-blind (DB) Treatment Period
NCT00570492 (17) [back to overview]	Mean Values for the Laboratory Parameters of Total Bilirubin and Creatinine
NCT00570492 (17) [back to overview]	Mean 24-hour Urinary Free Cortisol Excretion
NCT00570492 (17) [back to overview]	Mean Values for Urine pH
NCT00570492 (17) [back to overview]	Mean Hematology Values for Basophil, Eosinophil, Lymphocyte, White Blood Cell (WBC), Monocyte, Segmented Neutrophil (Neu), and Platelet Counts
NCT00570492 (17) [back to overview]	Mean Hematology Values for Red Blood Cells (RBCs)
NCT00570492 (17) [back to overview]	Mean Values for Hematocrit
NCT00570492 (17) [back to overview]	Mean Values for Hemoglobin
NCT00570492 (17) [back to overview]	Mean Values for the Laboratory Parameters if Albumin and Total Protein
NCT00570492 (17) [back to overview]	Mean Values for the Laboratory Parameters of Alkaline (Alk) Phosphatase (P), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST)
NCT00570492 (17) [back to overview]	Mean Values for the Laboratory Parameters of Glucose, Calcium, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN)
NCT00570492 (17) [back to overview]	Number of Participants With the Indicated Urinalysis Results for Urine Occult Blood (OB) and the Urine Leukocyte Esterase Test (LET)
NCT00570492 (17) [back to overview]	Number of Participants With the Indicated Urinalysis Results for Urine Glucose, Urine Ketones, and Urine Proteins
NCT00570492 (17) [back to overview]	Number of Participants With the Indicated Urinalysis Results for Urine Bilirubin and Urine Nitrite
NCT00570492 (17) [back to overview]	Number of Participants With the Indicated Urinalysis Results for Urine Appearance (App.)/Clarity and Color
NCT00570492 (17) [back to overview]	Number of Participants With the Indicated Shifts From Baseline in Nasal Examination (NE) Results
NCT00570492 (17) [back to overview]	Mean Values for Urine Specific Gravity
NCT00584987 (6) [back to overview]	RQLQ Score [4 Weeks]
NCT00584987 (6) [back to overview]	RQLQ Score [Baseline]
NCT00584987 (6) [back to overview]	Total Nasal Congestion Symptom Score
NCT00584987 (6) [back to overview]	Total NPIF
NCT00584987 (6) [back to overview]	RQLQ Score [6 Weeks]
NCT00584987 (6) [back to overview]	RQLQ Score [2 Weeks]
NCT00603044 (6) [back to overview]	IL-10 Staining Intensity
NCT00603044 (6) [back to overview]	Amount of TGF Secreted by Adenoid Cells After PHA Stimulation
NCT00603044 (6) [back to overview]	Amount of IL-10 Secreted by Adenoid Cells After PHA Stimulation
NCT00603044 (6) [back to overview]	Adjusted Volume of the Removed Adenoids
NCT00603044 (6) [back to overview]	Number of CD4 Pos/FOXP3 Positive Cells
NCT00603044 (6) [back to overview]	Number of CD25 Pos/FoxP3 Positive Cells
NCT00609674 (15) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in Both the Individual AM Reflective and PM Reflective Ocular Symptom Scores for Eyes Itching/Burning, Eyes Tearing/Watering, and Eye Redness
NCT00609674 (15) [back to overview]	Total Ocular Symptoms: Mean Percent Change From Baseline Over the Entire Treatment Period in Both the Daily rTOSS and the AM, Pre-dose iTOSS
NCT00609674 (15) [back to overview]	Individual Nasal Symptoms: Mean Change From Baseline Over the Entire Treatment Period in Individual Daily Reflective Nasal Symptom Scores and AM, Pre-dose Instantaneous Nasal Symptom Scores for Rhinorrhea, Nasal Congestion, Nasal Itching, and Sneezing
NCT00609674 (15) [back to overview]	Total Ocular Symptoms: Mean Change From Baseline Over the Entire Treatment Period in Both the AM Reflective Total Ocular Symptom Scores (rTOSS) and PM rTOSS
NCT00609674 (15) [back to overview]	Total Nasal Symptoms: Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS and AM, Pre-dose iTNSS
NCT00609674 (15) [back to overview]	Peak Nasal Inspiratory Flow (PNIF): Mean Change From Baseline in Daily, AM, and PM PNIF
NCT00609674 (15) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in Both Individual AM Reflective and PM Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion, Nasal Itching, and Sneezing.
NCT00609674 (15) [back to overview]	Individual Ocular Symptoms: Mean Change From Baseline Over the Entire Treatment Period in Both the Individual, Daily Reflective and the AM, Pre-dose Instantaneous Ocular Symptom Scores for Eyes Itching/Burning, Eyes Tearing/Watering, and Eye Redness.
NCT00609674 (15) [back to overview]	Total Ocular Symptoms: Mean Change From Baseline Over the Entire Treatment Period in AM, Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)
NCT00609674 (15) [back to overview]	Total Nasal Symptoms: Mean Change From Baseline Over the Entire Treatment Period in PM rTNSS
NCT00609674 (15) [back to overview]	Total Nasal Symptoms: Mean Change From Baseline Over the Entire Treatment Period in AM rTNSS
NCT00609674 (15) [back to overview]	Mean Change From Baseline to Endpoint in the Rhinoconjunctivitis Quality of Life Questionnaire With Standardised Activities (RQLQ[S])
NCT00609674 (15) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00609674 (15) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Ocular Symptom Scores (rTOSS)
NCT00609674 (15) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Scores (rTNSS)
NCT00623714 (2) [back to overview]	Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)
NCT00623714 (2) [back to overview]	Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)
NCT00633217 (3) [back to overview]	Mean Change From Baseline in AM Pre-dose FEV1
NCT00633217 (3) [back to overview]	Mean Change From Baseline in Peak Expiratory Flow
NCT00633217 (3) [back to overview]	Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) 2 Hours Post-dose of Blinded Study Drug
NCT00651118 (3) [back to overview]	Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00651118 (3) [back to overview]	Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)
NCT00651118 (3) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days
NCT00660517 (3) [back to overview]	Change From Baseline in Adult ( Greater Than 18 Years of Age) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days
NCT00660517 (3) [back to overview]	Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)
NCT00660517 (3) [back to overview]	Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00669617 (1) [back to overview]	Forced Expiratory Volume in 1 Second (FEV1) at 5 Minutes Post-dose
NCT00682643 (14) [back to overview]	Cumulative Proportion of Participants, as Measured as a Percentage, With an Intraocular Pressure (IOP) Event
NCT00682643 (14) [back to overview]	Change From Baseline in LOCS III Cortical Opacity (C) at Week 52 and Week 104
NCT00682643 (14) [back to overview]	Percent Change From Baseline in the Funduscopic Horizontal Cup-to-disc Ratio at Week 104
NCT00682643 (14) [back to overview]	Number of Participants With the Indicated Change From Baseline in LOCS III Posterior Subcapsular Opacity by Increments of 0.1 at Weeks 52 and 104
NCT00682643 (14) [back to overview]	Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) by Increments of 1 mm Hg at Week 52
NCT00682643 (14) [back to overview]	Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) by Increments of 1 mm Hg at Week 104
NCT00682643 (14) [back to overview]	Number of Participants With the Indicated Change From Baseline in Cortical Opacity by Increment Categories of >=0.3, >=0.5, and >=1.0 at Weeks 52 and 104
NCT00682643 (14) [back to overview]	Cumulative Proportion (CU) of Participants (Par.) With an Event, as Measured as a Percentage, for Posterior Subcapsular Opacity (P)
NCT00682643 (14) [back to overview]	Change From Baseline in the Daily Reflective Total Nasal Symptom Score (rTNSS) for the Indicated Study Periods
NCT00682643 (14) [back to overview]	Change From Baseline in Nuclear Color (NC) at Week 52 and Week 104
NCT00682643 (14) [back to overview]	Change From Baseline in Logarithm of the Minimum Angle of Resolution (LogMAR) Visual Acuity (VA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts at Week 52 and Week 104
NCT00682643 (14) [back to overview]	Change From Baseline in LOCS III Posterior Subcapsular Opacity at Week 52 and Week 104
NCT00682643 (14) [back to overview]	Change From Baseline in LOCS III Nuclear Opacity (NO) at Week 52 and Week 104
NCT00682643 (14) [back to overview]	Change From Baseline in Intraocular Pressure (IOP) at Weeks 52 and 104
NCT00691665 (4) [back to overview]	Mean Percent Change in Instantaneous Total Ocular Symptom Scores (iTOSS) From Baseline
NCT00691665 (4) [back to overview]	Mean Percent Change in Reflective Total Ocular Symptom Scores (rTOSS) From Baseline
NCT00691665 (4) [back to overview]	Mean Percent Change in Instantaneous Total Nasal Symptom Score (iTNSS) From Baseline
NCT00691665 (4) [back to overview]	Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline
NCT00692978 (1) [back to overview]	AUC Fluticasone Propionate (FP)
NCT00705341 (2) [back to overview]	Methacholine Challenge Test Result for Phase 2
NCT00705341 (2) [back to overview]	Predictive Value of Methacholine Challenge Test for Phase 1
NCT00706446 (1) [back to overview]	Number of Patients With Asthma Exacerbation
NCT00712335 (7) [back to overview]	Sputum RANTES Levels
NCT00712335 (7) [back to overview]	Sputum GM-CSF Levels
NCT00712335 (7) [back to overview]	Sputum IFN-gamma/IL-5 Ratios
NCT00712335 (7) [back to overview]	Sputum IL-8 Levels
NCT00712335 (7) [back to overview]	Sputum Eosinophil Percentages
NCT00712335 (7) [back to overview]	Sputum Eotaxin Levels
NCT00712335 (7) [back to overview]	Sputum Neutrophil Percentages
NCT00716963 (2) [back to overview]	The Magnitude of the Late Asthmatic Response, Expressed as a Percentage Change in FEV1.
NCT00716963 (2) [back to overview]	The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Change in FEV1.
NCT00730756 (9) [back to overview]	Mean Change From Baseline in AM and PM Reflective Individual Ocular Symptoms Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in AM and PM Reflective Individual Nasal Symptoms Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in Daily rTNSS Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in AM Pre-dose Instantaneous Individual Ocular Symptoms Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in Total Ocular Symptoms Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in Daily Reflective Individual Ocular Symptoms Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in Daily Reflective Individual Nasal Symptoms Score Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in AM rTNSS, PM rTNSS, and AM Pre-dose iTNSS Over the Entire Treatment Period (28 Days)
NCT00730756 (9) [back to overview]	Mean Change From Baseline in AM Pre-dose Instantaneous Individual Nasal Symptoms Over the Entire Treatment Period (28 Days)
NCT00740792 (3) [back to overview]	Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)
NCT00740792 (3) [back to overview]	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
NCT00740792 (3) [back to overview]	Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00783224 (1) [back to overview]	Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks
NCT00784550 (6) [back to overview]	Mean Change From Baseline in 2 Hour Post-dose FEV1 at Endpoint
NCT00784550 (6) [back to overview]	Mean Change From Baseline in 2 Hour Post-dose FVC at Endpoint
NCT00784550 (6) [back to overview]	Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Expiratory Volume in One Second (FEV1) at Endpoint
NCT00784550 (6) [back to overview]	Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-dose Forced Vital Capacity (FVC) at Endpoint
NCT00784550 (6) [back to overview]	Mean Change From Baseline in AM (Morning, Approximately 6-9 AM) Pre-Dose Inspiratory Capacity (IC) at Endpoint
NCT00784550 (6) [back to overview]	Mean Change From Baseline in Scores on the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) at Endpoint
NCT00791973 (2) [back to overview]	Total Eye Symptom Scores After Antigen Challenge
NCT00791973 (2) [back to overview]	Change in Tryptase Level From Baseline to Post-antigen Challenge
NCT00843193 (17) [back to overview]	PK Parameter: Volume of Distribution
NCT00843193 (17) [back to overview]	Number of Participants With Abnormal Urinanalysis Parameters of Potential Clinical Importance
NCT00843193 (17) [back to overview]	Number of Participants With Confirmed Positive Anti-GSK679586 Antibody Results After Initiation of Study Treatment
NCT00843193 (17) [back to overview]	Change From Baseline in ACQ-7 Over 16 Weeks and 24 Weeks
NCT00843193 (17) [back to overview]	Percentage of Participants Who Demonstrated a Clinically Meaningful Increase in FEV1 Over the 12 Week Assessment Period
NCT00843193 (17) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over the Dosing Interval (AUC (0-τ)).
NCT00843193 (17) [back to overview]	Change From Baseline in Asthma Control Questionnaire (ACQ-7) Over 12 Weeks
NCT00843193 (17) [back to overview]	Change From Baseline in FEV1 Over 16 Weeks and 24 Weeks
NCT00843193 (17) [back to overview]	Change From Baseline in Forced Expiratory Volume (FEV1) Over 12 Weeks.
NCT00843193 (17) [back to overview]	Number of Participants Who Demonstrated a Clinically Meaningful Change in ACQ-7 Over the 12 Weeks Assessment Period.
NCT00843193 (17) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Parameters of Potential Clinical Importance
NCT00843193 (17) [back to overview]	PK Parameter: Systemic Clearance of Parent Drug
NCT00843193 (17) [back to overview]	PK Parameter:Maximum Observed Concentration (Cmax)
NCT00843193 (17) [back to overview]	Number of Participants With Abnormal Vital Signs of Potential Clinical Importance: Systolic and Distolic Blood Pressure and Heart Rate.
NCT00843193 (17) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00843193 (17) [back to overview]	Number of Participants With Clinically Significant Abnormality in 12-lead Electrocardiogram (ECG)
NCT00843193 (17) [back to overview]	Number of Participants With Abnormal Hematological Parameters of Potential Clinical Importance
NCT00848965 (7) [back to overview]	Weighted Mean Nasal Airflow at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
NCT00848965 (7) [back to overview]	Weighted Mean Nasal Secretion at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
NCT00848965 (7) [back to overview]	Weighted Mean Total Nasal Symptom Score (TNSS) at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge [PSC]) in the Vienna Challenge Chamber (VCC)
NCT00848965 (7) [back to overview]	Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: 18S, B-actin, DUSP_1_T1, FKBP5, GAPDH, GILZ, PLAU, PTGS2, and RGS2
NCT00848965 (7) [back to overview]	Glucocorticoid (GC) Receptor Biomarker Levels in Nasal Epithelial Scraping Samples: CCL2
NCT00848965 (7) [back to overview]	Weighted Mean Global Symptom Score (GSS) at 5 Hours Post-dose (1-4 Hours Post-start of Challenge)
NCT00848965 (7) [back to overview]	Weighted Mean Eye Symptom Score at 2-5 Hours Post-dose (1-4 Hours Post-start of Challenge)
NCT00880906 (1) [back to overview]	Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE)
NCT00883168 (3) [back to overview]	Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)
NCT00883168 (3) [back to overview]	Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)
NCT00883168 (3) [back to overview]	Change From Baseline in Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
NCT00891436 (1) [back to overview]	Histamine Content in the Tears Was Measured.
NCT00895817 (1) [back to overview]	Number of Participants Who Responded
NCT00927758 (1) [back to overview]	Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)
NCT00975195 (27) [back to overview]	Time to First On-treatment COPD Exacerbation
NCT00975195 (27) [back to overview]	Time to First Moderate or Severe On-treatment COPD Exacerbation
NCT00975195 (27) [back to overview]	Proportion of Patients With at Least One Severe On-treatment COPD Exacerbation.
NCT00975195 (27) [back to overview]	Proportion of Patients With at Least One On-treatment COPD Exacerbation
NCT00975195 (27) [back to overview]	Proportion of Patients With ≥1 Moderate or Severe On-treatment COPD Exacerbation
NCT00975195 (27) [back to overview]	Number of Severe On-treatment COPD Exacerbations
NCT00975195 (27) [back to overview]	Number of On-treatment COPD Exacerbations
NCT00975195 (27) [back to overview]	Number of Moderate or Severe On-treatment COPD Exacerbations
NCT00975195 (27) [back to overview]	Change in On-treatment Exercise Capacity Measured by Six-minute Walk Test (6-MWT)
NCT00975195 (27) [back to overview]	Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Impact Domain
NCT00975195 (27) [back to overview]	Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Activity Domain
NCT00975195 (27) [back to overview]	Change in On-treatment Physician Global Evaluation
NCT00975195 (27) [back to overview]	Change in On-treatment PEFR as Measured by Home Based Spirometry
NCT00975195 (27) [back to overview]	Change in On-treatment Lung Function as Measured by Trough FEV1
NCT00975195 (27) [back to overview]	Change in On-treatment FVC as Measured by Home Based Spirometry
NCT00975195 (27) [back to overview]	Change in On-treatment FEV1 as Measured by Home Based Spirometry
NCT00975195 (27) [back to overview]	Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Symptoms Domain
NCT00975195 (27) [back to overview]	Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Sputum Impact Domain
NCT00975195 (27) [back to overview]	Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Symptoms Domain
NCT00975195 (27) [back to overview]	Change in On-treatment Cough and Expectoration as Measured by the CASA-Q: Cough Impact Domain
NCT00975195 (27) [back to overview]	Change in On-treatment BODE Index
NCT00975195 (27) [back to overview]	Time to First Severe On-treatment COPD Exacerbation
NCT00975195 (27) [back to overview]	Change in On-treatment Physical Health Status as Determined by Body Mass Index (BMI)
NCT00975195 (27) [back to overview]	Severity of On-treatment COPD Exacerbations
NCT00975195 (27) [back to overview]	Changes in On-treatment Dyspnoea as Measured by the Modified Medical Research Council (MMRC) Dyspnoea Scale
NCT00975195 (27) [back to overview]	Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Total Score
NCT00975195 (27) [back to overview]	Change in On-treatment St Georges Respiratory Questionnaire (SGRQ) Scores: Symptoms Domain
NCT00984659 (20) [back to overview]	Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Participant-completed (ParC) mMRC Score at Visit 2
NCT00984659 (20) [back to overview]	"SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CRQ-SAS Dyspnea Domain (DD) Response Rated as Better"
NCT00984659 (20) [back to overview]	"SOBDA Threshold for Response as Assessed by Mean Change From Baseline to the Last Treatment Week in the SOBDA Score Based on a CGI-C Response Rated as Better"
NCT00984659 (20) [back to overview]	Number of Participants Classified as Responders and Non-responders by Clinician Global Impression of Change Question (CGI-C) Response at Visit 3/PD
NCT00984659 (20) [back to overview]	Known Group Validity for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of the Physician-completed (PyC) mMRC Score at Visit 2
NCT00984659 (20) [back to overview]	Known Group Validity (KGV) for the SOBDA Questionnaire Measured as the Comparison of the Baseline SOBDA Score in the Indicated Categories of CGI-S Scores at Visit 2
NCT00984659 (20) [back to overview]	Convergent Validity for the SOBDA Questionnaire Measured as Correlations of the Baseline SOBDA Score With Participant-completed Modified Medical Research Council (mMRC) and Physician-completed mMRC Scores at Visit 2
NCT00984659 (20) [back to overview]	Change From the Previous Week to the Current Week's SOBDA Score by Participant-completed PGAC Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/PD (End of the 6-week Treatment Period or PD)
NCT00984659 (20) [back to overview]	Change From Baseline to Last Treatment Week in the SOBDA Score by Physician-completed mMRC and Participant-completed mMRC Responses at Visit 3/PD
NCT00984659 (20) [back to overview]	Change From Baseline to Last Treatment Week in the SOBDA Score by CRQ-SAS Dyspnea Domain (DD) Responses at Visit 3/PD
NCT00984659 (20) [back to overview]	Change From Baseline to Last Treatment Week in the SOBDA Score by CGI-C Responses at Visit 3/PD
NCT00984659 (20) [back to overview]	"SOBDA Threshold for Response Assessed as Mean Change From the Previous Week's SOBDA Score Based on a Participant-completed PGAC Score Rated of Better"
NCT00984659 (20) [back to overview]	Test-retest Reliability (T-RR) of SOBDA Scores Measured as the Difference in the SOBDA Weekly Score Between Week 1 and Week 2 of the 2-week Run-in Period
NCT00984659 (20) [back to overview]	SOBDA Threshold for Response Assessed as Mean Change From Baseline to Last Treatment Week in the SOBDA Score Based on Forced Expiratory Volume in One Second (FEV1) Change From Baseline of 50 Milliliters (mL) to <100 mL
NCT00984659 (20) [back to overview]	Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD) Assessed as Cronbach's Alpha Value
NCT00984659 (20) [back to overview]	Convergent Validity for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Clinician Global Assessment of Dyspnea Severity (CGI-S) Score at Visit 2
NCT00984659 (20) [back to overview]	Convergent Validity (CV) for the SOBDA Questionnaire Measured as the Correlation of the Baseline SOBDA Score With the Chronic Respiratory Disease Questionnaire-Self-Administered Standardized (CRQ-SAS) Dyspnea Domain Score at Visit 2
NCT00984659 (20) [back to overview]	Participants (Par.) Classified as Responders/Non-responders According to the Patient Global Assessment of Change (PGAC) Response at Days 8, 15, 22, 29, 36, and 43 and at Visit 3/Premature Discontinuation (PD) (the End of the 6-week Treatment Period or PD)
NCT00984659 (20) [back to overview]	Number of Participants Classified as Responders and Non-responders by Physician-completed and Participant-completed mMRC Response at Visit 3/PD
NCT00984659 (20) [back to overview]	Number of Participants Classified as Responders and Non-responders by CRQ-SAS Dyspnea Domain Response at Visit 3/PD
NCT00995475 (3) [back to overview]	Alveolar Nitric Oxide
NCT00995475 (3) [back to overview]	OUCC
NCT00995475 (3) [back to overview]	CRP
NCT00997620 (6) [back to overview]	Performance on Test of Variables of Attention (TOVA) - a Standardized Test of Cognitive Performance, Response Time for Targets.
NCT00997620 (6) [back to overview]	Performance on Test of Variables of Attention (TOVA) - a Standardized Test of Cognitive Performance, Errors of Commission.
NCT00997620 (6) [back to overview]	Performance on Test of Variables of Attention (TOVA) - a Standardized Test of Cognitive Performance
NCT00997620 (6) [back to overview]	Nasal Symptom Scores
NCT00997620 (6) [back to overview]	Change in Epworth Sleep Scale
NCT00997620 (6) [back to overview]	Change From Baseline in Nocturnal Rhinoconjunctivitis Quality of Life Questionaire
NCT01007253 (6) [back to overview]	Total Number of Eosinophils
NCT01007253 (6) [back to overview]	Change in Histamine Level (Across Nasal Challenges)
NCT01007253 (6) [back to overview]	Change in Tryptase Level (Across Nasal Challenges)
NCT01007253 (6) [back to overview]	Total Eye Symptoms Score Difference
NCT01007253 (6) [back to overview]	Total Nasal Symptoms Score Difference
NCT01007253 (6) [back to overview]	Total Number of Sneezes
NCT01018186 (27) [back to overview]	Change From Baseline in Albumin and Total Protein at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK), and Gamma Glutamyltransferase (GGT) at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Eosinophil Count, Total Absolute Neutrophil Count (ANC), Platelet Count, and White Blood Cell (WBC) Count at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Hemoglobin at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Hematocrit at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Number of Participants With the Indicated Shift From Baseline to High, Normal or no Change, and Low Post-Baseline Values for Urinary Cortisol Excretion
NCT01018186 (27) [back to overview]	Number of Participants With the Indicated Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Posterior Subcapsular Opacity (P) at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Ratio of 24-hour Urinary Cortisol Excretion at Week 52 to Baseline
NCT01018186 (27) [back to overview]	Change From Baseline in the Logarithm of the Minimum Angle of Resolution (LogMAR) Visual Acuity at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Change From Baseline in Horizontal Cup-to-disc Ratio at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Maximum Change From Baseline in Pulse Rate
NCT01018186 (27) [back to overview]	Number of Participants With the Indicated Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Cortical Opacity (C) at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Number of Participants With the Indicated Change From Baseline in Intraocular Pressure (IOP) at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Number of Participants With Evidence of Oral Candidiasis at Any Time Post-Baseline
NCT01018186 (27) [back to overview]	Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period
NCT01018186 (27) [back to overview]	Mean 24 Hour Holter Heart Rate for Participants With at Least 16 Hours of Recorded Data
NCT01018186 (27) [back to overview]	Maximum Change From Baseline in the QT Interval Using Bazett's Correction (QTcB) and QT Interval Using Fridericia's Correction (QTcF)
NCT01018186 (27) [back to overview]	Maximum Change From Baseline in Systolic Blood Pressure (SBP) and Minimum Change From Baseline in Diastolic Blood Pressure (DBP)
NCT01018186 (27) [back to overview]	Maximum 24 Hour Holter Heart Rate for Participants With at Least 16 Hours of Recorded Data
NCT01018186 (27) [back to overview]	Change From Baseline in the Percentage of Basophils, Eosinophils, Hematocrit, Lymphocytes, Monocytes, and Segmented Neutrophils in the Blood at Week 12, Week 28, and Week 52/Early Withdrawal
NCT01018186 (27) [back to overview]	Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Nuclear Opalescence (NO) at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Change From Baseline in Lens Opacities Classification System, Version III (LOCS III) Nuclear Color (NC) at Week 28 and Week 52
NCT01018186 (27) [back to overview]	Number of Participants With Severe Asthma Exacerbations During the Treatment Period
NCT01018186 (27) [back to overview]	Ratio of 24-hour Urinary Cortisol Excretion at Week 12 to Baseline
NCT01018186 (27) [back to overview]	Ratio of 24-hour Urinary Cortisol Excretion at Week 28 to Baseline
NCT01072149 (3) [back to overview]	Change From Period Baseline in Clinic Visit Trough FEV1 at the End of Each 28-day Treatment Period
NCT01072149 (3) [back to overview]	Time-adjusted Area Under the Curve (AUC) (i.e., Weighted Mean) for 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at the End of Each 28-day Treatment Period
NCT01072149 (3) [back to overview]	Change From Period Baseline in 25-hour Serial FEV1 at the End of Each 28 Day-treatment Period
NCT01086384 (3) [back to overview]	Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36
NCT01086384 (3) [back to overview]	Number of Severe Asthma Exacerbations
NCT01086384 (3) [back to overview]	Number of Participants With 1 or More Severe Asthma Exacerbations
NCT01086410 (22) [back to overview]	Tmax and Tlast of FF at Day 42
NCT01086410 (22) [back to overview]	Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
NCT01086410 (22) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Days 14, 28, 42, and Maximum Post-Baseline
NCT01086410 (22) [back to overview]	Change From Baseline in Pulse Rate at Days 14, 28, 42, and Maximum Post-Baseline
NCT01086410 (22) [back to overview]	Change From Baseline in Hemoglobin Values at Day 42/EW
NCT01086410 (22) [back to overview]	Change From Baseline in Hematocrit Values at Day 42/EW
NCT01086410 (22) [back to overview]	Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine Values at Day 42/EW
NCT01086410 (22) [back to overview]	AUC(0-t) for VI on Day 42
NCT01086410 (22) [back to overview]	Cmax for FF on Day 42
NCT01086410 (22) [back to overview]	Cmax for VI on Day 42
NCT01086410 (22) [back to overview]	Ratio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 42
NCT01086410 (22) [back to overview]	Ratio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 42
NCT01086410 (22) [back to overview]	Change From Baseline in Eosinophil, Total Neutrophil, Platelet, and White Blood Cell (WBC) Count Values at Day 42/EW
NCT01086410 (22) [back to overview]	Tmax and Tlast of VI at Day 42
NCT01086410 (22) [back to overview]	Plasma FF and VI Pharmacokinetic (PK) Concentration
NCT01086410 (22) [back to overview]	Change From Baseline in Albumin and Total Protein Values at Day 42/EW
NCT01086410 (22) [back to overview]	Change From Baseline in Basophil, Eosinophil, Lymphocyte, Monocyte, and Segmented Neutrophil Values at Day 42/Early Withdrawal (EW)
NCT01086410 (22) [back to overview]	Change From Baseline in Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 42/EW
NCT01086410 (22) [back to overview]	Ratio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 42
NCT01086410 (22) [back to overview]	Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42
NCT01086410 (22) [back to overview]	AUC(0-t) and AUC(0-24) for FF on Day 42
NCT01086410 (22) [back to overview]	Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) Values at Day 42/EW
NCT01092143 (2) [back to overview]	Asthma Control Questionnaire (ACQ) Mean Score Change From Baseline After Six Weeks of Treatment
NCT01092143 (2) [back to overview]	Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment
NCT01103934 (2) [back to overview]	Change From Baseline in Daytime Nasal Symptom Score (DNSS) Over 2 Week Randomized Treatment Period
NCT01103934 (2) [back to overview]	Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period
NCT01124422 (19) [back to overview]	Mean Change in Tidal Volume (VT) at Isotime During the Course of the ESWT From Baseline to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Tidal Volume (VT) Per Time Slope During the Course of the ESWT From Baseline to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Pre-dose and Post-dose Resting Inspiratory Capacity (IC) From Baseline (Week 4) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Scores on the Chronic Respiratory Disease Questionnaire Self-Administered Standardized (CRQ-SAS) Questionnaire From Week 4 to Week 8
NCT01124422 (19) [back to overview]	Mean Change in EIC at 2 to 3.5 Minutes During the Exercise Period From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Baseline Dyspnea Index (BDI) at Week 4 and Transition Dyspnea Index (TDI) at Week 8
NCT01124422 (19) [back to overview]	Mean Change in EDS at Isotime From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Exercise Endurance Time (EET) From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Exercise Inspiratory Capacity (EIC) at the End of Exercise From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Flow of Carbon Dioxide (V'CO2) Per Time Slope During the Course of the ESWT From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Flow of Oxygen (V'O2) Per Time Slope During the Course of the ESWT From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Heart Rate (HR) Per Time Slope During the Course of the ESWT From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in HR Per Time Slope During the Course of the ESWT Using Pulse Oximetry From Baseline to Week 8 (Non-OMS Subgroup)
NCT01124422 (19) [back to overview]	Mean Change in Minute Ventilation (V'E) Per Time Slope During the Course of the ESWT From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Ratio of Respiratory Rate (RR) to Tidal Volume (VT) or RR/VT at Isotime During the Course of the ESWT From Baseline to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Respiratory Exchange Ratio (RER) Per Time Slope During the Course of the ESWT From Baseline to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Respiratory Rate (RR) at Isotime During the Course of the ESWT From Baseline to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Respiratory Rate (RR) Per Time Slope During the Course of the ESWT From Baseline (Week 3) to Week 8
NCT01124422 (19) [back to overview]	Mean Change in Scores on the Exercise Dyspnea Scale (EDS) From Baseline (Week 3) to Week 8
NCT01128569 (4) [back to overview]	Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
NCT01128569 (4) [back to overview]	Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
NCT01128569 (4) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (AEs)
NCT01128569 (4) [back to overview]	Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
NCT01128595 (6) [back to overview]	EAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
NCT01128595 (6) [back to overview]	Provocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period
NCT01128595 (6) [back to overview]	Maximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
NCT01128595 (6) [back to overview]	Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
NCT01128595 (6) [back to overview]	LAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
NCT01128595 (6) [back to overview]	Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
NCT01134042 (11) [back to overview]	The Number of Participants Who Withdrew Due to Lack of Efficacy During the 24-week Treatment Period
NCT01134042 (11) [back to overview]	Change From Baseline in the Asthma Control Test (ACT) Scores at Week 12 and Week 24
NCT01134042 (11) [back to overview]	Change From Baseline in the Percentage of Rescue-free and Symptom-free 24-hour Periods at the End of the 24-week Treatment Period
NCT01134042 (11) [back to overview]	Clinic Visit 12-hour Post-dose FEV1at Week 24
NCT01134042 (11) [back to overview]	Mean Change From Baseline in Daily Morning Trough (AM) and Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period
NCT01134042 (11) [back to overview]	Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period
NCT01134042 (11) [back to overview]	Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at Weeks 4, 12, and 24
NCT01134042 (11) [back to overview]	Change From Baseline in Weighted Mean Serial FEV1 Over 0 to 4 Hours Post-dose at Week 24
NCT01134042 (11) [back to overview]	Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24/Early Withdrawal
NCT01134042 (11) [back to overview]	Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
NCT01134042 (11) [back to overview]	Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 24
NCT01147744 (12) [back to overview]	Mean Change From Baseline to the End of the 8-Week Treatment Period in Trough Forced Expiratory Volume in One Second (FEV1)
NCT01147744 (12) [back to overview]	Mean Change From Baseline in Daily Trough AM PEF Averaged Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in Day-time Asthma Symptom Score Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Number of Participants Who Withdrew Due to Lack of Efficacy During the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in the Percentage of Symptom-free Nights Averaged Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in the Percentage of Symptom-free Days Averaged Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in the Percentage of Rescue-free Nights Averaged Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in the Percentage of Rescue-free Days Averaged Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in Night-time Rescue SABA Usage Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in Night-time Asthma Symptom Score Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in Day-time Rescue Short Acting beta2-agonist (SABA) Usage Over the 8-Week Treatment Period
NCT01147744 (12) [back to overview]	Mean Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 8-Week Treatment Period
NCT01147848 (13) [back to overview]	Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)
NCT01147848 (13) [back to overview]	Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168
NCT01147848 (13) [back to overview]	Change From Baseline in Asthma Control Test (ACT) Scores at Day 168
NCT01147848 (13) [back to overview]	Number of Participants Obtaining a >=12% and >=200 mL Increase From Baseline in FEV1
NCT01147848 (13) [back to overview]	Serial FEV1 (0-24 Hours)
NCT01147848 (13) [back to overview]	Number of Participants With the Indicated Time to Onset of Bronchodilator Effect at Day 1
NCT01147848 (13) [back to overview]	Number of Healthcare Contacts Related to Asthma or the Treatment of Asthma From Baseline to Day 168
NCT01147848 (13) [back to overview]	Baseline FEV1 by Completion Status
NCT01147848 (13) [back to overview]	Change From Baseline in Trough FEV1 at Day 168
NCT01147848 (13) [back to overview]	"Percentage of Participants With No Problems in the EQ-5D Descriptive System Dimensions at Day 168/Week 24"
NCT01147848 (13) [back to overview]	Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168
NCT01147848 (13) [back to overview]	Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24
NCT01147848 (13) [back to overview]	Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)
NCT01159912 (6) [back to overview]	Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period
NCT01159912 (6) [back to overview]	Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12 and Week 24
NCT01159912 (6) [back to overview]	Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week Treatment Period
NCT01159912 (6) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods at the End of the 24-week Treatment Period
NCT01159912 (6) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods at the End of the 24-week Treatment Period
NCT01159912 (6) [back to overview]	Mean Change From Baseline in Daily Trough Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the First 12 Weeks and 24 Weeks of the 24-week Treatment Period
NCT01165138 (18) [back to overview]	Mean Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
NCT01165138 (18) [back to overview]	Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12
NCT01165138 (18) [back to overview]	Clinic Visit 12-hour Post-dose FEV1 at Week 12
NCT01165138 (18) [back to overview]	Mean Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
NCT01165138 (18) [back to overview]	Number of Participants Who Used the Inhaler Correctly or Incorrectly at Baseline, Week 2, and Week 4
NCT01165138 (18) [back to overview]	Number of Participants With the Indicated Reason for Incorrect Inhaler Use and Who Required Additional Instruction the Indicated Number of Times at Baseline, Week 2, and Week 4
NCT01165138 (18) [back to overview]	Serial FEV1 Over 0-1 Hour Post-dose at Randomization
NCT01165138 (18) [back to overview]	Weighted Mean Serial FEV1 Over 0-4 Hours Post-dose at Baseline and Week 12
NCT01165138 (18) [back to overview]	Mean Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
NCT01165138 (18) [back to overview]	Number of Participants With the Indicated Global Assessment of Change Responses at Week 4, Week 8, and Week 12/Early Withdrawal
NCT01165138 (18) [back to overview]	Number of the Indicated Unscheduled Asthma-related Healthcare Visits During the Treatment Period
NCT01165138 (18) [back to overview]	Change From Baseline in the Total Asthma Quality of Life Questionnaire (AQLQ) (+12) Score at Week 12/Early Withdrawal
NCT01165138 (18) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
NCT01165138 (18) [back to overview]	Change From Baseline in the Asthma Control Test (ACT) Score at Week 12
NCT01165138 (18) [back to overview]	Number of Participants Who Withdrew Due to Lack of Efficacy During the 12-week Treatment Period
NCT01165138 (18) [back to overview]	Number of Participants With Bronchodilator Effect
NCT01165138 (18) [back to overview]	Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Baseline
NCT01165138 (18) [back to overview]	Change From Baseline in Weighted Mean Serial FEV1 Over 0-24 Hours Post-dose at Week 12
NCT01184118 (3) [back to overview]	Number of Participants With Improved, Unchanged, and Worsened Anterior Tongue Strength (KPa) From Baseline With 16-week of High Dose Inhaled FP Treatment.
NCT01184118 (3) [back to overview]	Number of Participants With Improved, Unchanged, and Worsened Critical Closing Pressure (Pcrit) From Baseline With 16-week of High Dose Inhaled FP Treatment.
NCT01184118 (3) [back to overview]	Number of Participants With Improved, Unchanged, and Worsened Sleep Disorders Questionnaire (SA-SDQ) From Baseline With 16-week of High Dose Inhaled FP Treatment.
NCT01192178 (8) [back to overview]	Mean Percentage of Rescue-free Days
NCT01192178 (8) [back to overview]	Mean Percentage of Episode-free (EF) Days
NCT01192178 (8) [back to overview]	Mean Percentage of Asthma-control Days
NCT01192178 (8) [back to overview]	Mean Duration of Worsening Asthma Symptoms Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection
NCT01192178 (8) [back to overview]	Mean Percentage of Symptom-free Days
NCT01192178 (8) [back to overview]	Number of Asthma Exacerbations Associated With the Presence of Moderate or Severe URTS or a Confirmed RV Infection During the Peak Viral Period
NCT01192178 (8) [back to overview]	Total Number of Asthma Exacerbations Reported During the Treatment Period
NCT01192178 (8) [back to overview]	Mean Asthma Symptom Scores, as an Indicator of Severity, Associated With the Presence of Moderate or Severe Upper Respiratory Tract Symptoms (URTS) or a Confirmed Rhinovirus (RV) Infection at Baseline and During the Peak Viral Period
NCT01192191 (10) [back to overview]	Number of Participants for the Indicated Hematological Parameters Who Experienced Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)
NCT01192191 (10) [back to overview]	Number of Participants for the Indicated Clinical Chemistry and Urinalysis Parameters Who Experienced a Low, Normal, and High Levels at Baseline (BL) and Week 52/Withdrawal (WD)
NCT01192191 (10) [back to overview]	Change From Baseline in Heart Rate (HR) at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD
NCT01192191 (10) [back to overview]	Change From Baseline in Blood Pressure at Weeks 4, 8, 12, 16, 24, 32, 40, and 52; Week 24/WD; and Week 52/WD
NCT01192191 (10) [back to overview]	Number of Participants With Pneumonia During the Treatment Period
NCT01192191 (10) [back to overview]	Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period
NCT01192191 (10) [back to overview]	Number of Participants With Any Drug-related AE and Any Drug-related SAE Throughout the Treatment Period
NCT01192191 (10) [back to overview]	Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
NCT01192191 (10) [back to overview]	Change From Baseline in 24-hour Urinary Cortisol Excretion at Weeks 24 and 52/Withdrawal (WD)
NCT01192191 (10) [back to overview]	Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick at Baseline (BL) and Week 52/Withdrawal (WD)
NCT01216735 (2) [back to overview]	Flow-mediated Brachial Vasodilation (FMD% Peak Delta)
NCT01216735 (2) [back to overview]	Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo
NCT01231230 (1) [back to overview]	Maximum Change From Baseline in Airway Blood Flow (Qaw)
NCT01231464 (3) [back to overview]	Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Total Nasal Symptom Score (rTNSS)
NCT01231464 (3) [back to overview]	Mean Change From Baseline (Visit 2) to the End of Study (Visit 4/Early Withdrawal) in Nasal Finding Score by Rhinoscopy
NCT01231464 (3) [back to overview]	Mean Change From Baseline (Visit 2) to the End of Study (Visit 4/Early Withdrawal) in Severity of Overall Interference in Activities of Daily Living
NCT01244984 (23) [back to overview]	Laboratory Parameter of Hemoglobin at Baseline (Week -2), Week 12,Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Change From Baseline in Asthma Symptom Score During the Study Treatment
NCT01244984 (23) [back to overview]	Number of Participants With Severe Asthma Exacerbation During the Study Treatment
NCT01244984 (23) [back to overview]	Laboratory Parameter of Albumin and Total Protein (TP) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameters of Eosinophils, Platelet Count, White Blood Cell (WBC), and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameter of Bilirubin (Direct [BD], Indirect [BI], Total [BT], Creatinine, and Uric Acid at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the Study Treatment
NCT01244984 (23) [back to overview]	Laboratory Parameter of Urine Specific Gravity (USG) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameter of Chloride, Carbon Dioxide Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings
NCT01244984 (23) [back to overview]	Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
NCT01244984 (23) [back to overview]	Number of Rescue Medication Inhalations
NCT01244984 (23) [back to overview]	Laboratory Parameter of Hematocrit at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameter of Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH) at BL (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameter of Red Blood Cell Count at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Laboratory Parameter of Urine Potential of Hydrogen (pH) at Baseline (Week -2), Week 12, Week 24, and Week 52/WD
NCT01244984 (23) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour Periods
NCT01244984 (23) [back to overview]	Change From Baseline in the 24-hour Urinary Cortisol Excretion
NCT01244984 (23) [back to overview]	Change From Baseline in Heart Rate (HR)
NCT01244984 (23) [back to overview]	Change From Baseline in Diary Data - Morning (AM) Peak Expiratory Flow (PEF) and Evening (PM) PEF During the Study Treatment
NCT01244984 (23) [back to overview]	Change From Baseline in Blood Pressure
NCT01244984 (23) [back to overview]	Number of Participants for the Indicated Uninalysis Parameters Tested by Dipstick at Baseline (BL), Week 12, Week 24, and Week 52/WD
NCT01279057 (8) [back to overview]	PRIMARY: Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Superiority: Intent-to-Treat Population)
NCT01279057 (8) [back to overview]	PRIMARY: Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Equivalence: Per-Protocol Population)
NCT01279057 (8) [back to overview]	Mean Change From Baseline in Instantaneous Total Ocular Symptom Score (iTOSS) (Superiority: Intent-to-Treat Population)
NCT01279057 (8) [back to overview]	Mean Change From Baseline in Instantaneous Total Ocular Symptom Score (iTOSS) (Equivalence: Per-Protocol Population)
NCT01279057 (8) [back to overview]	Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS) (Equivalence: Per-Protocol Population)
NCT01279057 (8) [back to overview]	Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS) (Superiority: Intent-to-Treat Population)
NCT01279057 (8) [back to overview]	Mean Change From Baseline in Instantaneous Total Nasal Symptom Score (iTNSS) (Equivalence: Per-Protocol Population)
NCT01279057 (8) [back to overview]	Mean Change From Baseline in Instantaneous Total Nasal Symptom Score (iTNSS) (Superiority: Intent-to-Treat Population)
NCT01307462 (9) [back to overview]	Number of Subjects Were Able to Reduce Their Systemic Steroid Exposure by >=50%
NCT01307462 (9) [back to overview]	Number of Subjects Who Experienced Statistically Significant Changes in FVC, TLC, RV, DLCO
NCT01307462 (9) [back to overview]	Number of Subjects Who Failed Treatment
NCT01307462 (9) [back to overview]	Number of Subjects With Improvements in Other Chronic GVHD Characteristics
NCT01307462 (9) [back to overview]	Changes in Symptoms as Measured by Patient Self-report--Functional Assessment of Chronic Illness Therapy (FACT)
NCT01307462 (9) [back to overview]	Changes in Symptoms as Measured by Patient Self-report--Human Activities Profile (HAP)
NCT01307462 (9) [back to overview]	Changes in Symptoms as Measured by Patient Self-report--Lee Chronic GVHD Symptom Scale
NCT01307462 (9) [back to overview]	Changes in Symptoms as Measured by Patient Self-report--Short Form-36 (SF-36)
NCT01307462 (9) [back to overview]	Number of Subjects Who Experienced Grade 3-5 SAEs Attributable to FAM and Number of Subjects Who Stopped FAM as a Result
NCT01312961 (11) [back to overview]	Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Evening Asthma Symptom Scores to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Morning Asthma Symptom Scores to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12
NCT01312961 (11) [back to overview]	Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12
NCT01312961 (11) [back to overview]	Percentage of Participants With Composite Asthma Events
NCT01312961 (11) [back to overview]	Change From Baseline in Peak Expiratory Flow (PEF) to Week 12
NCT01312961 (11) [back to overview]	Percentage of Participants With Asthma Exacerbation
NCT01313676 (3) [back to overview]	Decline in Forced Expiratory Volume in 1 Second (FEV1)
NCT01313676 (3) [back to overview]	Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date
NCT01313676 (3) [back to overview]	Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date
NCT01315249 (11) [back to overview]	Inspiratory Capacity (IC) at All-time Points (26 Weeks)
NCT01315249 (11) [back to overview]	Mean Change From Baseline in Daily Number of Puffs of Rescue Medication
NCT01315249 (11) [back to overview]	Number of Participants With Adverse Events
NCT01315249 (11) [back to overview]	Focal Score of the Transitional Dyspnea Index (TDI)
NCT01315249 (11) [back to overview]	Total Score of the St. George's Respiratory Questionnaire (SGRQ-C)
NCT01315249 (11) [back to overview]	Forced Vital Capacity at All-time Points (Week 26)
NCT01315249 (11) [back to overview]	Forced Vital Capacity at All-time Points (Week 12)
NCT01315249 (11) [back to overview]	Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12
NCT01315249 (11) [back to overview]	Inspiratory Capacity (IC) at All-time Points (12 Weeks)
NCT01315249 (11) [back to overview]	Standardized Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12 Hours
NCT01315249 (11) [back to overview]	Change From Baseline in Symptom Scores Reported Using the Ediary
NCT01323621 (2) [back to overview]	Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84
NCT01323621 (2) [back to overview]	Time to Onset on Treatment Day 1
NCT01323634 (2) [back to overview]	Time to Onset on Treatment Day 1
NCT01323634 (2) [back to overview]	Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84
NCT01328964 (3) [back to overview]	Mean Monthly Asthma-related Costs (Pharmacy and Medical) During the Post-index Period
NCT01328964 (3) [back to overview]	Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years
NCT01328964 (3) [back to overview]	Number of Asthma-related Hospitalizations, Asthma-related Emergency Department (ED) Visits, and Combined Hospitalizations/ED Visits Represented Per 100 Person Years
NCT01331694 (2) [back to overview]	Time to First Chronic Obstructive Pulmonary Disease (COPD) Event
NCT01331694 (2) [back to overview]	Average Annual Adjusted Post-Index COPD-Related Costs
NCT01332292 (28) [back to overview]	Oropharyngeal Volume on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	AUC(0-t) on Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Heart Rate at Baseline and Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Inhaled Volume on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
NCT01332292 (28) [back to overview]	Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Baseline and Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Total Emitted Dose (TED) on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Hematocrit Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Cmax on Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Ex-throat Dose (ETD) and ETD <2 Microns on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Total Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Tmax and t at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Average Oropharyngeal Cross-sectional Area on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Serum Cortisol Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Inhalation Time on Days 1 and 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Change From Baseline in the Indicated Electrocardiographic (ECG) Parameters at the Indicated Time Points on Day 14 of the Respective Treatment Period
NCT01332292 (28) [back to overview]	Distance of Assessment on Days 1 and 14 of the Respective Treatment Period
NCT01332357 (1) [back to overview]	Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event
NCT01332461 (3) [back to overview]	Number of Participants Having a COPD-related Event Related to Chronic Obstructive Pulmonary Disease (COPD) Represented Per 100 Person-years
NCT01332461 (3) [back to overview]	Number of Participants Having a Hospitalization or Emergency Room (ER) Visit Related to Chronic Obstructive Pulmonary Disease (COPD) Represented Per 100 Person-years
NCT01332461 (3) [back to overview]	Mean Monthly COPD-related Costs Per Participant
NCT01336608 (3) [back to overview]	Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168)
NCT01336608 (3) [back to overview]	Change From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168
NCT01336608 (3) [back to overview]	Mean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period
NCT01337336 (4) [back to overview]	Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation
NCT01337336 (4) [back to overview]	Mean Annual COPD-related Costs Per Participant
NCT01337336 (4) [back to overview]	Number of Participants With the Indicated COPD-related Exacerbations
NCT01337336 (4) [back to overview]	Number of the Indicated COPD-related Exacerbations
NCT01342913 (3) [back to overview]	Time to Onset on Treatment Day 1
NCT01342913 (3) [back to overview]	Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84
NCT01342913 (3) [back to overview]	Change From Baseline in Trough FEV1 on Treatment Day 85
NCT01347060 (3) [back to overview]	Mean Number of Post-index Asthma-related Events Measured Using Medical and Pharmacy Claims
NCT01347060 (3) [back to overview]	Mean Asthma-related Costs in the Post-index Period
NCT01347060 (3) [back to overview]	Mean Number of Albuterol (Short-acting β-Agonists) Canisters Dispensed Per Pharmacy Claim Per Participant
NCT01365611 (6) [back to overview]	AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose of Ketorolac Tromethamine).
NCT01365611 (6) [back to overview]	t1/2z (the Terminal Half-life of Ketorolac Tromethamine, Where Possible)
NCT01365611 (6) [back to overview]	Tmax (the Time to Maximum Concentration of Ketorolac Tromethamine)
NCT01365611 (6) [back to overview]	AUC Inf (the AUC From Time Zero to Infinity, Where Possible)
NCT01365611 (6) [back to overview]	MRT (the Mean Residence Time of Ketorolac Tromethamine, Where Possible)
NCT01365611 (6) [back to overview]	Cmax (the Maximum Observed Plasma Concentration of Ketorolac Tromethamine)
NCT01365650 (6) [back to overview]	Tmax (the Time to Maximum Concentration)
NCT01365650 (6) [back to overview]	t1/2z (the Terminal Half-life, Where Possible)
NCT01365650 (6) [back to overview]	AUC 0-∞ (the AUC From Time Zero to Infinity, Where Possible)
NCT01365650 (6) [back to overview]	AUC 0-t (the Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Time Point Post-dose)
NCT01365650 (6) [back to overview]	Cmax (the Maximum Observed Plasma Concentration)
NCT01365650 (6) [back to overview]	MRT (the Mean Residence Time)
NCT01376245 (2) [back to overview]	Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169
NCT01376245 (2) [back to overview]	Mean Change From Baseline in Chronic Respiratory Disease Questionnaire Self-administered Standardized (CRQ-SAS) Dyspnea Domain Score at Day 168
NCT01381471 (2) [back to overview]	Mean Number of Pharmacy Claims by Participants During the Post-Index Period
NCT01381471 (2) [back to overview]	Mean Number of Healthcare Encounters Incurred by Participants During the Post-Index Period
NCT01387178 (3) [back to overview]	Number of COPD-related Healthcare Encounters
NCT01387178 (3) [back to overview]	Mean Number of COPD Exacerbations
NCT01387178 (3) [back to overview]	Post-index Period COPD-related, Unadjusted Costs
NCT01395888 (1) [back to overview]	Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84)
NCT01400906 (9) [back to overview]	Concentration of Exhaled Nitric Oxide (eNO) on Day 6 and Day 7 of Each Treatment Period
NCT01400906 (9) [back to overview]	LAR - Smokers: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following Post-treatment Allergen Challenge on Day 6 of Each Treatment Period
NCT01400906 (9) [back to overview]	Provocative Concentration of Methacholine Resulting in a 20% Reduction in FEV1 (PC20) on Day 7 of Each Treatment Period
NCT01400906 (9) [back to overview]	Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 and WM FEV1 Between 0-2 Hours (Hrs) After Allergen Challenge on Day 6 of Each Treatment Period
NCT01400906 (9) [back to overview]	Neutrophil and Eosinophil Cell Counts in Induced Sputum on Day 7 of Each Treatment Period
NCT01400906 (9) [back to overview]	Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen Challenge on Day 6 of Each Treatment Period
NCT01400906 (9) [back to overview]	Absolute Change From Baseline in FEV1 Post-dose on Day 1, Day 6 (Prior to Allergen Challenge), and Day 7
NCT01400906 (9) [back to overview]	LAR - Non-smokers: Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) After Allergen Challenge on Day 6 of Each Treatment Period
NCT01400906 (9) [back to overview]	LAR - Non-smokers: Absolute Change From Saline in WM FEV1 Between 4-10 Hrs Following Post-treatment Allergen Challenge on Day 6 of Each Treatment Period
NCT01430403 (22) [back to overview]	School Absences (Percent), Treatment Steps 2-5:Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Spirometry Measurements: FEV1:FVCx100, Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Number of Exacerbations Evaluated Monthly With Viral Respiratory Infections: Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Spirometry Measurements: FEV1:FVCx100, Treatment Steps 2-5: Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Occurrence of One or More Asthma Exacerbations (All Treatment Steps [Steps 2-5])
NCT01430403 (22) [back to overview]	Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted , Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Severity of Asthma Symptoms Associated With a Viral Infection:Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted, Treatment Steps 2-5:Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Virus-induced Exacerbations as Measured by an Exacerbation That is Associated With a Virus Detected Using the Nasal Mucus Samples
NCT01430403 (22) [back to overview]	Work Disruptions Due to Child's Asthma, Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Work Disruptions Due to Child's Asthma, Treatment Steps 2-5: Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Comparison of Home Allergen (Cockroach) Exposure and Asthma Exacerbations: Omalizumab Versus Placebo
NCT01430403 (22) [back to overview]	Occurrence of One or More Asthma Exacerbations (Treatment Steps 2-4)
NCT01430403 (22) [back to overview]	Percent Adherence to Asthma Medication, Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Percent Adherence to Asthma Medication, Treatment Steps 2-5: Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	School Absences (Percent), Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Asthma Control Test Score: Child Asthma Control Test (C-ACT), Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Asthma Control Test Score: Child Asthma Control Test (C-ACT), Treatment Steps 2-5: Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Asthma Control Test Scores: Asthma Control Test (ACT), Treatment Steps 2-5: Omalizumab vs. Placebo
NCT01430403 (22) [back to overview]	Asthma Control Test Scores: Asthma Control Test (ACT), Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Composite Asthma Severity Index (CASI), Treatment Steps 2-4: Omalizumab vs. ICS
NCT01430403 (22) [back to overview]	Composite Asthma Severity Index (CASI), Treatment Steps 2-5: Omalizumab vs. Placebo
NCT01431950 (5) [back to overview]	Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period
NCT01431950 (5) [back to overview]	Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
NCT01436071 (6) [back to overview]	Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
NCT01436071 (6) [back to overview]	Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period
NCT01436071 (6) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 12-week Treatment Period
NCT01436071 (6) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 12-week Treatment Period
NCT01436071 (6) [back to overview]	Number of Participants Who Withdrew Due to a Lack of Efficacy During the 12-week Treatment Period
NCT01436071 (6) [back to overview]	Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period
NCT01436110 (6) [back to overview]	Change From Baseline in Daily Morning (AM) PEF Averaged Over the 24-week Treatment Period
NCT01436110 (6) [back to overview]	Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period
NCT01436110 (6) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 24-week Treatment Period
NCT01436110 (6) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 24-week Treatment Period
NCT01436110 (6) [back to overview]	Number of Participants Who Withdrew Due to Lack of Efficacy During the 24-week Treatment Period
NCT01436110 (6) [back to overview]	Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 24-week Treatment Period
NCT01437995 (5) [back to overview]	Pulmonary Function: Change in FEV1/FVC Ratio
NCT01437995 (5) [back to overview]	Rate of Episodes of Poor Asthma Control
NCT01437995 (5) [back to overview]	Treatment Failure
NCT01437995 (5) [back to overview]	Change in Pulmonary Function: FEV1 and FVC
NCT01437995 (5) [back to overview]	Pulmonary Function- Change in Peak Expiratory Flow
NCT01439815 (5) [back to overview]	Change in Baseline Nasal Congestion Score on Day 0 to Average Nasal Congestion Score on Day 16
NCT01439815 (5) [back to overview]	Change in Baseline Nasal Itching Score on Day 0 to Average Nasal Itching Score on Day 16
NCT01439815 (5) [back to overview]	Change in Baseline Rhinorrhea Score on Day 0 to Average Rhinorrhea Score on Day 16
NCT01439815 (5) [back to overview]	Change in Total Nasal Signs and Symptoms Score From Baseline (Day 0) to Visit 5 (Day 16)
NCT01439815 (5) [back to overview]	Change in Baseline Sneezing Score on Day 0 to Average Sneezing Score on Day 16
NCT01453023 (32) [back to overview]	Ex-throat Dose (ETD) and ETD <2 Microns on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Inhaled Volume on Days 1 and 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
NCT01453023 (32) [back to overview]	Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Inhalation Time on Days 1 and 14 of of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Total Emitted Dose (TED) on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Tmax and Tlast of VI on Day 1 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Tmax and Tlast of FF on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	AUC(0-t) and AUC(0-4) of FF on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Cmax of FF on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Cmax of VI on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Hematocrit Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Serum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	AUC(0-t) and AUC(0-4) of VI on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Blood Glucose and Potassium Values on Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
NCT01453023 (32) [back to overview]	Change From Baseline in Heart Rate at Day1 and Day 14 of the Respective Treatment Period
NCT01462344 (8) [back to overview]	Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period
NCT01462344 (8) [back to overview]	Percentage of Asthma Control Days Over the 6-month Study Treatment Period
NCT01462344 (8) [back to overview]	Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period
NCT01462344 (8) [back to overview]	Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.
NCT01462344 (8) [back to overview]	Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)
NCT01462344 (8) [back to overview]	Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period
NCT01462344 (8) [back to overview]	Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period
NCT01462344 (8) [back to overview]	Percentage of Rescue-free Days Over the 6-month Study Treatment Period
NCT01475721 (5) [back to overview]	Number of Participants Experiencing at Least One Asthma Exacerbation
NCT01475721 (5) [back to overview]	Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation
NCT01475721 (5) [back to overview]	Number of Participants Experiencing at Least One Asthma Related Hospitalization , Endotracheal Intubation and Death
NCT01475721 (5) [back to overview]	Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours
NCT01475721 (5) [back to overview]	Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)
NCT01479621 (13) [back to overview]	Kaplan-Meier Estimate of Probability of Remaining in the Study at Week 12
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
NCT01479621 (13) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline in the Percentage of Rescue-Free 24-hour Periods During the 12-Week Treatment Period
NCT01479621 (13) [back to overview]	Change From Baseline In Weekly Average Of Daily Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period Inclusive of Flovent Diskus Data
NCT01479621 (13) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT01479621 (13) [back to overview]	Area Under The Curve From Time 0 Until The Last Measurable Concentration (AUC0-t) of Fp
NCT01479621 (13) [back to overview]	Oropharyngeal Exam Findings at Each Study Visit
NCT01479621 (13) [back to overview]	Time of Maximum Concentration (Tmax) of Fp
NCT01479621 (13) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Fp
NCT01498679 (5) [back to overview]	Mean Change From Baseline in the Percentage of Rescue-free 24- Hour (hr) Periods During the 12-week Treatment Period
NCT01498679 (5) [back to overview]	Mean Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period
NCT01498679 (5) [back to overview]	Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
NCT01498679 (5) [back to overview]	Change From Baseline in Total Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12
NCT01498679 (5) [back to overview]	Mean Change From Baseline in the Percentage of Symptom-free 24- Hour (hr) Periods During the 12-week Treatment Period
NCT01520688 (2) [back to overview]	Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID.
NCT01520688 (2) [back to overview]	Short-term Lower Leg Growth During Treatment With Flovent Discus 100 mcg BID or QVAR 80 mcg BID.
NCT01537133 (3) [back to overview]	Microbial Community Evenness
NCT01537133 (3) [back to overview]	Microbial Community Richness
NCT01537133 (3) [back to overview]	Microbial Community Diversity
NCT01554488 (9) [back to overview]	Percentage Fat Content (Fat Fraction) of Pharyngeal Upper Airway Surrounding Structures at Week 16
NCT01554488 (9) [back to overview]	Volume of Pharyngeal Upper Airway Surrounding Structures at Week 16
NCT01554488 (9) [back to overview]	Tongue Fatigability at Anterior Location at Week 16
NCT01554488 (9) [back to overview]	Percentage Fat Content (Fat Fraction) of the Tongue at Week 16
NCT01554488 (9) [back to overview]	Tongue Fatigability of Posterior Location at Week 16
NCT01554488 (9) [back to overview]	Tongue Volume at Week 16
NCT01554488 (9) [back to overview]	Upper Airway Critical Closing Pressure (Pcrit) at Week 16
NCT01554488 (9) [back to overview]	Tongue Strength at Anterior Location at Week 16
NCT01554488 (9) [back to overview]	Tongue Strength at Posterior Location at Week 16
NCT01563029 (8) [back to overview]	Change From Baseline in PM PEF Over the Last 7 Days of the Treatment Period (Week 12)
NCT01563029 (8) [back to overview]	Number of Withdrawals Due to Lack of Efficacy Throughout the 12-week Treatment Period
NCT01563029 (8) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 12-week Treatment Period
NCT01563029 (8) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 12-week Treatment Period
NCT01563029 (8) [back to overview]	Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 12)
NCT01563029 (8) [back to overview]	Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period in Children Who Could Perform the Maneuver
NCT01563029 (8) [back to overview]	Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
NCT01563029 (8) [back to overview]	Change From Baseline in Daily Pre-dose Morning (AM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 12-week Treatment Period
NCT01573767 (7) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour Periods During the 4-week Treatment Period
NCT01573767 (7) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour Periods During the 4-week Treatment Period
NCT01573767 (7) [back to overview]	Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period
NCT01573767 (7) [back to overview]	Change From Baseline in Daily Morning (AM) PEF Averaged Over the 4-week Treatment Period
NCT01573767 (7) [back to overview]	Change From Baseline in AM PEF Over the Last 7 Days of the Treatment Period (Week 4)
NCT01573767 (7) [back to overview]	Change From Baseline in Evening Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 4-week Treatment Period in Children Who Could Perform the Maneuver
NCT01573767 (7) [back to overview]	Change From Baseline in Evening (PM) PEF Over the Last 7 Days of the Treatment Period (Week 4)
NCT01576718 (14) [back to overview]	Time Of Maximum Observed Plasma Concentration (Tmax)
NCT01576718 (14) [back to overview]	24-Hour Urinary Cortisol Excretion at Baseline, Week 12 and Endpoint
NCT01576718 (14) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT01576718 (14) [back to overview]	Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)
NCT01576718 (14) [back to overview]	Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods
NCT01576718 (14) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
NCT01576718 (14) [back to overview]	Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
NCT01576718 (14) [back to overview]	Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
NCT01576718 (14) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT01576718 (14) [back to overview]	The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12
NCT01576718 (14) [back to overview]	Patients With Positive Swab Test Results for Oral Candidiasis
NCT01578278 (1) [back to overview]	Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSS
NCT01606306 (1) [back to overview]	Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.
NCT01622231 (25) [back to overview]	Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator
NCT01622231 (25) [back to overview]	Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
NCT01622231 (25) [back to overview]	Mean Percent Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Percent Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Percent Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline in Sneezing, Rhinorrhea, Nasal Congestion, and Nasal Itching Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline in Eye Itching, Tearing, and Redness Over the Entire Treatment Period, Week 1 to 2, Week 3 to 4, Week 7 to 8, and Week 11 to 12
NCT01622231 (25) [back to overview]	Mean Change From Baseline (BL) in Daily Variation of the 3 Total Nasal Symptom Score (3TNSS)
NCT01622231 (25) [back to overview]	Change From Baseline in Red Blood Cell (RBC) Count at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Platelet Count and White Blood Cell (WBC) Count at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Hemoglobin at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Hematocrit at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Direct Bilirubin, Total Bilirubin, and Creatinine at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Calcium, Chloride, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyltransferase (GGT) at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Albumin and Total Protein at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophil Count at Week 4 and Week 12/Early Withdrawal
NCT01622231 (25) [back to overview]	Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge)
NCT01622231 (25) [back to overview]	Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=6 to <15 Years
NCT01622231 (25) [back to overview]	Number of Participants With the Indicated Plasma Concentration of GW685698X for Participants Aged >=2 to <6 Years
NCT01622231 (25) [back to overview]	Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant
NCT01622569 (15) [back to overview]	Nasal Polyp Surgery Eligilbilty
NCT01622569 (15) [back to overview]	Patient Global Impression of Change (PGIC) Score
NCT01622569 (15) [back to overview]	Peak Nasal Inspiratory Flow (PNIF)
NCT01622569 (15) [back to overview]	Sinonasal Outcome Test 22 (SNOT-22) Total Score
NCT01622569 (15) [back to overview]	Change in Rhinorrhea Score (7-day Instantaneous Morning)
NCT01622569 (15) [back to overview]	Hyposmia Score (7-day Instantaneous Morning)
NCT01622569 (15) [back to overview]	Rhinosinusitis Disability Index (RSDI) Total Score
NCT01622569 (15) [back to overview]	Change in Total Polyp Grade
NCT01622569 (15) [back to overview]	Congestion/Obstruction Scores (7-day Instantaneous Morning)
NCT01622569 (15) [back to overview]	MOS Sleep-R Score
NCT01622569 (15) [back to overview]	Facial Pain or Pressure Score (7-day Instantaneous Morning)
NCT01622569 (15) [back to overview]	Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms
NCT01622569 (15) [back to overview]	Polyp Grade of 0 in at Least One Nostril
NCT01622569 (15) [back to overview]	SF-36v2 - Mental Component
NCT01622569 (15) [back to overview]	SF-36v2 - Physical Component
NCT01623310 (6) [back to overview]	Nasal Polyp Surgery Eligibility
NCT01623310 (6) [back to overview]	Patient Global Impression of Change (PGIC)
NCT01623310 (6) [back to overview]	Sinonasal Outcome Test 22 (SNOT-22) Total Score
NCT01623310 (6) [back to overview]	Adverse Events
NCT01623310 (6) [back to overview]	Summed Bilateral Nasal Polyp Grading Scale Score
NCT01623310 (6) [back to overview]	Lund-Mackay Total Score
NCT01623323 (1) [back to overview]	Adverse Events
NCT01624662 (16) [back to overview]	Nasal Congestion/Obstruction Score (7-day Instantaneous Morning)
NCT01624662 (16) [back to overview]	Rhinosinusitis Disability Index (RSDI) Total Score
NCT01624662 (16) [back to overview]	Number of Participants Eligible for Nasal Polyp Surgery
NCT01624662 (16) [back to overview]	Peak Nasal Inspiratory Flow (PNIF)
NCT01624662 (16) [back to overview]	Polyp Grade of 0 in at Least One Nostril
NCT01624662 (16) [back to overview]	SF-36v2 - Mental Component
NCT01624662 (16) [back to overview]	SF-36v2 - Physical Component
NCT01624662 (16) [back to overview]	Sinonasal Outcome Test 22 (SNOT-22) Total Score
NCT01624662 (16) [back to overview]	Number of Participants in Each Category of PGIC
NCT01624662 (16) [back to overview]	Facial Pain or Pressure Score (7-day Instantaneous Morning)
NCT01624662 (16) [back to overview]	Change in Total Polyp Grade
NCT01624662 (16) [back to overview]	Change in Total Nasal Polyp Score
NCT01624662 (16) [back to overview]	Change in Rhinorrhea Score (7-day Instantaneous Morning)
NCT01624662 (16) [back to overview]	Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms
NCT01624662 (16) [back to overview]	MOS Sleep-R Score
NCT01624662 (16) [back to overview]	Hyposmia Score (7-day Instantaneous Morning)
NCT01627327 (3) [back to overview]	Time to Onset on Treatment Day 1
NCT01627327 (3) [back to overview]	Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84
NCT01627327 (3) [back to overview]	Change From Baseline in Trough FEV1 at Treatment Day 84
NCT01630135 (16) [back to overview]	Mean Change From Baseline in the Individual Ocular Symptom Scores (Eye Itching, Tearing, and Redness) Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Change From Baseline in the Score of Troubles With Daily Life Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Change From Baseline in the Total Ocular Symptom Score (TOSS) Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Percent Change From Baseline (BL) in the TOSS for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Percent Change From Baseline (BL) in the TOSS Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Percent Change From Baseline in the 4TNSS Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Investigator
NCT01630135 (16) [back to overview]	Number of Participants With the Indicated Overall Response to Therapy, as Assessed by the Participant's Parent/Guardian or the Participant
NCT01630135 (16) [back to overview]	Number of Participants With the Indicated Scores for Rhinoscopy Findings (Swelling of Inferior Turbinate Mucosa, Color of Inferior Turbinate Mucosa, Quantity of Nasal Discharge, and Quality of Nasal Discharge) at Baseline, Week 1, and Week 2/EW
NCT01630135 (16) [back to overview]	Mean Change From Baseline in the 3 Total Nasal Symptom Score (3TNSS) Over the Entire Treatment Period
NCT01630135 (16) [back to overview]	Mean Percent Change From Baseline in 3TNSS Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Change From Baseline (BL) in the Total Ocular Symptom Score (TOSS) for the Baseline TOSS >0 Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Change From Baseline in 3TNSS at the Indicated Days
NCT01630135 (16) [back to overview]	Mean Change From Baseline in 3TNSS at Week 1 and Week 2
NCT01630135 (16) [back to overview]	Mean Change From Baseline in Rhinorrhea, Nasal Congestion, Sneezing, and Nasal Itching Over the Entire Treatment Period (ETP), at Week 1, and at Week 2
NCT01630135 (16) [back to overview]	Mean Change From Baseline in the 4 Total Nasal Symptom Score (4TNSS) Over the Entire Treatment Period, at Week 1, and at Week 2
NCT01686633 (6) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
NCT01686633 (6) [back to overview]	Change From Baseline in Clinic Visit Trough FEV1 at the End of the 12-week Treatment Period
NCT01686633 (6) [back to overview]	Change From Baseline in Daily Evening (PM) PEF Averaged Over the 12-week Treatment Period
NCT01686633 (6) [back to overview]	Change From Baseline in Daily Morning (AM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
NCT01686633 (6) [back to overview]	Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period
NCT01686633 (6) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
NCT01687283 (11) [back to overview]	Change From Baseline (Day 1 of Trt Period/Visit 2) in AM PEF Over 12 Weeks in Per Protocol Population
NCT01687283 (11) [back to overview]	Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-maximum Observed Plasma Concentration (Cmax)
NCT01687283 (11) [back to overview]	Mean Change in Percentage of Rescue-free 24-hour Periods From Baseline Over 12 Weeks
NCT01687283 (11) [back to overview]	Mean Change of Evening PEF From Baseline Over 12 Weeks
NCT01687283 (11) [back to overview]	Median Number of Times Rescue Medication Use Over 12 Weeks
NCT01687283 (11) [back to overview]	Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution- Time to Maximum Observed Plasma Concentration (Tmax)
NCT01687283 (11) [back to overview]	Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-area Under the Plasma Concentration-time Curve for the Dose Interval [AUC (0-τ)]
NCT01687283 (11) [back to overview]	Median Day-time and Night-time Symptom Scores Per Participant Over 12 Weeks
NCT01687283 (11) [back to overview]	Change of Clinical Lung Function Measurement Forced Expiratory Volume in One Second (FEV1) From Baseline Over 12 Weeks
NCT01687283 (11) [back to overview]	Mean Change in Percentage of Symptom-free 24-hour Periods From Baseline Over 12 Weeks
NCT01687283 (11) [back to overview]	Change From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population
NCT01687296 (8) [back to overview]	Clinical Assessment of Lung Function of Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) During the Treatment Period
NCT01687296 (8) [back to overview]	Median Day-time and Night-time Symptom Scores Over the Treatment Assessment Period
NCT01687296 (8) [back to overview]	Mean Global Evaluation for Efficacy by Participant/Parent and Investigator
NCT01687296 (8) [back to overview]	Mean Evening PEF on Diary Card Over the Treatment Assessment Period
NCT01687296 (8) [back to overview]	Mean Change From Baseline in Clinical Scoring Index at Day 5 and Day 8
NCT01687296 (8) [back to overview]	Mean Morning Peak Expiratory Flow (AM PEF) on Diary Card Over the Treatment Assessment Period in Intent-to-Treat (ITT) Population
NCT01687296 (8) [back to overview]	Mean Morning PEF on Diary Card Over the Treatment Assessment Period in Per Protocol (PP) Population
NCT01687296 (8) [back to overview]	Median Number of Use of Rescue Medications During Day and Night Over the Treatment Assessment Period
NCT01691885 (1) [back to overview]	Mean Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVI) at the End of the Overall Treatment Period
NCT01696214 (3) [back to overview]	The Asthma Symptom Utility Index (ASUI)
NCT01696214 (3) [back to overview]	Asthma Control Test
NCT01696214 (3) [back to overview]	Percent (%) Perdicted FEV1 Changes
NCT01706198 (23) [back to overview]	Annual Rate of Asthma-related Secondary Care Contacts
NCT01706198 (23) [back to overview]	Mean Annual Rate of Severe Asthma Exacerbations
NCT01706198 (23) [back to overview]	Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.
NCT01706198 (23) [back to overview]	Number of Participants With Adverse Drug Reactions (ADRs)
NCT01706198 (23) [back to overview]	Number of Participants With SAEs
NCT01706198 (23) [back to overview]	Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.
NCT01706198 (23) [back to overview]	Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.
NCT01706198 (23) [back to overview]	Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.
NCT01706198 (23) [back to overview]	Number of Participants With Fatal SAEs of Pneumonia
NCT01706198 (23) [back to overview]	Percentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52.
NCT01706198 (23) [back to overview]	Number of Participants With Time to First Asthma-related Primary Care Contact
NCT01706198 (23) [back to overview]	Mean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52.
NCT01706198 (23) [back to overview]	Time to Modification of Initial Therapy
NCT01706198 (23) [back to overview]	Percentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52.
NCT01706198 (23) [back to overview]	Percentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52.
NCT01706198 (23) [back to overview]	Percentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52.
NCT01706198 (23) [back to overview]	Time to First Severe Asthma Exacerbation.
NCT01706198 (23) [back to overview]	Time to First SAE of Pneumonia
NCT01706198 (23) [back to overview]	Number of Participants With Time to First Primary Care Contact
NCT01706198 (23) [back to overview]	Annual Rate of All On-treatment Primary Care Contacts
NCT01706198 (23) [back to overview]	Annual Rate of All On-treatment Secondary Care Contacts
NCT01706198 (23) [back to overview]	Annual Rate of Asthma-related Primary Care Contacts
NCT01706198 (23) [back to overview]	Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia
NCT01706328 (3) [back to overview]	Time to Onset on Treatment Day 1
NCT01706328 (3) [back to overview]	Change From Baseline Trough in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) on Treatment Day 84
NCT01706328 (3) [back to overview]	Change From Baseline in Trough FEV1 on Treatment Day 85
NCT01709903 (9) [back to overview]	Analysis of Trough FVC (L) Over the Whole Treatment Period
NCT01709903 (9) [back to overview]	Rescue Medication Use: Summary of the Mean Daily, Daytime and Nighttime Number of Puffs of Rescue Medication, by 4 Weekly Intervals
NCT01709903 (9) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1) Following 26 Weeks of Treatment to Demonstrate the Superiority of QVA 110/50μg o.d. to Fluticasone/Salmeterol 500/50 μg b.i.d
NCT01709903 (9) [back to overview]	Analysis of FEV1 (L) Trough Response (Pre-dose) Over the Whole Treatment Period
NCT01709903 (9) [back to overview]	Analysis of the TDI Focal Score Over the Whole Treatment Period
NCT01709903 (9) [back to overview]	Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-4 Hours
NCT01709903 (9) [back to overview]	Health Related Quality of Life Analysis of SGRQ Total Score After 26 Weeks of Treatment
NCT01709903 (9) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1) Following 26 Weeks of Treatment to Demonstrate the Non-inferiority of QVA149 110/50 μg o.d. to Fluticasone/Salmeterol 500/50 μg b.i.d
NCT01709903 (9) [back to overview]	Symptoms Reported Using E-diary Over 12 and 26 Weeks of Treatment
NCT01751113 (11) [back to overview]	Use of Rescue Medication (Number of Occasions Per 24-hour Period) as Recorded in the Daily Record Card at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Trough sRaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Trough sGaw Measured at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Trough FEV1/FVC Ratio, at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Post-dose FEV1/FVC Ratio (Measured at Trough) at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	AUC (0-4hr) Specific Airway Resistance (sRaw) After the Morning Dose of Each Study Medication at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Area Under the Curve Calculated From 0 to 4 Hours (AUC[0-4hr]) Specific Conductance (sGaw) After the Morning Dose of Study Medication at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Post-dose sRaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Post-dose sGaw at 30, 75, 120 and 240 Minutes Post Dose at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1), Forced Vital Capacity (FVC), Inspiratory Capacity (IC), RV, TLC, and TGV at Each Clinic Visit Prior to the Morning Dose and Before the Use of Rescue Medication at Day 28 of Each Treatment Period
NCT01751113 (11) [back to overview]	Post-dose FEV1, FVC, IC, RV, TLC and TGV (Measured at Trough) at Day 28 of Each Treatment Period
NCT01762800 (21) [back to overview]	Comparison of Number of Exacerbations Between Two Detection Methods: EXACT and Physician Diagnosis
NCT01762800 (21) [back to overview]	Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) Total Score
NCT01762800 (21) [back to overview]	Change From Baseline in FEV1
NCT01762800 (21) [back to overview]	Change From Baseline in CAT Total Score
NCT01762800 (21) [back to overview]	Time to First Switching to TRIPLE Therapy
NCT01762800 (21) [back to overview]	Time to First Exacerbation by Physician's Diagnosis
NCT01762800 (21) [back to overview]	Time to First Exacerbation by EXAcerbations of Chronic Pulmonary Disease Tool (EXACT)
NCT01762800 (21) [back to overview]	Percentage of Participants Who Were Able to Remain on the Randomized Treatment
NCT01762800 (21) [back to overview]	Percentage of Participants Who Used Relief Medication (Salbutamol)
NCT01762800 (21) [back to overview]	Forced Expiratory Volume in One Second (FEV1)
NCT01762800 (21) [back to overview]	Number of Participants in Each Treatment Efficacy Grade Evaluated by Participants
NCT01762800 (21) [back to overview]	Number of Participants in Each Treatment Efficacy Grade Evaluated by Physician
NCT01762800 (21) [back to overview]	Percentage of Participants Who Switched to TRIPLE Therapy
NCT01762800 (21) [back to overview]	Percentage of Participants Who Stepped Down From TRIPLE Therapy to Initial Randomized Treatment
NCT01762800 (21) [back to overview]	Percentage of Participants Who Required Additional Treatment to TRIPLE Therapy
NCT01762800 (21) [back to overview]	Percentage of Participants Who Dropped Out
NCT01762800 (21) [back to overview]	Percentage of Participants Managed by TRIPLE Therapy
NCT01762800 (21) [back to overview]	Continuation Percentage of Participants Managed by Randomized Treatment Plus TRIPLE Therapy
NCT01762800 (21) [back to overview]	E-RS Subscale Score
NCT01762800 (21) [back to overview]	EXACT Respiratory Symptoms (E-RS) Total Score
NCT01762800 (21) [back to overview]	EXACT Total Score.
NCT01772134 (4) [back to overview]	Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84
NCT01772134 (4) [back to overview]	Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12
NCT01772134 (4) [back to overview]	Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12
NCT01772134 (4) [back to overview]	Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
NCT01772147 (4) [back to overview]	Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12
NCT01772147 (4) [back to overview]	Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
NCT01772147 (4) [back to overview]	Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12
NCT01772147 (4) [back to overview]	Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84
NCT01772368 (6) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol
NCT01772368 (6) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol
NCT01772368 (6) [back to overview]	Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)
NCT01772368 (6) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Salmeterol
NCT01772368 (6) [back to overview]	Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment
NCT01772368 (6) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT01794741 (1) [back to overview]	Adverse Events Report
NCT01794780 (6) [back to overview]	COPD Exacerbation
NCT01794780 (6) [back to overview]	Change in Health Status Questionnaire MMRC
NCT01794780 (6) [back to overview]	Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score
NCT01794780 (6) [back to overview]	Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
NCT01794780 (6) [back to overview]	Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score
NCT01794780 (6) [back to overview]	Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
NCT01808339 (3) [back to overview]	Pre-treatment AM and PM Trough FEV1 on Day 14 of Each Treatment Period
NCT01808339 (3) [back to overview]	Number of Participants With Any Adverse Event (AE)
NCT01808339 (3) [back to overview]	Weighted Mean Forced Expiratory Volume in 1 Second (FEV1) Measured Over 24 Hours at Day 14 of Each Treatment Period
NCT01817764 (2) [back to overview]	Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84
NCT01817764 (2) [back to overview]	Change From Baseline in Trough FEV1 on Day 85
NCT01817790 (19) [back to overview]	Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms
NCT01817790 (19) [back to overview]	Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning
NCT01817790 (19) [back to overview]	Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS)
NCT01817790 (19) [back to overview]	Mean Change From Baseline in AM rTOSS
NCT01817790 (19) [back to overview]	Mean Change in Objective Assessment of Conjunctival Redness
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS)
NCT01817790 (19) [back to overview]	Mean Change From Baseline in PM rTOSS
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness
NCT01817790 (19) [back to overview]	Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering
NCT01817790 (19) [back to overview]	Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning
NCT01817790 (19) [back to overview]	Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities
NCT01817790 (19) [back to overview]	Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms
NCT01817790 (19) [back to overview]	End-of-treatment Assessment of Response to Therapy for Ocular Symptoms
NCT01817790 (19) [back to overview]	Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness
NCT01822899 (2) [back to overview]	Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85
NCT01822899 (2) [back to overview]	Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84
NCT01836471 (5) [back to overview]	Change From Baseline in ACQ-6 Score at Week 12 Non-atopic Compared to Atopic Patients at Week 12 - Full Analysis Set
NCT01836471 (5) [back to overview]	Change From Baseline in ACQ-6 Score at Week 12 Non-atopic and Atopic Patients at Week 12 - Full Analysis Set
NCT01836471 (5) [back to overview]	Change From Baseline in Trough FEV1 (L) in Atopic Patients at Week 12 - Full Analysis Set
NCT01836471 (5) [back to overview]	Change From Baseline in Trough FEV1 (L) in Non-atopic Compared to Atopic Patients at Week 12 - Full Analysis Set
NCT01836471 (5) [back to overview]	Change From Baseline in Trough FEV1 (L) in Non-atopic Patients at Week 12 - Full Analysis Set
NCT01845025 (9) [back to overview]	Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)
NCT01845025 (9) [back to overview]	Percentage of Days of School/Work Missed at 26 Weeks
NCT01845025 (9) [back to overview]	Percentage of Days With no Symptoms at 26 Weeks
NCT01845025 (9) [back to overview]	Percentage of Days With no Rescue Medication Use at 26 Weeks
NCT01845025 (9) [back to overview]	Percentage of Days With Nighttime Awakenings at 26 Weeks
NCT01845025 (9) [back to overview]	Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26
NCT01845025 (9) [back to overview]	Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks
NCT01845025 (9) [back to overview]	Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks
NCT01845025 (9) [back to overview]	Number of Asthma Exacerbations at 26 Weeks
NCT01881412 (6) [back to overview]	ED Visits for Asthma
NCT01881412 (6) [back to overview]	Unscheduled Primary Care Visits
NCT01881412 (6) [back to overview]	Quality-of-life Using the Integrated Therapeutics Group Child Asthma Short Form
NCT01881412 (6) [back to overview]	Primary Care Visits for Well Checks
NCT01881412 (6) [back to overview]	Oral Steroid Courses
NCT01881412 (6) [back to overview]	Hospitalizations for Asthma
NCT01907334 (1) [back to overview]	Total Airway Resistance Increase
NCT01908140 (2) [back to overview]	Transition Dyspnoea Index (TDI) Focal Score at Week 24
NCT01908140 (2) [back to overview]	Peak Forced Expiratory Volume in One Second (FEV1) at Week 24
NCT01915823 (3) [back to overview]	Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)
NCT01915823 (3) [back to overview]	Primary Efficacy
NCT01915823 (3) [back to overview]	Safety
NCT01915914 (12) [back to overview]	Median Time to the First Relapse of AD During the Maintenance Phase and Follow-up Phase
NCT01915914 (12) [back to overview]	Number of Participants With Post-study Assessment of Lotion Qualities (1) Using Questionnaire
NCT01915914 (12) [back to overview]	Number of Participants With Post-study Assessment of Lotion Qualities (2) Using Questionnaire
NCT01915914 (12) [back to overview]	Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Maintenance Phase and Follow-up Phase
NCT01915914 (12) [back to overview]	Numbers of Recurrent Participants at the End of the Follow-up Phase (Week 32)
NCT01915914 (12) [back to overview]	"Number of Participants With Treatment Success During the Acute Phase"
NCT01915914 (12) [back to overview]	Number of Participants With Post-study Assessment of Skin Emollients Using Questionnaire
NCT01915914 (12) [back to overview]	Time to the First Relapse of AD During the Maintenance Phase
NCT01915914 (12) [back to overview]	Change From Baseline in Cutaneous Atrophy Sign Score, Epidermal Thickening /Lichenification Sign Score and Abnormal Pigmentation Score Using Visual Analogue Scale (VAS) at the End of the Acute Phase
NCT01915914 (12) [back to overview]	Change From Baseline in QoL at the End of the Follow-up Phase
NCT01915914 (12) [back to overview]	Numbers of Recurrent Participants at the End of the Maintenance Phase (Week 20)
NCT01915914 (12) [back to overview]	Change From Baseline in Quality of Life (QoL) at the End of the Maintenance Phase
NCT01933984 (8) [back to overview]	Number of Episode of Nosocomial Pneumonia
NCT01933984 (8) [back to overview]	Mortality Rate
NCT01933984 (8) [back to overview]	∆Raw (the Difference Between Measured and Target Airway Resistance)
NCT01933984 (8) [back to overview]	Ventilator-free Days From Day 1 to 28
NCT01933984 (8) [back to overview]	The Participants of Breathing Without Assistance by Day 28
NCT01933984 (8) [back to overview]	Rapidity of ∆Raw Change
NCT01933984 (8) [back to overview]	Numbers of Episode of Drug-related Adverse Effect
NCT01933984 (8) [back to overview]	Number of Total Puff of Rescue Short-acting Bronchodilator
NCT01957150 (6) [back to overview]	Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Male Participants)
NCT01957150 (6) [back to overview]	Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Female Participants)
NCT01957150 (6) [back to overview]	Percentage Change From Baseline in Bone Mineral Density (BMD) Measured at Total Hip
NCT01957150 (6) [back to overview]	Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4) by Gender (Female Participants)
NCT01957150 (6) [back to overview]	Percentage Change From Baseline in BMD Measurements at Lumbar Spine (L1 to L4)
NCT01957150 (6) [back to overview]	Percentage Change From Baseline in BMD Measurements at Total Hip by Gender (Male Participants)
NCT01967173 (2) [back to overview]	The Primary Outcome is a Composite Measure That Uses Exacerbations, Asthma Control Days During the Last 12 of 14 Weeks of a Treatment Regimen, and Percent Predicted FEV1 at the End of a Treatment Regimen.
NCT01967173 (2) [back to overview]	The Primary Outcome is a Composite Measure That Uses Exacerbations, Asthma Control Days During the Last 12 of 14 Weeks of a Treatment Regimen, and Percent Predicted FEV1 at the End of a Treatment Regimen.
NCT01969721 (5) [back to overview]	Trough FEV1 Change From Patient Baseline After 6 Weeks of Treatment
NCT01969721 (5) [back to overview]	FEV1 Peak (0-3h) Change From Patient Baseline After 6 Weeks of Treatment
NCT01969721 (5) [back to overview]	FEV1 AUC (0-24h) Change From Patient Baseline After 6 Weeks of Treatment
NCT01969721 (5) [back to overview]	FEV1 AUC (12-24h) Change From Patient Baseline After 6 Weeks of Treatment
NCT01969721 (5) [back to overview]	FEV1 AUC (0-12h) Change From Patient Baseline After 6 Weeks of Treatment
NCT02019758 (10) [back to overview]	Percentage of Participants With Histologic Response of <15 Eos/Hpf
NCT02019758 (10) [back to overview]	Number of Subjects With Histologic Recurrence, Defined as ≥15 Eosinophils Per High-power Field, at Follow-up Endoscopy.
NCT02019758 (10) [back to overview]	Median Number of Days Until Symptom Recurrence (Aim 2)
NCT02019758 (10) [back to overview]	Mean Peak Eosinophil Count (Aim 2)
NCT02019758 (10) [back to overview]	Mean Endoscopic Severity Score at Recurrence (Aim 2)
NCT02019758 (10) [back to overview]	Post-treatment Dysphagia Score (Aim 1)
NCT02019758 (10) [back to overview]	Post-treatment Endoscopic Severity (Aim 1)
NCT02019758 (10) [back to overview]	Post-Treatment Maximum Eosinophil Count (Aim 1)
NCT02019758 (10) [back to overview]	Post-treatment Medication Compliance (Aim 1)
NCT02019758 (10) [back to overview]	Post-treatment Symptom Severity (Aim 1)
NCT02024204 (10) [back to overview]	Number of Participants With Positive Level of Bronchial Hyperreactivity (BHR)
NCT02024204 (10) [back to overview]	Forced Oscillation Technique (FOT) Measures
NCT02024204 (10) [back to overview]	Total IgE (Immunoglobulin E) Levels
NCT02024204 (10) [back to overview]	Total EoS (Eosinophil) Counts
NCT02024204 (10) [back to overview]	Number of Participants With Positive Level of Paradoxical Vocal Fold Movement (PVFM)
NCT02024204 (10) [back to overview]	Rhinosinusitis Score on International Classification of Sleep Disorders (ICSD)
NCT02024204 (10) [back to overview]	Score on Leicester Cough Questionnaire (LCQ)
NCT02024204 (10) [back to overview]	Levels of Fractional Exhaled Nitric Oxide (FeNO)
NCT02024204 (10) [back to overview]	Spirometry Measures
NCT02024204 (10) [back to overview]	Score on Voice Handicap Index 10 (VHI-10)
NCT02055352 (5) [back to overview]	Change in Health Status - mMRC
NCT02055352 (5) [back to overview]	Change in Health Status - SGRQ-C
NCT02055352 (5) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority)
NCT02055352 (5) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis).
NCT02055352 (5) [back to overview]	Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment
NCT02061280 (7) [back to overview]	Caregiver Research Participant Assessment Score at Study End (Visit 6, Week 12)
NCT02061280 (7) [back to overview]	Spirometry Quality Control Grade
NCT02061280 (7) [back to overview]	Adolescent Research Participant Assessment Score at Study End (Visit 6, Week 12)
NCT02061280 (7) [back to overview]	Asthma Control Test Score at Final Visit (Visit 6, Week12)
NCT02061280 (7) [back to overview]	Asthma Control Test Scores at Screening (Visit 1, Week -8)
NCT02061280 (7) [back to overview]	Caregiver Research Participant Assessment Score at Screening (Visit 1, Week -8)
NCT02061280 (7) [back to overview]	Adolescent Research Participant Assessment Score at Screening (Visit 1, Week -8)
NCT02066129 (5) [back to overview]	Number of Participants Hospitalized for Asthma
NCT02066129 (5) [back to overview]	Asthma Exacerbations
NCT02066129 (5) [back to overview]	Yellow Zone Albuterol Use
NCT02066129 (5) [back to overview]	Yellow Zone Asthma Symptoms
NCT02066129 (5) [back to overview]	Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma
NCT02094937 (8) [back to overview]	Least Squares Mean Change From Baseline in Daily Morning (AM) and Evening (PM) PEF Averaged During Period 2
NCT02094937 (8) [back to overview]	Percentage of Participants With 'Well-controlled Asthma' at the End of Period 2
NCT02094937 (8) [back to overview]	Proportion of Subjects With ACT Score >= 20 at Visit 11 (Week 20)
NCT02094937 (8) [back to overview]	"Percentage of Participants (Par) Withdrawn From the Study Due to Poorly-controlled Asthma During Period 2"
NCT02094937 (8) [back to overview]	Least Squares Mean Change From Baseline in Asthma Control Test (ACT) Score at the End of Period 2
NCT02094937 (8) [back to overview]	Least Squares Mean Change From Baseline in Clinic Visit Trough FEV1 at the End of Period 2
NCT02094937 (8) [back to overview]	Least Squares Mean Change From Baseline in the Percentage of Rescue Free 24 Hour (hr) Periods During Period 2
NCT02094937 (8) [back to overview]	Least Squares Mean Change From Baseline in the Percentage of Symptom Free 24 Hour Periods During Period 2
NCT02105974 (3) [back to overview]	Percentage of Rescue-free 24-hour Periods Over the Entire 12-week Treatment Period
NCT02105974 (3) [back to overview]	Time to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation
NCT02105974 (3) [back to overview]	Mean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 84
NCT02139644 (9) [back to overview]	Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
NCT02139644 (9) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT02139644 (9) [back to overview]	Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
NCT02139644 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
NCT02139644 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
NCT02139644 (9) [back to overview]	Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
NCT02139644 (9) [back to overview]	Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours Postdose (FEV1 AUEC0-12h) at Week 12
NCT02139644 (9) [back to overview]	Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02139644 (9) [back to overview]	Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
NCT02141633 (2) [back to overview]	Airway Blood Flow
NCT02141633 (2) [back to overview]	Echocardiogram
NCT02141854 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
NCT02141854 (9) [back to overview]	Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
NCT02141854 (9) [back to overview]	Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
NCT02141854 (9) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
NCT02141854 (9) [back to overview]	Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02141854 (9) [back to overview]	Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT02141854 (9) [back to overview]	Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
NCT02141854 (9) [back to overview]	Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12
NCT02141854 (9) [back to overview]	Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
NCT02164513 (7) [back to overview]	Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI
NCT02164513 (7) [back to overview]	Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count >=150 Cells Per Microliter at Baseline
NCT02164513 (7) [back to overview]	Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI
NCT02164513 (7) [back to overview]	Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI
NCT02164513 (7) [back to overview]	Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count >=150 Cells Per Microliter
NCT02164513 (7) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI
NCT02164513 (7) [back to overview]	Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI
NCT02175771 (6) [back to overview]	Participants With Potentially Clinically Significant Abnormal Vital Signs During the Treatment Period
NCT02175771 (6) [back to overview]	Shifts From Baseline to Endpoint in Electrocardiogram (ECG) Findings
NCT02175771 (6) [back to overview]	Analysis of 24-Hour Urine Cortisol Free Over the 26-Week Treatment Period
NCT02175771 (6) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Minute (FEV1) Over the 26-Week Treatment Period
NCT02175771 (6) [back to overview]	Participants With Positive Swab Test Results for Oral Candidiasis
NCT02175771 (6) [back to overview]	Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
NCT02180672 (10) [back to overview]	Child Behavior Checklist
NCT02180672 (10) [back to overview]	Purdue Peg Board
NCT02180672 (10) [back to overview]	Pediatric Quality of Life Inventory (PedsQL)
NCT02180672 (10) [back to overview]	The Epworth Sleepiness Scale
NCT02180672 (10) [back to overview]	Obstructive Apnea Hypopnea Index
NCT02180672 (10) [back to overview]	OAHI
NCT02180672 (10) [back to overview]	Nasal Obstruction Symptom Evaluation (NOSE)
NCT02180672 (10) [back to overview]	Conners Continuous Performance Test (CPT)
NCT02180672 (10) [back to overview]	Behavior Rating Inventory of Executive Function (BRIEF)
NCT02180672 (10) [back to overview]	Conners Abbreviated Symptom Questionnaire
NCT02194062 (2) [back to overview]	SNOT-22 Scores
NCT02194062 (2) [back to overview]	Lund-Kennedy Scoring for Nasal Endoscopy
NCT02230696 (3) [back to overview]	Mean Change From Baseline in the Mean Instantaneous Total Nasal Symptom Score (iTNSS)
NCT02230696 (3) [back to overview]	Mean Change From Baseline for Mean Reflective Total Nasal Symptom Score (rTNSS)
NCT02230696 (3) [back to overview]	Change From Baseline iTNSS Scores on Day 1 Post First Randomized Dose
NCT02232087 (6) [back to overview]	Max QTcB
NCT02232087 (6) [back to overview]	Max Heart Rate
NCT02232087 (6) [back to overview]	Max Plasma Glucose Level
NCT02232087 (6) [back to overview]	Relative Potency QTcB Interval
NCT02232087 (6) [back to overview]	Relative Potency Max Heart Rate
NCT02232087 (6) [back to overview]	Plasma Potassium Level
NCT02245672 (4) [back to overview]	FEV1 Trough Value (Bioequivalence)
NCT02245672 (4) [back to overview]	Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Bioequivalence)
NCT02245672 (4) [back to overview]	Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity)
NCT02245672 (4) [back to overview]	FEV1 Trough Value (Assay Sensitivity)
NCT02246920 (3) [back to overview]	Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.
NCT02246920 (3) [back to overview]	Superiority to Placebo
NCT02246920 (3) [back to overview]	Change From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14.
NCT02251379 (6) [back to overview]	Number of Asthma Exacerbations
NCT02251379 (6) [back to overview]	FEV1/FVC
NCT02251379 (6) [back to overview]	Exhaled Nitric Oxide
NCT02251379 (6) [back to overview]	Daily Inhaled Corticosteroid Dose
NCT02251379 (6) [back to overview]	Number of Asthma Symptom Days
NCT02251379 (6) [back to overview]	The Medication Treatment Step Assigned
NCT02260492 (3) [back to overview]	FEV1 Trough
NCT02260492 (3) [back to overview]	Number of Participants With Adverse Events
NCT02260492 (3) [back to overview]	Area Under the Serial FEV1-time Curve (AUC 0-12h)
NCT02301975 (7) [back to overview]	Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20
NCT02301975 (7) [back to overview]	Change From Baseline in the Percentage of Symptom-free 24-hour Periods
NCT02301975 (7) [back to overview]	Change From Baseline in the Percentage of Rescue-free 24-hour Periods
NCT02301975 (7) [back to overview]	Change From Baseline in PM FEV1 Using Per Protocol (PP) Population
NCT02301975 (7) [back to overview]	Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)
NCT02301975 (7) [back to overview]	Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population
NCT02301975 (7) [back to overview]	Change From Baseline in PM PEF
NCT02338362 (5) [back to overview]	Adherence
NCT02338362 (5) [back to overview]	Mean Intraocular Pressure
NCT02338362 (5) [back to overview]	Mean Visual Acuity
NCT02338362 (5) [back to overview]	Intraocular Pressure Elevation >20% From Baseline
NCT02338362 (5) [back to overview]	Side Effects
NCT02441114 (3) [back to overview]	Time to Maximum Concentration (Tmax)
NCT02441114 (3) [back to overview]	Maximum Observed Concentration (Cmax)
NCT02441114 (3) [back to overview]	Area Under the Concentration Versus Time Curve (AUClast)
NCT02446418 (3) [back to overview]	Change From Baseline in ACT Total Score at Week 24
NCT02446418 (3) [back to overview]	Percentage of Participants With Correct Use of Device, Defined as Not Making Any Critical or Non-critical Errors, at Week 12, and at Week 24 Independently of the Use at Week 12
NCT02446418 (3) [back to overview]	Change From Baseline in Asthma Control Test (ACT) Total Score at Week 12
NCT02502734 (2) [back to overview]	Mean Growth Rate in Lower-leg Growth, as Determined by Knemometry.
NCT02502734 (2) [back to overview]	Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Event (SAE).
NCT02516592 (5) [back to overview]	Change From Baseline in FVC (Forced Vital Capacity)
NCT02516592 (5) [back to overview]	Change From Baseline in Total Symptom Score- CAT (COPD Assessment Test)
NCT02516592 (5) [back to overview]	Transitional Dyspnea Index (TDI) Focal Score
NCT02516592 (5) [back to overview]	Change From Baseline in Mean Daily Use of Rescue Medication
NCT02516592 (5) [back to overview]	Change From Baseline in Trough Pre-dose FEV1 in Both Arms
NCT02554786 (27) [back to overview]	Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbations
NCT02554786 (27) [back to overview]	Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes
NCT02554786 (27) [back to overview]	Rescue Medication Usage
NCT02554786 (27) [back to overview]	Post Dose FEV1 (5 Minutes-1 Hour)
NCT02554786 (27) [back to overview]	Percentage of Participants Who Permanently Discontinued Study Medication Due to Asthma Exacerbations
NCT02554786 (27) [back to overview]	Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category
NCT02554786 (27) [back to overview]	Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
NCT02554786 (27) [back to overview]	Change Form Baseline in Percentage of Days With no Daytime Symptoms
NCT02554786 (27) [back to overview]	Percentage of Participants Achieving the Minimal Important Difference (MID) ACQ ≥ 0.5 at Weeks 26 and 52
NCT02554786 (27) [back to overview]	Change From Baseline in Percentage of Nights With no Night-time Awakenings
NCT02554786 (27) [back to overview]	Change From Baseline in Percentage of Asthma Symptoms Free Days
NCT02554786 (27) [back to overview]	Change Form Baseline in Percentage of Mornings With no Symptoms on Awakening
NCT02554786 (27) [back to overview]	Annual Rate of Asthma Exacerbations by Exacerbation Category
NCT02554786 (27) [back to overview]	Duration in Days of Asthma Exacerbations by Exacerbation Category
NCT02554786 (27) [back to overview]	Pre-dose FEV1 at Weeks 4 and 12
NCT02554786 (27) [back to overview]	Time to First Asthma Exacerbation by Exacerbation Category
NCT02554786 (27) [back to overview]	Trough Forced Expiratory Flow (FEF)Between 25% and 75% of FVC (FEF25-75)
NCT02554786 (27) [back to overview]	Trough Forced Vital Capacity (FVC)
NCT02554786 (27) [back to overview]	Asthma Quality of Life Questionnaire (AQLQ)
NCT02554786 (27) [back to overview]	Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment
NCT02554786 (27) [back to overview]	Asthma Control Questionnaire (ACQ-7) at Weeks 4, 12, 26 and 52
NCT02554786 (27) [back to overview]	Change From Baseline in Percentage of Rescue Medication Free Days
NCT02554786 (27) [back to overview]	Time to First Hospitalization for Asthma Exacerbation
NCT02554786 (27) [back to overview]	Total Amounts of Systemic Corticosteroids (in Doses) Used to Treat Asthma Exacerbations
NCT02554786 (27) [back to overview]	Trough FEV1 at Week 52
NCT02554786 (27) [back to overview]	Trough FEV1 Measured After 26 Weeks of Treatment
NCT02554786 (27) [back to overview]	Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26
NCT02569437 (5) [back to overview]	Subjective Symptom Composite Scoring
NCT02569437 (5) [back to overview]	Endoscopic Nasal Polyp Score
NCT02569437 (5) [back to overview]	Sino-nasal Outcome Test (SNOT 22)
NCT02569437 (5) [back to overview]	Visual Analog Scale
NCT02569437 (5) [back to overview]	Middle Meatus Culture
NCT02571777 (24) [back to overview]	Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category
NCT02571777 (24) [back to overview]	Duration in Days of Asthma Exacerbations by Exacerbation Category
NCT02571777 (24) [back to overview]	Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks
NCT02571777 (24) [back to overview]	Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks
NCT02571777 (24) [back to overview]	Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment
NCT02571777 (24) [back to overview]	Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52
NCT02571777 (24) [back to overview]	Annual Rate of Asthma Exacerbations by Exacerbation Category
NCT02571777 (24) [back to overview]	Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26
NCT02571777 (24) [back to overview]	Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks
NCT02571777 (24) [back to overview]	Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations
NCT02571777 (24) [back to overview]	Time to First Hospitalization for Asthma Exacerbation
NCT02571777 (24) [back to overview]	Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation
NCT02571777 (24) [back to overview]	Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes
NCT02571777 (24) [back to overview]	Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks
NCT02571777 (24) [back to overview]	Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks
NCT02571777 (24) [back to overview]	Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12
NCT02571777 (24) [back to overview]	Trough FEV1 at Week 52
NCT02571777 (24) [back to overview]	Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks
NCT02571777 (24) [back to overview]	Asthma Quality of Life Questionnaire (AQLQ) at Week 52
NCT02571777 (24) [back to overview]	Time to First Asthma Exacerbation by Exacerbation Category
NCT02571777 (24) [back to overview]	Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26
NCT02571777 (24) [back to overview]	Pre-dose FEV1 at Weeks 4 and 12
NCT02571777 (24) [back to overview]	Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ ≥ 0.5 at Week 26 and Week 52
NCT02571777 (24) [back to overview]	Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks
NCT02573233 (11) [back to overview]	Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12
NCT02573233 (11) [back to overview]	Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12
NCT02573233 (11) [back to overview]	Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12
NCT02573233 (11) [back to overview]	Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12
NCT02573233 (11) [back to overview]	Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12
NCT02573233 (11) [back to overview]	Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12
NCT02573233 (11) [back to overview]	Pharmacokinetics (PK) Assessment: Serum Functional Dupilumab Concentration
NCT02573233 (11) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02573233 (11) [back to overview]	Number of Participants With Antidrug Antibodies (ADA)
NCT02573233 (11) [back to overview]	Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12
NCT02573233 (11) [back to overview]	Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12
NCT02573870 (1) [back to overview]	Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs)
NCT02603393 (11) [back to overview]	Mean Change From Baseline in St. George's Respiratory Questionnaire
NCT02603393 (11) [back to overview]	Transition Dyspnea Index (TDI) Score
NCT02603393 (11) [back to overview]	Transition Dyspnea Index (TDI) Score
NCT02603393 (11) [back to overview]	Annualized Rate of COPD Exacerbations Requiring Hospitalisation
NCT02603393 (11) [back to overview]	Annualized Rate of COPD Exacerbations Requiring Treatment With Systemic Glucocorticosteroids and/or Antibiotics, Moderate Exacerbations Only
NCT02603393 (11) [back to overview]	Annualized Rate of Moderate or Severe COPD Exacerbations
NCT02603393 (11) [back to overview]	Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication
NCT02603393 (11) [back to overview]	Mean Change From Baseline in Forced Vital Capacity (FVC)
NCT02603393 (11) [back to overview]	Mean Change From Baseline in Post-dose Trough FEV1
NCT02603393 (11) [back to overview]	Mean Change From Baseline in St. George's Respiratory Questionnaire
NCT02603393 (11) [back to overview]	Mean Change From Baseline in Pre-dose Trough FEV1
NCT02610816 (9) [back to overview]	Change From Baseline in Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0) Generic Core Scales at 12 Weeks
NCT02610816 (9) [back to overview]	Percent of 1FED Non-responders on 4FED in Histologic Remission (<15 Eos/Hpf) at 12 Weeks in Phase 2
NCT02610816 (9) [back to overview]	Percent of Participants in Histologic Remission (<15 Eosinophils Per High Power Field) at 12 Weeks
NCT02610816 (9) [back to overview]	Change From Baseline in Pediatric Quality of Life Inventory Version 3.0 EoE Module (PedsQL 3.0 EoE) at 12 Weeks
NCT02610816 (9) [back to overview]	Percent of Participants With Positive and Negative Milk Skin Prick Tests Responding to 1FED
NCT02610816 (9) [back to overview]	Within-group Comparisons (Baseline v. Week 12) of PEESS V2.0 Scores
NCT02610816 (9) [back to overview]	Percent of Participants on Swallowed Glucocorticoids (SGC) in Histologic Remission (<15 Eos/Hpf) at 12 Weeks in Phase 2
NCT02610816 (9) [back to overview]	Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks
NCT02610816 (9) [back to overview]	Change From Baseline in Endoscopic Reference Score at 12 Weeks
NCT02712047 (7) [back to overview]	Change From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI
NCT02712047 (7) [back to overview]	Change From Baseline in FeNO Over the FF/VI Treatment Period
NCT02712047 (7) [back to overview]	Change From Baseline in FeNO Over the FF/VI Treatment Period
NCT02712047 (7) [back to overview]	Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Pre-treatment and for up to 7 Days After Cessation of Repeat Dose Treatment With FF/VI
NCT02712047 (7) [back to overview]	Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI
NCT02712047 (7) [back to overview]	Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI
NCT02712047 (7) [back to overview]	Change From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI
NCT02730351 (4) [back to overview]	Maximal Percent Decrease in FEV1 Following Exercise Challenge at 23 Hrs Post Evening Dose From Pre-exercise FEV1.
NCT02730351 (4) [back to overview]	Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1.
NCT02730351 (4) [back to overview]	Proportion of Participants With a 30 Min Post-challenge FEV1 no More Than 5 Percent Lower Than Pre-exercise FEV1 Following the Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.
NCT02730351 (4) [back to overview]	Weighted Mean 0-60 Min for Percentage Decrease From Pre-exercise FEV1 Following Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.
NCT02740543 (1) [back to overview]	Change in TSLP Gene Expression
NCT02748070 (2) [back to overview]	Lund Kennedy Endoscopy Score Over Time
NCT02748070 (2) [back to overview]	Sino-nasal Outcome Test (SNOT-22) Over Time
NCT02778867 (7) [back to overview]	Percent of Participants Following 6FED in Histologic Remission in Phase 2
NCT02778867 (7) [back to overview]	Percent of Participants in Complete and Partial Histologic Remission
NCT02778867 (7) [back to overview]	Percent of Participants in Histologic Remission (<15 Eos/Hpf)
NCT02778867 (7) [back to overview]	Change From Baseline in Total Endoscopic Reference Score
NCT02778867 (7) [back to overview]	Change From Baseline in Total Histology Scoring System
NCT02778867 (7) [back to overview]	Percent of Participants Following SGC in Histologic Remission in Phase 2
NCT02778867 (7) [back to overview]	Change From Baseline in Peak Eosinophil Count
NCT02874144 (5) [back to overview]	BSIT (Brief Smell Identification Test)
NCT02874144 (5) [back to overview]	Sinus CT Scan Scores by Lund-Mackay Scores
NCT02874144 (5) [back to overview]	SNOT-22 (Sino-Nasal Outcome Test-22) Score
NCT02874144 (5) [back to overview]	Visual Analog Scale (VAS)
NCT02874144 (5) [back to overview]	TOTAL POLYP SCORE (TPS)
NCT02885025 (8) [back to overview]	Peak Nasal Inspiratory Flow (PNIF) Change From Baseline to 3 Weeks of Randomly Assigned Treatment
NCT02885025 (8) [back to overview]	Interleukin 4 (IL4)
NCT02885025 (8) [back to overview]	Interleukin 1 Beta (IL1b)
NCT02885025 (8) [back to overview]	Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment
NCT02885025 (8) [back to overview]	Interleukin 8 (IL8)
NCT02885025 (8) [back to overview]	Interleukin 6 (IL6)
NCT02885025 (8) [back to overview]	Interleukin 5 (IL5)
NCT02885025 (8) [back to overview]	Interleukin 13 (IL13)
NCT02889809 (7) [back to overview]	Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02889809 (7) [back to overview]	Growth Velocity Over the First 12 Weeks of Double-blind Treatment Period
NCT02889809 (7) [back to overview]	Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period
NCT02889809 (7) [back to overview]	Change in Height Standard Deviation Scores (SDS) From Baseline to Endpoint
NCT02889809 (7) [back to overview]	Percentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period
NCT02889809 (7) [back to overview]	Percentage of Participants With Change in Growth Velocity Quartiles From Baseline to Endpoint
NCT02889809 (7) [back to overview]	Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry
NCT02924688 (12) [back to overview]	Number of Participants With Any Serious Adverse Event (SAE) and Common (>=3%) Non-SAE
NCT02924688 (12) [back to overview]	Number of Participants With Abnormal Hematology Values
NCT02924688 (12) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Values
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
NCT02924688 (12) [back to overview]	Annualized Rate of Moderate and Severe Asthma Exacerbations
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Asthma Control Questionnaire-7 (ACQ-7) Total Score at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Clinic FEV1 at 3 Hours Post Study Treatment at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Evaluating Respiratory Symptoms (E-RS) Total Score Over Weeks 21 to 24 (Inclusive) of the Treatment Period
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Pulse Rate at Week 24
NCT02924688 (12) [back to overview]	Mean Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 24
NCT02924688 (12) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG) Findings
NCT02980133 (8) [back to overview]	Change From Baseline in Asthma Control (Measured by Childhood Asthma Control Test [C-ACT] Score) Over the 12 Week Treatment Period
NCT02980133 (8) [back to overview]	For FS MDPI Versus Fp MDPI: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second (FEV1) at Week 12
NCT02980133 (8) [back to overview]	Time to First Onset of Effect
NCT02980133 (8) [back to overview]	Percentage of Participants Who Discontinued From Investigational Medicinal Product (IMP) for Asthma Exacerbation During the 12 Week Treatment Period
NCT02980133 (8) [back to overview]	For Fp MDPI Versus Placebo: Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at Week 12
NCT02980133 (8) [back to overview]	Change From Baseline in the Weekly Average of Total Daily (24 Hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1 Through 12
NCT02980133 (8) [back to overview]	Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1 Through 12
NCT02980133 (8) [back to overview]	Change From Baseline in the Weekly Average of Daily Trough Morning (Predose and Pre-Rescue Bronchodilator) Peak Expiratory Flow (PEF) Over the 12 Week Treatment Period
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 3200 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 400 mcg in Period 1
NCT02991859 (45) [back to overview]	Number of Participants With Clinically Significant Abnormal Chemistry Parameters
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 800 mcg in Period 1
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 800 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for FP 1000 mcg in Period 1
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for FP 1000 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for FP 2000 mcg in Period 1
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for FP 2000 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for FP 500 mcg in Period 1
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for FP 500 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability of Placebo in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 100 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 100 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 200 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 200 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 25 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 25 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 400 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 400 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 800 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FF 800 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FP 200 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FP 200 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FP 50 mcg in Period 1
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability for FP 50 mcg in Period 2
NCT02991859 (45) [back to overview]	PEFR as a Measure of Safety and Tolerability of Placebo in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 400 mcg in Period 2
NCT02991859 (45) [back to overview]	Forced Expiratory Volume in 1 Second (FEV 1) in Period 1
NCT02991859 (45) [back to overview]	Cortisol Suppression 0-24 Hours Weighted Mean-Dose Response Analysis
NCT02991859 (45) [back to overview]	Forced Expiratory Volume in 1 Second (FEV 1) in Period 2
NCT02991859 (45) [back to overview]	Forced Vital Capacity (FVC) in Period 1
NCT02991859 (45) [back to overview]	Forced Vital Capacity (FVC) in Period 2
NCT02991859 (45) [back to overview]	Number of Participants With Clinically Significant Abnormal Hematology Parameters
NCT02991859 (45) [back to overview]	Number of Participants With Clinically Significant Abnormal Urinalysis Parameters
NCT02991859 (45) [back to overview]	Provocative Concentration (PC) of Adenosine 5' Monophosphate (AMP) Causing a 20 Percent (%) Reduction in Forced Expiratory Volume in 1 Second (FEV1) (AMP PC20)- Dose Response Analysis
NCT02991859 (45) [back to overview]	Theraputic Index of BUD
NCT02991859 (45) [back to overview]	Theraputic Index of FF
NCT02991859 (45) [back to overview]	Theraputic Index of FP
NCT02991859 (45) [back to overview]	Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 100 mcg in Period 1
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 100 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 1600 mcg in Period 1
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 1600 mcg in Period 2
NCT02991859 (45) [back to overview]	Peak Expiratory Flow Rate (PEFR) as a Measure of Safety and Tolerability for BUD 3200 mcg in Period 1
NCT03012061 (6) [back to overview]	Mean Change From Baseline in Clinic FEV1 at 3 Hours Post Dose at Week 24
NCT03012061 (6) [back to overview]	Number of Participants With On-treatment Adverse Events (AE), Non-serious Adverse Events (Non-SAE)
NCT03012061 (6) [back to overview]	Mean Change From Baseline in Clinic Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24
NCT03012061 (6) [back to overview]	Mean Change From Baseline in On-treatment Pulse Rate
NCT03012061 (6) [back to overview]	Mean Change From Baseline in On-treatment Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03012061 (6) [back to overview]	Number of Participants With On-treatment Abnormal Electrocardiograms (ECG) Findings
NCT03055988 (9) [back to overview]	Change From Baseline in Aortic Distensibility After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in Aortic Augmentation Index After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in 1.5 Hour Post Dose Forced Vital Capacity (FVC) After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in 1.5 Hour Post Dose Forced Expiratory Volume in 1st Second (FEV1) After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in Central Systolic Pressure After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in Pulse Pressure After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in Pulmonary Artery Pulsatility After 6 Weeks of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment
NCT03055988 (9) [back to overview]	Change From Baseline in Functional Residual Capacity Body Plethysmography (FRCpleth) % Predicted After 6 Weeks of Treatment
NCT03063086 (6) [back to overview]	FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose
NCT03063086 (6) [back to overview]	FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose
NCT03063086 (6) [back to overview]	FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose
NCT03063086 (6) [back to overview]	FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)
NCT03063086 (6) [back to overview]	Trough FEV1 After 21 Days of Treatment
NCT03063086 (6) [back to overview]	Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period
NCT03158311 (8) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC)
NCT03158311 (8) [back to overview]	Change From Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75)
NCT03158311 (8) [back to overview]	Change From Baseline in Asthma Control Questionnaire (ACQ-7) Total Score
NCT03158311 (8) [back to overview]	Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Decrease From Baseline ACQ-7 ≥ 0.5
NCT03158311 (8) [back to overview]	Percentage of Patients Achieving the Minimally Clinically Important Difference (MCID) Change From Baseline AQLQ ≥ 0.5
NCT03158311 (8) [back to overview]	Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score
NCT03158311 (8) [back to overview]	Change From Baseline in AQLQ Total Score
NCT03158311 (8) [back to overview]	Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1)
NCT03191864 (28) [back to overview]	Percentage of Subjects With Mean 7-day EEsAI Total Score <20
NCT03191864 (28) [back to overview]	Percentage of Subjects With Mean 7-day EEsAI Total Score <20
NCT03191864 (28) [back to overview]	Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15
NCT03191864 (28) [back to overview]	Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF)
NCT03191864 (28) [back to overview]	Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52
NCT03191864 (28) [back to overview]	Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction
NCT03191864 (28) [back to overview]	Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52
NCT03191864 (28) [back to overview]	Number of Subjects With Oral and Esophageal Candidiasis
NCT03191864 (28) [back to overview]	Change in the Number of Dysphagia Episodes
NCT03191864 (28) [back to overview]	Change in the Number of Dysphagia Episodes
NCT03191864 (28) [back to overview]	Change From Baseline Global EoE Symptom Score
NCT03191864 (28) [back to overview]	Change From Baseline Global EoE Symptom Score
NCT03191864 (28) [back to overview]	Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52
NCT03191864 (28) [back to overview]	Number of Subjects Discontinuing Due to HPA Axis Suppression
NCT03191864 (28) [back to overview]	Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score
NCT03191864 (28) [back to overview]	Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score
NCT03191864 (28) [back to overview]	Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1
NCT03191864 (28) [back to overview]	Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2
NCT03191864 (28) [back to overview]	Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit
NCT03191864 (28) [back to overview]	Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit
NCT03191864 (28) [back to overview]	Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52
NCT03191864 (28) [back to overview]	Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores
NCT03191864 (28) [back to overview]	Percentage of Subjects Requiring Esophageal Dilation
NCT03191864 (28) [back to overview]	Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15
NCT03191864 (28) [back to overview]	Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit
NCT03191864 (28) [back to overview]	Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit
NCT03191864 (28) [back to overview]	Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test
NCT03191864 (28) [back to overview]	Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores
NCT03207243 (52) [back to overview]	Change Between Pre-dose and Post-dose of QRS Axis
NCT03207243 (52) [back to overview]	Change From Baseline Between Post-dose and Pre-dose in DBP and SBP
NCT03207243 (52) [back to overview]	Change From Baseline Between Post-dose and Pre-dose in Pulse Rate
NCT03207243 (52) [back to overview]	Change From Baseline in Asthma Control Questionnaire (ACQ-5) Total Score
NCT03207243 (52) [back to overview]	Change From Baseline in Cardiac Marker: Cardiac Troponin I
NCT03207243 (52) [back to overview]	Change From Baseline in Cardiac Marker: N-Terminal ProB-type Natriuretic Peptide
NCT03207243 (52) [back to overview]	Change From Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Gamma- Glutamyl Transferase (GGT) and Creatine Kinase (CK)
NCT03207243 (52) [back to overview]	Change From Baseline in Clinical Chemistry Parameters: Creatinine, Total Bilirubin and Direct Bilirubin
NCT03207243 (52) [back to overview]	Change From Baseline in Clinical Chemistry Parameters: Glucose, Potassium, Sodium, Calcium, Phosphate, Chloride, Urea and Carbon Dioxide (CO2)
NCT03207243 (52) [back to overview]	Change From Baseline in Clinical Chemistry Parameters: Total Protein and Albumin
NCT03207243 (52) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
NCT03207243 (52) [back to overview]	Change From Baseline in ECG Heart Rate
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocytes
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Erythrocytes Distribution Width (%)
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Hematocrit Level
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Hemoglobin
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin Concentration
NCT03207243 (52) [back to overview]	Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
NCT03207243 (52) [back to overview]	Change From Baseline in Maximum, Minimum and Average Changes in Heart Rate
NCT03207243 (52) [back to overview]	Change From Baseline in Mean Daily Rescue Medication Use (Albuterol/Salbutamol)
NCT03207243 (52) [back to overview]	Change From Baseline in Mean Daytime Asthma Symptom Score Over Each Four Weeks of the 16 Week Treatment Period
NCT03207243 (52) [back to overview]	Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) and Mean Evening PEF
NCT03207243 (52) [back to overview]	Change From Baseline in Percent Night-time Awakenings Due to Asthma Symptoms Requiring Rescue Medication Use
NCT03207243 (52) [back to overview]	Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia [QTcF] Interval and RR Interval
NCT03207243 (52) [back to overview]	Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)
NCT03207243 (52) [back to overview]	Change From Baseline in Pulse Rate (PR)
NCT03207243 (52) [back to overview]	Change From Baseline in QRS Axis
NCT03207243 (52) [back to overview]	Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score
NCT03207243 (52) [back to overview]	Change From Baseline in Supraventricular Couplets, Supraventricular Ectopics, Supraventricular Runs, Supraventricular Singles, Ventricular Couplets, Ventricular Ectopics, Ventricular Runs, Ventricular Singles
NCT03207243 (52) [back to overview]	Number of Hospitalizations or Emergency Room Visits Per Participants
NCT03207243 (52) [back to overview]	Number of Participants Reporting Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs)
NCT03207243 (52) [back to overview]	Number of Participants With Incidence and Titres of Anti- GSK3772847 Antibodies
NCT03207243 (52) [back to overview]	Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)
NCT03207243 (52) [back to overview]	Percent Change From Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration
NCT03207243 (52) [back to overview]	Percent Change From Baseline in Total Soluble ST2 Concentration
NCT03207243 (52) [back to overview]	Percentage of Participants With <=-0.5 Point ACQ-5 Score Decrease From Baseline (Responder)
NCT03207243 (52) [back to overview]	Percentage of Participants With at Least a 4 Units Improvement From Baseline of St. George's Respiratory Questionnaire (SGRQ)
NCT03207243 (52) [back to overview]	Serum Concentrations of GSK3772847
NCT03207243 (52) [back to overview]	Percentage of Participants With Inability to Titrate Inhaled Corticosteroids (ICS)
NCT03207243 (52) [back to overview]	Number of Participants Experiencing Asthma Related Hospitalization During the Study Period
NCT03207243 (52) [back to overview]	Percentage of Participants Who Have Pre-bronchodilator FEV1 Decrease From Baseline >7.5 %
NCT03207243 (52) [back to overview]	Percentage of Participants With >=0.5 Point Asthma Control Questionnaire (ACQ-5) Score Increase From Baseline
NCT03207243 (52) [back to overview]	Percentage of Participants With Clinically Significant Asthma Exacerbation
NCT03207243 (52) [back to overview]	Percentage of Participants With Clinically Significant Asthma Exacerbation or Inability to Titrate
NCT03207243 (52) [back to overview]	Percentage of Participants With Loss of Asthma Control Over Weeks 0-16
NCT03207243 (52) [back to overview]	Percentage of Participants With Loss of Asthma Control Over Weeks 0-6
NCT03207243 (52) [back to overview]	Rate Per 1000 Person-years of Participants With Hospitalization
NCT03207243 (52) [back to overview]	Time to Loss of Asthma Control
NCT03207243 (52) [back to overview]	Change Between Pre-dose and Post-dose of Heart Rate
NCT03207243 (52) [back to overview]	Change Between Pre-dose and Post-dose of PR Interval, QRS Duration, Uncorrected QT Interval, QTcF Interval and RR Interval
NCT03240575 (4) [back to overview]	Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment
NCT03240575 (4) [back to overview]	Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment
NCT03240575 (4) [back to overview]	Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment
NCT03240575 (4) [back to overview]	Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment
NCT03273946 (3) [back to overview]	Number of Participants With Any New, Unexpected AE or Safety Signal
NCT03273946 (3) [back to overview]	Number of Participants With Any Serious Adverse Event (SAE) or Non-SAE
NCT03273946 (3) [back to overview]	Number of Participants With Any Adverse Event (AE) or Adverse Drug Reaction (ADR)
NCT03387852 (3) [back to overview]	Change From Baseline at Week 12 in Post-bronchodilator Forced Expiratory Volume in 1 Second
NCT03387852 (3) [back to overview]	Percentage of Participants With Loss of Asthma Control
NCT03387852 (3) [back to overview]	Change From Baseline at Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
NCT03591068 (12) [back to overview]	Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved
NCT03591068 (12) [back to overview]	Assessment for Safety Through Nasal Examination
NCT03591068 (12) [back to overview]	Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade
NCT03591068 (12) [back to overview]	Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit
NCT03591068 (12) [back to overview]	Assessment for Safety From the Collection of Information for Concomitant Medications Usage
NCT03591068 (12) [back to overview]	Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests
NCT03591068 (12) [back to overview]	Assessment for Safety From Recording Vital Sign - Blood Pressure
NCT03591068 (12) [back to overview]	Assessment for Safety From Recording Vital Sign - Pulse
NCT03591068 (12) [back to overview]	Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video
NCT03591068 (12) [back to overview]	Sinonasal Outcome Test 22 (SNOT-22) Total Score
NCT03591068 (12) [back to overview]	Sniffin' Sticks N-butanol Test
NCT03591068 (12) [back to overview]	Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)
NCT03756883 (4) [back to overview]	Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment
NCT03756883 (4) [back to overview]	Baseline-adjusted Pre-dose FEV1 Measured in the Morning Following 28 Days of Treatment.
NCT03756883 (4) [back to overview]	Statistical Superiority of Test and Reference Over Placebo Treatment in Baseline-adjusted Area Under the Serial FEV1-time Curve
NCT03756883 (4) [back to overview]	Statistical Superiority of Test and Reference Over Placebo Treatment in Baseline-adjusted Pre-dose FEV1 Measured in the Morning Following 28 Days of Treatment
NCT03882047 (11) [back to overview]	Response to Therapy at Day 4 (Physician Evaluation)
NCT03882047 (11) [back to overview]	Response to Therapy at Day 15 (Physician Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis at Day 15 (Participant Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis at Day 15 (Physician Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis at Day 4 (Participant Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis at Day 4 (Physician Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in the Total Nasal Symptom Score at Day 15 (Physician Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in the Total Nasal Symptom Score at Day 4 (Physician Evaluation)
NCT03882047 (11) [back to overview]	Change From Baseline in Total Nasal Symptom Score Averaged Over Day 1 Through Day 15 (Based on Participant Diaries)
NCT03882047 (11) [back to overview]	Response to Therapy at Day 15 (Participant Evaluation)
NCT03882047 (11) [back to overview]	Response to Therapy at Day 4 (Participant Evaluation)
NCT03926026 (3) [back to overview]	COHORT 1: Mean Change From Baseline to Day 14 in the Composite (Sum) Score of Signs & Symptoms of Blepharitis
NCT03926026 (3) [back to overview]	COHORT 1 and 2 COMBINED: Mean Change From Baseline to Day 14 in the Composite (Sum) Score of Signs & Symptoms of Blepharitis
NCT03926026 (3) [back to overview]	COHORT 2: Mean Change From Baseline to Day 14 in the Composite (Sum) Score of Signs & Symptoms of Blepharitis
NCT04179461 (4) [back to overview]	Change in Composite Asthma Severity Index (CASI)
NCT04179461 (4) [back to overview]	Asthma Control Test (ACT)
NCT04179461 (4) [back to overview]	Adherence of Asthma Controller Medication
NCT04179461 (4) [back to overview]	Pulmonary Function Measured by Spirometry: Forced Expiratory Volume in 1 Second (FEV1) / Forced Vital Capacity (FVC)
NCT04652245 (2) [back to overview]	Change in Patient-assessed Instantaneous Total Nasal Symptom Score (TNSS) From Baseline Compared to Placebo
NCT04652245 (2) [back to overview]	Change in Patient-assessed Instantaneous Total Ocular Symptom Score (TOSS) From Baseline Compared to Placebo
NCT04677959 (13) [back to overview]	System Usability Scale (SUS) Overall Score for DS Group
NCT04677959 (13) [back to overview]	Change From Baseline in BIPQ Cognitive Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in Adherence to Maintenance Treatment (FS eMDPI) at Week 24 for the DS Group
NCT04677959 (13) [back to overview]	Change From Baseline in Beliefs About Medicines Questionnaire (BMQ) Concern Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in BIPQ Emotional Representations Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in BMQ Necessity Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in Brief Illness Perception Questionnaire (BIPQ) Illness Comprehensibility Subscale Score at Week 24
NCT04677959 (13) [back to overview]	Change From Baseline in Mean Weekly SABA Usage at Week 24 for the DS Group
NCT04677959 (13) [back to overview]	Change From Baseline in the Number of SABA-free Days at Week 24 for the DS Group
NCT04677959 (13) [back to overview]	Number of Decreased Doses of Inhaled Medication
NCT04677959 (13) [back to overview]	Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control
NCT04677959 (13) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment (WPAI) Asthma Questionnaire Score at Week 24
NCT04677959 (13) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT05169424 (13) [back to overview]	Total Costs of COPD-related HCRU
NCT05169424 (13) [back to overview]	Incidence Rate of Pneumonia Hospitalization (Diagnosis in Any Position)
NCT05169424 (13) [back to overview]	Total Costs of COPD or Pneumonia-related Health Care Cost and Resource Utilization (HCRU)
NCT05169424 (13) [back to overview]	Total Costs of COPD or Pneumonia Attributable HCRU
NCT05169424 (13) [back to overview]	Total Costs of All-cause HCRU
NCT05169424 (13) [back to overview]	Incidence Rate of Pneumonia Hospitalization (Diagnosis in Any Position) - Among Patients With no Baseline Exacerbation
NCT05169424 (13) [back to overview]	Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation After Cohort Entry - Among Patients With 2 or More Baseline Exacerbations
NCT05169424 (13) [back to overview]	Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation After Cohort Entry - Among Patients With 0 or 1 Baseline Exacerbation
NCT05169424 (13) [back to overview]	Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation After Cohort Entry
NCT05169424 (13) [back to overview]	Incidence Rate of Pneumonia Hospitalization (Diagnosis in Any Position) - Among Patients With 2 or More Baseline Exacerbations
NCT05169424 (13) [back to overview]	Incidence Rate of Pneumonia Hospitalization (Diagnosis in Any Position) - Among Patients With 0 or 1 Baseline Exacerbation
NCT05169424 (13) [back to overview]	Total Costs of Pneumonia-related HCRU
NCT05169424 (13) [back to overview]	Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation After Cohort Entry - Among Patients With no Baseline Exacerbation
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Sleep
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Physical Function
NCT05736874 (13) [back to overview]	Mean Days Benefit as Measured by the Symptom and Clinical Event Scale
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Pain
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Fatigue
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Social
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Depression
NCT05736874 (13) [back to overview]	Quality of Life (QOL) as Measured by the PROMIS-29 - Anxiety
NCT05736874 (13) [back to overview]	Time Unwell in Days as Measured by the Symptom and Clinical Event Scale
NCT05736874 (13) [back to overview]	Time to Sustained Recovery in Days
NCT05736874 (13) [back to overview]	Number of Participants With Mortality
NCT05736874 (13) [back to overview]	Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death
NCT05736874 (13) [back to overview]	Number of Participants With Hospitalization or Death

Change in Mean Nocturnal Asthma Symptom Score From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period

"Nocturnal asthma symptom was measured daily on a scale of 0 to 4 in response to the question How did you sleep last night?, with 0 as the best response and 4 as the worst response. The mean of the last 4 weeks of the 24-week fixed-dose steroid treatment period was calculated; for patients who discontinued prematurely, the mean of the last 28 days before discontinuation was calculated. A negative change in mean score indicated improvement." (NCT00079937)
Timeframe: Baseline to the end (last 4 weeks) of the 24-week fixed-dose steroid treatment period

Intervention	Units on a scale (Mean)
Omalizumab	-0.63
Placebo	-0.50

Intervention	Units on a scale (Least Squares Mean)
	Activity limitation	Emotional function	Symptoms	Overall (total)
Omalizumab	0.85	0.89	0.99	0.92
Placebo	0.76	0.91	0.93	0.89

Intervention	Scores on a scale (Mean)
	Activity limitation week 2	Activity limitation week 4	Activity limitation endpoint	Emotional function Week 2	Emotional function Week 4	Emotional function endpoint	Symptoms Week 2	Symptoms Week 4	Symptoms Endpoint	Overall score Week 2	Overall score Week 4	Overall score Endpoint
FP 100mcg BID	0.63	0.75	0.67	0.48	0.47	0.42	0.49	0.55	0.51	0.52	0.57	0.51
FSC 100/50mcg BID	0.78	0.93	0.89	0.44	0.56	0.53	0.39	0.52	0.48	0.49	0.62	0.59

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-1.66
Fluticasone Propionate + Placebo	-2.21

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.22
Fluticasone Propionate + Placebo	-0.25

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.52
Fluticasone Propionate + Placebo	-0.29

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.24
Fluticasone Propionate + Placebo	-0.14

Intervention	units on a scale (Median)
Fluticasone Propionate + Montelukast	-0.41
Fluticasone Propionate + Placebo	-0.47

Intervention	percentage of days (Mean)
	Baseline	0-6 weeks	6-16 weeks	16-26 weeks
FP 200 mcg	23.06	31.50	45.24	49.75
Salmeterol/FP 50/100 mcg Plus Placebo	22.78	31.58	44.60	50.45

Intervention	Eosinophil percentage (Mean)
Placebo/Placebo	3.5
Placebo/Salmeterol	2.4
Placebo/fFuticasone	0.54
Salmeterol/Fluticasone	2.4

Intervention	beats per min (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Week 28	Week 32	Week 36	Week 40	Week 44	Week 48	Week 52 / withdrawal
GW815SF 50/500 µg	-1.5	-1.6	-0.4	1.0	1.1	1.4	1.2	0.4	0.9	0.7	0.4	-0.2	0.8

Intervention	Millimeter of mercury (mmHg) (Mean)
	SBP, Week 4	SBP, Week 8	SBP, Week 12	SBP, Week 16	SBP, Week 20	SBP, Week 24	SBP, Week 28	SBP, Week 32	SBP, Week 36	SBP, Week 40	SBP, Week 44	SBP, Week 48	SBP, Week 52 / withdrawal	DBP, Week 4	DBP, Week 8	DBP, Week 12	DBP, Week 16	DBP, Week 20	DBP, Week 24	DBP, Week 28	DBP, Week 32	DBP, Week 36	DBP, Week 40	DBP, Week 44	DBP, Week 48	DBP, Week 52 / withdrawal
GW815SF 50/500 µg	0.5	-0.1	0.6	0.7	-0.8	0.2	-0.4	-1.8	1.1	0.4	-3.1	-4.1	0.3	-0.7	-1.2	0.3	0.3	-1.4	0.6	-0.6	-1.4	0.0	-1.3	-2.1	-2.9	-0.1

Intervention	Participants (Count of Participants)
	Week -2	Week 0	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24	Week 28	Week 32	Week 36	Week 40	Week 44	Week 48	Week52 / withdrawal
GW815SF 50/500 µg	1	1	3	7	7	9	9	9	6	7	7	7	4	4	8

Intervention	Participants (Count of Participants)
	TB, Baseline, > upper limit	TB, Week 4, > upper limit	TB, Week 12, > upper limit	TB, Week 12, < lower limit	TB, Week 24, > upper limit	TB, Week 36, > upper limit	TB, Week 36, < lower limit	TB, Week 52/ withdrawal, > upper limit	AL-P, Baseline, > upper limit	AL-P, Week 4, > upper limit	AL-P, Week 12, > upper limit	AL-P, Week 24, > upper limit	AL-P, Week 24, < lower limit	AL-P, Week 36, > upper limit	AL-P, Week 52/ withdrawal, > upper limit	ALT, Baseline, > upper limit	ALT, Week 4, > upper limit	ALT, Week 12, > upper limit	ALT, Week 24, > upper limit	ALT, Week 36, > upper limit	ALT, Week 52/ withdrawal, > upper limit	AST, Baseline, > upper limit	AST, Week 4, > upper limit	AST, Week 12, > upper limit	AST, Week 24, > upper limit	AST, Week 36, > upper limit	AST, Week 52/ withdrawal, > upper limit	Gamma GTP, Baseline, > upper limit	Gamma GTP, Baseline, < lower limit	Gamma GTP, Week 4, > upper limit	Gamma GTP, Week 4, < lower limit	Gamma GTP, Week 12, > upper limit	Gamma GTP, Week 12, < lower limit	Gamma GTP, Week 24, > upper limit	Gamma GTP, Week 24, < lower limit	Gamma GTP, Week 36, > upper limit	Gamma GTP, Week 36, < lower limit	Gamma GTP,Week 52/withdrawal, > upper limit	Gamma GTP,Week 52/withdrawal, < lower limit	LDH, Baseline, > upper limit	LDH, Week 4, > upper limit	LDH, Week 12, > upper limit	LDH, Week 24, > upper limit	LDH, Week 36, > upper limit	LDH, Week 36, < lower limit	LDH, Week 52/ withdrawal, > upper limit	TC, Baseline, > upper limit	TC, Baseline, < lower limit	TC, Week 4, > upper limit	TC, Week 4, < lower limit	TC, Week 12, > upper limit	TC, Week 12, < lower limit	TC, Week 24, > upper limit	TC, Week 24, < lower limit	TC, Week 36, > upper limit	TC, Week 36, < lower limit	TC, Week 52/ withdrawal, > upper limit	TC, Week 52/ withdrawal, < lower limit	Glucose, Baseline, > upper limit	Glucose, Baseline, < lower limit	Glucose, Week 4, > upper limit	Glucose, Week 4, < lower limit	Glucose, Week 12, > upper limit	Glucose, Week 12, < lower limit	Glucose, Week 24, > upper limit	Glucose, Week 24, < lower limit	Glucose, Week 36, > upper limit	Glucose, Week 36, < lower limit	Glucose, Week 52/ withdrawal, > upper limit	Glucose, Week 52/ withdrawal, < lower limit	Creatinine, Baseline, > upper limit	Creatinine, Baseline, < lower limit	Creatinine, Week 4, > upper limit	Creatinine, Week 4, < lower limit	Creatinine, Week 12, > upper limit	Creatinine, Week 12, < lower limit	Creatinine, Week 24, > upper limit	Creatinine, Week 24, < lower limit	Creatinine, Week 36, > upper limit	Creatinine, Week 36, < lower limit	Creatinine,Week 52/withdrawal, >upper limit	Creatinine,Week 52/withdrawal,	BUN, Baseline, > upper limit	BUN, Baseline, < lower limit	BUN, Week 4, > upper limit	BUN, Week 4, < lower limit	BUN, Week 12, > upper limit	BUN, Week 12, < lower limit	BUN, Week 24, > upper limit	BUN, Week 36, > upper limit	BUN, Week 52/ withdrawal, > upper limit	BUN, Week 52/ withdrawal, < lower limit	UA, Baseline, > upper limit	UA, Week 4, > upper limit	UA, Week 12, > upper limit	UA, Week 24, > upper limit	UA, Week 36, > upper limit	UA, Week 52/ withdrawal, > upper limit	Na, Baseline, > upper limit	Na, Week 4, > upper limit	Na, Week 4, < lower limit	Na, Week 12, > upper limit	Na, Week 24, > upper limit	Na, Week 36, > upper limit	Na, Week 52/ withdrawal, < lower limit	K, Baseline, > upper limit	K, Baseline, < lower limit	K, Week 4, > upper limit	K, Week 12, > upper limit	K, Week 12, < lower limit	K, Week 24, > upper limit	K, Week 24, < lower limit	K, Week 36, > upper limit	K, Week 52/ withdrawal, > upper limit	K, Week 52/ withdrawal, < lower limit	Cl, Baseline, > upper limit	Cl, Baseline, < lower limit	Cl, Week 4, > upper limit	Cl, Week 4, < lower limit	Cl, Week 12, > upper limit	Cl, Week 12, < lower limit	Cl, Week 24, > upper limit	Cl, Week 24, < lower limit	Cl, Week 36, > upper limit	Cl, Week 52/ withdrawal, > upper limit	Cl, Week 52/ withdrawal, < lower limit	Ca, Baseline, > upper limit	Ca, Baseline, < lower limit	Ca, Week 4, > upper limit	Ca, Week 4, < lower limit	Ca, Week 12, > upper limit	Ca, Week 12, < lower limit	Ca, Week 24, > upper limit	Ca, Week 36, > upper limit	Ca, Week 52/ withdrawal, > upper limit	Ca, Week 52/ withdrawal, < lower limit
GW815SF 50/500 µg	1	2	3	1	5	2	1	4	18	15	15	18	1	12	13	5	4	7	6	3	4	9	6	6	9	4	5	15	9	17	10	14	8	12	8	12	8	15	10	10	11	8	14	10	1	9	17	13	19	16	21	8	20	10	22	10	27	10	40	2	42	4	42	4	31	3	34	5	45	3	8	8	9	8	8	1	9	4	9	3	7	6	31	1	16	1	23	1	18	21	22	1	35	31	29	19	21	32	2	2	1	2	6	2	3	2	1	2	4	2	3	2	7	3	2	1	1	4	1	2	2	3	2	3	1	3	3	2	3	1	3	1	7	4	3	1

Intervention	Participants (Count of Participants)
	Urine protein, Week 4, 1+ to 3+	Glucose, Week 4, 3+ to 4+	Urine protein, Week 12, 1+ to 2+	Urine protein, Week 12, 1+ to 3+	Glucose, Week 12, 2+ to 4+	Glucose, Week 12, 3+ to 4+	Urine protein, Week 24, 1+ to 2+	Urine protein, Week 24, 1+ to 3+	Glucose, Week 24, 1+ to 2+	Glucose, Week 24, 1+ to 4+	Glucose, Week 24, 2+ to 4+	Urine protein, Week 36, 1+ to 2+	Urine protein, Week 36, 1+ to 3+	Glucose, Week 36, 1+ to 4+	Glucose, Week 36, 2+ to 4+	Glucose, Week 36, 3+ to 4+	Urine protein, Week 52/withdrawal, 1+ to 3+	Glucose, Week 52/withdrawal, 1+ to 2+	Glucose, Week 52/withdrawal, 1+ to 4+	Glucose, Week 52/withdrawal, 2+ to 4+
GW815SF 50/500 µg	1	1	1	1	1	1	1	1	1	2	1	1	1	1	2	1	1	2	1	1

Intervention	Participants (Count of Participants)
	RBC, Baseline, < lower limit	RBC, Week 4, < lower limit	RBC, Week 12, < lower limit	RBC, Week 24, > upper limit	RBC, Week 24, < lower limit	RBC, Week 36, > upper limit	RBC, Week 36, < lower limit	RBC, Week 52/Withdrawal, > upper limit	RBC, Week 52/Withdrawal, < lower limit	Hb, Baseline, > upper limit	Hb, Baseline, < lower limit	Hb, Week 4, < lower limit	Hb, Week 12, < lower limit	Hb, Week 24, < lower limit	Hb, Week 36, < lower limit	Hb, Week 52/Withdrawal,	Hematocrit, Baseline, > upper limit	Hematocrit, Baseline, < lower limit	Hematocrit, Week 4, > upper limit	Hematocrit, Week 4, < lower limit	Hematocrit, Week 12, > upper limit	Hematocrit, Week 12, < lower limit	Hematocrit, Week 24, > upper limit	Hematocrit, Week 24, < lower limit	Hematocrit, Week 36, < lower limit	Hematocrit,Week 52/Withdrawal,< lower limit	PC, Baseline, > upper limit	PC, Baseline, < lower limit	PC, Week 4, > upper limit	PC, Week 4, < lower limit	PC, Week 12, > upper limit	PC, Week 12, < lower limit	PC, Week 24, > upper limit	PC, Week 24, < lower limit	PC, Week 36, > upper limit	PC, Week 36, < lower limit	PC, Week 52/Withdrawal, > upper limit	PC, Week 52/Withdrawal, < lower limit	WBC, Baseline, > upper limit	WBC, Baseline, < lower limit	WBC, Week 4, > upper limit	WBC, Week 4, < lower limit	WBC, Week 12, > upper limit	WBC, Week 24, > upper limit	WBC, Week 24, < lower limit	WBC, Week 36, > upper limit	WBC, Week 36, < lower limit	WBC, Week 52/Withdrawal, > upper limit	Basophils, Baseline, > upper limit	Basophils, Week 4, > upper limit	Basophils, Week 12, > upper limit	Basophils, Week 36, > upper limit	Basophils, Week 52/Withdrawal, > upper limit	Eosinophils, Baseline, > upper limit	Eosinophils, Week 4, > upper limit	Eosinophils, Week 12, > upper limit	Eosinophils, Week 24, > upper limit	Eosinophils, Week 36, > upper limit	Eosinophils,Week 52/Withdrawal,> upper limit	Neutrophils, Baseline, > upper limit	Neutrophils, Baseline, < lower limit	Neutrophils, Week 4, > upper limit	Neutrophils, Week 4, < lower limit	Neutrophils, Week 12, > upper limit	Neutrophils, Week 24, > upper limit	Neutrophils, Week 36, > upper limit	Neutrophils, Week 36, < lower limit	Neutrophils,Week 52/Withdrawal,>upper limit	Neutrophils,Week 52/Withdrawal,< lower limit	Lymphocytes, Baseline, > upper limit	Lymphocytes, Baseline, < lower limit	Lymphocytes, Week 4, < lower limit	Lymphocytes, Week 12, < lower limit	Lymphocytes, Week 24, < lower limit	Lymphocytes, Week 36, < lower limit	Lymphocytes,Week 52/Withdrawal,< lower limit	Monocytes, Baseline, > upper limit	Monocytes, Week 4, > upper limit	Monocytes, Week 12, > upper limit	Monocytes, Week 24, > upper limit	Monocytes, Week 36, > upper limit	Monocytes, wEEK 52/Withdrawal,> upper limit
GW815SF 50/500 µg	30	36	36	1	21	1	22	1	33	1	15	20	20	13	14	27	4	10	1	13	1	13	1	9	12	17	3	8	1	7	7	6	5	4	2	6	4	2	4	2	3	3	2	5	1	5	2	7	1	1	4	1	2	17	10	10	8	8	10	5	5	7	3	6	15	9	2	11	1	2	10	16	17	25	16	19	31	47	37	25	28	14

Intervention	Participants (Count of Participants)
	Cataract, Baseline	Cataract, Week 24	Cataract, Withdrawal	Glaucoma, Baseline	Glucoma, Week 24	Glucoma, Withdrawal
GW815SF 50/500 µg	3	2	3	4	4	4

Intervention	µg/dL (Geometric Mean)
	Baseline	Week 24	Week 52/Withdrawal
GW815SF 50/500 µg	9.41	10.08	8.49

Intervention	Liter per second (Mean)
	V25, Baseline	V25, Week 8	V25, Week 12	V25, Week 16	V25, Week 20	V25, Week 24	V25, Week 28	V25, Week 32	V25, Week 36	V25, Week 40	V25, Week 44	V25, Week 48	V25, Week 52	V25, Week 52/ withdrawal	V50, Week 4	V50, Week 8	V50, Week 12	V50, Week 16	V50, Week 20	V50, Week 24	V50, Week 28	V50, Week 32	V50, Week 36	V50, Week 40	V50, Week 44	V50, Week 48	V50, Week 52	V50, Week 52/ withdrawal
GW815SF 50/500 µg	0.018	0.021	0.015	0.016	0.012	0.017	0.012	0.009	0.018	0.022	0.015	0.010	0.017	0.012	0.044	0.076	0.054	0.060	0.040	0.047	0.049	0.053	0.046	0.053	0.046	0.038	0.059	0.045

Intervention	Scores on a scale (Mean)
	Breathlessness, treatment period	Cough, treatment period	Sputum, treatment period	Nighttime awakenings, treatment period
GW815SF 50/500 µg	-0.2	0.0	0.0	-0.1

Intervention	Score on a scale (Mean)
	Baseline	Average Change from Baseline During Period II
Fluticasone	1.78	-0.44
Montelukast	1.82	-0.41
Placebo	1.90	-0.27

fluticasone

Description

Cross-References

Synonyms (52)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (6)

Bioassays (25)

Research

Studies (2,847)

Market Indicators

Research Demand Index: 76.28

Study Types

Clinical Trials (588)

Trial Overview

Trial Outcomes

Change in Mean Nocturnal Asthma Symptom Score From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period

Change in Mean Daily Number of Puffs of Asthma Rescue Medication From Baseline to the End (Last 4 Weeks) of the 24-week Fixed-dose Steroid Treatment Period

Percentage of Participants With at Least 1 Adverse Event

Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period

Rate of Clinically Significant Asthma Exacerbations Per Patient in the 52-week Treatment Period

Change in Pediatric Asthma Quality of Life Questionnaire (Standardized) [PAQLQ(S)] Scores From Baseline to the End of the 24-week Fixed-dose Steroid Treatment Period (Week 24)

Percent of Symptom-free Days

Four-hour Serial Post-dose FEV1 Area Under the Curve (AUC) on Treatment Day 1

Percent of Rescue-free Days

Maximal Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Following Exercise Challenge at Week 4

Change From Baseline in Morning Peak Expiratory Flow (AM PEF)

Change From Baseline in Evening (PM) PEF

Change From Baseline in Pediatric Asthma Quality of Life Questionnaire (PAQLQ)

Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period

Change From Baseline in Sneezing Symptom Score Over 2 Week Randomized Treatment Period

Change From Baseline in Runny Nose Symptom Score Over 2 Week Randomized Treatment Period

Change From Baseline in Other Symptom Score Over 2 Week Randomized Treatment Period

Change From Baseline in Stuffy Nose Symptom Score Over 2 Week Randomized Treatment Period

The Time to Clearance of the Disease

Change From Baseline in the m-EASI (Eczema Area Severity Index) Score.

Maximum Post-exercise Percent (%) Fall in FEV1

Time to Recovery to Within 5% of Baseline FEV1

Maximum FEV1 % Predicted Following First Beta-agonist Use

Average (Avg) %-Change in FEV1 After First Beta (β)-Agonist Use and Prior to Second β-agonist Use

Area Under the Curve for %-Change From Pre-exercise Baseline FEV1 in Liters (L), From 0 to 20 Minutes (AUC(0-20))

Treatment Failure

Mean Change From Baseline in Percentage Predicted Forced Expiratory Volume in One Second (FEV1) at Week 26

Percentage of Symptom-free Days During the Entire Treatment Period

Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period

Percent Change From Baseline in RINT Measurements at Week 26

Mean Change From Baseline in Provocation Dose (PD20) Causing a 20% Fall in FEV1 at Week 26

Geometric Means of Nitric Oxide (NO) at Week 26

Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 26

Number of Asthma Exacerbations Per Treatment Group at Week 26

Mean Change From Baseline in Midexpiratory Flow (MEF 50) at Week 26

Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge

Interleukin 8 (IL8)

Sputum Inflammatory Cell Counts

Total Sputum Eosinophils

Mean Change From Baseline in Pulse Rate

Mean Change From Baseline in Peak Expiratory Flow (PEF)

Mean Area Under the Plasma Concentration-time Curve From Zero up to the Last Quantifiable Plasma Concentration [AUC (0-t)] of Salmeterol

Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs)

Number of Participants With Abnormal Oropharyngeal Examination Findings

Number of Participants With Abnormal (Outliers From the Normal Range) Clinical Chemistry Parameters

Number of Participants With Abnormal (Shift From Baseline) Urinalysis Parameters

Number of Participants With Abnormal (Outliers From the Normal Range) Hematology Parameters

Number of Participants With Abnormal (Clinically Significant) Ophthalmological Examinations Findings

Number of Participants With Abnormal (Clinically Significant) Electrocardiogram (ECG) Findings

Mean Level of Plasma Cortisol 2

Mean Change From Baseline in Weight

Mean Change From Baseline in Maximal Expiratory Flow Rate at 25% (V25) and 50% (V50) of Vital Capacity

Mean Change From Baseline in Level of Plasma Cortisol 1

Mean Change From Baseline in Forced Vital Capacity (FVC)

Intervention	Participants (Number)
Standard Asthma ED Discharge Therapy	18
ICS Prescription + Standard Asthma ED Discharge Therapy:	32

Intervention	L/sec (Mean)
Fluticasone Propionate/Salmeterol (FSC)	0.15
Montelukast (MON)	0.04

Intervention	Percentage of asthma symptom-free days (Mean)
Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)	34.8
Fluticasone Propionate/Salmeterol (FSC)	37.1

Intervention	Percentage of rescue-free days (Mean)
Fluticasone Propionate + Salmeterol & Montelukast (FSC+MON)	41.2
Fluticasone Propionate/Salmeterol (FSC)	42.9

Intervention	Percentage of rescue-free days (Mean)
Fluticasone Propionate/Salmeterol (FSC)	37.5
Montelukast (MON)	26.7

Intervention	Points on a Scale (Mean)
Flut Prop/Salmeterol/Flut Nasal Spray (FSC+FPANS)	-2.0
Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)	1.7

Intervention	Points on a Scale (Mean)
Fluticasone Prop/Salmeterol/Montelukast (FSC+MON)	-2.3
Fluticasone Prop/Salmeterol/Flut Nasal Spray (FSC+FPANS)	-3.0

Intervention	L/min (Mean)
Flut Prop/Salmeterol/Montelukast (FSC+MON)	30.9
Fluticasone Propionate/Salmeterol (FSC)	35.2

Intervention	L/sec (Mean)
Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)	0.27
Fluticasone Propionate/Salmeterol (FSC)	0.13

Intervention	Logarithm (mg/mL) (Mean)
	Baseline PC20 small-particle AMP	Baseline PC20 large-particle AMP	Post-Treatment PC20 small-particle AMP	Post-Treatment PC20 large-particle AMP
Ciclesonide	4.9	3.7	6.6	4.5
Fluticasone	5.2	3.0	6.0	4.3